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ABSTRACT
Migration of myogenic cells is an important step in myogenesis and skeletal
muscle repair. Migration is required for the cells to reach the site of damage, for
their alignment and subsequent fusion. Limited migration is also one of the
limitations of proposed therapies of diseases, such as Duchenne Muscular
Dystrophy (DMD). Therefore, revealing the regulators of myogenic cell migration
is important for improving our knowledge of myogenesis, but could also be
applied in therapies for conditions, associated with loss of muscle mass and
muscle weakness.
In this thesis, extracellular and intracellular regulation of C2C12 myoblast
migration was investigated. It was demonstrated that medium conditioned by
myotube cultures in vitro, is capable of inducing the migration and chemotaxis of
myoblasts. A model of serially passaged myoblasts was used to reveal potential
changes in the migratory behaviour of these cells, in the context of skeletal
muscle ageing. PI3K/AKT and MAPK/ERK pathways were investigated and their
requirement for the process of myoblast migration was revealed. Further
activation of these pathways with phospho-tyrsoine phosphatase and PTEN
inhibitor Bpv(Hopic) was associated with larger increases in myoblast migration.
Silencing of either PI3K/AKT or MAPK/ERK signalling pathways, in a situation
where the other pathway remained activated, resulted in a significant inhibition of
myoblast migration. Similarly, inhibition of FAK signalling, using the PF-228
inhibitor did not significantly affect PI3K/AKT and MAPK/ERK pathways, but
resulted in reduced myoblast migration, suggesting the indispensability of
individual signalling pathways for myoblast migration in response to myotube
CM, regardless of the activity of other signalling pathways. Finally, considering
the link between myoblast fusion and migration and in an attempt to propose
genetic targets for future research, an investigation was made on the expression of
Spire and Formin genes, involved in actin polymerisation and intracellular
trafficking, in myoblasts undergoing differentiation and fusion. The expression of
these genes was revealed in C2C12 myoblasts and it was demonstrated that the
expression levels of two of these genes (Spire1 and Formin1) are altered
following inhibition of myoblast differentiation/fusion by both 10µM Bpv(Hopic)
and serial passaging, suggesting their potential association with these processes.
Further investigations to reveal the function of Spire and Formin genes and their
protein products in skeletal muscle are proposed.
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1CHAPTER 1
21. INTRODUCTION
1.1. OVERVIEW
Skeletal muscle is a remarkable tissue, which is able to adapt to a variety of
stimuli and physiological demands. However, it also responds to different
pathological conditions, associated with loss of muscle mass or muscle wasting,
leading to weakness, loss of functional independence or even death. These
maladaptations can occur as a consequence of ageing, traumatic injuries, muscular
dystrophies, cancer cachexia and other diseases. Finding muscle-specific
treatments for these conditions will help improve the health and lifestyle of
millions of people worldwide and will reduce the increasing health and socio-
economic burden associated with symptoms of muscle loss. Significant research
efforts have been focused on developing treatments for devastating diseases, such
as Duchenne muscular dystrophy (DMD), and clinical trials have been performed,
but with limited success. Further work is needed in all areas of muscle research.
Improving our understanding of the mechanisms and the molecular regulators that
control processes, such as muscle development and regeneration, may provide us
with important tools in our struggle to improve the symptoms associated with
various conditions or diseases affecting skeletal muscle.
1.2. SKELETAL MUSCLE DEVELOPMENT
All skeletal muscles, excluding those of the head, originate from the somites and
are formed in a highly complicated yet coordinated process involving different
classes of progenitor cells (including embryonic myoblasts, foetal myoblasts and
satellite cells) and a variety of internal and external cues. For detailed reviews on
the origin of muscle and muscle progenitor cells and the regulators involved, see:
(Bailey et al., 2001, Buckingham et al., 2003, Cossu and Biressi, 2005, Hawke
and Garry, 2001, Messina and Cossu, 2009).
Somites are masses of mesoderm in the developing vertebrate embryo,
distributed along the two sides of the neural tube, adjacent to the notochord
(Figure 1.1). Somites develop into distinct cellular compartments that later
become the dermis (dermatome), vertebrae (sclerotome) and skeletal muscle
(myotome).  A somite is divided into the epaxial (which gives rise to the back
musculature) and hypaxial (giving rise to limb, abdominal and intercostal
3musculature) domains (Buckingham et al., 2003, Christ and Ordahl, 1995, Kablar
et al., 1997).
Figure 1.1. A schematic representation of a somite. Somite is separated into
epaxial and hypaxial regions, with its surrounding structures, including the notochord,
neural tube and dorsal aorta, which can provide signals regulating the fate and movement
of precursor cells. Precursor cells originating from the epaxial region of a somite
contribute to the back musculature, while precursor cells from the hypaxial region
migrate to the newly formed limb buds.  Figure is adapted from (Hawke and Garry,
2001).
Progenitor cells, originating in the hypaxial domain of the somite, delaminate
and migrate into the limb bud, where they proliferate and express myogenic
determination factors. It is thought that local factors from neighboring tissues
provide the instructions for the muscle progenitor cells to migrate, proliferate and
initiate the myogenic differentiation program (Buckingham et al., 2003, Hawke
and Garry, 2001). The first muscle fibres, known as primary fibres, form around
embryonic days 11-14 in mouse limbs. Around embryonic days 14-16, initially
smaller in size, secondary fibres form parallel to the primary fibres and
innervation begins (Cossu and Biressi, 2005, Messina and Cossu, 2009, Ontell
and Kozeka, 1984). It is thought that two distinct cell types contribute to primary
(embryonic myoblasts) and secondary fibres (foetal myoblasts). Biressi et al.
show that purified embryonic and foetal myoblasts express different genes,
4revealing that they are intrinsically different cell populations (Biressi et al., 2007),
which is also supported by an observation that they also behave differently in cell
culture (Cossu and Molinaro, 1987).
After secondary fibre formation, basal lamina develops around each fibre and at
this stage satellite cells, playing a central role in postnatal myogenesis and muscle
regeneration, can be morphologically identified, lying between the basal lamina
and the fibre. During peri- and post-natal periods, satellite cells divide at a slow
rate and part of their progeny fuse with adjacent fibres to contribute new nuclei
and thus increase the size of the fibres (Cossu and Biressi, 2005, Messina and
Cossu, 2009). At the end of postnatal growth, satellite cells enter in a quiescent
state, but can later be activated to contribute to muscle regeneration, if muscle
damage occurs (reviewed in (Charge and Rudnicki, 2004)).
The exact origin of satellite cells of the trunk and limbs remains debatable.
Different concepts proposed origins of the satellite cells from the somites, from
preexisting lineages, such as embryonic, foetal myoblasts, or endothelial cell
precursors, or from both somitic and nonsomitic sources (Hawke and Garry, 2001,
De Angelis et al., 1999, Zammit et al., 2006). However, the prevalent concept to
date is that all muscle progenitors, including satellite cells, derive from the
somites (Schienda et al., 2006, Schultz and McCormick, 1994, Gros et al., 2005).
1.3. MOLECULAR REGULATORS OF MUSCLE DEVELOPMENT
The coordination of the events required for morphological development of the
skeletal musculature, is extremely complex, involving a variety of intrinsic and
extrinsic factors. Most of the knowledge of the embryology of myogenesis comes
from experimental manipulations of chick embryos and chick/quail chimeras and
gene knockout studies in mice, which have revealed a great amount of
information on the external and internal cues guiding this process. These studies
have provided a relatively good understanding of the main molecular regulators
driving the development of muscle and are described below.
In the newly formed somites, progenitors respond to signals, such as Wnt
proteins, Sonic hedgehog homolog (SHH) and Bone morphogenic proteins
(BMPs), which are derived from anatomically adjecent structures, such as the
neural tube, notochord, the overlaying ectoderm and the aorta (Cossu et al., 1996,
Hawke and Garry, 2001, Maroto et al., 1997, Miller et al., 1999, Munsterberg and
5Lassar, 1995). Pax-3 gene is important during limb development for the activation
of myogenic regulatory factors (MRFs), such as Myf5 and MyoD (Maroto et al.,
1997, Tajbakhsh et al., 1997). MyoD and myf5 expression is important for muscle
precursor cell determination to a myogenic fate, as shown in double Myf5/MyoD
mutants, where no skeletal muscle forms, as cells in the somite do not locate
correctly to sites of myogenesis and therefore adopt non-myogenic fates
(Rudnicki et al., 1993, Tajbakhsh et al., 1996). It is generally considered that
MyoD and Myf5 play central roles in myogenic fate determination, while
Myogenin, MRF4 and Mef2 are involved in the process of terminal differentiation
of the committed precursor cells into muscle fibres. It is known that cells that
migrate from the somite have not yet activated the myogenic determination genes
of the MyoD family, and they only start expressing these when they reach their
final location, triggered by signalling molecules from the local environment, such
as Wnt and SHH (Buckingham et al., 2003, Cossu and Borello, 1999, Tajbakhsh
et al., 1998, Tajbakhsh and Buckingham, 1994). Before muscle progenitors
upregulate the expression of MyoD and Myf5, in order to form skeletal muscle,
they need to proliferate locally. Fibroblast growth factors (FGF) signalling is
thought to be important for myoblast proliferation (Edom-Vovard et al., 2001,
Prykhozhij and Neumann, 2008) and also migration in the limb (Webb et al.,
1997).
In addition to Pax3, other genes, such as c-Met, msx1 and Lbx, are important for
myogenic precursor cells during development (Bendall et al., 1999, Brohmann et
al., 2000, Gross et al., 2000, Wang and Sassoon, 1995, Yang et al., 1996). c-Met,
a tyrosine kinase receptor for HGF, produced by non-somatic mesodermal cells is
important for both delamination and migration of the precursor cells from the
somites (Dietrich et al., 1999). In mutant mouse embryos, which lack functional
c-Met or HGF, skeletal muscle is absent from the limbs (Bladt et al., 1995,
Schmidt et al., 1995). Lbx1 is a transcription factor, which is also implicated in
the migration of the cells from the somite (Schafer and Braun, 1999). Along with
other factors important for embryonic myogenesis, gene expression of both Lbx1
and c-Met are also shown to be dependent on Pax3 (Epstein et al., 1996,
Mennerich et al., 1998).
As muscle is able to regenerate after damage, it is thought that this process
shares many similarities with embryonic myogenesis on a molecular level, but
differences are also proposed. Zhao and Hoffman have used samples of
6regenerating muscle to demonstrate that embryonic positional signals, such as
Wnt, SHH, and BMP, are not induced in postnatal muscle regeneration (Zhao and
Hoffman, 2004). Others have later shown that Wnt is important for myogenic
progenitor proliferation and differentiation during post-natal myogenesis and
regeneration and that SHH also plays roles in post-natal muscle regeneration
(Brack et al., 2008, Le Grand et al., 2009, Straface et al., 2009). Embryonic
myogenesis and regeneration indeed share similarities in the requirement of
factors involved in muscle proliferation and differentiation, such as FGFR4,
MyoD, Myf5 and Myogenin (Cornelison and Wold, 1997, Grounds et al., 1992,
Zhao and Hoffman, 2004). Fusion and migration mechanisms are also similar: c-
Met and HGF signalling, for example, remain of major importance for satellite
cells activation and migration during adult muscle regeneration (Bischoff, 1997,
Tatsumi et al., 1998, Zhao and Hoffman, 2004). Thus, muscle regeneration and
muscle development share similarities on a molecular level, but further research
will reveal in greater detail the regulators driving both processes. In the following
chapters, the regenerative capacity of satellite cells and their progeny will be
reviewed, along with their potential involvement in proposed therapies for muscle
degenerative diseases, such as DMD.
1.4. POSTNATAL SKELETAL MUSCLE REGENERATION AND
PLASTICITY
Postnatally, adult mammalian skeletal muscle is a relatively stable tissue with
little turnover of nuclei - no more than 1-2% of myonuclei are replaced every
week (Schmalbruch and Lewis, 2000). The constitutive cell type and the
contractile unit of skeletal muscle, the multinucleated myofibre, is terminally
differentiated and incapable of mitotic activity.  Nevertheless, skeletal muscle has
a remarkable ability to adapt to various stimuli and physiological demands, such
as exercise, disuse, denervation, hypoxia, nutritional intervention, genetic
disorders and others (Charge and Rudnicki, 2004, Fluck and Hoppeler, 2003,
Hawke and Garry, 2001). It has the ability of rapid regeneration following injury
(e.g. extensive physical activity, such as resistance training) and is able to increase
(hypertrophy) or decrease (atrophy) in mass. This is possible due to the activity of
a small population of cells resident in adult skeletal muscle, known as satellite
cells, which make possible its regenerative ability, even after repetitive injury.
7This is of major importance, because if skeletal muscle is left unrepaired, it can
lead to loss of muscle mass, locomotive deficiency and ultimately even death.
1.5. SATELLITE CELLS ARE OF MAJOR IMPORTANCE OF MUSCLE
REPAIR
Satellite cells, first described by Mauro in 1961 (Mauro, 1961), and thus
considered as providing the oldest known stem cell niche, are small mononuclear
cells sandwiched between the basement membrane/basal lamina and the
plasmalemma of mature muscle fibres. They are present in all skeletal muscles,
although differently distributed (Gibson and Schultz, 1982). Under normal
physiological conditions, satellite cells are quiescent. They are characterised by
small nucleus with increased amounts of heterochromatin, compared to myofibre
nuclei, reduced nuclear to cytoplasmic ratio and reduced organelle numbers,
which suggests lower transcription activity and supports the notion that they are
normally in a quiescent state (Schultz et al., 1978, Snow, 1983). However, upon
injury, satellite cells are activated and are able to proliferate, self-renew and
differentiate. Their progeny are able to fuse with each other or with preexisting
myofibres, thus promoting regeneration of damaged muscles by contributing new
myonuclei to muscle fibres undergoing repair (reviews: (Kuang et al., 2008,
Zammit, 2008)). Indeed, resistance training studies have demonstrated increased
satellite cell activity and addition of myonuclei to muscles that undergo
hypertrophy (Adams, 2006, Kadi et al., 1999), underpinning their importance not
only to repair processes, but also for hypertrophy. Further evidence for this has
been provided by selective irradiation experiments, causing death or preventing
proliferation of satellite cells, which resulted in reduced muscle regeneration and
hypertrophy (Adams et al., 2002, Alameddine et al., 1989, Li et al., 2006,
Quinlan et al., 1995, Rosenblatt and Parry, 1992). Thus, it is commonly accepted
that satellite cells and their fusion competent progeny of myoblasts, by supplying
myonuclei to growing or regenerating myofibres, are responsible for skeletal
muscle plasticity and ability to repair and grow in mass after e.g. traumas or
exercise (reviews: (Adams, 2006, Charge and Rudnicki, 2004, Hawke and Garry,
2001).
81.6. MUSCLE REGENERATION PHASES
Muscle regeneration following injury, is known to involve two phases -
degenerative and regenerative phases (Carosio et al., 2011, Charge and Rudnicki,
2004, Crisco et al., 1994). The degenerative phase, following muscle injury,
involves the events leading to necrosis of the muscle fibres: disruption of the
myofibre sarcolemma, increased myofibre permeability leading to calcium influx,
activation of calpain proteases that induce the cleavage of myofibrillar and
cytoskeletal proteins, which subsequently leads to proteolysis of the myofibres
(Belcastro et al., 1998, Bodensteiner and Engel, 1978, Charge and Rudnicki,
2004, Kwak et al., 1993, Oberc and Engel, 1977). The disruption of the myofibre
sarcolemma results in increased serum levels of CK, which is normally restricted
to the myofibre cytosol. This increase in serum CK levels is an event usually
observed after mechanical stress or in muscle degenerative diseases (Coulton et
al., 1988, Nicholson et al., 1979, Percy et al., 1979). The damaged tissues are
thought to release factors, which attract circulating inflammatory cells to the
injured site, in order to clear the debris, and the last can also activate the satellite
cells and thus trigger the muscle repair process/regeneration phase (Bischoff,
1986, Fielding et al., 1993, Lescaudron et al., 1999, Tidball, 1995, Tidball, 2005).
Neutrophils are the first inflammatory cells to infiltrate the site of muscle injury,
followed by macrophages (Belcastro et al., 1996, Fielding et al., 1993, Tidball,
1995). Inflammatory cells contribute not only to cell debris removal, but also to
facilitating the regenerating phase of damaged muscle (Arnold et al., 2007,
Lescaudron et al., 1999, Merly et al., 1999, Robertson et al., 1993, St Pierre and
Tidball, 1994). Macrophages are shown to secrete growth factors and cytokines
that can activate satellite cells and induce proliferation of myoblasts (Cantini and
Carraro, 1995, Cantini et al., 1994, Massimino et al., 1997, Merly et al., 1999). It
is demonstrated that neutrophils play a prominent role in muscle regeneration,
possibly due to their ability to clear debris by phagocytosis and to recruit other
inflammatory cells (Teixeira et al., 2003). It has also been demonstrated that
reduction of the inflammatory response by pharmacological depletion of
monocytes/macrophages leads to moderately impaired repair of the injured
muscle (Summan et al., 2006). These studies support the notion that inflammatory
cells act as an integral part of muscle regeneration processes by clearing cellular
9debris and also by providing mediators necessary for the complete regeneration of
injured muscle.
The regenerative phase of post-injured skeletal muscle is mediated through the
activity of the satellite cells residing within the muscle tissue (Figure 1.2). The
expansion of myogenic cells provides a source of new myonuclei for regenerating
myofibres and, as previously discussed, numerous experiments have demonstrated
the importance of proliferating myogenic precursors for this process. Under
normal physiological conditions, satellite cells are quiescent, but in response to
secreted factors released in the damaged environment (after injury, exercise or in
pathological conditions and degenerative diseases), they are activated. They
migrate to the site of damage, proliferate to generate a progeny of myoblasts,
which are capable of fusing with damaged myofibres and of differentiating in
order to promote muscle repair (reviewed in (Charge and Rudnicki, 2004, Hawke
and Garry, 2001, Turner and Badylak, 2011)). Satellite cell activation is not
restricted to the damaged site; damage to fibre triggers activation and migration of
satellite cells along the entire length of the fibre, and in rare conditions satellite
cells from adjacent muscles are able to be recruited (Schultz et al., 1985, Schultz
et al., 1986).
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Figure 1.2. The stages of adult skeletal muscle regeneration.
After myofibre damage, resident satellite cells are activated, migrate to the damaged area
and proliferate to generate a progeny of fusion competent myoblasts. Some of the satellite
cells will self-renew and return to quiescent stage to contribute to future regeneration
events. The generated progeny of myoblasts will fuse with each other or add new
myonuclei to the damaged myofibre, thus promoting its repair. Figure is adapted from
(Hawke and Garry, 2001).
It has been suggested that other non-muscle stem cell populations can also
participate in the muscle regeneration process or in maintaining the satellite cell
pool (reviewed in (Otto et al., 2009)), including: neural stem cells (Galli et al.,
2000), bone marrow (Ferrari et al., 1998), mesenchymal stem cells (Young et al.,
2001), adipose tissue stem cells (Di Rocco et al., 2006). However, the level of
their contribution remains elusive and more research is needed in this area. The
contribution of non-muscle stem cell populations and their potential involvement
in muscle regeneration is beyond the scope of this review.
It is thought that quiescent satellite cells do not express genes belonging to the
MRF family (MyoD, Myogenin, MRF4), with the exception of Myf5 (Beauchamp
et al., 2000, Zammit et al., 2004a). Once activated, satellite cells enter the cell
cycle, proliferate as myoblasts and upregulate the expression of MyoD and Myf5
genes, providing the myogenic fate determination required for further
differentiation and muscle repair (Charge and Rudnicki, 2004, Cooper et al.,
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1999, Cornelison et al., 2000, Cornelison and Wold, 1997, Creuzet et al., 1998,
Smith et al., 1994, Yablonka-Reuveni and Rivera, 1994, Zammit, 2008).
Following the proliferation phase, myogenin and MRF4 upregulation will trigger
the differentiation of the myoblasts, followed by permanent exit from the cell
cycle.
It is considered that the temporal balance between pathways, such as Notch and
Wnt, is of major importance in regulating the proliferation and differentiation of
satellite cells. Notch appears to be important for satellite cell proliferation,
blocking differentiation until there are sufficient numbers of progenitor cells for
repair (Conboy and Rando, 2002, Kuang et al., 2007). Wnt is an important
regulator of differentiation, while GSK3b is reported to mediate the cross-talk
between Notch and Wnt pathways to precisely coordinate the events of
proliferation and differentiation (Brack et al., 2008).
Activation of muscle-specific proteins, such as Myosin heavy chain (MHC),
characterise the differentiation phase, which is followed by the fusion of the cells
with the damaged muscle fibre in order to promote its repair (Charge and
Rudnicki, 2004). Myoblasts can also fuse with each other, forming myotubes to
initiate de novo formation of myofibres within the basal lamina of cells that have
been destroyed (Doherty et al., 2005). Fusion alone, is a complex process
involving variety of cytoskeletal and transmembrane proteins and signalling
mechanisms. Cadherins and calpains are some of the proteins shown to have
important functions in the process of myoblast fusion (Dourdin et al., 1999,
Kaufmann et al., 1999).  The regeneration process is finalised after the
remodelling of connective tissue and blood vessels and the functional recovery of
skeletal muscle.
1.7. MARKERS OF SATELLITE CELLS
Since their discovery, the identification of specific satellite cell markers has
facilitated the research in the area of muscle regeneration. These markers include
Pax7, M-cadherin, Myf5, c-Met, CD34, Calveolin-1, Syndecans -3 and -4 (Allen
et al., 1995, Beauchamp et al., 2000, Cornelison et al., 2001, Cornelison and
Wold, 1997, Irintchev et al., 1994, Seale et al., 2000, Volonte et al., 2005). All
satellite cells express Pax7 (an orthologue of Pax3), which is present in both
quiescent and activated states, and its expression is downregulated upon myogenic
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differentiation (Halevy et al., 2004, Seale et al., 2000). Pax3 is expressed only in
quiescent satellite cells in a few muscle groups (Relaix et al., 2006, Tedesco et al.,
2010). Pax 7 is shown to be required for satellite cells survival and maintenance,
demonstrated by the fact that Pax7-null animals show defects in regenerative
myogenesis (Oustanina et al., 2004). Pax7 -/- mice, whose muscles have satellite
cells absence, fail to grow postnatally, show a 50% decrease in body weight and
die within 2 weeks after birth (Mansouri et al., 1996, Seale et al., 2000).
However, Lepper et al., applying Cre/loxP lineage tracing and conditional gene
inactivation, have suggested that Pax7, along with Pax3, may not be required
during adult limb muscle regeneration, even after repetitive injury, which is in
obvious contrast with the essential roles of these genes during embryonic
myogenesis (Lepper et al., 2009). It seems, therefore, that Pax7 may be required
up to the juvenile period when progenitor cells transition into quiescence.
1.8. SELF-RENEWAL OF SATELLITE CELLS
Satellite cells are a heterogeneous population, consisting of stem cells and
committed myogenic progenitors and that not all of them possess stem cell
properties (Kuang et al., 2008, Kuang et al., 2007, Schultz, 1996, Zammit, 2008).
It is suggested that approximately 80% of the satellite cells divide rapidly and
contribute to muscle regeneration, while the other 20% serve as “reserve cells” to
replenish the satellite cell pool. This supports the notion that satellite cells are able
to self-renew - an important characteristic of a stem cell, allowing the
maintenance of the number of cells for future regeneration events (Kuang et al.,
2007, Sacco et al., 2008). As described by Otto et al., in order for the satellite cell
pool to be maintained, a proportion of the satellite cell progeny must either stop
itself from progressing down the myogenic lineage and revert back to quiescent
state, or they must alternatively divide asymmetrically to form both differentiated
and non-differentiated progeny (Otto et al., 2009). There is evidence that both
scenarios may occur in vivo, which means that they are not mutually exclusive
(Kuang et al., 2007, Zammit et al., 2004b). Signalling pathways, such as Notch
and Wnt seem to differentially regulate symmetric and asymmetric division of
satellite cells (Conboy and Rando, 2002, Le Grand et al., 2009).
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1.9. COMMON EXTRACELLULAR FACTORS REGULATING MUSCLE
REGENERATION
After muscle injury, myogenic progenitors and subsequent muscle regeneration
can be regulated by different stimuli from various sources, such as signals
released from injured fibres or from invading inflammatory cells (Bischoff, 1986,
Chen and Quinn, 1992, Merly et al., 1999, Tidball, 2005). Such factors, involved
in the regulation of satellite cell activation, include HGF (Tatsumi et al., 1998),
nitric oxide (NO) (Anderson, 2000, Wozniak and Anderson, 2007) and possibly
FGF (Floss et al., 1997). These and other factors have been shown to exert effects
on muscle regeneration not only by directly influencing myogenic cells, but also
indirectly by influencing other important components/processes, such as
inflammatory cells, angiogenesis, neuron formation and extracellular matrix
secretion. A schematic representation of the complexity of growth factors
influencing satellite cells is presented on Figure 1.3.
14
Figure 1.3. Soluble factors in myogenesis.
Many soluble factors may be released from different tissues or cells that can modulate the
activity of satellite cells and control processes, such as proliferation, migration or
differentiation of both myogenic and non-myogenic cells. The balance of these soluble
factors can ultimately determine the state of the muscle tissue or the regeneration process.
Figure adapted from (Hawke and Garry, 2001).
Below, the effects of some of the most well-studied growth factors on satellite
cells and skeletal muscle adaptation are summarised. A detailed review of the
involvement of different soluble factors during muscle regeneration would be
beyond the scope of this thesis. More detailed information is provided in the
following reviews (Charge and Rudnicki, 2004, Hawke and Garry, 2001,
Husmann et al., 1996, Karalaki et al., 2009).
Members of the FGF family, despite a wide variety of functions, are mostly
known for their mitogenic effects. FGF6 is of particular interest in skeletal muscle
repair, as its expression is muscle specific and is upregulated during muscle
regeneration (Floss et al., 1997, Kastner et al., 2000). Sources of FGF include the
infiltrating macrophages (Tidball, 1995) or the damaged muscle itself, depending
on the degree of injury (Clarke et al., 1993). Four receptors for FGFs have been
identified (FGFR 1-4), all are transmembrane tyrosine kinases, of which FGFR-1
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and FGFR-4 are most prominent in satellite cells. In addition to their proposed
role in regulating satellite cell activation, FGFs have mostly been implicated in
mediating myogenic proliferation and inhibiting differentiation (Allen and
Boxhorn, 1989, Charge and Rudnicki, 2004, Doumit et al., 1993, McFarland et
al., 1993, Rosenthal et al., 1991, Sheehan and Allen, 1999, Yablonka-Reuveni et
al., 1999, Kastner et al., 2000). MAP kinase signalling pathway is important for
the FGF-mediated effect on proliferation (Jones et al., 2001).
Transforming growth factor beta (TGF-β) belongs to a family of growth factors,
consisting of TGF β1, β2 and β3, transducing their signals through the SMAD
family of proteins (Whitman, 1998). Myostatin is also known as a member of this
family. TGF-β is released by platelets and also secreted by muscle cells and is
known to inhibit both proliferation and differentiation of satellite cells, although
the actions of TGF-β often vary depending on which other growth factors are
present (Allen and Boxhorn, 1987, Assoian and Sporn, 1986, Lafyatis et al., 1991,
Lefaucheur and Sebille, 1995, Husmann et al., 1996, McLennan and Koishi,
2002). Like FGF, it is able to stimulate angiogenesis (Roberts et al., 1986) and the
synthesis of extracellular matrix (ECM) proteins (Ignotz and Massague, 1986).
TGF-β exerts indirect functions on muscle regeneration by modulating the
immune response - it is known to be chemotactic and to activate monocytes,
which also induce angiogenesis and secrete growth factors (Husmann et al.,
1996). Other roles of TGFs during muscle regeneration, reviewed in (McLennan
and Koishi, 2002), include motor neuron survival and reduced myoblast fusion.
Insulin growth factors (IGFs) are well known for their proliferation and
differentiation effects, influencing muscle metabolism and stimulating protein
synthesis. IGFs are upregulated in regenerating muscle (Edwall et al., 1989,
Krishan and Dhoot, 1996, Levinovitz et al., 1992) and are well known promoters
of cell survival (mediated by Phosphoinositide 3-kinase (PI3K) pathway),
proliferation and differentiation, influencing myogenic regulatory factors, which
lead to muscle hypertrophy (Adams and McCue, 1998, Allen and Boxhorn, 1989,
Coleman et al., 1995, Florini et al., 1991, Vandenburgh et al., 1991, Stewart and
Rotwein, 1996). Increasing the levels of IGF-I within muscle cells by various in
vivo and in vitro methods leads to increases in muscle mass and sustained or
enhanced hypertrophy (Adams and McCue, 1998, Barton-Davis et al., 1998,
Chakravarthy et al., 2000, Musaro et al., 2001). The effects of IGF-I on muscle
hypertrophy are due to both activation of satellite cell proliferation, allowing more
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myonuclei to fuse to existing myofibres, and to increasing the protein synthesis in
existing myofibres (Bark et al., 1998, Barton-Davis et al., 1998, Musaro et al.,
1999, Musaro and Rosenthal, 1999, Semsarian et al., 1999). IGFs may also be
implicated in promoting muscle reinnervation during muscle repair (Vergani et
al., 1998).
Leukaemia inhibitory factor (LIF) and interleukin-6 (IL-6) are members of the
IL-6 family of cytokines, sharing common receptor component and mediating
their actions through shared signalling pathways (Hibi et al., 1996, Pennica et al.,
1995).  LIF acts as proliferating factor (Bower et al., 1995, Spangenburg and
Booth, 2002) and can be produced by regenerating muscle to increase the rate
and extent of muscle regeneration (Barnard et al., 1994, Kurek et al., 1996b,
White et al., 2001). It is thought that LIF stimulates myoblast proliferation by
JAK2-STAT3 signalling pathways (Spangenburg and Booth, 2002). LIF and IL-6
expression in healthy muscle is low, with their expression increased in injured
muscle, suggesting trauma factor roles (Kurek et al., 1996b). The role of LIF
during muscle regeneration is supported by studies demonstrating that skeletal
muscle regeneration is attenuated after injury in mice with targeted mutation of
LIF, while exogenous administration of LIF improved the regenerative process
(Kurek et al., 1997). In addition, in vivo administration of LIF to the site of injury
in mdx mice results in increased rate of muscle regeneration (Austin et al., 2000,
Kurek et al., 1996a), supporting its beneficial function for muscle repair. IL-6 has
a role in regulating the inflammation process after muscle injury and is implicated
in muscle repair (Gadient and Patterson, 1999, Toumi et al., 2006), in glucose
metabolism and glycogen sparing (Glund et al., 2007, Keller et al., 2003a, Keller
et al., 2003b).
Hepatocyte growth factor (HGF), or scatter factor, is a key factor involved in the
activation of satellite cells after injury, stimulating their proliferation and
inhibiting their differentiation (Allen et al., 1995, Gal-Levi et al., 1998, Miller et
al., 2000, Tatsumi et al., 1998). HGF is able to transduce its downstream signals
via its tyrosine kinase receptor, c-Met, which is broadly expressed in quiescent
satellite cells (Anastasi et al., 1997). HGF transcripts and protein levels are
increased during regeneration and it has been shown to be present in crushed
muscle extract, known for its activating effect on satellite cells (Jennische et al.,
1993, Suzuki et al., 2002, Tatsumi et al., 1998, Tatsumi et al., 2001). HGF is able
to activate quiescent satellite cells by activating the p38-MAPK and PI3K
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signalling pathways (Shi and Garry, 2006) or, alternatively, by down regulating
caveolin-1 expression, leading to up-regulation of the ERK pathway (Volonte et
al., 2005).
An important consideration of all cytokines and growth factors in muscle repair,
is that the functions exerted by these soluble factors, depend on the concentrations
in which they are present and on their interaction with other factors. For example,
HGF and TGF-β both act as chemoattractants for satellite cells at lower
concentrations, but not at high concentrations (Bischoff, 1997). Similarly,
Platelet-derived growth factor (PDGF) at low doses was shown to induce
migration of fibroblasts, while high doses induced proliferation (De Donatis et al.,
2008). In this way, cells are able to respond differently to an increasing gradient
of stimulus. Interaction of different secreted factors with each other must also be
considered. For example, low doses of IGF-I, co-incubated with non-apoptotic
doses of Tumor necrosis factor-alpha (TNF-α), lead to myoblast cell death not
exerted by the respective concentrations of these two factors on their own (Saini
et al., 2008).  Therefore, although we have a good idea of how different soluble
factors can influence myogenic precursors in isolation and at specific doses, a
better understanding is required on how these factors may interact with each other
and what intracellular pathways and regulators would be differentially affected.
1.10. SKELETAL MUSCLE AND AGEING
Aged skeletal muscle is characterised with a decline in functional properties,
including power, strength and endurance, partly due to the overall reduction in
size of the muscles and to the switch in fibre type with age fibres (reviewed in
(Brack and Rando, 2008)). The progressive and generalised loss of skeletal
muscle mass and strength is known as sarcopenia, a term commonly used to
describe age-related changes that occur within skeletal muscle (Cruz-Jentoft et al.,
2010, Doherty, 2003). Both intrinsic and extrinsic factors have been investigated
and shown to be altered in aged muscle and a decrease in the number of satellite
cells has also been reported. In mouse models, at birth satellite cells contribute to
approx. 30% (neonatal) of the sublaminar muscle nuclei, but decrease to ~ 2-4%
in adult animals (Charge and Rudnicki, 2004, Hawke and Garry, 2001, Snow,
1977). The reduction of satellite cell number has long been considered as one of
the reasons for the age related muscle decline in its capacity to regenerate (Gibson
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and Schultz, 1983).  However, studies have been divergent, showing either a
significant decline in the number of satellite cells in aged muscle, or little change
or even increased numbers in aged compared to young muscles (which could also
be explained by the differences in species, ages, muscle types compared and
experimental procedures used for counting) (Brack and Rando, 2008). Brack and
Rando suggested that although the reduced number of satellite cells in very old
individuals can indeed contribute to the decline in regenerative potential, this
decline with age is more severe than can be accounted for on the basis of even the
largest estimates of decline in satellite cells number.  Therefore, the functionality,
not only the number, of muscle progenitors with age may be impaired.
Previous research has suggested that the proliferative potential of isolated
satellite cells is reduced with age when they are passaged in culture conditions,
coinciding with telomere shortening, and thus replicative senescence of satellite
cells with ageing (Decary et al., 1997, Schultz and Lipton, 1982, Webster and
Blau, 1990). However, it has also been suggested that telomerase activity is
retained in old muscle and it is only the myoblast progeny, when induced to
differentiate that show deterioration of telomerase activity (O'Connor et al.,
2009). Other intrinsic factors have been proposed to play a role in ageing of
skeletal muscle. Reports have revealed that expression levels of regulators of
muscle differentiation, such as S100B and RAGE, are altered in old vs. young
human satellite cells (Beccafico et al., 2010). Using a C2C12 in vitro model of
multiple population doublings, which retains telomerase activity, Sharples et al.,
in our laboratories, reported that myoblasts subjected to multiple divisions
displayed intrinsic differences in their growth and differentiation potential, as
compared to low passage of cells, including altered IGF-I, myogenin, IGFBP-5
and IGFBP-2 expression and changes in the levels of Akt and c-Jun N-terminal
kinases (JNK)1/2 phosphorylation (Sharples et al., 2011). Importantly, reduced
expression of myogenic regulatory factors, such as myoD and myogenin, coincide
with reduced differentiation of senescent myoblasts (Bigot et al., 2008). These
data strongly suggest that intrinsic changes may play a major role in skeletal
muscle ageing and sarcopenia.
Changes in the systemic environment are also associated with sarcopenia. It is
known that old muscle is able to regenerate when transplanted in young animal,
while regeneration of young muscle transplanted in old animal is impaired
(Carlson and Faulkner, 1989), suggesting that the host environment is also of
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major importance in muscle functionality and regenerative potential (Brack and
Rando, 2007). Furthermore, parabiotic experiments, which unite the circulatory
system of two animals, demonstrated rejuvenation of aged progenitor cells (both
in vivo and in vitro) by exposure to a young systemic environment and vice versa
– with a decline in functionality of young satellite cells exposed to an older
systemic environment (Conboy et al., 2005).
How can the extrinsic environment be altered with age, so that it affects the
muscle regeneration capacity? It is known that the inflammatory response is very
important for muscle regeneration (Tidball, 2005). Possible explanation for the
effect of the old systemic environment to muscle regeneration is the reduced rates
of phagocytic removal of muscle debris in old animals, coinciding with slow
muscle regeneration (Grounds, 1987, Zacks and Sheff, 1982). Higher levels of pro
inflammatory cytokines, such as IL-6 and TNF-α, are also associated with lower
muscle mass and strength in older men and women (Visser et al., 2002). A decline
in the Notch signalling pathway with age is another explanation (Conboy et al.,
2005). Notch is a major pathway regulating the activation and expansion of
satellite cells during embryogenesis (Vasyutina et al., 2007) and in the adult
(Conboy and Rando, 2002); furthermore, forced activation of Notch signalling in
injured muscle of aged mice restores regenerative potential to this tissue (Conboy
et al., 2003). On the other hand, Wnt signalling has been shown to be increased in
aged muscle and in myogenic progenitors exposed to aged serum, potentially the
cause of the increase in tissue fibrosis in aged muscle (Brack et al., 2007).  IGF
signalling is also altered in old systemic environment. As previously discussed,
IGF-I is important for muscle regeneration (Musaro and Rosenthal, 2006,
Scicchitano et al., 2009). It stimulates myogenic differentiation and proliferation
and muscle hypertrophy (Engert et al., 1996, Musaro et al., 2001, Musaro et al.,
1999, Musaro and Rosenthal, 1999, Musaro and Rosenthal, 2006, Rosenthal and
Cheng, 1995). It is reported that IGF-I declines during postnatal life (Velasco et
al., 1998), which is possibly linked to muscle atrophy with age and a decline in
regeneration capacity. Supporting the important role of IGF signalling in ageing
muscles, studies in which transgenic mice overexpressing the local form of IGF-I
demonstrated sustained muscle mass and efficient regenerative mechanisms in
senescent muscles, compared with wildtype animals (Musaro et al., 2001).
Therefore, changes in both the systemic environment and in the muscle progenitor
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cells themselves are possibly responsible for the decline in muscle mass and
strength with age and warrant further investigation.
1.11. PROPOSED THERAPIES FOR MUSCULAR DYSTROPHIES OR
TRAUMAS
Muscular dystrophies are hereditary muscle diseases, characterised by chronic
skeletal muscle weakness and degeneration. The most severe case, Duchenne
Muscular Dystrophy, is a genetic X-linked recessive disease that affects
approximately one in 3,500 male births. It is caused by mutations in the
dystrophin gene, including insertions or deletions, causing frameshift errors,
which lead to the dystrophin protein being completely or partially lost (Hoffman
et al., 1988, Hoffman and Dressman, 2001, Muntoni et al., 2003). Dystrophin is
the largest gene in the human genome (2.4Mb of length with 79 exons), it encodes
a cytoplasmic protein, which participates in connecting the cytoskeleton of a
muscle cell to the surrounding ECM through the cell membrane. It is important
for keeping the integrity of a muscle cell, as it protects muscle fibres from injury
when they contract and relax (Blake et al., 2002, Petrof, 2002). When dystrophin
is missing, as in DMD patients, this leads to vulnerability and damage of muscle
fibres during contraction, resulting in constant damage-repair cycles. As a
consequence, muscle damage prevails and patient mobility is highly affected,
resulting in wheelchair dependency by the age of 10-12 years and in most cases
death due to respiratory failure between the age of 17 and 30 (reviews: (Cossu and
Sampaolesi, 2007, Emery, 2002, Nowak and Davies, 2004, Quattrocelli et al.,
2010)).
Depletion of the satellite cell pool is observed in muscular dystrophy patients due
to continuous activation and repair of damaged fibres (Jejurikar and Kuzon, 2003,
Webster and Blau, 1990). Satellite cells, triggering the muscle regeneration
process, are unable to comply with the rate of damage and cannot ultimately
compensate for the devastating degeneration that is constantly taking place in the
muscle tissue. Furthermore, due to the continuous damage-repair cycles, it has
been shown that satellite cells undergo telomere erosion, or senescence, which
may further contribute to reducing the regeneration response after muscle damage
and worsening the condition of the patients (Lund et al., 2007). Fibrosis, or scar
tissue formation, is a common feature in the muscles of DMD patients, which
causes muscle dysfunction and contributes to the severity of the DMD phenotype
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(Zhou and Lu, 2010). To date, the only clinical treatments for muscular dystrophy
are steroid administration and assisted ventilation to facilitate breathing when
ventilator muscles are affected. They result in amelioration of the symptoms, but
either show side effects or are only able to provide slightly longer life without
providing a cure to the disease (Cossu and Sampaolesi, 2004, Daftary et al.,
2007). Currently, there is no cure for DMD. There is, however, extensive research
focused on finding a therapy to alleviate the symptoms associated with this
devastating disease. Different approaches have been tested in animal models, as
described below, some of culminating in promising results, but human clinical
trials have failed to produce satisfactory improvement in the mobility and muscle
strength of the patients (reviewed in: (Aartsma-Rus et al., 2010, Otto et al., 2009,
Palmieri and Tremblay, 2010, Palmieri et al., 2010, Quattrocelli et al., 2010,
Smythe et al., 2000, Smythe et al., 2001, Sugita and Takeda, 2010)).
The two main approaches proposed for treatment of DMD are endogenous
activation and exogenous delivery of muscle cells. The first strategy aims at
activating, or reinforcing, the endogenous pool of cells by different molecules,
including IGF-I, in order to induce muscle hypertrophy to override the loss in
muscle mass (Abmayr et al., 2005, Cassano et al., 2008, Pelosi et al., 2007). The
second, more promising approach relies on delivering exogenous factors (gene or
cell therapies) to the patient, to improve muscle regeneration.
The gene therapies, including the exon skipping approach or forced read-through
of premature stop codons, target the dystrophin gene product (Benchaouir et al.,
2007, Lu et al., 2003). Approximately 15% of DMD patients carry a mutation
within the dystrophin gene, which encodes a premature stop codon, thus causing
production of an incomplete dystrophin protein (Aartsma-Rus et al., 2006,
Aartsma-Rus et al., 2010). A forced read-through therapy, through the
introduction of specific drugs, aims at forcing cells to ignore the preferentially
mutated stop codon. Alternatively, and due to mutations of the dystrophin gene,
the open reading frame may be disrupted, leading to prematurely truncated,
nonfunctional dystrophin protein (Monaco et al., 1988). The exon skipping
approach would permit, by introducing antisense oligonucleotides, the splicing of
an mRNA molecule, so that an exon is skipped and the open reading frame is
restored, ultimately enabling the improved expression of dystrophin. This method
would still lead to the production of an incomplete dystrophin protein, however it
would be partially functional, which would therefore decrease the severity of the
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disease (Aartsma-Rus et al., 2010, Spitali et al., 2009, van Deutekom et al.,
2001). The gene therapies, however, are not a solution for patients in advanced
stage of the disease, where muscle tissue is already largely infiltrated by fibrotic
tissue. Additional disadvantages, requiring solution or additional research, are the
need for periodic redelivery, potential side effects, host immune responses and the
need for optimising efficiencies (Aartsma-Rus et al., 2010, Adams et al., 2007,
Fletcher et al., 2007). Adeno-associated virus (AAV) is emerging as a vector
choice for muscle gene therapy applications (Athanasopoulos et al., 2004, Sugita
and Takeda, 2010, Yang et al., 2011), but further research and clinical trials are
needed to understand whether effective clinical treatments may be  applied.
Given the ongoing complexities of the gene therapies, cell therapy is being
investigated as a promising alternative approach to treat muscular dystrophies,
which has attracted a lot of attention. Cell therapy relies on the delivery of
exogenous cells (by systemic or local injections), which would fuse with damaged
dystrophic muscles, repair them and by contributing their myonuclei, containing
the normal variant of the gene, at least partially restore the normal musculature
and reduce the futile repair cycles culminating in muscle loss. Different types of
cells with myogenic potential are considered as potential candidates for
transplantation, including embryonic stem cells, induced pluripotent stem cells
(iPSs), bone marrow derived stem cells (BMSCs), circulating progenitors and
myogenic cells (Satellite cells and myoblasts) (Bhagavati and Xu, 2005, Gussoni
et al., 2002, Nakagawa et al., 2008, Peault et al., 2007). Extensive research is still
ongoing to verify which would be the most appropriate cell type to use for cell
therapy.
A large proportion of the research focused on DMD has been based on using
transgenic animals, such as the mdx mouse, carrying the X-linked mutation of the
dystrophin gene, which mimics the DMD genotype in humans. Transplantation of
healthy myoblasts to this model was first reported as early as in 1989, as an
attempt to restore dystrophin expression in immunodeficient mdx mice (Partridge
et al., 1989).  In mdx mice, myoblast transfer therapy shows beneficial effects -
protecting muscles from damage by exercise (Brussee et al., 1998). Myoblast
transfer therapy is also promising, because some of the transplanted myoblasts
survive as muscle precursor cells in the tissue and are subsequently able to repair
damaged muscle fibres (Morgan et al., 1993, Yao and Kurachi, 1993). Although
significant improvement of muscle regeneration and functionality was achieved
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after cell therapy in mdx mice, clinical trials in humans were far less successful.
Clinical trials in the early 90s produced limited positive results (Mendell et al.,
1995, Tremblay et al., 1993). Three main problems were associated with the low
survival of transplanted cells, limited spreading and migration of transplanted
cells and immune rejection (Fan et al., 1996, Gussoni et al., 1997, Moens et al.,
1996, Skuk et al., 2004, Smythe et al., 2001).
It is known that after severe traumatic injury, the natural repair mechanisms are
not sufficient to return the muscle in its pre-damaged state, which leads to
formation of scar tissue and diminished functionality (Menetrey et al., 1999,
Turner and Badylak, 2011). Therapeutic strategies to improve the regenerative
capacity of skeletal muscle tissue following traumas are required. Tissue
engineering and in vitro tissue synthesis are potential therapies, however,  this
technology is still not sufficiently advanced and other problems, such as
biocompatibility and issues of functional integration of this tissue in the human
body remain to be resolved (Koning et al., 2009, Turner and Badylak, 2011). Cell
therapies, such as myoblast transplantation, are not only proposed for muscular
dystrophies, but can also potentially be applied in treating loss of muscle tissue
after traumas (review: (Turner and Badylak, 2011)). Therefore, an ability to
enhance the process of muscle regeneration would highly depend on improving
our understanding of the factors and regulators that control it.
1.12. CELL MIGRATION
As suggested above, part of the problem associated with cell therapy for DMD
may be enabling the cells to migrate to and home in the DMD muscle. Similarly,
cell migration is an essential process in the development and maintenance of
multicellular organisms. Important events, such as tissue development, immune
responses and wound healing all depend on the migration capacity of various cell
types. Cell migration is a highly complicated process, still not completely
understood, which can depend on various extracellular cues and requires the
synchronous activity of many intracellular factors (Lauffenburger and Horwitz,
1996, Raftopoulou and Hall, 2004, Ridley, 2001, Welf and Haugh, 2011). Cell
migration can be affected by soluble extracellular factors, acting across extensive
distances, or by the extracellular matrix. These extracellular factors elicit different
intracellular responses in a cell, which can include the activation or inhibition of
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signal transduction pathways and target molecules, gene transcription,
reorganization of the cytoskeleton, changes in the distribution or trafficking of
cell surface receptors. Each of these intracellular processes is highly complicated,
involving many molecules, and it is both fascinating and extremely challenging to
comprehend and assemble the entire picture of how all of these events are
coordinated and synchronized in order to drive cell migration. Many of the studies
investigating these processes and their regulators have been conducted in
Dyctiostelium, fibroblasts or neutrophils and although the main intracellular
mechanisms driving cell migration are thought to be conserved and shared among
eukaryotes, it needs to be considered that the process of cell migration has not
been investigated in detail in muscle progenitor cells and that some differences
may exist between different cell types.
As discussed above, muscle regeneration requires satellite cells to migrate to the
site of injury in order to participate in the process of muscle repair. In order to
fuse into multinucleated myotubes, myoblasts must align with each other and
migration is a requirement for this process to occur. Limited cell spreading and
migration is one of the reported problems related to proposed cell therapies of
DMD, although recent articles question this concept (Lafreniere et al., 2009, Skuk
et al., 2011). Therefore, more research is needed to elucidate the mechanism of
muscle precursor cells migration, both in vitro and in vivo. By revealing which
extra- and intracellular factors are regulating the migration of muscle progenitor
cells, we may better understand the processes of myogenesis, regeneration and
ultimately apply this knowledge for therapies of hereditary muscle diseases,
improving muscle regeneration and muscle function.
1.13. “STEPS” OF CELL MIGRATION
In order to migrate, the cell must establish stable adhesions with the substratum,
preferentially formed at the leading edge. Contractile forces must then be
generated for the cell to propel forward, while the adhesion complexes remain
fixed on the substratum and eventually reach the rear of the cell (Ananthakrishnan
and Ehrlicher, 2007, Lauffenburger and Horwitz, 1996, Schwartz and Horwitz,
2006). The process of cell migration may be separated in the following steps:
polarisation of the cell membrane, formation of cell protrusions at the leading
edge and stable contacts between the cell and the extracellular substrate,
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contraction of the cytoskeleton leading to translocation of the cell and release of
the cell-substrate contacts at the rear of the cell (Lauffenburger and Horwitz,
1996). These events must be highly coordinated and are regulated by a variety of
intracellular signalling molecules, including mitogen-activated protein kinase
(MAPK) cascades, lipid kinases, small GTPases, phospholipases,
Serine/Threonine and Tyrosine kinases, cytoskeleton modifying proteins and
scaffold proteins (Raftopoulou and Hall, 2004).
Polarisation of the cell, or establishing a front and rear end, is an important
requirement for persistent migration. It is coupled with the extension of
membrane processes at the cell front, including lamellipodia and filopodia (Nobes
and Hall, 1999). Lamellipodia are broad, flat, sheet-like structures, serving as a
site for newly formed adhesive contacts, thus enabling the cell to propel forward
and move. Filopodia are thin, needle-like projections, considered to have cell
substrate exploratory functions and involved in determining the direction of
movement (Mejillano et al., 2004, Parsons et al., 2010). Upon activation by
migratory stimuli, both structures are coupled with local actin polymerization and
both contain actin and actin-associated proteins.
Formation of attachment sites, or focal adhesions, is an important step for the
movement of adherent cell types. Focal adhesions establish the link of the cell to
the ECM via adhesion receptors, such as integrins. Upon ligand binding, integrins
cluster and recruit actin filaments and signalling proteins to their cytoplasmic
domain, thus forming focal adhesions. Integrins, in addition to being cell surface
receptors that interact with the ECM, are also able to mediate various intracellular
signals (Brakebusch and Fassler, 2003, Hynes, 2002). Ligated integrins can serve
to mediate signals to PI3K and Ras homolog gene family (Rho) of small GTPases,
which can regulate cytoskeletal dynamics and myosin-dependent contraction
(Berrier and Yamada, 2007). Thus, integrins are important for processes, such as
cell adhesion, migration and maintenance of cell polarity. Formation of adhesive
complexes is coupled by the phosphorylation of a group of cytoskeletal associated
proteins upon cell adhesion to a substratum, including focal adhesion kinase
(FAK), paxillin and tensin (Lo et al., 1994, Schaller and Parsons, 1994, Turner,
1994). Stress fibres also play a role in cell adhesion. They are contractile
cytoskeletal structures, which are anchored at focal adhesions, linking the cell to
the extracellular matrix and are considered as major mediators of cell contraction
(Kaunas et al., 2005, Pellegrin and Mellor, 2007).
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Cell body contraction, as discussed in Ridley (2001), is dependent on
actinomyosin contractility and can be regulated by Rho (Ridley, 2001). Stress
fibres and their associated focal adhesions are driving forces for cell contraction
and the importance of their regulation by Rho may differ according to the cell
type and whether the cells are adherent or not.  Contractility is also important for
the disassembly of focal adhesions (Lauffenburger and Horwitz, 1996, Schwartz
and Horwitz, 2006), suggesting that cell migration requires synchronization
between finely coordinated events, rather than just a sequence of independent
steps.
Rear release, or “tail” detachment, is an important factor for a cell to move
forward and it can often be a limiting step of cell migration (Cox and
Huttenlocher, 1998, Palecek et al., 1998, Ridley, 2001). During rear release, a
large proportion of the integrins are left on the substratum as the cell detaches and
moves forward (Regen and Horwitz, 1992). However, integrins remaining on the
cell surface are also able to be transported to the cell anterior to serve for new
adhesion formation. In slowly moving cells, such as myoblasts, “tail” detachment
appears to depend on the action of the protease calpain, which degrades focal
adhesion components at the rear of cells (Glading et al., 2000, Ridley, 2001).
Integrin recycling may also be a key regulator of cell adhesions, integrin turnover
and thus cell migration (Caswell and Norman, 2006, Jones et al., 2006, Pellinen
and Ivaska, 2006). A schematic representation of the steps of cell migration is
presented in Figure 1.4.
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Figure 1.4. A model of the steps required for cell migration to occur.
In order to migrate, a cell needs to extend membrane protrusions, such as filopodia (not
shown) or lamellipodia, allowing the cell to pull forward. The cell then needs to contract,
in order to propel forward, and at the same time release its “tail”. All these steps are
mediated by members of the Rho family of small GTPases. Model proposed by (Ridley,
2001).
In recent years there has been increasing attention on the importance of the
endo/exocytic cycle of integrins as an important regulator of cell motility
(Caswell and Norman, 2006, Jones et al., 2006, Pellinen and Ivaska, 2006).
Different kinases, modulators of the actin cytoskeleton and members of the Rab
small GTPases and Arf GTPase families have been implicated as regulators of
this process. In particular, the Rabip4 protein, an effector of Rab4, might be an
interesting candidate for further investigation in skeletal muscle myoblasts
(Fouraux et al., 2004, Vukmirica et al., 2006). Studies in NIH-3T3 fibroblasts
have demonstrated that overexpression of Rabip4, involved in regulation of av-
integrins traffic, leads to an increased motility of cells, while Rabip4 knock-down
resulted in reduced cell motility (Vukmirica et al., 2006). To our knowledge,
studies of integrin recycling and how it affects migration of myogenic precursor
cells are still lacking. Altering the rates of integrin recycling, therefore, might be
an approach to modify the motility of myogenic precursor cells and possibly
improve the spreading of donor myoblasts in dystrophic muscles.
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1.14. RHO GTPASES
The Rho family of GTPases, and in particular Rho, Cell division control protein
42 homolog (cdc42) and Ras-related C3 botulinum toxin substrate (Rac), seem to
play a pivotal role in regulating signal transduction pathways that link cell surface
receptors to a variety of intracellular responses important for cell migration (for
detailed reviews: (Raftopoulou and Hall, 2004, Ridley, 2001). They are best
known as regulators of the actin cytoskeleton, but also cell polarity, gene
expression, microtubule dynamics and vesicular trafficking. The Rho family of
GTPases act as molecular switches, cycling between active GTP-bound and
inactive GDP-bound states (Moon and Zheng, 2003, Schmidt and Hall, 2002,
Zheng, 2001). When activated, they can interact with downstream cellular target
proteins (effectors), in order to elicit different intracellular responses (Bishop and
Hall, 2000).
Rac and Cdc42 regulate the polymerization of actin to form lamellipodial and
filopodial protrusions, involved in propelling the cell forward and defining the
direction of movement. Cdc42 and Rac are required at the front of migrating cells
(Nobes and Hall, 1995, Raftopoulou and Hall, 2004). Rac is important for
regulation of actin polymerization and formation of membrane protrusions, such
as lamellipodia. In migrating fibroblasts, Rac is concentrated at the leading edge
of the cell (Kraynov et al., 2000).  Cdc42 is required for filopodia formation,
involved in determining the direction of cell migration and cell polarity, but
doesn’t seem to be important for the ability of a cell to move (Ridley, 2001, Sepp
and Auld, 2003). Rac and Cdc42 regulation of protrusion formation is established
via the activation of the Ser/Thr kinase PAK. PAKs can act on different substrates
implicated in actin cytoskeleton rearrangement (Szczepanowska, 2009). PAKs
can activate LIM kinase (LIMK), which inhibits cofilin, a protein involved in
actin filament disassembly, and thus allows the accumulation of polymerized actin
at the leading edge of cells (Arber et al., 1998, Cau and Hall, 2005, Edwards et
al., 1999, Obermeier et al., 1998, Stanyon and Bernard, 1999, Szczepanowska,
2009). Members of the WASp/SCAR/WAVE family of scaffold proteins
(Wiskott-Aldrich syndrome protein = WASp; Suppressor of cAMP receptor =
SCAR; WASP-family verpolin homologous = WAVE) are also key regulators of
actin polymerization through stimulation of the actin-related protein 2/3 (Arp2/3)
complex, which is able to initiate the actin polymerization process (Takenawa and
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Miki, 2001, Weaver et al., 2003). Cdc42 can activate WASp and neuronal
Wiskott-Aldrich Syndrome protein (N-WASp), while Rac interacts with the
Scar/WAVE family (Eden et al., 2002, Rohatgi et al., 1999, Rohatgi et al., 2000,
Rohatgi et al., 2001). A schematic representation of these events is presented on
Figure 1.5.
Figure 1.5. Regulation of actin polymerization by Rac and Cdc42. Figure
adapted from (Raftopoulou and Hall, 2004).
Rho, along with other signals, such as Src tyrosine kinase, FAK and PAK, is
thought to be important for focal adhesion disassembly (Ridley, 2001). It is also
involved in the assembly of actin:myosin filaments, which allows the contraction
of the cell and propelling of its cell body forward. A target of Rho is the Ser/Thr
kinase p160-Rho-associated protein kinase (p160ROCK) and together they are
also important in rear cell detachment in leukocytes and macrophages (Alblas et
al., 2001, Nobes and Hall, 1999, Worthylake and Burridge, 2003). Similar to
PAK, in its active state p160ROCK activates LIMK, which inactivates cofilin,
leading to stabilization of actin filaments within actin:myosin filament bundles
(Maekawa et al., 1999, Sumi et al., 2001). p160ROCK, via phosphorylation of the
myosin binding subunit (MBS) of myosin light chain phosphatase, leads to
increase myosin2 activity, which cross-links actin filaments to generate
contractile forces (Amano et al., 2000, Hall, 2005, Kawano et al., 1999,
Totsukawa et al., 2000). The Rho-mammalian diaphanous (mDia) pathway is also
linked to regulating focal adhesion turnover and actin stress fibres (Satoh and
Tominaga, 2001, Yamana et al., 2006), both important respectively for tail
retraction and for cell contraction. A schematic representation of these events is
presented on Figure 1.6. Together these studies illustrate the complexities of cell
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migration and exemplify that malfunctions in any one of these processes could
impact on the migratory capacity of cells.
Figure 1.6. Regulation of actin cytoskeleton structures by by Rho. Figure
adapted from (Raftopoulou and Hall, 2004).
1.15. PTEN/PI3K PATHWAY INVOLVEMENT IN CELL MIGRATION
The PTEN/PI3K/AKT pathway is an important pathway regulating the signalling
of multiple biological processes, such as cell survival, proliferation and migration
(Blanco-Aparicio et al., 2007, Dahia, 2000, Leslie et al., 2005). PI3Ks are able to
phosphorylate the inositol ring of phosphatidylinositol 4,5 bisphosphate (PIP2)
converting it into phosphatidylinositol 3,4,5 trisphosphate (PIP3), which binds
Akt kinase/PKB, leading to its translocation to the plasma membrane where it is
activated by PDK1 (Figure 1.7) (Blanco-Aparicio et al., 2007, Engelman et al.,
2006, Kandel and Hay, 1999). Akt activation is important for processes, such as
glucose metabolism, cell proliferation, survival, transcription and cell migration
(Zhao, 2007). Phosphatase and tensin homologue deleted on chromosome 10
(PTEN), a dual protein/lipid phosphatase, antagonizes PI3K via the
dephosphorylation of PIP3, converting it back to PIP2, leading to negative
regulation of Akt and other downstream targets (Cully et al., 2006, Yamada and
Araki, 2001).  On the contrary, loss of PTEN function results in accumulation of
PIP3 and activation of Akt, thus perpetuating the effect of PI3K activation (Figure
-1.7).
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Figure 1.7. Opposing actions of PI3K and PTEN on phospholipids. Once
activated by the binding of a ligand to a membrane receptor, PI3K phosphorylates PIP2 to
PIP3, leading to PDK1 translocation to the plasma membrane, which then is able to
phosphorylate and activate Akt. PI3K/Akt pathway is involved in many processes, such
as cell survival, proliferation, migration. PTEN acts as a negative regulator of PI3K and
Akt by dephosphorylating PIP3 to PIP2. Figure adapted from (Planchon et al., 2008).
Adding to the migration story above, PI 3-kinases and PIP3 are known as
regulators of cell polarity and migration (Stephens et al., 2002). PI3K and PIP3 co
localise at the centres of actin polymerization at the leading edge of migrating
cells (Funamoto et al., 2002, Merlot and Firtel, 2003). Localisation of PI3-kinase
at the front of migrating cells, has been shown to be coupled with a decreased
distribution of its antagonist PTEN at the front, but increased abundance at the
rear (Funamoto et al., 2002, Iijima and Devreotes, 2002). Spatially regulated
PI3K/PTEN signalling is thus believed to underlie cell polarisation and directional
cell migration (Comer and Parent, 2007, Iijima and Devreotes, 2002). Rac
activation is also dependent on PI3K activity, and inhibitors of PI3K are shown to
block Rac activation (Royal et al., 2000, Sander et al., 1998). The production of
PIP3 leads to an increase in active Rac in many cell types and overexpression of
constitutively activated PI 3-kinase in fibroblasts generates extensive lamellipodia
and membrane ruffling through Rac activation (Reif et al., 1996). PI3K and Rac
are able to directly interact with each other and Rac activation also stimulates
PI3K, leading to the production of PIP3, thus a positive feedback loop exists,
which has the potential to influence migration (Benard et al., 1999, Bokoch et al.,
1996, Genot et al., 2000, Hawkins et al., 1995, Servant et al., 2000).
32
As described by Zhao (2007), PTEN has two functional domains - the C2
domain and a phosphatase domain (Zhao, 2007). The C2 domain binds membrane
lipids, while the phosphatase domain carries the enzymatic function of the protein
by catalysing the dephosphorylation of PIP3 to PIP2. Manipulation of cell
migration by PTEN can be regulated not only by its effect on PIPs, but also via its
protein phosphatase activity (Dey et al., 2008, Leslie et al., 2007, Maier et al.,
1999) and independently through its C2 domain (Okumura et al., 2005,
Raftopoulou et al., 2004). However, the protein phosphatase function of PTEN is
important for its function. Dey et al. demonstrated that in glioma cells PTEN is
able to control integrin-directed migration in a lipid phosphatase, PI3K/AKT
independent manner (Dey et al., 2008). PTEN has been shown to dephosphorylate
FAK and to inhibit the integrin-mediated cell spreading and migration on
fibronectin (Gu et al., 1998, Gu et al., 1999). It is also able to inhibit ERK/MAPK
pathway, after both integrin and growth factor activation, at the the level of Shc,
reducing its phosphorylation and interaction with downstream targets, such as
Grb2. PTEN seems to control two migratory pathways: 1) directionally persistent
migration induced by FAK/p130-Cas, characterised by extensive organization of
actin microfilaments and focal adhesions and 2) ShC/MEK1 - random type of
motility with less actin cytoskeletal and focal adhesion organization (Figure 1.8).
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Figure 1.8. PTEN exerts effects on FAK and MAPK signalling to regulate cell
migration. As described by Gu et al. (Gu et al., 1998, Gu et al., 1999), integrins (via
FAK and Shc/MAPK/ERK) and Growth factors (via Shc/MAPK/ERK) are both involved
in regulation of cell movement. PTEN can dephosphorylate, and thus inhibit, both FAK
and Shc and in this way regulate two distinct pathways involved in either persistent or
random cell movement.
In mammalian cells genetically lacking PTEN, migration is increased compared
to cells normally expressing the phosphatase (Liliental et al., 2000, Suzuki et al.,
2003).  Liliental et al. demonstrated that PTEN deficiency resulted in increased
fibroblast motility by Rac1 and Cdc42 dependent mechanisms (Liliental et al.,
2000). PTEN inhibition by pharmacological agents, such as bisperoxovanadium
(BpV) compounds, has been shown to result in enhancement of epithelial cell
migration, as shown by a wound healing model (Lai et al., 2007). Inhibition of
PTEN by Bpv compounds has been shown to culminate in increased levels of
phospho-Akt (Lai et al., 2007, Schmid et al., 2004). Indeed Castaldi et al. have
demonstrated that high concentrations (10µM) of BpV are able to block myoblast
differentiation and to induce myogenic cells to acquire gene expression profile of
circulating progenitors, while maintaining their myogenic potential (Castaldi et
al., 2007). BpV treated C2C12 cells, delivered by intra-arterial injection in
dystrophic mice, were able to reach muscle tissue and contribute to muscle repair
with higher efficiency compared to untreated cells. However, the effect of PTEN
inhibition or BpV compounds on myoblast migration itself was not studied.
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1.16. MAPKS IN CELL MIGRATION
In addition to the pathways described above, Mitogen-activated protein (MAP)
kinases, which are serine/threonine specific protein kinases that respond to a
variety of extracellular stimuli, also regulate many cellular processes (Pearson et
al., 2001). MAP kinases form the MAPK cascade, consisting of three enzyme -
MAP kinase (MAPK), MAPK kinase kinase (MAPKK) and MAPK kinase kinase
kinase (MAPKKK). MAPKs, including JNK, p38 and ERK, control a vast array
of physiological processes (Johnson and Lapadat, 2002), including cell migration
(reviewed in (Huang et al., 2004b)).
JNK has been shown to be involved in regulating cell migration, with its
inhibition leading to reduced cell migration. It has been shown to regulate said
migration through modulating the phosphorylation of paxillin and the subsequent
formation of focal adhesions (Huang et al., 2008, Kimura et al., 2008, Wei et al.,
2010). JNK has also been implicated in regulating cytoskeleton reorganization by
influencing regulators, such as profilin and cortactin, which are upregulated by
active JNK and downregulated by dominant negative JNK mutant (Jasper et al.,
2001). As described by Huang et al., many JNK substrates have been identified,
of which paxillin, spir, DCX, MAP1B and MAP2 are all candidates, all are also
directly involved in cell migration (Huang et al., 2004b).
p38 is less well characterised in terms of its involvement in cell migration,
although it is known that its pharmacological inhibition can reduce migration
(Saika et al., 2004, Sharma et al., 2003). It is believed that the involvement of p38
in cell migration may be accomplished via its effects on MAPKAP 2/3 and
cytoskeletal regulators, such as paxillin (Huang et al., 2004a, Huang et al., 2004b)
and caldesmon (Goncharova et al., 2002b).
ERKs 1/2 are also known as regulators of cell migration, being stimulated by
variety of extracellular cues, which are able to activate the Ras-Raf-MEK1/2-
ERK1/2 signalling pathway (Johnson and Lapadat, 2002, Seger and Krebs, 1995).
Pharmacological inhibition of the ERK pathway by PD98059 and UO126 has
been demonstrated to reduce cell migration in various cell types, including
myoblasts (Al-Shanti et al., 2011, Huang et al., 2004b, Lind et al., 2006,
Teranishi et al., 2009, Webb et al., 2000). Furthermore, dominant negative ERK
and MEK1 inhibit cell migration, while active MEK1 can promote migration (Jo
35
et al., 2002, Lai et al., 2001, Webb et al., 2000). Various downstream targets of
ERK1/2 may exert effects on cell migration. As described by Huang et al. (Huang
et al., 2004b), ERK may regulate cell migration by exerting effects on integrin
activation, Myosin light-chain kinase (MLCK), FAK, calpain, paxilin and thus
regulating the actin cytoskeleton, membrane protrusion and focal adhesion
turnover (Chou et al., 2003, Glading et al., 2004, Leloup et al., 2007, Nguyen et
al., 1999, Teranishi et al., 2009, Webb et al., 2004).
1.17. MATRIX METALLOPROTEINASES
Having investigated the complex intracellular signalling pathways, involved in
manipulating cell migration, it is important to remember they do not function in
isolation. For the satellite cells to migrate to the injured site and to participate in
myofibre repair, the surrounding ECM needs to be degraded or remodeled. Matrix
metalloproteinases (MMPs) are integral to this process.  They degrade ECM
constituents, thereby facilitating migration and tissue remodeling (Nagase and
Woessner, 1999). Myoblasts have been shown to migrate through the basement
membrane and through connective tissue barriers, such as the endomysium and
perimysium (Hughes and Blau, 1990, Phillips et al., 1990, Watt et al., 1994).
MMPs are expressed in skeletal muscle in vitro and their inhibition leads to a
decrease in the migration speed of myoblasts (Nishimura et al., 2008).
Overexpression of MMP-1 or MMP-2 on the other hand, increased the migration
of myoblasts in vitro (Allen et al., 2003). MMP9 overexpression has been
demonstrated to improve myoblast migration and engraftment (Morgan et al.,
2010). Thus, matrix metalloproteinases are key to successful migration of
myogenic precursors and to muscle regeneration. PI3K and MAPK pathways have
been implicated in regulating MMP9 production in the HT1080 metastatic cell
line and brain astrocytes (Kim et al., 2001, Arai et al., 2003), however, little is
known about what regulates the expression of MMPs in myogenic precursors and,
therefore, further research is needed in this area.
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1.18. MIGRATION OF MYOGENIC PRECURSORS
Although many regulators of cell migration have been elucidated in different cell
types, relatively little research has focused on the field of myogenic progenitor
cell migration. Due to the limited dispersion of transplanted/injected cells in
proposed DMD therapies, this therapeutic strategy may be more successful if
myoblast migration were improved. Therefore, research has mostly focused on the
effects that certain mitogenic factors or proteolytic enzymes exert on myoblast or
satellite cell chemotaxis or movement. A few soluble factors have been reported
to act as chemoattractants for satellite cells or myoblasts - among them HGF, IL-
4, TGFβ, TNFα, RANTES (a.k.a. CCL5), PDGF-A, PDGF-B, FGF, IGF-I and
platelet lysate (Amano et al., 2002, Bischoff, 1997, Corti et al., 2001, Lafreniere
et al., 2004, Lafreniere et al., 2006, Ranzato et al., 2009, Torrente et al., 2003).
As previously discussed, it is important to note that the action of certain soluble
factors may be altered by their concentration. It is thus obligatory, not only to
know which soluble factors act as chemoattractants, but also to understand how
they can interact with each other and what intracellular events are responsible for
the effects they exert on the cell. Critically, few myogenic migration inhibitors
have been investigated. Sphingosine-1 phosphate is one of the proposed inhibitors
of myoblast migration acting via Rho-dependent mechanisms (Becciolini et al.,
2006). Prostacyclin GI2 (PGI2) is another inhibitor acting as a brake for
migration, which also enhances cell fusion (i.e. facilitates cell-cell contact)
(Bondesen et al., 2007). Interestingly, it has previously been demonstrated that
myoblasts lacking MyoD migrate longer distances into host muscle, although it
remained unclear whether this occurred due to increased proliferation or enhanced
migration capacity (Smythe and Grounds, 2001). It seems logical that migration
and fusion are two linked processes. It will be interesting to further investigate
whether migration is indeed dependent on differentiation/fusion and how
blocking/inhibiting one will influence the other.
Regulators of cell adhesion and ECM degradation have been studied in relation
with myoblast migration. Calpains are also shown to regulate myoblast migration
by influencing the formation of stress fibres and focal adhesions (Dedieu et al.,
2004, Leloup et al., 2006), while MMPs are suggested to facilitate the migration
of myoblasts by participating in the remodeling of the ECM (Allen et al., 2003,
Chen and Li, 2009, El Fahime et al., 2000, Nishimura et al., 2008, Wang et al.,
37
2009). The urokinase-type plasminogen Activator (uPA) serine protease,
implicated in ECM degradation, is also known to regulate myoblast migration. It
was reported that expression of uPA was elevated by treatment with growth
factors, increasing myoblasts migration, and that its inhibition by serine protease
inhibitor (aprotinin) or specific uPA inhibitor (amiloride), resulted in reduced
myoblast migration in vivo (El Fahime et al., 2002).
Signalling pathways, including MAPK and PI3K pathways, have been implicated
as regulators of myoblast migration, although results have been divergent (Al-
Shanti et al., 2011, Leloup et al., 2007, Kawamura et al., 2004, Kim et al., 2011,
Ranzato et al., 2009, Suzuki et al., 2000). Both N-WASP and WAVE2, which are
activated downstream of PI3K, are required for the migration of myoblasts via
lamellipodia formation induced by HGF (Kawamura et al., 2004). Ras and Ral
pathways are also shown to be involved in myoblast migration (Suzuki et al.,
2000). Akirin1 has been elucidated as a possible regulator of chemotaxis of both
macrophages and myoblasts via reorganisation of their actin cytoskeletons,
leading to more efficient lamellipodia formation via a PI3K dependent pathway
(Salerno et al., 2009). Recent work in our laboratory has implicated the necessity
of MAPK and PI3K pathways for migration of C2 cells, demonstrating that
pharmacological inhibition of both pathways leads to a decrease in their migration
in response to foetal bovine serum (Al-Shanti et al., 2011). However, considering
the lack of general agreement and insufficient research on the role of signalling
pathways in myoblast migration, it was hypothesised that further research is
needed in this field.
1.19. AIMS, OBJECTIVES AND HYPOTHESIS
The aim of this thesis is to elucidate the cellular and molecular regulators of
skeletal muscle regeneration, in the context of myoblast migration. The initial
objectives were to explore the contribution of factors released from myogenic
cells on the migration of myoblasts, thus exploring the extracellular factors
regulating the process. The regulation of myoblast migration was also investigated
in the context of ageing, using a model of serially passaged C2C12 myoblasts.
Subsequent objectives were to link the migration of myogenic cells, in response to
these secreted factors, to signalling pathways, thus exploring the extracellular-
mediated, intracellular regulation of myoblast migration.  It would also be
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revealed what effect the modulation of signalling pathways would exert on
myoblast migration, potentially suggesting targets to enhance their migratory
capacity. Finally, in an attempt to propose new genetic targets for investigation in
skeletal muscle, potentially linked with fusion and migration, the expression of 4
genes (Spire1, Spire2, Formin1 and Formin2) involved in actin polymerization
were assessed. It was hypothesised that myogenic cells would release factors
capable of increasing migration of C2C12 myoblasts and that signalling pathways,
such as PI3K/AKT and MAPK/ERK, would be required for this increase. It was
hypothesised that serial passaging of myoblasts would lead to changes in the
migratory behaviour of these cells. Finally, it was hypothesised that genes
involved in actin polymerization (such as Spire1, Spire2, Formin1 and Formin2)
would be expressed in C2C12 myoblasts and that their expression would be
altered with differentiation/fusion.
The C2C12 cell line in this thesis was chosen due to the capability of these cells
to differentiate and form large multinucleated myotubes. It is also a very popular
model of investigation of skeletal muscle myogenesis and considered as a useful
tool for exploring the regulation of myogenesis at both genetic and protein level.
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CHAPTER 2
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2. MATERIALS AND METHODS
2.1. MATERIALS, GENERAL EQUIPMENT AND SPECIALIZED
SOFTWARE
2.1.1. CHEMICALS, SOLVENTS AND REAGENTS
All general chemicals and solvents (analytical (AnalaR) or molecular
biology/tissue culture grade) were purchased from Sigma (Poole, UK) and BDH
(Poole, UK), unless otherwise specified. All inhibitors were purchased from
Merck-Calbiochem (Darmstadt, Germany), unless otherwise specified.
2.1.2. CELL CULTURE
All cell culture experiments were performed under a Class II microbiological
safety cabinet (Labcaire SC-R Recirculating Class II, North Somerset, UK). All
cell incubations were performed in Triple Red Laboratory Technology Nuaire DH
Autoflow CO2 Air Jacketed Incubator (Buckinghamshire, UK). Liquid, media
and supernatants were discarded using an IBS Integra Biosciences Vacusafe
Comfort (Chur, Switzerland). All solutions used for cell culture were prepared
with distilled water from Elgastat option 4 water purifier (Elga Ltd., High
Wycombe, UK). Cell microscopy and photography were performed using Leica
Microsystems (Wetzlar, Germany) CMS GMbH light microscope (Leica
DMI6000B) with digital photography, recording capabilities (Leica CTR 6000),
using Leica Application Suite software (Wetzlar, Germany). For fluorescent
microscopy, images were taken using Leica DMI 6000B imageing system with
FITC-fluorescence L5 filter cube (excitation wavelength=480/40nm).
2.1.3. CELL CULTURE REAGENTS
Sterile Lonza BioWhittaker Dulbecco’s Modified Eagle’s Medium (DMEM) w/
4.5g Glucose per Liter, w/ L-Glutamine (584mg/L) was purchased from
BioWhittaker (Wokingham, UK). Heat-inactivated (hi) foetal bovine serum (FBS)
was purchased from Gibco (Paisley, UK) and hi horse serum (HS) - from
Southern Group Laboratory (Corby, UK). Sterile penicillin-streptomycin solution
and 10x trypsin solution were purchased from BioWhittaker (Wokingham, UK).
Non-sterile L-glutamine was purchased from BDH (Poole, UK) and non-sterile
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Gelatin type A from porcine skin was purchased from Sigma-Aldrich Chemie
(Steinheim, Germany). Phosphate buffered saline (PBS) tablets were from Oxoid
Ltd. (Basingstoke, UK). All solutions were prepared non-sterile in distilled water
and were sterilized by autoclaving at 121ºC in a bench top autoclave from
Prestige Medical (Birmingham, UK) before usage in cell culture.
2.1.4. PLASTICWARE
Tissue culture flasks (T75 and T175), 12 and 6 well Nunclon™Δ surface multi-
well dishes were purchased from Nunc Life Sciences, Thermo Fisher Scientific
(Rockslide, Denmark). 96 well plates for protein assays were also purchased from
Nunc Life Sciences, Thermo Fisher Scientific (Rosklide, Denmark). 24 well plate
Corning® Costar® cell culture plates, used for transwell insert assays, were
purchased from Sigma-Aldrich (Dorset, England). MicroAmp® Optical 96-Well
Reaction Plates for Applied Biosystems StepOnePlus Real-time PCR system were
purchased from Applied Biosystems (Warrington, UK). 96 well plates for Bio-
Rad Chromo4TM real-time PCR detector were purchased from Bio-Rad (Hercules,
CA, USA). BD Falcon 96 well clear UV plates for use with Creatine Kinase assay
were purchased from BD Biosciences (San Jose, CA, USA). Cryogenic vials, 15m
and 50ml sterile centrifuge tubes, cell scrapers and pipette tips for tissue culture,
biochemistry and flow cytometry were purchased from Fisher Scientific
(Loughborough, UK). Aerosol resistant tips (ARTTM), used for RNA work, were
from Molecular BioProducts Inc. (San Diego, CA, USA) and 0.25, 0.5, 1.5 ml
RNase Free Microfuge tubes for RNA work were purchased from Applied
Biosystems (Ambion-The RNA Company, Cheshire, UK). 0.5, 1.5 and 2 ml tubes
were also purchased from Eppendorf (Hamburg, Germany) Syringes were from
Terumo (Leuven, Belgium) and syringe filters (0.22 µM) from Corning, (Lowell,
MA, USA).  6.5mm permeable polycarbonate transwell® membrane supports
(8.0µm pore size), packaged in 24 well plates, were from Corning® Costar® and
purchased from Sigma-Aldrich (Dorset, England).
2.1.5. LIVE IMAGING
Live imaging microscopy was performed using Leica DMI6000B microscope
equipped with an autoflow incubator, CO2 controller, heating unit and
temperature controller, thus allowing maintenance of 5% CO2, 37ºC atmosphere.
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Videos were generated and exported using the Leica Application Suite software
(Wetzlar, Germany).
2.1.6. BIOCHEMICAL ASSAYS
All values from protein and CK assays were obtained using a Bio-Tek ELISA
plate reader (Winooski, VT, USA). BCA protein assay reagents for protein assay
were purchased from Pierce (Division of Thermo Fisher Scientific, Rosklide,
Denmark) and for CK assay - from Catachem, Inc. (Connecticut, NE, USA).
2.1.7. REAL-TIME PCR
RNA concentrations and purity were assessed using a Biotech Photometer (WPA
UV1101, Biochrom, Cambridge, UK). Two Real-time PCR systems were used: a
Bio-Rad Chromo4TM real-time PCR detector (Hercules, CA, USA) and Applied
Biosystems StepOnePlus Real-time PCR system. Results were analyzed by
Opticon Monitor version 3.1.32 (MJ Geneworks Inc., Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) and StepOne Software v2.2.2 (Applied Biosystems, Life
Technologies). Reagents for real time PCR were from Applied Biosystems
(Carlsbad, CA, USA).
2.1.8. SDS-PAGE AND WESTERN LIGAND BLOTTING
Proteins were loaded on polyacrylamide gels and were electrophoresed on a
Jencons TV200 Twin Plate Wide Mini-gel electrophoresis unit (Jencons, a VWR
division, East Grinstead, West Sussex, UK), purchased from Sci-plas (Cambridge,
UK), using Hoefer mighty slim 5X20 Power supply (Holliston, MA, USA). Pre-
made running buffer (10x TGS) was from Bio-Rad (Bio-Rad Laboratories Ltd.,
Hertfordshire, UK). Semi-dry protein transfer on nitrocellulose membranes was
performed by Semi Dry Unit-V20-SDB (Witec AG, Littau, Germany) with
Hoefer DC Power Supply PS3000 (Holliston, MA, USA). Hybond ECL
Nitrocellulose membranes were purchased from GE Healthcare Life Sciences,
(Buckinghamshire, UK). HRP substrate used was West Dura or West Femto
Supersignal kits (Pierce, Rockford, IL, USA). Chemiluminescence was detected
on Biorad Imaging System (Hercules, CA, USA) with Quantity One Software
4.6.2 (Bio-Rad, Hercules, CA, USA).
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2.1.9. FLOW CYTOMETRY
Flow Cytometry was performed on BD FACSCaliburTM (Becton Dickinson,
Franklin Lakes, NJ, USA) with Cell Quest Pro Software (Becton Dickinson,
Franklin Lakes, NJ, USA). Cell cycle analysis was performed using ModfitTM
software (Verity Software House, Topsham, ME, USA). Reagents for Flow
cytometry were purchased from BD (BD Biosciences, San Jose, CA, USA).
2.2. METHODS AND PROTOCOLS
2.2.1. CELL CULTURE
All cell culture experiments were performed with the C2C12 cell line, which was
purchased from the American Tissue Culture Collection (ATCC; Rockville, MD,
USA).
2.2.1.1. INDUCING PROLIFERATION AND DIFFERENTIATION OF
C2C12 MYOBLASTS
Cells were induced to proliferate and expanded in 10% foetal bovine serum
(FBS) DMEM media, containing 1% Pen-strep (10000 U/ml) and 200mM L-
glutamine (known as Growth media=GM). C2C12 myoblasts are able to
differentiate and fuse into myotubes upon serum withdrawal (Blau et al., 1985,
Tollefsen et al., 1989). Myoblasts were induced to differentiate and to fuse into
myotubes, once confluency was achieved, upon withdrawal of GM and addition
of 2% horse serum (HS) DMEM media, containing 1% Pen-strep (10000 U/ml)
and 200mM L-glutamine (DM). Figure 2.1 demonstrates the differences between
proliferating myoblasts kept in GM and myoblasts, which have undergone
differentiation and fusion into multinucleated myotubes following transfer to and
culture in DM. For all experiments, cells were seeded on flasks or multi-well
dishes, pre-coated for 15min at room temperature with 0.2% Gelatin.
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Figure 2.1. Myoblasts are capable of fusing with each other to form
multinucleated myotubes. Myoblasts supplemented with 10% FBS DMEM (GM) are
induced to proliferate and do not differentiate and fuse into myotubes until highly
confluent (A). Differentiation is induced, following washing, once GM is replaced with
2% HS DMEM (DM). Extensive myotube formation is evident following 5 days in 2%
HS DMEM (DM) 10x objective; (B). Multinucleated myotubes are formed following
fusion of mononucleated myoblasts 20x objective, 1.6x magnification (C).
2.2.1.2. PASSAGING OF CELLS
Passaging of cells was performed by aspirating culture media, washing cells with
PBS to remove any remaining serum, trypsinizing with 0.05% Trypsin/0.02%
Ethylenediaminetetraacetic acid (EDTA) for 3-5 minutes at 37ºC to detach cells
adhered to the substrate and resuspending the cells in pre-warmed GM (in at least
1:6 ratio of trypsin:GM) to deactivate the action of the trypsin. For cell counting,
cell suspension was prepared in a 1:1 dilution in trypan blue stain (Bio Whittaker,
Wokingham, UK) and cells were counted with a Neubauer haemocytometer
(Assistent, Sondheim, Germany). Viable cells exclude the trypan blue dye and
only the dead cells, where membrane integrity is disrupted, are positively stained.
After cells were counted and the numbers adjusted for dilution and stock volumes,
cells were seeded with GM in a flask or a multi-well dish, pre-coated with 0.2%
Gelatin. Working volumes were normally 15ml of media for T75 flask, 2ml of
media/well for a 6-well multidish and 1ml of media/well for a 12-well plate.
2.2.1.3. CELL CRYOPRESERVATION AND RESURRECTION
For preparation of cell stocks, confluent cell monolayers were trypsinized and
cells counted with a Neubauer haemocytometer, as described in section 2.2.1.2.
Cell numbers were diluted in GM to 1×106 cells.ml-1. 10% dimethyl sulphoxide
(DMSO; BDH, Poole, UK) was added to the cell suspension in a dropwise
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manner and cells were transferred to 1ml cryovials. Cryovials were placed into
freezing chambers purchased from Nalgene (Rochester, NY, USA) containing
isopropyl alcohol and the chamber was transferred for overnight storage at -80ºC.
This procedure allows gradual freezing of the cells at a rate of -1ºC.minˉ1, which
allows the reduction in metabolism of the cells and allows enhanced survival upon
resuscitation. Following overnight incubation at -80ºC, cryovials were transferred
to liquid nitrogen for long term storage. The growth of ice crystals is reduced in
liquid nitrogen, thus enhancing cell survival during long term storage.
For restoring cell stocks from liquid nitrogen, cryovials were placed at room
temperature in a cell culture safety cabinet until thawed and cell suspension
quickly transferred to a 0.2% Gelatin pre-coated flask, containing warm GM.
2.2.2. WOUND HEALING ASSAY WITH LIVE IMAGING
EXAMINATION
In order to investigate the migration potential of C2C12 cells in response to
specific factors, a wound healing assay was established. In the wound healing
assay, a scratch/wound was created in a monolayer of confluent cells, usually
using a pipette tip, and the progress of wound closure by the cells was observed
over time. The advantages of this method is that it is easy to perform and
relatively cheap, while at the same time, if combined with Live imaging
microscopy and appropriate analyses, it can provide useful information not only
on the migration of cells, but also on their behavior, morphology, proliferation
and cell death.
2.2.2.1. WOUND HEALING METHOD
Cells were seeded in pre-gelatinised 12 well plates at a confluency of 80,000
cells/well in GM. Once 80-90% confluency was reached (generally, on the next
day after seeding), GM was removed, cell monolayers were washed with PBS and
0.1% FBS DMEM media, containing 1% Pen-Strep (10000 U/ml) and 200mM L-
glutamine, was added (known as quiescent media). Cells were incubated for 20
hours in quiescent media before a wound was made, using a sterlized pipette tip,
and live imaging examination of the wound closure was initiated. Live imaging
for wound healing/cell migration studies was performed using Leica DMI6000B
microscope equipped with an autoflow incubator, maintaining 5% CO2
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atmosphere at 37ºC. C02 controller, temperature controller and heating unit were
turned on the day before the experiment was initiated for the atmosphere
conditions inside the incubator to be stabilised. Multi-well dishes containing the
wounded cell monolayers were placed on a movable stage inside the incubator, X
and Y coordinates were set in 4 random locations along the length of each wound
and images were acquired every 15min at 10x magnification.  To study migration
in the absence of conflicting proliferation, cell monolayers were pre-incubated for
3hrs in 10µg/ml of Mitomycin-C, (purchased from Sigma-Aldrich (Dorset,
England)) before live imaging was initiated.
2.2.3. LIVE IMAGING MIGRATION ANALYSIS
Migration analyses were performed using Keynote’09 software version 5.1.1.
(Apple Inc.), which was employed to draw lines, separated by equal distances,
into images of the wound healing videos, enabling the creation of cell movement
trajectories frame by frame into exported .AVI videos of migrating cells. ImageJ
v1.45i software was used to count cells in different zones of the wounds and to
track and calculate the distance of migration trajectories of cells.
2.2.4. CELL DEATH ANALYSIS BY LIVE IMAGING
To ensure consistency of data collection, cell death analyses during wound
healing assays were performed using the same live imaging movies generated and
analysed for cell migration. Each live imaging clip was separated into 6 equal
areas using Keynote’09 software version 5.1.1. (Apple Inc.). The number of dying
cells were manually counted frame by frame in each area for the duration of the
movie. Dying cells were clearly obvious as floating cell bodies in the supernatant.
The numbers of dying cells from the 6 random fields were summed and
represented as the number of dying cells in each movie field over the total number
of cells (alive+dead) in the same fields.  At least 3 replicate movies were analysed
per experiment.
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2.2.5. TRANSWELL INSERTS MIGRATION ASSAY
2.2.5.1. PRINCIPLE
Transwell inserts allow the examination of chemotaxis. As shown on Figure 2.2,
each transwell insert has an anchored microporous membrane, which is placed in
a multi-well dish, thus providing upper and lower compartments. The upper
compartment is inoculated with the cell suspension, while the lower compartment
contains the chemoattractants or media to be tested. Usually, media composition
in the upper and lower compartments differ, with cells suspended in serum-free
(SF) media  in the upper chamber, so that a chemoattractant gradient is
established across the micrporous membrane. This allows the cells in the upper
compartment to migrate through the pores towards the lower compartment
containing chemoattractants. Once cells have migrated through the pores, they
adhere on the under-side of the membrane. Non-migrating cells on the upper side
of the microporous membrane can be removed by gentle swabbing (thus not
damaging the membrane or dislodging cells on the lower side), enabling the
fixing, staining and counting of the migrated cells.
Figure 2.2. Transwell inserts representation. On the left, a schematic
representation of a transwell insert. Cells, placed in the upper compartment, can cross the
microporous membrane toward chemoattractants present in the lower compartment. On
the right, a photograph of transwell inserts placed in a 12 well plate. Pictures were taken
from Corning Transwell Permeable Supports Selection and User Guide (Corning
Incorporated, CLS-CC-007W REV3, printed in USA, 2006).
2.2.5.2. METHOD
Trypsinized cells (see section 2.2.1.2) were centrifuged for 10min at 500g.
Supernatant containing GM was discarded and cells were washed with PBS,
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followed by another centrifugation for 10min at 500g. Cell pellets were
resuspended in SF media, cells were counted and myoblast numbers were
adjusted to 120, 000 cells/ml.
Corning® Costar® 6.5mm permeable polycarbonate transwell membrane
supports (8.0µm pore size) were placed in 24 well dishes, with each well (e.g.
lower compartment) containing 600µL of test media. 200µL of the cell suspension
(120,000 cells/ml) was added in a dropwise manner to the upper compartment of
the transwell insert. Having initially optimised the timing of the experiments, it
was determined that after 4h the experiment should be terminated. Each insert was
washed by transfer to 600µL PBS, followed by fixation with 2.5% gluteraldehyde
for 15min (Fisher Scientific, Fair Lawn, NJ, USA). Adherent cells were
permeabilized for 3min in 0.5% Triton X-100 (BDH Labs, Poole, England),
before staining for at least 20min at RT in Gill’s no.1 haematoxylin (Thermo
electron corp., Runcorn, UK), followed by a wash in 0.04% NH4OH (Acros
Organics, Geel, Belgium). Moist cotton buds were used to gently remove the cells
on the upper membrane of the insert, ensuring only migrated cells remained on
the membrane. Migrated cells were visualized on Leica DMI6000B inverted
microscope and 3 random fields per insert were photographed. Cell counting was
performed using Cell Counter plugin of ImageJ v1.45i.
2.2.6. PHALLOIDIN-FITC STAINING
Phalloidin is a toxin, which binds specifically to F-actin. When labelled with
fluorescein molecules, such as FITC, phalloidin enables the visualization of the
actin cytoskeleton within cells. Phalloidin staining was a useful tool to clearly
visualize the morphology of well developed myotubes.
Phalloidin staining was performed directly in the multi-well dishes, in which the
cell monolayers were grown. Cell monolayers were washed in PBS and fixed for
20min in freshly prepared 3.7% formaldehyde solution (H20) (Fischer Scientific,
Loughborough, UK). Cell monolayers were incubated for 3min in 0.5% Triton X-
100 followed by 30min at RT with 15µg/ml phalloidin-FITC (Sigma, St. Lois,
MO, USA). Images were obtained using Leica DMI 6000B imaging system and a
FITC-fluorescence L5 filter cube (excitation wavelength = 480/40nm).
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2.2.7. BIOCHEMICAL ASSAYS
Protein assays were performed to measure the quantity of proteins in cell lysates
prior to e.g. electrophoresis and Western blotting examination, in order to
normalize loading.  Protein determination was also employed in conjunction with
CK assays to normalize enzyme activity to protein content.
2.2.7.1. PROTEIN ASSAY
Samples for protein assay were prepared by adding 200µL per well (for 6 well
plate) lysis buffer (composed of: 10 mM TrisCl, 5mM EDTA, 50 mM sodium
chloride, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 100 μM sodium
orthovanadate, 1 mM PMSF and 1% Triton X-100) for SDS PAGE analyses or
150µL per well (for 6 well plate) of Tris Mes Triton (TMT buffer; composed of:
0.05M Tris/Mes and 1% Triton-X100) for CK analyses. Following removal of
cells from the substrata, using a scraper, lysed cells were collected and
centrifuged for 2min at 8,000g to pellet and discard insoluble debris; samples
were stored at -20ºC until further analysis.
For the protein determination, BSA protein standards were prepared in either
lysis (for western blot) or TMT (for CK assay) buffers at concentrations of 4, 2, 1,
0.5, 0.25, 0.125, 0.0625 and 0 mg.ml-1. Standards were prepared by diluting
200mg BSA (in 0.9% sodium chloride and sodium azide a preservative; Pierce,
Rockford, IL, USA) in 4.8ml buffer to obtain a 40mg.ml-1 stock solution; 200 µL
were diluted in 1.8ml buffer (lysis or TMT) to obtain the first standard of 4mg.ml-
1. The remaining protein standards were prepared by serial dilutions of the
4mg.ml-1 sample.
Protein assay was performed using BCA Protein Assay purchased from Pierce
(Rockford, IL, USA). BCA reagents A & B were mixed in ratio 1:50. 200µL of
the mixed solution was added in a 96 well plate with 10µL of the protein samples
or standards. The 96 well plate was incubated at 37ºC and absorbance was
recorded after 45 or 60 minutes at 630 nM using a Bio-Tek ELISA plate reader
(Winooski, VT, USA). Standard curves were automatically generated by plotting
the average blank-corrected 630nM measurement of the loaded BSA standards
against pre-programmed known concentrations in mg.ml-1 and sample
concentrations were calculated from the standard curve.
50
2.2.7.2. CREATINE KINASE (CK) ASSAY
CK assay was used to measure the in vitro differentiation of C2C12
mononucleated myoblasts into multinucleated myotubes. Samples were prepared
as described above. A commercially available CK assay kit was employed
(Catachem Inc., Connecticut, NE, USA). Reagents of the kit were mixed
according to manufacturer’s instructions and following addition of  6-10µL of
each sample to the wells, 200µL of the mix was added to the wells of the 96 well
UV plate (BD Biosciences, San Jose, CA, USA) using a multichannel pipette.
The plate was incubated for 3min on a shaker at RT before being read on a Bio-
Tek ELISA plate reader at 340nm absorbance. Readings were taken every minute
for up to 10min. First and last readings were usually used to calculate the CK
activity, according to the following equation:
CK (U.l-1) = (ΔA.min-1 × TV × 1000) ÷ (6.22 × SV)
ΔA.min-1 = (Final Absorbance - Initial Absorbance) ÷ (Final Reading Time –
Initial Reading time (mins))
Where:
ΔA.min-1 = Change in absorbance per minute at 340 nM
TV              =  Total volume (ml)
1000 =  Conversion of units per ml to units per litter.
6.22          = Millimolar absorptivity of NADH at 340nM
SV            = Sample volume (ml)
Therefore, using 8 μl of sample and 200 μl of reagent the following equation
applies:
CK (U.l-1) = (ΔA.min-1 × 0.208 × 1000) ÷ (6.22 × 0.008)
2.2.8. WESTERN BLOTS
Western blots were performed to detect and quantify specific proteins in cell
extracts isolated from C2C12 myoblasts subject to different treatments. Briefly,
the method is based on isolating proteins from cell lysates and subjecting them to
electrophoretic separation using SDS polyacrylamide gel electrophoresis (SDS-
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PAGE). Separated proteins are transferred to a nitrocellulose membranes and
primary antibodies specific to the proteins of interest are applied. Secondary
antibodies, specific to the primary antibodies, are labelled with horseradish
peroxidase (HRP) enzyme, which is able to produce a luminescent signal upon
incubation with appropriate substrate. This enables, using appropriate capture
systems, the detection and quantification of the proteins of interest.
2.2.8.1. SAMPLE PREPARATION
Cells were subjected to specific treatments for pre-determined periods of time
before being lysed, as detailed above. Following protein extraction and
determination of concentration, samples were loaded according to protein (30µg
per sample in a maximum 90µL total volume used). 10µL of Color Burst
Electrophoresis markers (Sigma, Poole, UK), diluted in lysis buffer, were
prepared alongside the samples, as a reference for the molecular weight of
migrating proteins (in kDA). 1/5 of the total sample volume of 5x Laemmli
Sample buffer (6.8ml dH20, 2ml 0.5M Tris pH 6.8, 3.2ml Glycerol, 3.2ml 10%
SDS, 0.8ml 2-mercaptoethanol, 1.6ml 1% bromophenol blue) was added to each
sample. Samples and standards were boiled at 100ºC for 5min, in order to reduce
disulphide bonds and facilitate protein denaturation, followed by immediate
transfer to ice.
2.2.8.2. GEL ELECTROPHORESIS
Samples, prepared in section 2.2.8.1. were subjecedt to SDS polyacrylamide gel
electrophoresis (SDS-PAGE). Acrylamide, mixed with bisacrylamide, is able to
form a polymer network/mesh when mixed with ammonium persulfate (APS) and
N,N,N,N'-tetramethylenediamine (TEMED), which catalyzes the polymerization
of the reaction. Proteins are able to migrate through the polyacrylamide mesh of
the gel and are thus separated by size. Treating the samples with reducing agents,
such as 2-mercaptoethanol, and adding sodium dodecyl sulfate (SDS) to the gels,
helps to denature secondary or tertiary structures, disulfide bonds, and to maintain
the proteins in a denatured state. SDS also negatively charges proteins and allows
them to migrate to the positively charged electrode through the polyacrylamide
gel. This allows the separation of proteins by molecular weight (with no influence
of charge), as smaller proteins migrate through the pores of the gel faster than
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larger ones. The higher the percentage of acrylamide, the slower the migration of
proteins through the gel. According to the percentage of acrylamide, gels are
composed of a stacking gel (usually 5% acrylamide; 3.75ml 30% Acrylamide 1%
BIS, 1.12ml of 1.1M Tris HCL ph 6.8, 0.225ml 10% SDS, 17.4ml H20, 22.5µL of
Tetramethylethylenediamine (TEMED), 337.5µL of APS), allowing fast
migration of proteins and their aligning for separation, and a resolving gel
(usually 6-12% acrylamide; 8.65% acrylamide: 11.35ml of 30% Acrylamide 1%
BIS, 8.4ml 1.5M Tris Base pH 8.9, 1.35ml 10% SDS, 18ml dH20, 13.12µL
TEMED, 306.25µL ammonium per-sulphate (APS)), which enables protein
separation by size. A schematic representation of how the gels are structured is
presented on Figure 2.3.
Figure 2.3. SDS polyacrylamide gel preparation. Gels are prepared as a stacking
gel (usually containing 5% Acrylamide) poured on top of a resolving gel (usually
containing 6-12% acrylamide). Samples are loaded into wells, formed by inserting a
plastic comb into the stacking gel before it has polymerized. Once current is applied,
negatively charged proteins migrate to the positive electrode. This allows the separation
of proteins by size, as larger molecular weight proteins migrate more slowly through the
pores of the gels, while smaller proteins are able to migrate more quickly.  Source of
image: www.siumed.edu (date accessed: 1st March 2012)
Gels were assembled using a Jencons TV200 Twin Plate Wide Mini-Gel
Electrophoresis Unit, which was placed in a tank with 1x Running TGS buffer (25
mM Tris, pH 8.3, 192 mM glycine, 0.1% SDS in dH20) (Bio-Rad Laboratories
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Ltd., Hertfordshire, UK). Following preparation of the resolving gel and the
stacking gel, protein samples were loaded and voltage (175V) was applied until
the bromophenol blue dye, included in the sample buffer, reached the interface
between the stacking and the resolving gels. Voltage was subsequently decreased
to 125V until the bromophenol blue dye reached the end of the resolving gel.
2.2.8.3. ELECTROPHORETIC TRANSFER
Following gel electrophoresis, proteins were transferred to nitrocellulose
membrane to enable immune-detection. Semi-dry transfer was performed using
the Witec AG, Semi Dry Unit-V20-SDB. Gel and nitrocellulose membrane were
washed in transfer buffer (114 nM glycine, 19 mM Tris base, 33% methanol; pH
8.3) and sandwiched between 4 sheets of Whatman filter paper (Schleicher &
Schuell, GmbH, Dassel, Germany), pre-immersed in transfer buffer. The proteins
were electro-transferred from the gel to the nitrocellulose membrane at 20V for 90
min. using a Hoefer power supply. A schematic representation of the method is
shown in Figure 2.4.
Figure 2.4. A representation of the semi-dry protein transfer method. Proteins
are pulled from the gel to a nitrocellulose membrane using electric current, while
retaining the same position they had on the gel. Source of picture: www.Wikipedia.org
(date accessed: 1st March 2012)
The effectiveness and uniformity of the transfer were confirmed, following
washing of the nitrocellulose membrane, in 0.1% Ponceau S in 5% acetic acid
(Sigma, Poole, U.K). Ponceau S staining of proteins is reversible and can be
completely removed by washing the membrane in dH20, followed by 1x TBST
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buffer (1.21gr Trizma-Base, 8.78gr NaCl, 1ml Tween 20, dH20 to 1L, pH 7.4). A
representative picture of nitrocellulose membrane following transfer of proteins
and staining with Ponceau S is shown in Figure 2.5; uniformity of protein loading
is illustrated.
Figure 2.5. Ponceau S staining. Effectiveness and uniformity of protein transfer from
the gel to the nitrocellulose membrane was verified with Ponceau S staining. Ineffective
transfer, or incorrect protein loading would be evident with Ponceau S staining, therefore
this acts as a secondary loading and primary transfer control. Red labels on the left
indicate the molecular weight (in kDA), identified by the inclusion of a lane with Color
Burst Electrophoresis markers.
2.2.8.4. BLOCKING
In order to detect specific proteins of interest following transfer, antibodies
targeted against these proteins need to be incubated with the membrane. However,
the nitrocellulose membrane has the strong ability to non-specifically bind
proteins and therefore the possibility exists that the antibodies, which are proteins
themselves, can bind to many sites of the nitrocellulose membrane and thus cause
noise, difficulties in interpreting results or even false positive results. This can be
avoided by blocking unbound sites of the membrane in solutions containing
generic proteins, normally non-fat dry milk, gelatin or BSA, which bind to all free
sites of the nitrocellulose membrane, thus reducing non-specificity and high
background. Depending on the secondary antibodies used, nitrocellulose
membranes were blocked for 1h at RT in either tris-buffered saline – 0.1%  tween
20 plus 5% non-fat dry milk (TBST-M) or in 1% BSA (TBST-BSA).
55
2.2.8.5. DETECTION
Following blocking, membranes were incubated with primary antibody
overnight at RT, followed by incubation with horseradish peroxidase (HRP)-
conjugated secondary antibody diluted in blocking solution for 1h at RT. Steps
were separated by washing the membranes with dH20, followed by 3 washes in 1x
TBST for 15min each. All secondary antibodies were labelled with horseradish
peroxidase (HRP). HRP is an enzyme, which participates in a chemical reaction
when incubated with substrate which is oxidized by HRP, using hydrogen
peroxide as the oxidizing agent, resulting in the production of a luminescent
signal. This allows the detection and quantification of target proteins. The whole
process is summarized on Figure 2.6.
Figure 2.6. Detection and quantification of target proteins. Target proteins,
transferred to nitrocellulose membranes, are bound by primary antibodies, which are
recognized by enzyme-conjugated secondary antibodies. The enzyme, such as HRP,
participates in a chemical reaction when a specific substrate is added, resulting in the
emission of a detectable signal. The light signal can be detected by a camera, enabling the
semi-quantification of the target proteins present on the nitrocellulose membrane. Source
of picture: www.leinco.com (date accessed: 1st March 2012)
Enhanced chemiluminescence (ECL) HRP substrate, West Dura Supersignal
(Pierce, Rockford, IL, USA), was applied to induce enzymatic reaction with the
HRP tag of the secondary antibodies and chemiluminescence, proportionate to the
amount of protein, was captured using the Biorad Imaging System (Hercules, CA,
USA). Densitometry was further applied for quantifying the proteins. Where
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appropriate, all phopshorylated forms of proteins investigated were normalized
either to their respective total protein levels or to beta-actin. Antibodies were
purchased from New England Biolabs (Hertfordshire, UK) or Promega
(Southampton, UK), unless otherwise specified.
2.2.8.6. NITROCELLULOSE MEMBRANE STRIPPING
Nitrocellulose membranes, requiring antibodies to be stripped to enable re-
probing, were incubated for 45min at 60ºC with stripping buffer (10ml 10% SDS,
6.25ml 0.5M Tris, 0.4ml 2-mercaptoethanol, 33.5ml H20). Nitrocellulose
membranes were washed for 1hr with dH20, followed by 3 washes for 15min in
TBST. The incubation with 2-mercaptoethanol containing stripping buffer was
performed in a biosafety cabinet.
2.2.9. RNA EXTRACTION
RNA was isolated from cells using Guanidinium thiocyanate-phenol-chloroform
extraction, with Trizol® reagent (Invitrogen, Life Technologies, Paisley, UK).
Trizol contains phenol and Guanidinium thiocyanate, which have cell lysing and
protein denaturing actions, thus also preventing the activity of RNAse and DNAse
enzymes. Following cell treatments, 330µL of Trizol® per well of a 6 well plate
was added to the cell monolayers and plates were incubated for 5min at RT. Cell
lysates were collected following scraping with a cell scraper to disrupt the cells,
and stored at -20ºC until further analysis. For RNA isolation, chloroform: Trizol®
in 1:5 ratio was added to the lysate, solution was mixed, incubated for 10min., RT
and centrifuged for 16min at 12,000xg. Chloroform, along with the phenol
contained in the Trizol® reagent, causes the proteins to denature and precipitate
and separates the RNA into an aqueous supernatant. Following addition of
chloroform and centrifugation, a visible separation of the solution into three
phases is visible (aqueous phase, interphase and organic phase), as shown in
Figure 2.7. The majority of the RNA is present in the aqueous phase, while DNA
and proteins are in the interphase and organic phases respectively. Following
separation of the solution into three phases, the aqueous phase was transferred to a
new tube and equal volume of ice-cold isopropanol was added. Isopropanol
precipitates and recovers the RNA from the aqueous phase, which becomes
visible as a pellet after 10min of centrifugation at 12,000xg. The RNA pellet was
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washed with 75% EtOH, centrifuged at 8,000xg for 10min and air dried. Tris-
EDTA (TE) buffer (Applied Biosystems, Ambion, Cheshire, UK) was added to
reconstitute the RNA.
Figure 2.7. Trizol lysate phase separation. Following addition of chloroform to the
Trizol® lysate and centrifugation, the solution is separated into 3 phases. RNA is isolated
from the aqueous phase. Source of picture: www.openwetware.org (date accessed: 1st
March 2012)
After reconstitution in TE buffer, RNA concentration and purity were assessed
by UV spectroscopy, using a Biotech Photometer (WPA UV1101, Biochrom,
Cambridge, UK). The absorbance of the diluted RNA sample was measured at
260 and 280 nm. Absorbance at 260nm was used to determine the RNA
concentration, as it is known that A260 reading of 1.0 is equivalent of 40µg/ml of
RNA. A 260/280 ratio was used to assess the purity of RNA - it is known that a
260/280 ratio of 1.8-2.1 indicates a good purity of RNA solution, which can be
used for Real-time PCR.
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2.2.10. REAL-TIME PCR
2.2.10.1. PRINCIPLE
Gene expression can be altered in response to various conditions or different
stages of cell development and is a key step in how many cellular processes,
including differentiation, are accomplished. A commonly used method for
investigating gene expression is Real-time PCR (RT-PCR), which quantifies the
amount of mRNA molecules produced by a specific gene after it is transcribed.
The method relies on converting the previously isolated mRNA (section 2.2.9)
into complementary DNA (cDNA) by reverse transcription and amplifying the
cDNA, while detecting in real time the amount of amplified DNA molecules
(hence, the method is named Real-time PCR). The detection of amplified product
is performed by labeling the DNA with molecules emitting fluorescence, which is
proportionally increased with the amplification of the cDNA molecules with each
cycle of the reaction. Two commonly used fluorescent tags in Real-time PCR are
SYBR® Green dye and TaqMan® probes. SYBR® Green dye is the cheaper
alternative - it  binds to all double stranded DNA and is able to detect all
amplified double-stranded DNA molecules. However, it may also detect non-
specific reaction products. TaqMan® probes are more expensive, but can be
synthesized for each unique target sequence and are therefore emitting
fluorescence only when the specific PCR product is amplified. Comparison of
both chemistries is presented on Figure 2.8.
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Figure 2.8. Comparison of PCR products in Real-time PCR between SYBR®
Green and TaqMan® chemistries. TaqMan® detection is more specific, as it uses a
specially designed probe for each target sequence, which emits fluorescence only when
the target sequence has been replicated. SYBR® Green dye is less specific, as it binds to
any double stranded DNA present in the reaction. Source of figure:
www.appliedbiosystems.com (date accessed: 1st March 2012)
The increase in fluorescence with each cycle is detected enabling estimation of
the rate of amplification and the abundance of the cDNA molecules generated.
The higher the gene expression, i.e. the starting concentration of cDNA, the fewer
number of amplification cycles it will take for the levels of fluorescence to reach a
certain threshold (represented as Ct value). Thus, the lower the Ct value, the
higher the gene expression level. Comparison of Ct values between different
samples is therefore indicative of how gene expression between these samples
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differ. Figure 2.9 shows an example of 3 samples with different gene expression
levels and how this is represented by their Ct values.
Figure 2.9. Real-time PCR Ct value. Real-time PCR analysis demonstrates the
number of cycles required for 3 different samples to reach a specific fluorescence
threshold (represented by their Ct value). The lower the Ct value, or the number of cycles
required to reach the fluorescence threshold, the higher the expression of the gene. Thus,
the sample represented by the green curve is the one with highest gene expression
(Ct=21.75), followed by the blue one (Ct=26.5) and the red sample is the one with the
lowest gene expression (Ct=27.1).
For the DNA amplification to take place in PCR, target DNA needs to be mixed
with several other reaction components: 1) Pair of primers - short DNA fragments
that serve as the starting point for DNA synthesis and defining the sequence to be
amplified; 2) DNA polymerase - the enzyme that catalyzes the reaction (Taq
polymerase is commonly used for PCR); 3) dNTPs -
deoxynucleotidetriphosphates, the building blocks for DNA synthesis; 4) Cations,
such as Mg2+, acting as co-factors of DNA-polymerase enzyme and 5) buffer
maintaining the correct pH required for the reaction to occur.
Optimum temperature conditions are required for DNA amplification. PCR
reaction mix is subject to cycles of repeated heating and cooling, which allows the
denaturation/melting of the complementary DNA strands and their separation into
single strands, the annealing of the primers and the extension of the newly
synthesized DNA strands by the DNA polymerase. The denaturation/melting of
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the double stranded DNA molecules is accomplished by breaking the hydrogen
bonds at 94-98ºC. The temperature then needs to be decreased to 50-65ºC for the
primers to anneal. Taq DNA polymerase has an optimum activity temperature of
75-80ºC, although a temperature of 72ºC is commonly used. AmpliTaq Gold®
DNA Polymerase, used in this thesis, consolidates the annealing and extension
steps into one, at 60ºC.
2.2.10.2. METHOD
Both SYBR® Green- and TaqMan®-based detection approached were used in
this thesis.
2.2.10.2.1. SYBR® GREEN
For SYBR® Green detection, Power SYBR® Green RNA-to-CT 1 step kit was
used (Applied Biosystems, San Jose, CA, USA). The kit contained both
AmpliTaq Gold® DNA Polymerase, required for DNA amplification and
ArrayScript™ UP Reverse Transcriptase, the enzyme required for the reverse
transcription of mRNA into cDNA. Final reaction volumes were 15µL per
reaction, composed of 6µL RNA (10ng/µL), 7.5µL master Mix containing the
Taq polymerase enzyme, 1.5µL primer mix and 0.12µL RT enzyme. The PCR
reactions were performed on Bio-Rad Chromo4TM real-time PCR detector
(Hercules, CA, USA) with Opticon Monitor version 3.1.32 (MJ Geneworks Inc.,
Bio-Rad Laboratories, Inc., Hercules, CA, USA) and also on Applied Biosystems
StepOnePlus Real-time PCR system with StepOneTM Software v2.2.2 (Applied
Biosystems Life technologies). The following program was used:
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Stage Step Temperature Time
Holding Reverse transcription 48ºC 30 min
Holding Activation of TAQ
polymerase
95ºC 10 min
Cycling
(40 cycles)
Denaturation 95ºC 15 sec
Annealing/Extension 60ºC 1 min
Melt Curve
generation
Denaturation 95ºC 15 sec
Annealing 60ºC 15 sec
Denaturation 95ºC 15 sec
As SYBR® Green is able to detect any double stranded DNA, including primer
dimers, contaminating DNA or non-specific products, it is important to perform
melting curve analyses to confirm the specificity of the amplification. Melting
curve analyses measure the temperature-dependent dissociation of the two DNA
strands. As temperature is gradually increased, a sharp increase in fluorescence is
observed when the product is amplified and a sharp decrease - at melting
temperature (Figure 2.10). The temperature at which this peak appears is specific
for each amplicon, depending on its size. Thus, a specific product is characterised
with a sharp peak, while multiple peaks indicate non-specific amplification.
Figure 2.10. Melting curve in Real-time PCR. Generation of melting curve is
important to verify the specificity of the amplification when SYBR® Green dye is used.
A sharp peak, as shown on the figure, is indicative of specific amplification, while the
presence of additional peaks would indicate non-specific amplification, primer dimers or
contamination.
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The following predesigned primer sets were ordered from Quiagen and were
used with the SYBR-Green detection method: Polr2b (QT00154602), MyoD
(QT00101983) and Myogenin (QT00112378).
2.2.10.2.2. TAQMAN®
For TaqMan® detection, TaqMan® RNA-to-CT™ 1-Step Kit was used (Applied
Biosystems, San Jose, CA, USA). The kit contained both AmpliTaq Gold® DNA
Polymerase, required for DNA amplification and ArrayScript™ UP Reverse
Transcriptase, the enzyme required for the reverse transcription of mRNA into
cDNA. Final reaction volume was 20µL per reaction, composed of 8.5µL of RNA
(10ng/µL), 10µL master Mix containing the DNA polymerase enzyme, 1µL of
primers mix and 0.5µL RT enzyme. Applied Biosystems StepOnePlus Real-time
PCR system with StepOne Software v2.2.2 (Applied Biosystems, Life
Technologies) was used. The following program cycles were used:
Stage Step Temperature Time
Holding Reverse Transcription 48ºC 15 min
Holding Activation of TAQ
polymerase
95ºC 10 min
Cycling
(40 cycles)
Denaturation 95ºC 15 sec
Annealing/Extension 60ºC 1min
The following predesigned primer sets were ordered from Applied Biosystems
and were used with the TaqMan® detection method: Polr2b (Mm00464214_m1),
MyoD (mm00440387_m1), Myogenin (mm00446194_m1), Spire1
(mm01258168_m1), Spire2 (mm00552235_m1), Formin1 (mm00439021_m1)
and Formin2 (mm00444598_m1).
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2.2.10.3. ANALYSIS
Relative quantification of gene expression was determined automatically by
Opticon Monitor version 3.1.32 (MJ Geneworks Inc., Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) and StepOne Software v2.2 (Applied Biosystems, Life
Technologies). The relative quantification is based on analyzing changes in gene
expression relative to a reference sample (control). One sample from the
experiments was set as a calibrator/control and fold change to this calibrator was
determined for all samples of the experiment. All samples were normalized to a
housekeeping gene (Polr2b), which expression is known to remain consistent in
C2C12 cells, regardless of the treatment.
2.2.11. FLOW CYTOMETRY
2.2.11.1. PRINCIPLE
Flow cytometry is a technique, which can be used for counting and examining
the properties of particles or cells passing through a stream of liquid. A laser beam
is directed to the stream of liquid and detectors are aimed at the point where the
stream passes through the light beam. Detectors are oriented in line with the beam
(Forward Scatter = FSC) or perpendicular to it (Side scatter = SSC). When a cell
passes through the laser beam, it causes the light to be scattered and caught by the
detectors, which provides information on the volume of the cell (FSC) or the inner
complexity of the cell (SSC). Fluorescent detectors may also give information on
fluorescent chemicals found in cells (Figure 2.11).
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Figure 2.11. A schematic representation of the mechanisms of Flow
cytometry. Picture source: www.gene-quantification.de (date accessed: 1st March
2012)
2.2.11.2. PROPIDIUM IODIDE AND CELL CYCLE EXAMINATION
One of the applications of Flow cytometry is the examination of the cells in
different phases of the cell cycle. To achieve this, propidium iodide (PI) is used.
PI is an intercalating agent - binding DNA between the bases. It is also a
fluorescent molecule. Once PI binds to nucleic acids, its fluorescence is enhanced.
Thus, when cells are permeabilized and treated with PI, their DNA content can be
examined by Flow cytometry. Cells in the G2-phase of the cell cycle have
duplicated their DNA content and would therefore emit double the fluorescence of
the cells in the G1 phase. Cells can be sorted into three groups: cells in G1-phase
(“gap” phase, before cells undergo cellular division), cells in S-phase (DNA
replication phase) and cells in G2/M-phase (mitosis phase, twice the DNA of the
G1 phase).
2.2.11.3. METHOD
20hrs after cell treatment, monolayers were washed with PBS and cells were
detached with trypsin (as described in 2.2.1.2.), harvested in a 15ml centrifuge
tube and pelleted by centrifugation for 10min at 500g. The supernatant was
removed, cells were washed with PBS and centrifuged. After centrifugation, the
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PBS supernatant was removed and cells were fixed with 5ml of 75% EtOH, which
was added in a dropwise manner to the cell pellet while vortexing. Samples were
stored at -20ºC overnight before centrifugation and removal of the EtOH
supernatant. Cells were washed twice with PBS and 0.5ml PBS was retained with
the cell pellet to enable resuspension. Cells were mixed and transferred to 3 ml
BD Falcon flow cytometry tubes (BD Biosciences, San Jose, CA, USA). 50 μl of
ribonuclease A (RNAse) (50 μg.ml-1) and 10µL of PI (50 μg.ml-1) were added to
the cell solution. RNAse treatment was necessary as PI is also able to bind to
RNA molecules. After 30min incubation at room temperature, samples were
stored at 4ºC for flow cytometric analysis 24 h later.
2.2.11.4. ANALYSIS
Flow cytometric analysis was performed on Cell Quest Pro software. Cell cycle
was analyzed using ModfitTM software (Verity Software House, Topsham, ME,
USA), which allows analysis of cells in G1/S/G2/M phases of the cell cycle.
2.2.12. STATISTICAL ANALYSES
Statistical analyses and significance of data were determined using GraphPad
Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California
USA, www.graphpad.com. Statistical significance for interactions between two
paired groups was determined with a Paired t-test, while unpaired t-test was used
for unpaired groups. Statistical significance for interactions between more than
two groups was determined with a one-way ANOVA, or with a one-way repeated
measures ANOVA, when matched observations were investigated. When more
than one factor was present, two-way ANOVA was performed to investigate for
significances of factors or interactions, or two-way repeated measures (mixed
model) ANOVA, when matched observations were investigated. When
significances of factors were indicated by two-way ANOVA, this was followed
up by examining the statistical significance for interactions between more than
two groups within the factor with a One-way ANOVA with Bonferroni post-hoc
analysis, or with a t-test for examination between two groups. All results are
presented as mean +/- standard error of the mean (SEM). All values below p<0.05
were considered as significant.
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CHAPTER 3
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3. MYOTUBE CONDITIONED MEDIA ENHANCES C2C12 MYOBLAST
MIGRATION
3.1. INTRODUCTION
Skeletal muscle regeneration requires the recruitment of muscle progenitor cells,
known as satellite cells, to the site of injury. They are normally quiescent cells,
but in response to muscle damage, they become activated, migrate to the site of
injury and proliferate to generate a progeny of myoblasts, which are capable of
fusing with damaged myofibres to promote muscle repair and restore normal
tissue architecture (reviewed in (Charge and Rudnicki, 2004, Hawke and Garry,
2001, Turner and Badylak, 2011). The process of migration is important for
myoblast alignment and their subsequent fusion into multinucleated myotubes
(Louis et al., 2008, Rochlin et al., 2010). Furthermore, insufficient cell spreading
and migration has long been considered as one of the limiting steps in proposed
cell therapies of Duchenne Muscular Dystrophy, although recent articles question
this concept (Lafreniere et al., 2009, Skuk et al., 2011). Revealing in more details
the regulators of myoblast migration may contribute to our understanding of the
process of muscle regeneration, as well as open new avenues for better treatments
of muscular dystrophies or improvement of skeletal muscle regeneration.
Following muscle injury, various factors are secreted from both the damaged
muscle tissue or infiltrating inflammatory cells (Bischoff, 1986, Chen and Quinn,
1992, Merly et al., 1999, Tidball, 2005). The effect of soluble factors on
myogenic progenitors migration was investigated in vitro and some have been
reported to act as chemoattractants for satellite cells or myoblasts - among them
HGF, IL-4, TGFβ, TNFα, PDGF-A, PDGF-B, FGF, IGF-I and platelet lysate
(Amano et al., 2002, Bischoff, 1997, Corti et al., 2001, Lafreniere et al., 2004,
Lafreniere et al., 2006, Ranzato et al., 2009, Torrente et al., 2003). It is important
to note that the action of growth factors may be altered by their concentration. For
example, higher concentrations of HGF are suggested to inhibit, rather than
induce migration of myoblasts (Bischoff, 1997). Similarly, PDGF at low doses
was shown to induce migration, while high doses induced proliferation (De
Donatis et al., 2008). This underlies the importance of investigating in more detail
not only the independent action of soluble factors on myogenic cells, but reveal
the complexity of the microenvironment and the exact composition of the
biochemichal milieu, which influences the behavior of cells contributing to
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muscle regeneration under different physiological conditions. To accomplish this
immense task, it is important to begin with improving our understanding of how
factors released from different cell types and niches affect processes, such as cell
migration, contributing to muscle regeneration, in both healthy or pathological
states. It has long been known, for example, that crushed muscle extract contains
factors, such HGF, which are able to induce activation and migration of satellite
cells (Bischoff, 1997, Tatsumi et al., 1998). Recent studies have  begun to
investigate the expression pattern and secretome of skeletal muscle cells and the
expression of chemokines during myogenesis in vitro (Chan et al., 2011, Cui et
al., 2009, Griffin et al., 2010, Henningsen et al., 2010, Henningsen et al., 2011).
Griffin et al. demonstrated that approximately 80 chemokines were expressed by
primary myoblasts in vitro, with most mRNAs being detected at the time of
differentiation and fusion, with their abundance dramatically dropping after that
time point (Griffin et al., 2010).  Furthermore, media conditioned by
differentiating myoblasts at the time of fusion, was able to induce myocyte
migration. It is possible that chemokines expressed during myogenesis regulate
myoblast proliferation and survival and might be key for positioning myoblasts
for fusion. These observations, however, also suggest that fusing myoblasts may
secrete factors to induce migration of myogenic cells and thus recruit more
myonuclei to contribute to the myotube formation and muscle growth. To our
knowledge, no other studies have focused on how the milieu of secreted factors at
different stages of myogenesis affects myoblast migration. In particular, no
studies have been performed to investigate whether mature growing myotubes or
myotubes in a state of starvation or atrophy would secrete factors inducing
myoblast migration. In this situation, recruitment of mononuclear cells may also
be needed to reduce the impact of degnerating myotubes. Furthermore, it would
also be important to reveal which signalling pathways are central to the migration
of myoblasts in response to secreted factors. Based on previous studies, some of
the potential candidates would include MAPK and PI3K pathways, which have
previously been implicated as regulators of myoblast migration (Al-Shanti et al.,
2011, Leloup et al., 2007, Kawamura et al., 2004, Kim et al., 2011, Ranzato et al.,
2009, Suzuki et al., 2000). However, how modulation of different signalling
pathways affect the migration of myoblasts, remains a relatively unexplored field.
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3.2. AIMS, OBJECTIVES AND HYPOTHESIS
The main aim was to reveal the impact of secreted factors by muscle cells on
myoblast migration and the role of underlying signalling pathways in this process.
It was hypothesised that mature myotubes or atrophying or injured myotubes
would secrete factors, able to induce myoblast migration and that PI3K/AKT and
MAPK/ERK pathways would be involved in the regulation of this process.
Therefore, the objectives were to investigate whether myotubes, grown in SF
media, would secrete factors into this medium, which would be able to induce
subsequent mononuclear myoblast migration. It was also tested whether myotubes
injured by mechanical damage would release factors inducing comparable or
enhanced migration. Migration would be assessed by wound healing assay and
chemotactic responses using transwell inserts. Western blots would assess how
MAPK/ERK and PI3K/AKT pathways are regulated in myoblasts treated with the
conditioned media (CM) and how selective inhibition of these pathways with
inhibitors, such as LY204002 (for PI3K) and UO126 (for MAP/ERK), would
affect the migration of myoblasts.
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3.3. MATERIALS AND METHODS
3.3.1. CELL CULTURE
C2C12 myoblasts were cultured in a humidified 5% CO2 atmosphere at 37ºC.
Cells were grown in 10% foetal bovine serum (FBS) DMEM media, containing
1% Pen-strep (10000 U/ml) and 200mM L-glutamine (Growth media, GM), in
T75 flasks until confluent and split into multidish plates for experiments. In order
to initiate differentiation, C2C12 cells were grown in 6 well plates until
confluency was achieved, monolayers were washed with PBS and incubated in
2% horse serum (HS) DMEM media, containing 1% Pen-strep (10000 U/ml) and
200mM L-glutamine (Differentiation media, DM). For differentiation experiments
lasting for more than 3 days, DM was refreshed on the third day.
3.3.2. CONDITIONED MEDIA GENERATION
C2C12 myoblasts in 6 well plates were triggered to differentiate into myotubes,
in the presence of DM. To generate CM, cell monolayers were washed 2 times
with PBS, SF DMEM, w/ 1% Pen-Strep (10000 U/ml), w/ 1% L-glut 200mM
(SF) was added and plates were incubated for 3 hours in a humidified 5% CO2
atmosphere at 37ºC, in order to reduce the possibility of any residual serum
compononents left in the wells. Cell monolayers were washed twice with PBS and
SF media was added for conditioning by the cells. CM, incubated with 5 day old
myotubes for 3 days, was deisgnated as 5-8do (do=day old) CM. A schematic
representation of conditioned media generation:
Following aspiration, CM was filtered through a sterile 0.22µm syringe filter, in
order to remove cell debris, and stored for several days at 4ºC until used.
Preliminary experiments tested generation of conditioned media at different stages
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of myotube development. The 5-8 day old time point was chosen due to the
greater size of myotubes at this time and due to obtaining most consistent results
at this time point.
For generation of media conditioned by crushed or wounded cells, the same
procedure as described above was performed, however, after SF media addition,
monolayers were damaged with a cell scraper until completely detached from the
plate.  Media and damaged cells were then incubated in a humidified 5% CO2
atmosphere at 37ºC for 3 days, together with control plates, where monolayers
were not crushed. 3 days later, media was filtered through a sterile 0.22µm
syringe filter, in order to clean all cell debris, and stored for several days at 4ºC
until used.
3.3.3. CELL TREATMENTS AND RECONSTITUTION OF INHIBITORS
Inhibitors were purchased from Merck-Calbiochem (Darmstadt, Germany).
Inhibitors were diluted, according to manufacturer’s instructions, in DMSO and
stored at -20ºC. All inhibitors were kept in mM concentration stocks and parts of
the stocks were diluted to working concentrations in appropriate DMEM media
before cell treatments. For cell treatments, equivalent concentrations of DMSO
were added to control wells.
3.3.4. WOUND HEALING ASSAY AND LIVE IMAGING
Cells were grown in pre-gelatinised 12 well plates in GM until ~80-90%
confluent. Cell monolayers were washed 3 times with PBS and DMEM 0.1% FBS
media (quiescent media = QM) was added and incubated for 20h with the cells. In
the last 3 hours of incubation with QM, 10µg/ml Mitomycin-C (Sigma-Aldrich)
was added, in order to block proliferation, and monolayers were wounded with a
sterile pipette tip, generating a wound of approximately 600µm in size. Wound
healing with live imaging microscopy is described in section 2.2.2.1.
3.3.5. LIVE IMAGING MIGRATION ANALYSIS
Migration analysis was performed by Keynote’09 software version 5.1.1.
(Apple Inc.), which was used to place lines into wound healing videos, which
were separated by equal distance of each other, and to create cell movement
73
trajectories frame by frame into exported .AVI videos of migrating cells. ImageJ
v1.45i software was used to count cells in different zones of the wounds and to
track and calculate the distance of migration trajectories of cells.
3.3.6. CELL DEATH QUANTIFICATIONS BY LIVE IMAGING
The numbers of dying cells were counted frame by frame in each area for the
duration of the movie, as described in section 2.2.4.
3.3.7. PHALLOIDIN STAINING
Phalloidin staining was performed directly in the multidishes wells, as described
in section 2.2.6.
3.3.8. TRANSWELL INSERTS
C2C12 cells were grown in T75 flasks in the presence of GM, washed 3 times
with PBS and detached from the flask by trypsinizing with 0.05% Trypsin/0.02%
Ethylenediaminetetraacetic acid (EDTA) for 3-5 minutes at 37ºC. Cells were
resuspended in GM and were centrifuged for 10min at 500g. Supernatant
containing GM was discarded and cells were washed with PBS, followed by
another centrifugation for 10min at 500g. Cell pellets were resuspended in SF
media, cells were counted and myoblast numbers were adjusted to 120,000
cells/ml. These cells were used with transwell inserts, method is described in
section 2.2.5.2.
3.3.9. WESTERN BLOTS
Sample collection and preparation for SDS-PAGE was performed as described
in section 2.2.8.1. Gel electrophoresis, membrane transfer, blocking and detection
steps were performed, as described in sections 2.2.8.2-2.2.8.5. Primary AKTpan,
pAKT, b-actin and ERKpan rabbit IGg antibodies were purchased from New
England Biolabs (Hertfordshire, UK) and were incubated with membranes
overnight at RT in 1:1000 concentration, diluted in 5% BSA/TBST. Primary
pERK1/2 rabbit antibodies were purchased from Promega and were incubated
with membranes overnight at RT in 1:5000 concentration, diluted in 0.1%
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BSA/TBST. Secondary Goat Anti-rabbit HRP-conjugated antibodies were
purchased from MP Biomedicals (United Kingdom) and were incubated with
membranes for 1h at RT 1:5000 concentration, diluted in blocking solution.
Membranes were blocked for 1h at RT in 5% non-fat dry milk/TBST (for
antibodies purchased from New England Biolabs) or in 1% BSA/TBST for
pERK1/2.
3.3.10. RNA ISOLATIONS AND REAL-TIME PCR
RNA extraction and TaqMan® Real-time PCR methods were performed as
described in sections 2.2.9 and 2.2.10, respectively. The following predesigned
primer sets were ordered from Applied Biosystems and were used with the
TaqMan® detection method: Polr2b (Mm00464214_m1), MyoD
(mm00440387_m1), Myogenin (mm00446194_ m1).
3.3.11. STATISTICAL ANALYSES
Statistical analyses and significance of data were determined using GraphPad
Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California
USA, www.graphpad.com. Statistical significance for interactions between two
paired groups was determined with a Paired t-test, while unpaired t-test was used
for unpaired groups. Statistical significance for interactions between more than
two groups was determined with a one-way ANOVA, or with a one-way repeated
measures ANOVA, when matched observations were investigated. All results are
presented as mean +/- standard error of the mean (SEM). All values below p<0.05
were considered as significant.
3.4. METHOD DEVELOPMENT
3.4.1. WOUND HEALING ASSAY METHOD SET-UP
In order to investigate the migration potential of C2C12 cells in response to
specific factors, a wound healing assay was established. Wound healing assay is a
widely used model to investigate the migration of adherent cell types on
extracellular matrices, which provides with the possibility to quantify migration
and observe the morphology and behaviour of migration cells. It is an easy and
75
inexpensive method to set up, which, combined with Live imaging microscopy,
also provides sufficient information on various cell processes, such as migration,
proliferation, cell death, cell morphology. Considering the high number of
experiments planned in this thesis, the wound healing assay was considered as the
most appropriate tool to quantify myoblast migration. In the wound healing assay,
a scratch/wound is created in a monolayer of confluent cells, usually using a
pipette tip, and the progress of wound closure by the cells is observed over time.
Different stages of the wound healing experiment preparations are illustrated in
Figure 3.1. Wound size was approximately 600µm in length, although slight
variations between experiments were impossible to avoid. Wound sizes between
different wells were compared before each live imaging experiment was initiated,
so that different treatments would be applied to wells with comparable wound
sizes. Following wounding, cell monolayers were washed twice with PBS, in
order to remove cell debris, and media with different composition or treatments
were added to each well. After the X and Y coordinates on the microscope were
set, live imaging movies were initiated, lasting for 20hrs, with frames being
captured every 15min. Preliminary optimization experiments were tested at
different time periods for performing the wound healing assay. 20 hours was
chosen as the most appropriate period, considering the wound size and the speed
of closure of the wound with different conditions tested.
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Figure 3.1. Optimization of wound healing assay. Cell monolayers were grown in
10% FBS media (GM) until approx. 80-90% confluent (A). GM was replaced with 0,1%
FBS (Quiescent media) and cells were incubated for a further 20h (B). The cell
monolayer was damaged (C) and wound closure/migration was captured with live
imaging microscopy, usually for 20hrs (D).
To study migration in the absence of conflicting proliferation, cell monolayers
were pre-incubated for 3hrs in 10µg/ml of Mitomycin-C, (purchased from Sigma-
Aldrich (Dorset, England)) before live imaging was initiated. Preliminary
experiments observing the velocity of wound closure between cells treated with
10µg/ml of Mitomycin-C and control media in the absence of Mitomycin-C,
demonstrated that while proliferation was blocked with Mitomycin-C, the rate of
wound closure and cell migration were not visually affected between treatments
(Figure 3.2), with only a few proliferation events observed in the first 18hours of
wound closure. Thus, the very low proportion of proliferation events, occurring
without Mitomycin-C treatment, did not exert any visually detectable effects on
the overall extent of migration. Never the less, although proliferation did not
apparently influence the migratory capacity of cells during wound healing, in
order to focus solely on the migration of cells and facilitate the migration analysis,
it was decided to perform the live imageing wound closure experiments in the
presence of 10µg/ml of Mitomycin-C. In order to verify the block of cell
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proliferation following Mitomycin-C stimulation, observation was performed of
multiple videos, which confirmed no visible proliferation events during the period
of wound closure observed. Further proliferation assays were not performed, as
satisfactory results were obtained from visual observations, indicating no
proliferating cells during the migration/wound closure of cells. Furthermore, even
if Mitomycin-C does not completely block proliferation of myoblasts in all
experiments analysed, the number of proliferation events during wound closure in
the presence of Mitomycin-C would be low enough to presume that wound
closure is accomplished by migration and not by cell division.
Figure 3.2. Effect of Mitomycin-C on myoblast migration. No visible difference
in cell migration was observed between cells incubated with (A) and without (B) 10µg/ml
of Mitomycin-C in the first 20h of wound closure.
3.4.2. WOUND HEALING LIVE IMAGING MIGRATION ANALYSIS
Cell migration in wound healing assays is normally analysed and quantified
using several approaches - most commonly, by analyzing the percentage of
wound area closed by cells, by counting the total number of cells infiltrating the
wound, or by tracking individual cells from both sides of the wound and
estimating the distance travelled by these cells. Usually, one of these approaches
is selected. However, it must be noted that different cell types might migrate
differently. Preliminary observations of the manner in which C2C12 myoblasts
migrated during wound healing assays, demonstrated that many of the myoblasts
exhibited random movement, migrating individually and the wound was not
closed by a collective migration of the myoblasts in a sheet-like manner. Thus,
analysis solely of the total number of cells infiltrating the wound, which examines
collective cell migration, might not be the most appropriate analysis for all wound
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healing experiments involving myoblasts. Therefore, different approaches of
analyzing myoblast migration during wound healing were tested and assessed,
with the idea that combination of two or more analyses would provide a better
indication of how myoblast migration is affected by different treatments.
A method of analysis for counting the number of cells infiltrating the wound was
therefore established. Given the independent migration of these cells, the wound
area was divided into 3 areas of equal size and not only were the total number of
cells in the wound area calculated, but also the number of cells infiltrating the
central most area of the wound. The division of the wound into 3 distinct areas
was accomplished by drawing (using relevant software) 4 lines along the length of
the wound, with equal spacing between the marker lines, essentially dividing the
wound into tertiles. Equal spacing between the lines was verified using
Keynote’09 software version 5.1.1. (Apple Inc.). As shown in Figure 3.3, the first
and last lines (marked with red arrows) indicate the edges of the wound, before
the cells started to migrate. The lines marked with green arrows encompass the
central area of the wound. On the same figure, counts were performed using
ImageJ v1.45i to indicate how many cells in total had infiltrated the wound for a
given time period and what percentage of them were situated in the central area of
the wound. This methodology not only provided information relating to the
number of cells migrating but also their capacity for linear migration.  In this
example, 63 cells in total infiltrating the wound were counted in (A), with 8% in
the middle of the wound area, vs 99 cells in total infiltrating the wound in (B),
with 25% in the middle of the wound. This indicates significantly more migration
in condition B. The percentage of cells in the middle of the wound also provides a
good indication of the rate of cell migration e.g. cells reaching the centre/h which
was apparently enhanced in (B) vs (A).
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Figure 3.3. Demonstration of the demarcations established in a wound
healing assay. To ascertain migration potential, the total number of cells infiltrating the
wound was established. These photomicrographs reveal an example of how the cell count
analysis was verified between two different types of wound closure. A condition inducing
visually less wound closure, indicated fewer number of cells (n = 63) infiltrating the
wound following cell count analysis (A), as compared to a condition inducing visually
greater wound closure (B), resulting in higher number of cells following cell count
analysis (n = 99 cells). Quantification of the percentage of cells in the middle of the
wound also confirms these observations: 8% in the centre (A) vs 25% (B). Red arrows
depict the lines marking the wound edge and green arrows the lines marking the central
1/3 of the wound site.
Another example of the cell counting method is provided in Figure 3.4. Counts
indicated equivalent numbers of total cells infiltrating the wound between (A) and
(B), however double the proportion of cells in the middle of the wound in (B) vs
(A), suggesting enhanced cell spreading in (B) vs (A). This suggests that analysis
of the total cell numbers infiltrating the wound may not always be indicative of
the degree and nature of cell migration. A combination of different analyses might
help obtaining better information on cell migration than using only one approach.
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Figure 3.4. An example of cell count analysis. These photomicrographs reveal an
example of how the cell count analysis was verified, by examining two different types of
wound closure. Cell count analysis demonstrates equivalent total number of cells
infiltrating the wound between type/condition A and type/condition B, but double the
percentage of cells infiltrating the middle part of the wound in B vs A, suggestive of more
cell migration and spreading of cells in the wound in condition B.
In addition to the method above, and in an attempt to look at directional
migration, another cell migration assessment method was established to assess
how the average migration distance of myoblasts is affected by different
treatments. Cell tracking analysis was performed by selecting 8 cells from both
sides of the wound, and the trajectories of these cells were created by tracking
frame by frame their movement. The trajectories, drawn as lines, were exported as
“.jpeg” files and their length was measured using ImageJ v1.45i. The average
length of all 16 trajectories per movie was established. At least 3 movies per
experimental group were analysed for every experimental protocol. The final
results were calibrated to a size marker, included in the live imaging movies, and
converted to µm units (Figure 3.5). Derived data for experimental studies
illustrated that cell tracking analyses confirmed the results from the cell counting
analyses.
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Figure 3.5. Illustrative photomicrographic quantification of cell migration
using tracking of the migration distance. These photomicrographs reveal an
example of how the migration distance analysis was verified, by examining two different
types of wound closure. Visually reduced wound closure in condition A resulted in lower
average migration distance (222um), as compared to condition B (average migration
distance of 400um), which also demonstrated visually enhanced wound closure.
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3.5. RESULTS
3.5.1. CELL CULTURE MEDIA, CONDITIONED IN VITRO BY C2C12
MYOTUBES IS CAPABLE OF INDUCING WOUND CLOSURE OF
C2C12 MYOBLASTS
Having established these novel methods, for the purpose of our experiments, the
hypothesis that myogenic cells are capable of secreting factors, which induce
wound healing and migration was examined. SF DMEM media was incubated
with well developed myotube cultures for 3 days, thus obtaining CM (as described
in methods section 3.3.2). Preliminary wound healing assays were performed to
visually compare the effect of the CM vs non-conditioned control SF media on
wound closure. Consistent wound closure results were obtained using media
conditioned for 3 days with 5do myotube cultures (i.e. 5-8do CM), or with 8-11do
CM. Photomicrographic representation illustrates the accelerated wound closure
observed with CM, compared to slower and incomplete closure with control SF
(Figure 3.6). Furthermore, the numbers of floating, dead cells appears to be
reduced in CM vs SF conditions.
Figure 3.6. Photomicrographic representation of wound healing assay (20h
post wound). Enhanced induction in wound closure at 24h is observed with CM
incubated for 3 days with 5do myotubes (5-8do CM) (A) vs control SF media (B). (10x
magnification). Images are representative of at least 4 experiments performed in
duplicate.
A change in morphology between the cells incubated with CM vs SF was also
observed and was most evident when cells were incubated for 48h (Figure 3.7).
Cells in CM demonstrated a more elongated morphology, with filopodial
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protrusions visible, while the cells incubated in SF demonstrated morphology
more characteristic of senescent cells – being round in shape, and displaying
easily visible perinuclear zones and centrally located nuclei.
Figure 3.7. Subconfluent cultures of C2C12 myoblasts incubated for 48h in
CM or SF. Morphological differences between the cell culture conditions were
observed, with myoblasts in CM (A) having a more compact, elongated shape, with
visible protrusions, such as filopodia (white arrows), while the myoblasts incubated in SF
(B) possessed more rounded morphology, with easily visible centrally located nuclei.
(20x magnification). Images are representative of 2 experiments performed in duplicate.
3.5.2. OPTIMIZATION OF MYOBLAST MIGRATION: COMPARISONS
OF CONDITIONED MEDIA, SERUM FREE-MEDIA, GROWTH MEDIA
AND DIFFERENTIATION MEDIA
Initial studies observed accelerated wound closure with CM vs. SF. To
determine the specificity of these observations and to optimize conditions, the
effects of CM on wound closure were compared with the effects of GM and DM.
The migration was initially assessed morphologically and subsequently quantified
by cell counting and tracking. As shown on Figure 3.8(A), CM, DM and GM, are
capable of inducing wound healing to a greater extent than SF; with GM
appearing most potent.
Total counts of the number of cells infiltrating the wound after 20h of culture
(Figure 3.8B) demonstrated an increase in infiltrating numbers with GM vs CM
(158 +/-13 vs 84 +/- 6, p<0.01, equivalent to 188% increase), GM vs DM (158 +/-
13 vs 77 +/-6, p<0.001, equivalent to 205% increase) and GM vs SF (158 +/- 13
vs 36 +/- 0, p<0.0001, equivalent to 438% increase). Significantly more cells were
also present within the wound site with CM vs SF (84 +/- 6 vs 36 +/-0, p<0.05,
equivalent to 233% increase) and also with DM vs SF (77 +/-5 vs 36 +/-0, p<0.05,
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equivalent to 213% increase). No significant difference, with regard to migration
into the wound site, was found between CM and DM.
Analysis on the percentage of cells in the middle of the wound (Figure 3.8C)
demonstrated significant increase with GM vs CM (22.3 +/- 2.4% vs 12 +/- 2%,
p<0.01), GM vs DM (22.3 +/-2.4% vs 8 +/- 3.2%, p<0.001) and GM vs SF (22.3
+/-2.4% vs 3 +/- 2.1% p<0.0001). Significant increases were also observed with
CM vs SF (12 +/-2% vs 3 +/- 2.1%, p<0.01), but not between DM vs SF or CM vs
DM.
Figure 3.8. Wound healing assay with cell count analysis (CM, DM, GM, SF).
Wound healing assay (20h) comparing the effects of CM, DM, GM and SF indicated
accelerated wound closure with CM, DM and GM, compared to SF, with GM appearing
most potent (A). (10x magnification).  Quantification of the total number of cells
infiltrating the wound after 20h (B): impact of culture conditions was investigated on
migration; significant increases were observed with GM vs CM (p<0.01, represented by
*), GM vs DM (p<0.001, represented by a) and GM vs SF (p<0.0001, represented by c);
significant increases were observed with CM vs SF (p<0.05, represented by #); and with
DM vs SF (p<0.05, represented by b). Quantification of the percentage of cells in the
centre of the wound (C): significant increase observed with GM vs CM (p<0.01,
represented by *), GM vs DM (p<0.001, represented by a) and GM vs SF (p<0.0001,
represented by b); significant increases were observed with CM vs SF (p<0.01,
represented by #). Data are representative of 3 experiments performed in duplicate. (p-
values were obtained by using a One-way repeated measures ANOVA).
In order to consolidate these data and to decrease the potential of subjectivity, a
tracking methodology was established to monitor the migration of individual cells
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into the wound area (described in methods chapter 3.4.2) and under the influence
of the selected culture media. Cell tracking analyses support the results presented
above, regarding the potency of culture media and the impact on cellular
migration (Figure 3.9). Morphological tracking (Figure 3.9A) suggested GM to be
most potent at promoting migration from the wound edge to the centre, followed
by CM, DM and SF.  Analyses of cell tracking, illustrated in Figure 3.9(B),
demonstrated significant increases in migration distance with GM vs CM (580 +/-
60µm vs 392 +/-21µm, p<0.05, equivalent to 48% increase), GM vs DM (580 +/-
60µm vs 329 +/-20µm, p<0.01, equivalent to 76% increase) and GM vs SF (580
+/-60µm vs 219 +/-3.5µm, p<0.001, equivalent to 264% increase). Migration
distance was also increased with CM vs SF (392 +/-21µm vs 219 +/-3.5µm,
p<0.05, equivalent to 79% increase). No significant difference was observed
between CM vs DM or between DM and SF, using ANOVA analysis for all 4
groups, however, when DM and SF were directly compared in a paired t-test
significance was achieved with DM vs SF (329 +/-20µm vs 219 +/-3.5µm,
p=0.03, equivalent to 50% increase). These analyses confirm the observational,
morphological assessments above.
Wishing to determine the impact of cell death on migration capacity, dying cells
per arbitrary field of view were quantified. As shown on Figure 3.9(C),
percentage dead cells was significantly increased in SF vs CM (12.2 +/- 1.3% vs
1.77 +/-1%, p<0.0001), SF vs DM (12.2 +/-1.3% vs 0.18 +/-0.13%, p<0.0001,)
and SF vs GM (12.2 +/-1.3% vs 0 +/-0%, p<.0001). No significant differences
were found between CM, GM and DM.
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Figure 3.9. Cell tracking and cell death analysis (CM, DM, GM, SF). Cell
tracking comparing the effects of CM, DM, GM and SF. (A) (10x magnification).
Quantification of cell migration distance (B). Significant increases were observed with
GM vs CM (p<0.05, represented by *), GM vs DM (p<0.01, represented by a) and GM vs
SF (p<0.001, represented by b). Significant increase was also observed with CM vs SF
(p<0.05, represented by #).  Cell death quantification (C). Significant increases in cell
death were evident with SF vs CM (p<0.0001, represented by *), SF vs GM (p<0.0001,
represented by a) and SF vs DM (p<0.0001, represented by b). No significant difference
in cell death was found between CM, GM and DM. Data are representative of 3
experiments performed in duplicate. (p-values obtained by One-way repeated measures
ANOVA)
3.5.3. IMPACT OF CULTURE CONDITIONS ON CHEMOTAXIS.
Having determined differential effects of culture conditions on the capacity of
cells to migrate into wound sites and to remain adherent to the extracellular matrix
(ECM) coating the culture dishes, it was further planned to also ascertain the
impact of culture conditions on chemotaxis of cells through transwell membranes,
in order to substantiate culture conditions for future experimentation. Therefore,
chemotaxis in the presence of CM, DM, GM or SF was examined using transwell
inserts (Figure 3.10). Following transfer of equivalent cell numbers to the upper
chambers of the transwell inserts in SF culture medium, cells were incubated for 4
hours in CM, DM, GM or SF before experimentation was terminated. Cells
adherent to the underside of the transwell membrane were stained and examined.
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As is evident in Figure 3.10, CM (A) and DM (B) induced greater chemotaxis
than SF (D) and, surprisingly, than GM (C).
Figure 3.10. Examination of chemotaxis by transwell inserts (CM, DM, GM,
SF). Images are representative of the underside of the transwell following 4 hours of
incubation.  Cells were seeded on the top of the transwells in SF culture medium, with
CM (A), DM (B), GM (C) and SF (D) in the lower chambers. Following 4 hrs of
incubation, CM (A) and DM (B) induced increased chemotaxis compared to GM (C) and
SF (D). (10x magnification, 1.6x zoom). Data are representative of 3 experiments
performed in duplicate.
Quantifications and analysis of the number of cells on the bottom surface of the
porous membranes (Figure 3.11), demonstrated significant increases in
chemotaxis with CM vs SF (253 +/-42 vs 4 +/-2.5, p<0.01, equivalent to 6325%
increase) and with DM vs SF (199 +/-8 vs 4 +/-2.5, p<0.01, equivalent to 4975%
increase). Increases were also observed with CM vs GM (p<0.01, 253 +/-42 vs 22
+/-2, equivalent to 1150% increase) and DM vs GM (p<0.01, 199 +/-8 vs 22 +/- 2,
equivalent to 905% increase). No significant differences were observed between
GM and SF or between CM and DM.
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Figure 3.11. Transwell inserts cell quantifications (CM, DM, GM, SF).
Significant increases were observed with CM vs SF (p<0.01, represented by #) and DM
vs SF (p<0.01, represented by b). Increases were also observed with CM vs GM (p<0.01,
represented by *) and DM vs GM (p<0.01, represented by a). No significant difference
was indicated between GM and SF or between DM and CM. Data are representative of 3
experiments performed in duplicate. (p-values obtained by One-way repeated measures
ANOVA)
GM strongly induced wound closure and migration of C2C12 myoblasts, but,
surprisingly, did not largely increase their chemotaxis in the transwell migration
assay. To examine this discrepancy, the effect of media dilution was examined
using transwell inserts. As shown on Figure 3.12, GM diluted in 1:5 ratio with SF
media (equivalent to 2% FBS content in the diluted GM), was more potent at
inducing chemotaxis through the transwells compared to standard GM containing
10% FBS, suggesting that the inclusion of high-serum in transwell wells, contrary
to what was expected and also evident by enhanced cell migration with wound
healing, was not inducing cell chemotaxis, but was decreasing it.
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Figure 3.12. Transwell inserts cell quantifications between GM 10% and GM
2%. Standard GM (10% FBS) (A) is less potent at inducing myoblast chemotaxis
through transwell inserts, compared to GM diluted 1:5 with SF media (equivalent to 2%
FBS) (B).(10x magnification). Data are representative of 3 experiments performed in
duplicate.
3.5.4. MEDIA CONDITIONED BY VIABLE OR SERUM
STARVED/ATROPHYING MYOTUBES IS MORE POTENT AT
INDUCING MIGRATION AND WOUND HEALING COMPARED TO
MEDIA CONDITIONED BY INJURED/CRUSHED MYOTUBES
As detailed above, SF media conditioned for 3 days by mature myotubes can
induce wound healing, cell survival and transwell chemotaxis. 5 do myotubes
incubated for 3 days in SF media display a reduction in the density of the
myotubes in culture and increased rates of atrophy (as confirmed morphologically
by a decreased myotube size) or death over the 72 h culture period (Figure 3.13).
90
Figure 3.13. Changes in morphology of myotube cultures during conditioning
with SF media for 3 days. Atrophy of the 5 day-old myotubes was observed
morphologically during the 3 days of incubation with SF media. Top panels show phase-
contrast photos (20x objective), while bottom panels - phalloidin-FITC staining (20x
objective). Data are representative of 2 experiments performed in duplicate.
It was investigated whether factors released from dead cells, or possibly their
cellular contents, were able to induce wound closure and myoblast migration to a
degree higher or comparable to the myotubes in CM or to DM. Comparisons were
made (by wound healing assay) of the effect of media conditioned for 3 days with
well developed 5do myotubes (CM) vs media conditioned for 3 days in the
presence of mechanically injured/crushed myotubes (CM-crushed). As shown in
Figure 3.14(A) and perhaps in contrast to the expectation that factors from
mechanically damaged cells may have enhanced migration compared with CM,
wound closure was reduced with CM-crushed vs CM medium.
Quantification of cell counts within the wound site, demonstrated significant
decreases in the total number of cells infiltrating the wound (Figure 3.14B) with
CM-crushed vs CM (43 +/-5.5 vs 84 +/-5, p<0.05, equivalent to 95% decrease).
Furthermore, the percentage of the cells in the middle of the wound area (Figure
3.14C) was also significantly lower with CM-crushed compared to CM (1.5 +/-
0.65% vs 15.5 +/- 0.9%, p<0.001).
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Figure 3.14. Wound healing assay with cell count analysis (CM vs CM-
crushed). Wound healing assay comparing the effects on wound closure of media
conditioned for 3 days with well developed, 5 do myotubes (CM) vs media conditioned
for 3 days with mechanically crushed myotubes (CM-crushed) (A).  Wound healing cell
migration count quantifications (B). Quantification of the total number of cells infiltrating
the wound after 20h: significant decrease observed with CM-crushed compared to CM
(p<0.05, represented by *). Quantification of the percentage of cells in the middle of the
wound (C): significant decrease observed with CM-crushed vs CM (p<0.001, represented
by *). Data are representative of 4 experiments performed in duplicate. (p-values
obtained by paired t-test)
Once again, to validate the above observation, cell tracking analyses were
performed and visually confirmed the reduction in migration with CM-crushed vs
CM as illustrated morphologically (Figure 3.15A) and substantiated by
quantification (Figure 3.15B).  Cell tracking analyses demonstrated a significant
reduction of cell migration distance with CM-crushed vs CM (213 +/- 21µm vs
380+/- 10µm, p<0.01, equivalent to 78% decrease), following 20h incubation.
Once again, wishing to determine whether culture conditions were impacting on
the adherence/survival of migrating cells, dead cell numbers were quantified for
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20h post wounding (Figure 3.15C).  No significant differences in cell death were
observed with CM vs CM-crushed (2.8 +/-0.32% vs 3.48 +/-1.22%, p=0.59).
Figure 3.15. Cell tracking and cell death analysis (CM vs CM-crushed). Cell
tracking comparing the effects of CM vs CM-crushed on cell migration into a wound area
(A). (10x magnification). Quantification of cell migration distance (B). Significant
reduction with CM-crushed vs cm (p<0.01, represented by *).  Cell death quantifications
(C). No significant difference was observed between CM and CM-crushed. Data are
representative of 3 experiments performed in duplicate. (p-values obtained by paired t-
test)
Finally, chemotactic responses of myoblasts to CM and CM-crushed were
imvestigated using transwell inserts (Figure 3.16). Cells moved to the underside
of the porous membrane with CM-crushed, however there was a distinctive
clustering of cells on the bottom of the membrane, which was not observed with
CM.
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Figure 3.16. Examination of cell chemotaxis by transwell inserts comparing
CM vs CM-crushed. Large numbers of cells were present on the underside of the
membrane in response to CM (A). Cell chemotaxis was also observed in response to CM-
crushed, however cells were clustered in groups of cells (B). (10x magnification). Data
are representative of 3 experiments performed in duplicate.
3.5.5. PI3K AND ERK1/2 PATHWAYS ARE ACTIVATED BY CM, GM
AND DM, BUT NOT BY SF
In order to determine the impact of culture conditions on signalling pathways,
which may be important for cellular migration, cells were cultured as for wound
healing assay and at 15 or 30 min following transfer to relevant culture media,
lysates were extracted and subsequently subjected to Western blot analyses in
order to measure the activation of members of the PI3K and MAPK pathways, in
particular pAKT (ser473) and pERK 1/2, in response to GM, DM, SF and CM
(Figure 3.17). The data below suggest that both ERK and Akt are not activated by
SF.  CM does induce more sustained pAkt activation compared to SF, but is not as
potent as either GM or DM.  Although all 3 triggers (GM, DM, CM) induce
potent pERK1/2 activation at 15 min, this is less sustained, as compared to pAkt,
and its activation declines at 30 min. with the slope of decline appearing steepest
in CM.
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Figure 3.17. Western blots (GM, DM, SF, CM). Western blots examining the
activation of members of the PI3K and MAPK signalling pathways in the presence of
GM, DM, SF and CM for 15 and 30 min. β-Actin, Akt-pan and ERK-pan were included
as controls. 30 ug total protein loaded per lane. Data are representative of at least 4
experiments.
Wishing to quantify these apparent observations, blots were subjected to further
analysis using Quantity One software. Phospho-Akt levels were first quantified
across the 4 different media conditions and the two time points (Figure 3.18). All
values are represented as percentage of the calibrator (GM 15m), which was set
to 100%. Significantly lower pAKT activity was observed with SF compared to
GM at both 15m (4.2 +/-0.86% vs 100%, p<0.0001) and 30m (7.8 +/-4%vs 86.4
+/-7%, p<0.0001). pAkt was also significantly lower in SF vs DM at both 15m
(4.2 +/-0.86% vs 67.6 +/-10%, p<0.01) and 30m (7.8 +/-4% vs 66.8 +/-9.9%,
p<0.0001). Significantly lower pAKT levels were observed with SF vs CM at
both 15m (4.2 +/-0.86% vs 53 +/-13.6%, p<0.05) and 30m (7.8 +/-4% vs 30 +/-
8.4%, p<0.05). Levels of pAKT were reduced with CM compared to GM at both
15m (53 +/-13.6% vs 100%, p<0.05) and 30m (30 +/-8.4% vs 86.4 +/-7%,
p<0.0001). Significant reduction was observed in pAKT activity with DM vs GM
at 30m (66.8 +/-9.9% vs 86.4 +/-7%, p<0.05) and with CM vs DM at 30m (30+/-
8.4% vs 66.8 +/-9.9%, p<0.0001).
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Figure 3.18. pAKT quantification (GM, DM, SF, CM). Following treatments,
SDS PAGE and Western blotting, membranes were subjected to quantification for further
analyses. Significantly lower pAKT levels were observed with SF vs GM at both 15m
(p<0.0001, represented by *) and 30m (p<0.0001, represented by *). Lower pAKT
activity was also observed with SF vs DM at both 15m (p<0.01, represented by a) and
30m (p<0.0001, represented by a). Reduced pAKT levels were observed with SF vs CM
at both 15m (p<0.05, represented by b) and 30m (p<0.01, represented by b). Lower levels
of pAKT activity was present with CM vs GM at both 15m (p<0.05, represented by #)
and 30m (p<0.0001, represented by #).  pAKT levels were also lower with DM vs GM at
30m (p<0.05) and CM vs DM at 30m (p,0.0001). Data are representative of 5
experiments. (p-values obtained by One-way repeated measures ANOVA)
As for pAkt, phospho-ERK 1/2 levels were quantified following incubation in
the 4 different culture media for 15 or 30 min (Figure 3.19). All values are
represented as percentage of the calibrator (GM 15m), which was set to be 100%.
Significant reductions of pERK1/2 levels were observed with SF vs GM at both
15m (13.75 +/-6.36% vs 100%, p<0.0001) and 30m (3.5+/-1.66% vs 73.25 +/-
3.1%, p<0.0001), SF vs DM at both 15m (13.75 +/-6.36% vs 88.25 +/-4.68%,
p<0.0001) and 30m (3.5 +/-1.66% v 59.75 +/-7.1%, p<0.001) and SF vs CM at
15m (13.75 +/-6.36% vs 83 +/-6.1%, p<0.0001). Lower pERK1/2 was present
with CM vs GM at 30m (83 +/-6.1% vs 100%, p<0.0001) and CM vs DM at 30m
(13.25+/-5.62% vs 59.75 +/-7.1%, p<0.001). Significant reduction of pERK1/2
levels at 30m vs 15m were observed with GM (73.25 +/- 3.1% vs 100%, p<0.01),
DM (59.75 +/-7.1% vs 88.25 +/-4.68%, p<0.01) and CM (13.25 +/-5.62% vs 83
+/-6.1%, p<0.01).
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Figure 3.19. pERK 1/2 quantification (GM, DM, SF, CM). Following treatments,
SDS PAGE and Western blotting, membranes were subjected to quantification for further
analyses. Significantly lower levels of pERK1/2 were observed with SF vs GM at both
15m (p<0.0001, represented by *) and 30m (p<0.0001, represented by *). Lower
pERK1/2 activity was also observed with SF vs DM at both 15m (p<0.0001, represented
by a) and 30m (p<0.001, represented by a) and SF vs CM at 15m (p<0.0001, represented
by b). pERK1/2 activity was lower with CM vs GM at 30m (p<0.0001, represented by #)
and with CM vs DM at 30m (p<0.001, represented by d). Significant reduction of
pERK1/2 levels at 30m vs 15m was observed with GM (p<0.01, represented by t), DM
(p<0.01, represented by t) and CM (p<0.01, represented by t). Data are representative of 4
experiments performed in duplicate. (p-values obtained by One-way repeated measures
ANOVA)
3.5.6. REDUCTION OF MYOGENIN EXPRESSION WITH CM VS DM.
Having investigated the impact of culture conditions on cell migration and the
potential underlying signalling pathways, the impact of culture conditions on the
expression of myogenic regulatory factors, myogenin and myoD, was next
questioned.  Since investigating positive regulators of migration was of main
interest, SF was not included in these studies. RT-PCRs were performed to
investigate the expression of MyoD and Myogenin, 24h after treatment with DM,
GM or CM. A 24 hour time point was chosen, due to the fact that these myogenic
regulatory factors are known to show a peak of expression in the beginning of
differentiation, which decreases in later time points. All data are represented in
arbitrary units and compared to the calibrator (DM), which was set to 1. As shown
in Figure 3.20(A), significant reductions in the expression of Myogenin were
97
observed with GM vs DM (0.16 +/-0.06 vs 1, p<0.001, equivalent to 6.25 fold
decrease) and with CM vs DM (0.5 +/-0.06 vs 1, p<0.01, equivalent to 2 fold
decrease). Reductions were also observed with GM vs CM (0.16 +/-0.06 vs 0.5
+/-0.06, p<0.05, equivalent to 3.125 fold decrease). These data suggest that while
all three triggers are able to promote migration, GM and CM are more potent at
suppressing the myogenic pathway in favour of migration, than DM.
MyoD expression (Figure 3.20B) was less influenced by culture conditions. No
significant differences were found between any of the treatments.
Figure 3.20. Myogenin and MyoD expression (DM, GM, CM). Myogenin
expression 24h after treatment with DM, GM and CM (A). All values are represented as
fold change to the calibrator (DM), which was set to 1 (mean Ct value (MyoD) = 21.98
+/-0.16; mean Ct value (Myogenin) = 21.79 +/-1.05) Significant reductions were
observed with GM vs DM (p<0.001, represented by *), CM vs DM (p<0.01, represented
by #) and GM vs CM (p<0.05, represented by a). MyoD expression 24h after treatment
with DM, GM and CM (B). No significant difference was observed between any of the
treatments. Data are representative of 3 experiments performed in duplicate. (p-values
obtained by One-way repeated measures ANOVA)
3.5.7. MYOBLAST MIGRATION, INDUCED BY CONDITIONED MEDIA,
IS REDUCED BY INHIBITION OF PI3K/AKT AND MAPK/ERK
PATHWAYS WITH LY294002 AND UO126
It was observed that myotube CM was able to induce myoblast migration and to
activate signalling pathways, such as PI3K/AKT and MAPK/ERK, which are
linked to, among other cellular responses, regulating cellular migration. Inhibitors
of PI3K/AKT and MAPK/ERK pathways, respectively LY294002 and UO126,
were used to investigate how silencing of these signalling pathways would affect
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the migration capacity of myoblasts induced to migrate by CM. In order to
confirm the specificity and effect of both inhibitors on levels and activation of
these specific proteins, western blots were performed against pAKT (Ser473) and
pERK 1/2 (Figure 3.21). Large decreases in the levels of pAKT, as compared to
control CM, at both 15m and 30m were obvious in the presence of 10µM
LY294002, while pERK1/2 levels were not affected. On the contrary, in the
presence of 5µM UO126, pERK1/2 was largely inhibited, as compared to control
CM, at both 15m and 30m, while pAKT levels were not affected. Total Akt, ERK
and beta-actin were used as loading controls.  As is evident from the figure for
Akt and beta-actin, loading was consistent across all samples.  The apparent
discrepancy evident with pan ERK antibodies e.g. a reduction in ERK levels in
the presence of CM and LY at 15 and 30 min. was investigated further and was
found to occur as a consequence of competition between the pERK1/2 and pan-
ERK antibodies (all pERK1/2 blots were run before membranes being stripped
and reprobed with pan ERK antibodies), with pERK1/2 phosphorylation reducing
pan-ERK binding, rather than a reduction in total ERK occurring (data not
shown).
Figure 3.21. Western blots (CM with 10µM LY294002 and 5µM UO126).
Western blots examining the levels of pAKT (Ser473) and pERK 1/2 at 15 and 30 min in
response to CM (lanes 1 + 4=CM), CM+10µM LY294002 (lanes 2 + 5=LY) and
CM+5µM UO126 (lanes 3 + 6 =UO). Data are representative of 4 experiments.
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Blots were subjected to further analyses using Quantity One software. Phospho-
Akt and Phospho-ERK1/2 levels were quantified across the 3 different treatments
conditions and the two time points. All values are represented as percentage of the
calibrator (CM 15m), which was set to 100%.
Quantification and analyses of pAKT levels (Figure 3.22) indicated significant
reductions with CM+10µM LY294002 vs CM at both 15m (19.75% +/-2.36 vs
100%, p<0.001) and 30m (27.25% +/-2.21 vs 88% +/-15.56, p<0.05). Significant
reductions in pAkt were also observed with CM+10µM LY294002 vs CM+5µM
UO126 at both 15m (19.75% +/-2.36 vs 91.25% +/-11.44, p<0.01) and 30m
(27.25% +/-2.21 vs 80% +/-11.47, p<0.05). No significant reduction in pAKT
levels was observed with CM+5µM UO126 vs CM.
Figure 3.22. Quantification of pAKT (CM with 10µM LY294002 and 5µM
UO126). Quantification of pAKT levels in response to CM, CM+10µM LY294002 and
CM+5µM UO126 indicated significant reductions with CM+10µM LY294002 vs CM at
both 15m (p<0.001, represented by *) and 30m (p<0.05, represented by *) and with
CM+10µM LY294002 vs CM+5µM UO126 at both 15m (p<0.01, represented by #) and
30m (p<0.05, represented by #). Data are representative of 4 experiments. (p-values
obtained by One-way repeated measures ANOVA)
Quantification and analysis of pERK1/2 levels (Figure 3.23) indicated
significant reductions in pERK1/2 activation with CM+5µM UO126 vs CM at
15m (3% +/-1.15 vs 100%, p<0.0001) and CM+5µM UO126 vs CM+10µM
LY294002 at 15m (3% +/-1.15 vs 83.67% +/-15.45, p<0.001). No significant
difference in pERK 1/2 levels was indicated with CM+10µM LY294002 vs CM at
15min. No significant change was observed between any of the treatments at 30
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min, despite levels of pERK1/2 remaining visually lower with UO126 treatment.
Significant reductions of pERK1/2 levels with time was also observed at 30m vs
15m with both CM (17.67% +/-6.33 vs 100%, p<0.001) and CM+10µM
LY294002 (18% +/-2.89 vs 83.67% +/-15.45, p<0.05).
Figure 3.23. Quantification of pERK1/2 (CM with 10µM LY294002 and 5µM
UO126). Quantification or pERK1/2 levels in response to CM, CM+LY294002 and
CM+UO126 indicated significant reductions with CM+5µM UO126 vs CM at 15m
(p<0.0001, represented by *) and CM+5µM UO126 vs CM+LY294002 at 15m (p<0.001,
represented by #). Significant reductions in the pERK 1/2 levels were observed at 30m vs
15m with both CM (p<0.001, represented by t) and LY (p<0.05, represented by t). Data
are representative of 4 experiments. (p-values obtained by One-way repeated measures
ANOVA)
After observations that both inhibitors were reducing the phosphorylation levels
of pAKT and pERK1/2 in a specific manner, wound healing assays were
performed in the presence of CM, CM+10µM LY294002 and CM+5µM UO126,
in order to determine the effect of inhibiting these signalling pathways on the
migration of myoblasts (Figure 3.24A). Results from these morphological studies,
as expected, suggested inhibited migration in the presence of either LY294002 or
UO126, compared with CM alone, over 20 h.
Quantifications and statistical analyses of cell counts infiltrating the wound site
(Figure 3.24B), indicated significant reductions in the total number of cells when
treated with CM+10µM LY294002 vs CM (47 +/- 5 vs 71 +/- 4 cells, p<0.05,
equivalent to 39% decrease) and with CM+5µM UO126 vs CM (51 +/- 7 vs 71
+/- 4 cells, p<0.05, equivalent to 28% decrease). Significant reductions were also
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apparent in the percentage of cells present in the centre of the wound site with
CM+10µM LY294002 vs CM (3.4 +/-0.5 vs 11.1 +/-1.8 %, p<0.01) and with
CM+5µM UO126 vs CM (4.8 +/-1.36 vs 11.1 +/-1.8 %, p<0.01) (Figure 3.24C).
Figure 3.24. Wound healing assay with cell count analysis (CM with 10µM
LY294002 and 5µM UO126). Wound healing assay comparing the effects on wound
closure of CM, CM+10µM LY294002 and CM+5µM UO126 following 20h incubation
(A). Quantification of the total number of cells infiltrating the wound after 20h
incubation, indicated a significant decrease in the number of cells with both CM+10µM
LY294002 vs CM (p<0.05, represented by *) and CM+5µM UO126 vs CM (p<0.05,
represented by #) (B).  Quantification of the percentage of cells in the middle of the
wound indicated a significant decrease with both CM+10µM LY294002 vs CM (p<0.01,
represented by *) and CM+5µM UO125 vs CM (p<0.01, represented by #) (C). All data
are representative of 5 experiments performed in duplicate. (p-values obtained by One-
way repeated measures ANOVA)
To confirm the cell count quantification data, migration tracking analyses were
performed to examine the effect of CM, CM+10µM LY294002 and CM+5µM
UO125 on cell migration distance. Once again, these morphological findings
confirmed the observations made above (Figure 3.24) and suggested reductions in
migration distance as a consequence of incubations with either inhibitor vs CM
alone (Figure 3.25A).  Further detailed analyses of the actual cell migration
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distance (Figure 3.25B) confirmed that cell migration was inhibited with
CM+10µM LY294002 vs CM (236 +/-7 µm vs 357 +/-16 µm, p<0.001,
equivalent to 51% decrease) and with CM+5µM UO126 vs CM (227 +/-15.5 µm
vs 357 +/-16 µm, p<0.0001, equivalent to 57% decrease), thus strengthening and
validating the data obtained in Figure 3.24, above.
Cell death quantifications and analyses (Figure 3.25C) indicated significant
increases in the percentage of dead cells with CM+10µM LY294002 vs CM (4.16
+/-1% vs 1.7 +/- 0.4 %, p<0.05) and with CM+10µM LY294002 vs CM+5µM
UO125 (4.16 +/-1% vs 0.84 +/-0.2 %, p<0.05). No significant difference in cell
death was indicated between CM and CM+5µM UO126.
Figure 3.25. Cell tracking and cell death analysis (CM with 10µM LY294002
and 5µM UO126). Migration tracking comparing the effects of CM, CM+10µM
LY294002 and CM+5µM UO126 on myoblast migration distance following 20h
incubation (A). Quantification of cell migration distance indicated significant inhibition
of migration with CM+10µM LY294002 vs CM (p<0.001, represented by *) and
CM+5µM UO126 vs CM (p<0.0001, represented by #) (B). Data are representative of 5
experiments performed in duplicate.  Cell death quantifications indicated increased cell
death with CM+10µM LY294002 vs CM (p<0.05, represented by *) and with CM+10µM
LY294002 vs CM+ 5µM UO126 (p<0.05, represented by a) (C). Data are representative
of 4 experiments performed in duplicate. (p-values obtained by One-way repeated
measures ANOVA)
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SUMMARY OF MAJOR FINDINGS
- Myotubes release soluble factors in vitro, capable of inducing both migration and
chemotaxis of C2C12 myoblasts, as demonstrated by the wound healing assay
and the transwell insert assay.
- Enhanced myoblast migration following stimulation by media containing soluble
factors released by myotubes (conditioned media), is also associated with
activation of PI3K/AKT and MAPK/ERK signalling pathways.
- Migration of myoblasts stimulated by myotube conditioned media is reduced
when PI3K/AKT and MAPK/ERK signalling pathways are inhibited with
LY294002 or UO126.
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3.6. DISCUSSION
3.6.1. MEDIA CONDITIONED BY MATURE MYOTUBES IS ABLE TO
INDUCE WOUND HEALING AND MIGRATION OF MYOBLASTS
Media conditioned by 5do mature myotubes was able to induce migration
compared to control SF media. This was demonstrated by wound healing assay
analysis, resulting in 233% increase in the total number of cells infiltrating the
wound, of which nearly 10% more were situated in the middle of the wound, with
CM vs SF. These results were also supported by cell tracking analyses, indicating
79% increase in the distance migrated by cells stimulated with CM vs SF.
Morphology of the cells stimulated with CM also differed significantly, as
compared to the morphology of cells incubated in SF media. Cells in CM
possessed more elongated morphology with visible protrusions, such as filopodia,
suggestive of their increased migration capacity, compared to the quiescent
morphology of cells incubated in SF media. Finally, cell death levels were also
increased with SF media, compared to CM. All of these observations suggested
that factors, possibly secreted by the myotubes, were responsible for stimulating
myoblast migration and survival.
In order to optimise the migration assays and analyses, the effects induced by CM
were compared to those of relevant controls, namely GM and DM - both known
for their induction of, respectively, proliferation and differentiation of C2C12
cells. It was assessed how these two different media, containing an abundance of
growth factors, would compare to the myotube CM in inducing myoblast
migration. Both wound healing and transwell insert assays were performed to
compare the impact of GM, DM, CM and SF on cell migration or chemotaxis. All
three media (GM, DM and CM) induced significantly higher levels of migration,
as compared to SF media in the wound healing assays, with GM being most
potent and DM and CM equipotent. Transwell inserts, investigating the
chemotaxis of myoblasts in response to the 4 different media, however,
demonstrated different results. As expected, no chemotaxis was induced by SF
media. CM and DM, however, induced extensive levels of chemotaxis of the
cells, confirming the hypothesis that factors are released from myotubes that are
able to induce myoblast migration and chemotaxis. GM, however, which induced
extensive migration in the wound healing assay, surprisingly induced very little
chemotaxis through the transwell inserts. It was suggested that this discrepancy
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might be due to the very high concentrations of serum growth factors in the
media. Previous reports have suggested that growth factors, such as PDGF, HGF,
TGF-beta, are less potent at inducing chemotaxis at higher concentration than at
lower concentrations (Bischoff, 1997, De Donatis et al., 2008). Therefore, the
concentration of serum in the GM used for transwell insert assays was reduced to
assess whether chemotaxis of myoblasts would be increased. Diluted GM at a 1:5
ratio with SF media, indeed, induced greater chemotactic response of myoblasts,
as compared to non-diluted GM. These results indicated that wound healing assay
and transwell inserts should not always be considered as equivalent assays for
investigating cell migration and that certain combinations of growth factors and or
proteases might exert different effects on adherent cell movement/migration and
on chemotactic movement.
3.6.2. MEDIA CONDITIONED BY LIVING MYOTUBES IS MORE
POTENT AT INDUCING MIGRATION AND WOUND HEALING, AS
COMPARED TO MEDIA CONDITIONED BY FACTORS RELEASED
FROM DAMAGED MYOTUBES
It was demonstrated that SF media incubated for 3 days with mature myotubes
(CM) was conditioned with factors, capable of inducing myoblast migration. It
was visually observed that the myotubes incubated in SF media were decreasing
in size with time. As reported by other studies, a cell culture model of serum
deprivation/starvation of myotubes mimics to certain extend muscle wasting and
atrophy and may increase the levels of myofibrillar proteolysis and apoptosis
(Nakashima et al., 2005, Stevenson et al., 2005). Therefore, it was not possible to
initially ascertain whether the factors inducing myoblast migration were secreted
by the viable myotubes or whether they were being released from the dying or
atrophying cells. Although excessive washes were performed before SF media
was added to the myotubes for conditioning, the possibility existed that there
might also be factors unspecifically bound to the cells or the wells from
incubations with media containing serum (during the growth or early
differentiation phases of the experiments) and that these factors might
subsequently be released into the SF media. In order to check for specificity and
also to estimate how the release of potential factors from dead myotubes
compared to the myotube CM, the effect on migration of the CM was compared to
the effect of media conditioned in the presence of mechanically damaged
myotubes. It was demonstrated that media conditioned for 3 days by the living
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myotube cultures was significantly more potent at inducing myoblast migration in
wound healing assays, as compared to media conditioned by mechanically
damaged myotubes over the same period of time. Transwell insert assays
demonstrated that chemotaxis of myoblasts was induced by the media conditioned
by crushed myotubes, although clustering of the cells crossing the membrane was
observed. The data from both assays suggested that the resultant conditioned
media from damaged or non-damaged myotubes are two distinct media,
composed either of different factors or of different concentrations/combination of
factors, hence the altered migration and chemotaxis data, suggesting that secreted
factors are indeed capable of manipulating the migration of myoblasts. Previous
studies have demonstrated that media conditioned by myocytes at the time of their
fusion is capable of inducing their migration (Griffin et al., 2010). Migration itself
is important for cell alignment and a prerequisite step for cell fusion. Therefore, it
is possible that myogenic cells, upon commencement and progression of the
fusion process, release factors, which induce the migration and recruitment of
other myogenic cells, which would contribute with their myonuclei during the
fusion process. It is proposed that similar situation is observed also with mature or
atrophying myotubes - factors inducing myoblast migration are released, capable
of recruiting more myogenic cells for fusion enabling the maintenance, the growth
or repair of myotubes. These factors could also have effects on other processes or
cell types, such as inflammatory cells. Studies investigating the secretome of
differentiating muscle have indeed confirmed that a variety of factors are secreted,
including factors involved in cell motility (Henningsen et al., 2010). However,
further investigation is required into how the combination of these secreted factors
is affecting migration of myoblasts and the signalling pathways involved.
3.6.3. PI3K/AKT AND MAPK/ERK SIGNALLING PATHWAYS ARE
INDUCED IN RESPONSE TO CM AND THEIR INHIBITION LEADS TO
REDUCED MYOBLAST MIGRATION
Following the findings that myotube CM is able to induce migration of
myoblasts, the potential signalling pathways involved in this process were
investigated. In preliminary studies it was addressed how PI3K/AKT and
MAPK/ERK pathways, previously shown to be of importance for myoblast
migration (Al-Shanti et al., 2011, Leloup et al., 2007), would be regulated in
response to CM. Investigations of these pathways in response to GM and DM
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were therefore also assessed. Results showed that all three media, which induced
migration (GM, DM and CM), also resulted in increased levels of pAKT and
pERK1/2, as compared to SF, which did not induce migration nor activation of
these pathways. However, although DM induced a stronger activation of both
PI3K/AKT and MAPK/ERK pathways, as compared to CM, migration analyses
indicated equivalent, if not slightly greater induction of migration with CM vs
DM.  It is possible that at later time points, which were not investigated, DM
triggered a stronger differentiation response, as compared to cells incubated in
CM, the increased expression of myogenin in DM vs. CM underpins this
hypothesis. PCRs indeed demonstrated that cells incubated in DM are able to
upregulate by 2-fold the expression of Myogenin, an early marker of
differentiation, as compared to cells incubated in CM. As suggested by other
studies, differentiating myoblasts, although still migrating, do so at a slower pace,
as compared to undifferentiated cells (Griffin et al., 2010). Therefore, it is
possible that even though signalling pathways important for migration are
activated at early time points, triggering of cell differentiation at later time points
can override these signals. Furthermore, it must not be forgotten that PI3K and
ERK1/2 activation are also key pathways integral for the differentiation process
(Foulstone et al., 2004). In order to verify if PI3K/AKT and MAPK/ERK
signalling pathways are indeed required for myoblast migration in response to
CM, selective inhibitors were used (LY294002 for PI3K/AKT and UO126 for
MAPK/ERK pathway). Inhibition of each pathway, not affecting the
phosphorylation or total protein levels of the other one, resulted in reduced cell
migration. Previous reports in our group demonstrated similar results for PI3K
and MAPK pathways, although under different culture conditions (GM) and with
different cell types (C2 myoblasts) (Al-Shanti et al., 2011). Current data
substantiate these observations and suggest that regardless of the stimulus, these
two pathways (as well as others not investigated) are required for unrestricted
myoblast migration. An interesting avenue for further investigation would be to
study how upregulation of these two pathways would influence the migration of
myoblasts and explore potential cross-talk between the two.
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3.6.4. CONCLUSIONS AND THESIS DIRECTIONS
It was demonstrated that serum free media conditioned by mature myotubes was
able to induce migration of myoblasts in a wound healing model and chemotaxis
in transwell inserts. It was suggested that factors secreted by myotubes are
inducing this response, although identification of these factors was beyond the
scope of this thesis. Involvement of PI3K/AKT and MAPK/ERK pathways was
also assessed. Both pathways were shown to be upregulated in response to CM
and their inhibition resulted in reduced, if not abolished migration. These studies
propose interesting avenues for further research. In particular, it would be
interesting to explore the potential links between the contribution of secreted
factors and the migration of myoblast to muscle debilitating events or conditions,
such as ageing and sarcopenia.
The possibility of age related changes in the way myogenic precursors respond
to signals from the local environment, potential alterations in paracrine signalling,
associated with signalling pathways activation/reduction in the context of cell
migration, was considered as an interesting avenue of investigation. Therefore, in
the next chapter, a link was established between the results obtained from media
conditioning experiments, the involvement of signalling pathways in myoblast
migration and skeletal muscle ageing.
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CHAPTER 4
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4. SERIALLY PASSAGED C2C12 CELLS DEMONSTRATE ALTERED
MIGRATION BEHAVIOUR
4.1. INTRODUCTION
Aged skeletal muscle is characterised by a decline in functional properties,
including power, strength and endurance, partly due to the overall reduction in
size of the muscles and to their intrinsically reduced functional muscle fibres
(reviewed in (Brack and Rando, 2008)).  The degenerative loss of skeletal muscle
mass and strength with age is known as sarcopenia. Both intrinsic and extrinsic
factors have been investigated and shown to be altered in aged muscle. The
systemic environment is of major importance, as shown by parabiotic murine
pairing studies, where rejuvenation of aged progenitor cells (both in vivo and in
vitro) occurred by exposure to a young systemic environment and vice versa – a
decline in functionality of young satellite cells exposed to an old systemic
environment (Conboy et al., 2005). It is also known that old muscle is able to
regenerate when transplanted into young animals, while regeneration of young
muscle transplanted in old animals is impaired (Carlson and Faulkner, 1989),
further underlying the importance of the extrinsic environment in the process of
sarcopenia. However, the potential role of alterations in the intrinsic mechanisms
of myogenic precursor cells in ageing is not entirely elucidated. Reports have
revealed that expression levels of regulators of muscle differentiation, such as
S100B and RAGE, are altered in old vs. young human satellite cells (Beccafico et
al., 2010), suggesting that intrinsic mechanisms are also important. It is known
that the proliferative potential of isolated satellite cells is reduced with age when
they are passaged, coinciding with telomere shortening, resulting in replicative
senescence of satellite cells with ageing (Decary et al., 1997, Schultz and Lipton,
1982, Webster and Blau, 1990). Reduced expression of myogenic regulatory
factors, such as MyoD and Myogenin, coincide with reduced differentiation of
senescent myoblasts (Bigot et al., 2008). However, it has also been suggested that
telomerase activity is retained in old muscle and it is only the myoblast progeny,
when induced to differentiate, that show deterioration of telomerase activity
(O'Connor et al., 2009). Using a C2C12 in vitro model of multiple population
doublings, which retains telomerase activity, Sharples et al. have proposed a
model to investigate the impact of cellular divisions on myoblast behavior. They
reported that myoblasts subjected to multiple divisions displayed intrinsic
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differences in their growth and differentiation potential, as compared to low
passage of cells, including altered IGF-I, myogenin, IGFBP-5 and IGFBP-2
expression and changes in the levels of Akt and JNK1/2 phosphorylation
(Sharples et al., 2011). Thus, in the absence of senescence and the presence of
retained telomerase activity, C2C12 myoblasts subjected to serial passaging are
still demonstrating characteristics that mimic the molecular regulation of atrophy
seen in elderly skeletal muscle.
It is not well known how migration of myoblasts is affected during the process
of ageing. Reports have indicated that migration is retarded in myoblasts isolated
from aged vs young mice and rats (Dumke and Lees, 2011, Siriett et al., 2007).
Dumke et al. have also demonstrated that myogenic precursors isolated from
young, but not from old skeletal muscle, are responsive to chemotactic factors
released from activated T cells. To our knowledge, no studies have investigated
the effect of multiple divisions on myoblast migration. Sharples et al. have
demonstrated that intrinsic changes reduced the capacity of C2C12 cells to
differentiate and fuse into myotubes, but their migration was not assessed
(Sharples et al., 2011). Potential differences in the secretome of serially passaged
myogenic cells have not been investigated either.
4.2. AIMS, OBJECTIVES AND HYPOTHESIS
The main aim was to reveal the potential changes in migration capacity of
myoblasts undergoing multiple divisions and also to identify differences in the
impact of CM from aged vs young myotubes on migration, which would provide
clues for further investigations in the field of muscle ageing and sarcopenia.
Objectives were: 1) to compare, using wound healing assays, the migration
capacity of high passage vs low passage C2C12 myoblasts in response to myotube
CM and 2) to investigate whether there were differences between media
conditioned by low vs high passage C2C12 cells in their ability to induce
myoblast migration. It was hypothesized that there would be differences between
high and low passage myoblasts and their capacity to migrate and also differences
in the ability of media conditioned by low and high passage cells to stimulate cell
migration.
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4.3. METHODS
4.3.1. CELL CULTURE
C2C12 myoblasts were cultured in a humidified 5% CO2 atmosphere at 37ºC.
Cells were grown in the presence of (GM) in T75 flasks until confluent and split
into multiwell plates for experiments. In order to initiate differentiation, C2C12
cells were grown in 6 well plates until confluency was achieved, monolayers were
washed with PBS and differentiation media (DM) was added to the cell
monolayers. When differentiation experiments were performed for 5days, DM
was replaced with fresh media at d3, allowing the replenishment of factors present
in the media and maintaining the optimum pH for longer incubation of the cells in
the same media typeA schematic representation of performing differentiation
experiments and obtaining 5 day old myotubes:
4.3.2. CONDITIONED MEDIA GENERATION
p5 and p50 C2C12 myoblasts were triggered to differentiate into myotubes for 5
days in 6 well plates. For both p5 and p50 cells, conditioned media was generated,
as described in section 3.3.2.
4.3.3. WOUND HEALING ASSAY AND LIVE IMAGEING
Cells were grown in pre-gelatinised 12 well plates in GM until ~80-90%
confluent. For wound healing assay comparing between p5 and p50 myoblasts, it
was established that equal confluencies for migration studies were achieved by
seeding 80,000 cells/ml of p5 cells and 100,000cells/ml of p50 cells in a 12 well
plate. Cell monolayers were washed 3 times with PBS and DMEM 0.1% FBS
media (quiescent media = QM) was added and incubated for 20h with the cells. In
the last 3 hours of incubation with QM, 10µg/ml Mitomycin-C (Sigma-Aldrich)
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was added, in order to block proliferation, and monolayers were wounded with a
sterile pipette tip, generating a wound of approximately 600µm in size. Wound
healing with live imaging microscopy is described in section 2.2.2.1.
4.3.4. ANALYSIS OF CELL MIGRATION
Cell migration was analysed with Keynote’09 software version 5.1.1. (Apple
Inc.) and ImageJ v1.45i software, as described in section 3.4.2.
4.3.5. CELL DEATH QUANTIFICATIONS BY LIVE IMAGEING
The numbers of dying cells were counted frame by frame in each area for the
duration of the movie, as described in section 2.2.4.
4.3.6. WESTERN BLOTS
Sample collection and preparation for SDS-PAGE was performed as described in
section 2.2.8.1. Gel electrophoresis, membrane transfer, blocking and detection
steps were performed, as described in sections 2.2.8.2-2.2.8.5. Primary AKTpan,
pAKT, b-actin and ERKpan rabbit IGg antibodies were purchased from New
England Biolabs (Hertfordshire, UK) and were incubated with membranes
overnight at RT in 1:1000 concentration, diluted in 5% BSA/TBST. Primary
pERK1/2 rabbit antibody was purchased from Promega and was incubated with
membranes overnight at RT in 1:5000 concentration, diluted in 0.1% BSA/TBST.
Secondary Goat Anti-rabbit HRP-conjugated antibodies were purchased from MP
Biomedicals (United Kingdom) and were incubated with membranes for 1h at RT
1:5000 concentration, diluted in blocking solution. Membranes were blocked for
1h at RT in 5% non-fat dry milk/TBST (for antibodies purchased from New
England Biolabs) or in 1% BSA/TBST for pERK1/2.
4.3.7. RNA ISOLATIONS AND REAL-TIME PCR
RNA extraction and TaqMan® Real-time PCR methods were performed as
described in sections 2.2.9 and 2.2.10, respectively. The following predesigned
primer sets were ordered from Applied Biosystems and were used with the
114
TaqMan® detection method: Polr2b (Mm00464214_m1), MyoD
(mm00440387_m1) and Myogenin (mm00446194_m1).
4.3.8. CREATINE KINASE (CK) ASSAY
Samples for CK assay were prepared by adding 150µL per well (for 6 well plate)
of Tris Mes Triton (TMT buffer; composed of: 0.05M Tris/Mes and 1% Triton-
X100). Assay was performed, as described in section 2.2.7.2.
4.3.9. SERIAL PASSAGING
C2C12 cells at passage 20 (P20) were seeded in a T75 flasks at a concentration
of 500,000cell/ml and allowed to proliferate in GM for 48h before being passaged
to a new T75 flask. Upon passaging, total numbers of cells were counted, with
aproximately 2.5 million cells per flask being yielded at confluency, thus ensuring
that 48h was sufficient time for cells to perform 2 full divisions. Cycles of
passaging were repeated 30 times until reaching 50 passages (thus, C2C12 cells
were designated as p50). Considering that approximately 2.25 cell doublings were
initiated over 48h, 30 repeated passaging events would yield approximately 68
cell population doublings.
4.3.10. STATISTICAL ANALYSES
Statistical analyses and significance of data were determined using GraphPad
Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California
USA, www.graphpad.com. Statistical significance for interactions between two
paired groups was determined with a Paired t-test, while unpaired t-test was used
for unpaired groups (e.g. when comparing between p5 and p50 groups). Statistical
significance for interactions between more than two groups was determined with a
one-way ANOVA, or with a one-way repeated measures ANOVA, when matched
observations were investigated. All results are presented as mean +/- standard
error of the mean (SEM). All values below p<0.05 were considered as significant.
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4.4 RESULTS
4.4.1. SERIALLY PASSAGED C2C12 MYOBLASTS (P50)
DEMONSTRATED AN IMPAIRED CAPACITY TO DIFFERENTIATE
COMPARED TO LOW PASSAGE (P5) CELLS
In order to confirm the differences in fusion/differentiation capacity, p5 and p50
myoblasts were incubated until confluent and DM media was added for 3 days.
Phase contrast microscopy (Figure 4.1) demonstrated reduced capacity of p50
cells to fuse into myotubes compared with p5.
Figure 4.1. Phase-contrast microscopy investigating the effects of DM on p5
or p50 myoblasts. Enhanced myotubes formation was observed with p5 (A) myoblasts
vs p50 myoblasts (B), incubated in DM for 3 days. Data are representative of 4
experiments performed in duplicate. 10x objective used.
In order to verify the phase-contrast microscopy observations, CK activity was
measured in the two different myoblast passages (Figure 4.2). The data from CK
assays supported the phase-contrast microscopy images, showing significant
decreases in CK activity with p50 cells treated with DM vs p5 cells treated with
DM for 72 hrs (836.75 +/-90.48 mU/mg vs 1123.2 +/-66.43 mU/mg, p<0.05,
equivalent to 1.34 fold decrease).
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Figure 4.2. CK assay, measuring CK activity between p5 and p50 myoblasts
incubated for 3 days with DM. Significant decreases in CK activity were present
with p50 in control DM vs p5 cells in control DM (p<0.05, represented by *). Data are
representative of 4 experiments performed in duplicate. (p-values obtained by unpaired t-
test)
MyoD and Myogenin gene expression were examined in p5 and p50 myoblasts
in response to DM (Figure 4.3). Reductions in MyoD expression were observed
with passage in p50 myoblasts treated with DM vs p5 myoblasts treated with DM
at d1 (0.56 +/-0.01 vs 1, p<0.0001, equivalent to 1.79 fold decrease). Similar to
MyoD, passage influenced the expression of Myogenin. Significant decreases
were observed with p50 myoblasts vs p5 myoblasts treated with DM at day1 (0.43
+/-0.02 vs 1, p<0.0001, equivalent to 2.33 fold decrease).
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Figure 4.3. Examining the gene expression of MyoD and Myogenin between
p5 and p50 myoblasts at d1 following treatment with DM. MyoD gene
expression indicated significant decrease with p50 myoblasts vs p5 myoblasts (p<0.0001,
represented by *). Values are represented as fold change to the calibrator (p5 d1), which
was set to 1 (mean Ct value =24.54 +/-0.24). (A). Myogenin gene expression indicated
significant decrease with p50 myoblasts vs p5 myoblasts (p<0.0001, represented by *).
Values are represented as fold change to the calibrator (p5 d1), which was set to 1 (mean
Ct value =19.21 +/-0.06). (B). Data are representative of 4 experiments performed in
duplicate. (p-values obtained by unpaired t-test)
4.4.2. SIGNIFICANTLY HIGHER LEVELS OF P-ERK1/2 AND
ELEVATED LEVELS OF P-AKT WITH P50 MYOBLASTS VS P5
MYOBLASTS IN RESPONSE TO CM
Western blots were performed to investigate the potential altered activation of
PI3K/AKT and MAPK/ERK between p5 and p50 cells in response to myotube
CM (Figure 4.4). The levels of pAKT and pERK1/2 appeared to increase in
response to CM with high passage vs low passage cells. Importantly, temporal
differences were apparent, particularly for pERK1/2, where at 30 and 45 minutes
ERK1/2 phosphorylation was reduced in p5 cells, but remained elevated in p50
cells.
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Figure 4.4. Western blots (p5 vs p50 myoblasts in CM). Westerns blots were
performed to investigate the activation of PI3K/AKT and MAPK/ERK between p5 and
p50 cells in response to CM. Data are representative of at least 4 experiments.
In order to statistically evaluate the western blot results, images of the exposed
membranes were subjected to further analyses using Quantity One software.
Phospho-Akt and Phospho-ERK1/2 levels were quantified between the 2 different
passages and the 3 time points. All values are represented as percentage of the
calibrator (p5 15m), which was set to 100%.
Analysis of pAKT (Ser 473) was performed in response to CM between p5 and
p50 cells (Figure 4.5). pAKT levels were elevated in p50 vs p5 myoblasts at all
time points examined, however, statistical significance was not achieved across
the 11 repetitions performed.
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Figure 4.5. Quantification of pAKT levels (p5 vs p50 myoblasts in CM). No
significant increases were observed with p50 vs p5 myoblasts in response to CM. Data
are representative of 11 experiments. (p-values obtained by unpaired t-test)
Analyses of pERK1/2 data (Figure 4.6) revealed significant increases in ERK1/2
phosphorylation between p50 and p5 cells at 30m (48.73 +/-5.42% vs 18.82 +/-
2.28%, p<0.001) and at 45m (38.45 +/-6% vs 16.37 +/-3.3%, p<0.01). Significant
reductions with time were also observed with p5 at 30m vs 15m (18.82 +/-2.28%
vs 100%, p<0.0001) and at 45m vs 15m (16.37 +/-3.3% vs 100%, p<0.0001),
confirming the observations made based on the blots above. Reduction with time
was observed also with p50 at 30m vs 15m (48.73 +/-5.42% vs 134.73 +/-17.68%,
p<0.0001) and at 45m vs 15m (38.45 +/-6% vs 134.73 +/-17.68%, p<0.0001).
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Figure 4.6. Quantification of pERK1/2 levels (p5 vs p50 myoblasts in CM).
Quantification of pERK1/2 levels in response to CM between p5 and p50 myoblasts
indicated significant increases with p50 vs p5 at 30m (p<0.001, represented by *) and
45m (p<0.01, represented by *). Reductions with time were observed with both p5 and
p50 at 30m vs 15m (p<0.0001 for both p5 and p50, represented by t) and at 45m vs 15m
(p<0.0001 for both p5 and p50, represented by x). Data are representative of 11
experiments. (p-values obtained by unpraired t-test)
4.4.3. SERIALLY PASSAGED (P50) C2C12 MYOBLASTS
DEMONSTRATED HIGHER MIGRATION CAPACITY, AS COMPARED
TO LOW PASSAGE (P5) MYOBLASTS, IN RESPONSE TO MEDIA
CONDITIONED BY P5 MYOTUBES
Previous studies have investigated the capacity of serially passaged C2C12 cells
to differentiate, fuse and form myotube cultures (Sharples et al., 2011), however
their ability to migrate was not addressed. It was hypothesized that the ability of
myoblasts to migrate would also be altered as a consequence of artificial ageing
through serial passaging. Furthermore, elevated levels of pAKT and pERK1/2, as
demonstrated in Figure 4.5 and Figure 4.6, suggested that differences in the
migration between cells of high and low passage could be expected, based on the
data derived from the previous chapter. In order to investigate this, the migration
capacity of serially passaged (p50) C2C12 myoblasts was compared to that of low
passage myoblasts (p5) in response to media conditioned by p5 myotubes. Wound
healing assays were performed to investigate the rate of wound closure between
myoblasts of high and low passage (Figure 4.7). Visual observations suggested
that p50 cells migrated more rapidly to the centre of the wounds, compared to p5
cells (Figure 4.7A). Although subsequent quantification and analyses of the total
number of cells infiltrating the wound as a whole indicated no significant
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difference between p5 and p50 cells (Figure 4.7B), significant increases in the
percentage of cells in the middle of the wound were however, observed with p50
vs p5 cells (22.5% +/-1.66 vs 9.75% +/-2.25, p<0.01), confirming the
morphological observations made below and suggesting higher capacity of
serially passaged myoblasts to migrate and spread across the wound area (Figure
4.7C).
Figure 4.7. Wound healing assay with cell count analysis (p5 vs p50
myoblasts in CM). Wound healing assay comparing the morphological differences
between high passage (p50) and low passage (p5) C2C12 myoblasts infiltrating the
wound over 20h in response to media conditioned by p5 myotubes (A).  Quantification of
the total number of cells infiltrating the wound indicated no significant difference
between high passage (p50) vs low passage (p5) of myoblasts (B).  Quantification of the
percentage of cells infiltrating the central area of the wound indicated significant increase
with p50 vs p5 (p<0.01, represented by *) (C). Data are representative of 4 experiments
performed in duplicate. (p-values obtained by unpaired t-test)
Migration tracking was performed to compare the migration distance of p5 and
p50 myoblasts in response to p5-CM (Figure 4.8A). These studies indicated quite
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clearly that migration distance over a fixed period of time was enhanced in P50 vs
p5 cells. Indeed, further analyses indicated significant increases in migration
distance with p50 vs p5 myoblasts (409 +/-32.6µM vs 300 +/-23.8µM, p<0.05,
equivalent to 36% increase; Figure 4.8B). Cell death quantification and analyses
indicated no differences between p5 and p50 myoblasts (Figure 4.8C).
Figure 4.8. Cell tracking and cell death analysis (p5 vs p50 myoblasts in CM).
Migration tracking comparing the distance migrated between p5 vs p50 myoblasts (A).
Analysis indicated significant increase in the migration distance with p50 vs p5 (p<0.05,
represented by *) (B). Analysis of cell death indicated no significant difference between
p5 vs p50 myoblasts (C). Data are representative of 5 experiments performed in
duplicate. (p-values obtained by unpaired t-test)
4.4.4. MEDIA CONDITIONED BY P50 CELLS ARE LESS POTENT IN
INDUCING MIGRATION IN WOUND HEALING ASSAY THAN MEDIA
CONDITIONED BY P5 CELLS
Having determined that p50 cells are less potent at morphological, biochemical
and associated molecular (reduced myoD and myogenin expression)
differentiation than p5 cells and that this was associated with an improved
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migration capacity of p50 vs p5 cells in response to media conditioned by p5
myotubes, it was also determined whether there were potential alterations in the
secretome of cells following serial passaging. To achieve this end, it was
investigated whether media conditioned by serially passaged C2C12 cells would
enable improved migration in p5 cells to the same extent as media conditioned by
p5 myotubes. Similar to the media conditioning experiments performed in chapter
3, p5 or p50 C2C12 myoblasts were grown to confluence and transferred to DM
for 5 days, before being transferred to SF media for a further 3 days. The CM
from p5 myotubes was compared to CM from p50 myotubes in migration assays
using wounded p5 cells. Morphological assessment suggested that p50 CM when
added to p5 cells reduced migration, compared to p5 CM being added to p5 cells
(Figure 4.9A). Further analyses of the wound healing assay investigated the total
number of cells infiltrating the wound and consolidated the observations,
indicating significant decreases with p50 CM vs p5 CM on p5 migration (43 +/- 4
vs 78 +/-9, p<0.05; Figure 4.9B). Furthermore, the percentage of cells in the
middle of the wound was also significantly reduced with P50 CM vs P5 CM
(12.33% +/-1.76 vs 2% +/-1, p<0.01; Figure 4.9C).
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Figure 4.9. Wound healing assay with cell count analysis (p5 myoblasts with
p5 CM or p50 CM). Wound healing assay comparing the number of of p5 C2C12
myoblasts infiltrating the wound after 20h, in response to media conditioned by p5 cells
(p5 CM) and media conditioned by p50 cells (p50 CM) (A).  Quantification of the total
number of cells infiltrating the wound indicated significant decreases with p50 CM vs p5
CM (p<0.05, represented by *) (B). Quantification of the percentage of cells infiltrating
the central area of the wound indicated significant decrease with p50 CM vs p5 CM
(p<0.01, represented by *) (C). Data are representative of 3 experiments performed in
duplicate. (p-values obtained by paired t-test)
To confirm these observations, cell tracking of p5 cells was performed between
P5 CM and P50 CM cultures and data again suggested that migration distance by
p5 cells, in the presence of p50 CM was reduced when compared to p5 cells in the
presence of p5 CM (Figure 4.10A). Further analyses indicated significant
decreases in p5 migration, with p50 vs p5 CM (224µM +/-40.7 vs 342µM +/-32.1,
p<0.05; Figure 4.10B). Percentage cell death analyses indicated significant
increases in p5 dead cell numbers with p50 CM vs p5 CM (6.43% +/-0.78 vs
1.35% +/-0.42, p<0.05; Figure 4.10C), however, values are still low and would
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likely not account for the reduction in migration potential in the presence of p50
CM.
Figure 4.10. Cell tracking and cell death analysis (p5 myoblasts with p5 CM
or p50 CM). Cell tracking analysis demonstrating the migration potential of p5 C2C12
myoblasts induced to migrate with p5 CM or p50 CM (A).  Analysis indicated significant
decreases in cell migration distance with p50 CM vs p5 (p<0.05, represented by *) (B).
Cell death analyses indicated significant increases with p50 CM vs p5 CM (p<0.05,
represented by *) (C). Data are representative of 3 experiments performed in duplicate.
(p-values obtained by paired t-test)
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SUMMARY OF MAJOR FINDINGS:
- Serially passaged C2C12 myoblasts (p50) demonstrate impaired capacity
to differentiate, as compared to low passage myoblasts (p5), but p50
myoblasts demonstrate enhanced migration capacity in response to
myotube conditioned media, as compared to p5 myoblasts.
- Increased migration capacity of p50 vs p5 myoblasts, stimulated by
myotube conditioned media, is associated with enhanced PI3K/AKT and
MAPK/ERK signalling.
- Media conditioned by p50 myoblasts is less potent in inducing C2C12 cell
migration, as compared to media conditioned by p5 myoblasts.
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4.5. DISCUSSION
4.5.1. SERIALLY PASSAGED C2C12 MYOBLASTS (P50)
DEMONSTRATED IMPAIRED CAPACITY TO DIFFERENTIATE
COMPARED TO LOW PASSAGE C2C12 MYOBLASTS (P5)
In order to verify the effect of multiple divisions on myoblast differentiation
capacity, C2C12 cells were serially passaged until reaching 50 passages (p50) and
were compared with low passage of cells (p5). Visually, p50 cells formed much
smaller myotubes, as compared to p5 cells. The reduced differentiation of p50
cells was confirmed by the reduced CK activity and reduced gene expression
levels of MyoD and Myogenin. These data were confirmed in a recent article,
which further demonstrated significant reduction in IGF-1 transcript expression,
decreased phosphorylation of Akt and increased phosphorylation of JNK1/2 in
myoblasts of high vs low passage (Sharples et al., 2011). Thus, intrinsic changes
following multiple divisions were obviously affecting the ability of murine
myoblasts to differentiate, even in the absence of proliferative senescence.
4.5.2. SERIALLY PASSAGED (P50) C2C12 MYOBLASTS
DEMONSTRATED ELEVATED LEVELS OF P-AKT AND P-ERK1/2 IN
RESPONSE TO CM, AS COMPARED TO LOW PASSAGE (P5) OF
MYOBLASTS, WHICH WAS ASSOCIATED WITH HIGHER
MIGRATION CAPABILITY OF P50 VS P5 MYOBLASTS
Having observed reduced differentiation ability of high (p50) vs low (p5)
passage of myoblasts, it was investigated whether intrinsic differences between
these cells would also lead to changes in their migration ability. Firstly, it was
investigated how PI3K/AKT and MAPK/ERK pathways were affected by p5
myotube CM. Surprisingly, elevated levels of pAKT and pERK1/2 in p50 vs p5
myoblasts were found, in response to myotube CM. This was associated with
increased migration distance by p50 vs p5 cells, while treatment with LY294002
and UO126 inhibitors, as expected, resulted in visually reduced migration of p50
myoblasts (results not shown), suggesting that PI3K/AKT and MAPK/ERK
pathways are required for their migration. Increased levels of pAKT and
pERK1/2, accompanied with increased migration of p50 cells were unexpected,
considering previous studies by Sharples et al., demonstrating no changes in
pERK1/2 levels and decreased levels of pAKT with high vs low passage of
C2C12 myoblasts, in response to DM (Sharples et al., 2011), however, the cells
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compared in that manuscript were p20 vs p5 myoblasts and were cultured in DM,
not CM. Furthermore, myoblasts isolated from old mice and rats were reported to
have retarded migration, as compared to myoblasts isolated from young species
(Dumke and Lees, 2011, Siriett et al., 2007). The regulation of signalling
pathways, therefore, seems to be altered depending on the external factors,
possibly paracrine signals as well as potentially, the numbers of doublings
completed. These results, to our knowledge, are the first to report an enhanced
migration ability of myoblasts, artificially aged by serial passaging. The
observations of reduced differentiation capacity, but increased migration, suggests
a potential link between these two processes, which seem to be inversely related -
with migration being increased when differentiation capacity is impaired,
however, the differential culture conditions must be respected and differentiation
studies of p5 vs p50 cells, both in p5 CM should be performed. Another concept
worth considering is the potential difference in paracrine signalling of myogenic
cells, which can be altered following multiple divisions of these cells.
4.5.3. MEDIA CONDITIONED BY P50 CELLS ARE LESS POTENT IN
WOUND HEALING ASSAYS THAN MEDIA CONDITIONED BY P5
CELLS
In chapter 3, it was demonstrated that media conditioned by myotubes is able to
enhance myoblast migration, compared to the non-conditioned serum free
medium. The question was asked whether there would be differences in the
factors secreted by myoblasts of high vs low passage. P50 myoblasts, as
previously discussed, mimic to a certain extent the molecular regulation of
atrophy seen in elderly skeletal muscle. It was investigated whether media
conditioned by p50 myotubes would exert different migratory response in
myoblasts, as compared to media conditioned by p5 myotubes. Using a wound
healing assay, it was reported that p5 myoblasts indeed have significantly retarded
migration when stimulated by media conditioned by p50 myotubes, as compared
to media conditioned by p5 myotubes. It must be noted, however, that p50
myotubes were significantly smaller in size, as compared to p5 myotubes. This
difference in morphology, therefore, could have contributed to the difference in
secreted factors conditioning the media. Further studies would be required to
compare between the secretome of both cell passages and reveal whether there are
differences in the expression of factors, which might influence the migration of
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cells. These initial studies, however, propose interesting avenues for further
research. The potential alterations in the secretome and paracrine signalling of
aged skeletal muscle or myogenic precursors is an unexplored field and
investigating these events in more details could improve our knowledge of muscle
regeneration and sarcopenia.
4.5.4. CONCLUSIONS
The effect of serial passaging on the behavior of C2C12 myoblasts was
investigated. It was confirmed that high passages of myoblasts have impaired
potential to differentiate and to fuse into multinucleated myotubes, as seen by
morphological examination, as well as by reduced levels of CK activity and
lowered expression of MyoD and Myogenin genes. However, high passage
myoblasts demonstrated elevated levels of pAKT and pERK1/2, in response to p5
myotube CM, as compared to low passage of myoblasts. This was associated with
increased migration distance, as examined by wound healing assay. It was also
proposed that there are differences in the factors secreted by high vs low passage
of myoblasts. Media conditioned by p50 myotubes induced significantly less
migration, as examined by wound healing assay with p5 myoblasts, compared to
media conditioned by p5 myotubes. These initial studies suggest intrinsic
differences in myoblasts undergoing multiple divisions, even in the absence of
senescence and propose interesting avenues for future research into the field of
molecular regulation of muscle ageing, migration and sarcopenia.
4.5.5. THESIS DIRECTIONS
P5 and p50 myoblasts demonstrated significant differences in their migration
behavior. PI3K/AKT and MAPK/ERK pathways were activated more strongly
with p50 cells, as compared to p5 cells, which was associated with increased
migration with the serially passaged myoblasts. In chapter 3, it was also
demonstrated that PI3K/AKT and MAPK/ERK pathways were required for
myoblast migration in response to myotube CM, thus further supporting their
importance for the process. Here, it was also demonstrated that media conditioned
by p50 C2C12 cells was less potent in inducing p5 migration, as compared to
media conditioned by p5 cells. In order to further investigate in sufficient detail
the expression profile and secreted factors between myogenic cells of low and
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high passage, various approaches were required, including PCR arrays to
investigate the expression of a list of selected genes related to migration, or mass
spectrometry, which would reveal the secreted proteins into the supernatant. Due
to time and cost constraints, it was decided that these studies should be the topic
for future projects and were unfortunately beyond the scope of this thesis.
As a consequence and considering the results obtained for the link between the
PI3K/AKT and MAPK/ERK signalling pathways and myoblast migration, it was
decided that the focus of the next chapter of the thesis would be given to studies
investigating the importance of signalling pathways to myoblast migration. P5
myoblasts, with p5 myotube CM to stimulate their migration, were therefore
further used as a model to investigate how modulation of signalling pathways by
different inhibitors would affect the migration of myoblasts in response to signals
released from myogenic cells.
131
CHAPTER 5
132
5. MAPK/ERK AND PI3K/AKT PATHWAYS ARE REQUIRED FOR
BPV(HOPIC)-INDUCED C2C12 MYOBLAST MIGRATION.
REQUIREMENT OF FAK PATHWAY FOR MYOBLAST MIGRATION
5.1. INTRODUCTION
In chapter 3, it was demonstrated that serum free media conditioned by
myotubes (CM) was able to enhance myoblast migration, resulting in the
activation of PI3K/AKT and MAPK/ERK pathways and that inhibition of these
pathways results in decreased migration. Activation of these pathways, in
response to myotube CM, was also associated with increased migration of p50 vs
p5 cells, incubated with p5 CM, as demonstrated in chapter 4. Various studies
have linked cell migration to PI3K and MAPK pathways. Pharmacological
inhibition of MAPK/ERK pathway by PD98059 or UO126 has been demonstrated
to reduce cell migration, not only here, but also in various other studies and cell
types (Huang et al., 2004b, Lind et al., 2006, Teranishi et al., 2009, Webb et al.,
2000). Furthermore, dominant negative ERK and MEK1 are demonstrated to
inhibit cell migration, while active MEK1 can promote it (Jo et al., 2002, Lai et
al., 2001, Webb et al., 2000). PI3K has been implicated in regulating cell
migration and polarity (Cain and Ridley, 2009, Stephens et al., 2002). PI3K
involvement in migration has been investigated in various cell types and has been
demonstrated to be required for this process (Goncharova et al., 2002a, Hannigan
et al., 2002, Irani et al., 2002, Kusch et al., 2000, Vanhaesebroeck et al., 1999, Ye
et al., 2008). Few articles, however, have investigated the intracellular regulation
of myoblast migration. Kawamura et al. have demonstrated that PI3K activity is
necessary for the HGF-induced lamellipodial formation in C2C12 myoblasts and
for their chemotactic migration (Kawamura et al., 2004). This is supported by a
recent study, showing that PI3K-inhibitors reduce the rate of cell migration (Kim
et al., 2011). Previous reports from our group have demonstrated that migration of
C2 myoblasts, triggered by 20% serum, is reduced by treatments with PI3K and
MEK inhibitors, respectively LY294002 and PD98059 (Al-Shanti et al., 2011).
Ranzato et al. have also demonstrated a decreased myoblast migration, in both
wound healing and transwell inserts, in response to platelet lysate, after treatment
with PI3K inhibitor wortmannin, but not with MEK inhibitor PD98059 (Ranzato
et al., 2009). Others, however, have suggested that PI3K and ERK pathways may
not be responsible for chemotaxis in C2C12 cells, as inhibitors of PI3K and MEK
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did not affect the chemotactic migration of C2C12 cells toward bFGF, HGF and
IGF-1 (Suzuki et al., 2000). Leloup et al. have shown that ERK/MAPK signalling
pathway is required for IGF-I, TGF-β1 and insulin mediated migration, as
inhibition of this pathway by PD98059 resulted in reduced migration (Leloup et
al., 2007). However, as opposed to other articles, they found no inhibition of
migration after inhibiting the PI3K/AKT pathways with LY294002. Thus, results
on the PI3K and MAPK pathways regulation of myogenic migration have not
been entirely unanimous. It seems that regulation of myoblast migration by these
two pathways may depend on the extracellular environment, the trigger and the
type of cell movement. Furthermore, it is not entirely clear whether crosstalk or
any redundancy between these pathways may exist in regulating myoblast
migration, as has been demonstrated for smooth muscle cells (Campbell et al.,
2004). Revealing in more details, the involvement of PI3K and MAPK pathways
in myoblast migration, might not only contribute to our understanding of muscle
myogenesis, but it could also be applied in proposed treatments for muscular
dystrophies. Limited spreading/migration, along with low survival of transplanted
cells and immune rejection, has been known to be one of the limiting factors in
proposed therapies of Duchenne muscular dystrophy (Fan et al., 1996, Gussoni et
al., 1997, Moens et al., 1996, Skuk et al., 2004, Smythe et al., 2001). Although,
following recent publications it remains debatable whether migration is indeed a
major limiting factor (Lafreniere et al., 2009, Skuk et al., 2011), enhancing it may
still propose a possibility for improving the results from proposed therapies for
DMD and, therefore, further research in this area is needed. Investigating
myogenic cell migration is not only important for proposed DMD therapies, but,
migration being important for repair, it may have implications post surgery and
also vast implications for athletes. Thus, finding factors to improve the migration
of myoblasts might be of particular interest. Such factors would ideally improve
migration without affecting the capacity of myoblasts to differentiate.
The negative effects of PTEN on cell migration have been widely investigated,
due to its mutations in cancer, and studies have demonstrated that its
downregulation results in enhanced migration of a variety of cell types (Dasari et
al., 2010, Liliental et al., 2000, Tamura et al., 1998). PTEN is known to regulate
cell migration by its lipid phosphatase activity - catalysing the dephosphorylation
of PIP3 to PIP2, thus inhibiting the PI3K/AKT pathway - and also via its protein
phosphatase activity and its C2 domain (Dey et al., 2008, Leslie et al., 2007,
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Raftopoulou et al., 2004, Zhao, 2007). MAPK/ERK and FAK pathways are also
reported to be regulated by PTEN (Cully et al., 2006, Gu et al., 1998, Gu et al.,
1999, Yamada and Araki, 2001). BpV compounds, acting as PTEN inhibitors,
have been demonstrated to enhance cell migration in epithelial cells (Lai et al.,
2007, Mihai et al., 2012, Zhao, 2007). Castaldi et al., to our knowledge the only
publication investigating the effects of BpV compounds on skeletal muscle
myoblasts, have demonstrated that C2C12 cells treated with high concentrations
(10µM) of Bpv, were able to reach muscle tissue via the circulation and contribute
to muscle repair with higher efficiency compared to untreated cells (Castaldi et
al., 2007). They also demonstrated that high concentrations of BpV reduced
myoblast differentiation, although in a reversible manner. Its effect on myoblast
migration, however, was not investigated. Given the effects of BpV compounds
on epithelial cells, the data from PTEN inhibition in other cell types and the link
between PTEN and PI3K/AKT and MAPK/ERK signalling, it was proposed that
using lower concentrations of BpV compounds may be an attractive approach for
enhancing myoblast migration thus providing a tool for investigating the
pathways regulating this process.
5.2. AIMS, OBJECTIVES AND HYPOTHESIS
The main aim was to reveal the roles of the PI3K signalling pathways in the
regulation of myoblast migration. The objectives were to investigate how BpV
compounds, in particular Bpv(Hopic), at different concentrations would affect the
migration of C2C12 myoblasts. Its effect on differentiation would also be
examined. PTEN has been known to affect other pathways, such as FAK/Src (Gu
et al., 1998, Gu et al., 1999), and therefore the potential involvement of the FAK
pathway in regulating myoblast migration would also be investigated. Further
objectives were also to reveal whether MAPK/ERK and PI3K/AKT pathways
would be upregulated by Bpv(Hopic) and whether their inhibition by LY294002
and UO126 would still lead to reduced migration, even if the other pathway
remained activated. It was hypothesised that BpV(Hopic) would affect the
migration of myoblasts and that PI3K, MAPK and FAK pathways could
demonstrate certain levels of redundancy in regulating C2C12 cells migration.
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5.3. METHODS
5.3.1. CELL CULTURE
C2C12 myoblasts were cultured in a humidified 5% CO2 atmosphere at 37ºC.
Cells were grown in the presence of GM in T75 flasks until confluent and split
into multidish plates for experiments. In order to initiate differentiation, C2C12
cells were grown in 6 well plates until confluency was achieved, monolayers were
washed with PBS and differentiation media (DM) was added to the cell
monolayers. When differentiation experiments were performed for 5days, DM
was changed with a fresh media at d3.
5.3.2. CONDITIONED MEDIA GENERATION
C2C12 myoblasts in 6 well plates were triggered to differentiate into myotubes, in
the presence of DM. Conditioned media was generated, as described in section
3.3.2.
5.3.3. CELL TREATMENTS AND RECONSTITUTION OF INHIBITORS
All inhibitors were purchased from Merck-Calbiochem (Darmstadt, Germany).
Inhibitors were diluted, according to manufacturer’s instructions, in either DMSO
or H20 and stored at -20ºC. FAK II inhibitor PF-228 was stored at 4ºC. All
inhibitors were kept in mM concentration stocks which were diluted to working
concentrations in appropriate DMEM media before cell treatments. For cell
treatments, where appropriate, equivalent concentrations of DMSO or H20 were
added to control wells.
5.3.4. WOUND HEALING ASSAY AND LIVE IMAGEING
Cells were grown in pre-gelatinised 12 well plates in GM until ~80-90%
confluent. Cell monolayers were washed 3 times with PBS and DMEM 0.1% FBS
media (quiescent media = QM) was added and incubated for 20h with the cells. In
the last 3 hours of incubation with QM, 10µg/ml Mitomycin-C (Sigma-Aldrich)
was added, in order to block proliferation, and monolayers were wounded with a
sterile pipette tip, generating a wound of approximately 600µm in size. Wound
healing with live imaging microscopy is described in section 2.2.2.1.
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5.3.5. ANALYSIS OF CELL MIGRATION
Cell migration was analysed with Keynote’09 software version 5.1.1. (Apple
Inc.) and ImageJ v1.45i software, as described in section 3.4.2.
5.3.6. CELL DEATH QUANTIFICATIONS BY LIVE IMAGEING
The numbers of dying cells were counted frame by frame in each area for the
duration of the movie, as described in section 2.2.4.
5.3.7. WESTERN BLOTS
Sample collection and preparation for SDS-PAGE was performed as described
in section 2.2.8.1. Gel electrophoresis, membrane transfer, blocking and detection
steps were performed, as described in sections 2.2.8.2-2.2.8.5. Primary AKTpan,
pAKT, b-actin, pFAK, FAKpan and ERKpan rabbit IGg antibodies were
purchased from New England Biolabs (Hertfordshire, UK) and were incubated
with membranes overnight at RT in a 1:1000 dilution in 5% BSA/TBST. Primary
pERK1/2 rabbit antibody was purchased from Promega and was incubated with
membranes overnight at RT at a 1:5000 dilutionj in 0.1% BSA/TBST. Secondary
Goat Anti-rabbit HRP-conjugated antibodies were purchased from MP
Biomedicals (United Kingdom) and were incubated with membranes for 1h at RT
1:5000 concentration, diluted in blocking solution. Membranes were blocked for
1h at RT in 5% non-fat dry milk/TBST (for antibodies purchased from New
England Biolabs) or in 1% BSA/TBST for pERK1/2. Primary py20 mouse
monoclonal antibody was purchased from Santa Cruz and was incubated with
membranes overnight at RT at a 1:500 dilution in TBST. Secondary anti-mouse
antibody, raised in Goat, was purchased from Millipore and diluted in blocking
solution (0.25% gelatin/TBST).
5.3.8. RNA ISOLATIONS AND REAL-TIME PCR
RNA extraction and Real-time PCR methods were performed as described in
sections 2.2.9 and 2.2.10, respectively. Both SYBR® Green detection and
TaqMan® detection were performed. The following predesigned primer sets were
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ordered from Quiagen and were used with the SYBR-Green detection method:
Polr2b (QT00154602), MyoD (QT00101983) and Myogenin (QT00112378).The
following predesigned primer sets were ordered from Applied Biosystems and
were used with the TaqMan® detection method: Polr2b (Mm00464214_m1),
MyoD (mm00440387_m1), Myogenin (mm00446194_m1).
5.3.9. CREATINE KINASE (CK) ASSAY
Samples for CK assay were prepared by adding 150µL per well (for 6 well
plate) of Tris Mes Triton (TMT buffer; composed of: 0.05M Tris/Mes and 1%
Triton-X100). Assay was performed, as described in section 2.2.7.2.
5.3.10. FLOW CYTOMETRY
For investigating cell cycle, cells were collected 20hrs post treatment. Sample
preparation and Propidium iodide method for FACS are described in section
2.2.11.
5.3.11. STATISTICAL ANALYSES
Statistical analyses and significance of data were determined using GraphPad
Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California
USA, www.graphpad.com. Statistical significance for interactions between two
paired groups was determined with a Paired t-test, while unpaired t-test was used
for unpaired groups. Statistical significance for interactions between more than
two groups was determined with a one-way ANOVA, or with a one-way repeated
measures ANOVA, when matched observations were investigated. When more
than one factor was present, two-way ANOVA was performed to investigate for
significances of factors or interactions, or two-way repeated measures (mixed
model) ANOVA, when matched observations were investigated. When
significances of factors were indicated by two-way ANOVA, these were followed
up by examining the statistical significance for interactions between more than
two groups within the factor with a One-way ANOVA with Bonferroni post-hoc
analysis, or with a t-test for examination between two groups. All results are
presented as mean +/- standard error of the mean (SEM). All values below p<0.05
were considered as significant.
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5.4 RESULTS
5.4.1. DIFFERENTIATION OF C2C12 MYOBLASTS IS SIGNIFICANTLY
AFFECTED BY 10 µM, BUT NOT BY 1 µM BPV(HOPIC)
First, it was investigated whether the differentiation of myoblasts was affected
by Bpv(Hopic) treatment, as suggested by other studies demonstrating inhibition
of C2C12 differentiation using 10µM BpV (Castaldi et al., 2007). Three different
concentrations of Bpv(Hopic), 1µM, 2µM and 10µM in DM were incubated for 3
days with confluent myoblasts. Phase-contrast microscopy was used to visually
estimate the fusion of myoblasts into multinucleated myotubes (Figure 5.1). As
seen in the figure, myoblasts incubated in control DM for 3 days, had comparable
morphology to cells incubated with DM+1µM Bpv(Hopic) and DM+2µM
Bpv(Hopic), with all of these treatments inducing differentiation and visible
myotube formation. By contrast, DM+10µM Bpv(Hopic), inhibited the formation
of myotubes.
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Figure 5.1. Effects of different concentrations of BpV(Hopic) on myotube
formation. Phase-contrast microscopy images comparing the effects of 3 days
incubation with DM (A), DM+1µM Bpv(Hopic) (B), DM+2µM Bpv(Hopic) (C) and
DM+10µM Bpv(Hopic) (D) on the fusion of myoblasts into multinucleated myotubes.
DM, DM+1µM Bpv(Hopic) and DM+2µM Bpv(Hopic) do not demonstrate visual
differences in morphology, while DM+10µM Bpv(Hopic) completely blocked
fusion/differentiation. Data are representative of 5 experiments performed in duplicate.
In order to verify the phase-contrast microscopy data, CK assays were
performed, measuring the activity of the CK enzyme (a marker for myoblast
differentiation in vitro) at 72 hrs following the 4 different treatment regimes
(Figure 5.2). Analyses demonstrated significant reductions in CK activity and
hence myotube formation, with DM+10µM Bpv(Hopic) vs DM (352.6 +/-15.17
vs 791.8 +/-37.12, p<0.001, equivalent to 2.25 fold decrease) and a small, but
statistically significant decrease with CM+2µM Bpv(Hopic) vs DM (712 +/-33.68
vs 791.8 +/-37.12, p<0.05, equivalent to 1.11 fold decrease).
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Figure 5.2. CK assay (DM with different concentrations of BpV(Hopic). CK
assay, measuring the CK activity after treatment of C2C12 cells for 3 days with DM,
DM+1µM Bpv(Hopic), DM+2µM Bpv(Hopic) and DM+10µM Bpv(Hopic), indicated
significant reductions with DM+10µM Bpv(Hopic) vs DM (p<0.001, represented by *)
and with DM+2µM Bpv(Hopic) vs DM (p<0.05, represented by #). Data are
representative of 5 experiments performed in duplicate. (p-values obtained by One-way
repeated measures ANOVA)
To investigate the differentiation inhibitory effect of Bpv(Hopic) at a
transcriptional  level, RT-PCRs were performed to examine the expression of 2
key genes involved in regulating myogensis, myoD and myogenin (Figure 5.3).
Expression levels of myoD and myogenin were examined 24h post addition of
DM, DM+1µM Bpv(Hopic), DM+2µM Bpv(Hopic) or DM+10µM Bpv(Hopic).
As seen in Figure 5.3(A), significant reductions in MyoD expression levels were
detected with DM+10µM Bpv(Hopic) vs DM (0.44 +/-0.08 vs 1, p<0.0001,
equivalent to 2.27 fold decrease), vs DM+1µM Bpv(Hopic) (0.44 +/-0.08 vs 0.92
+/- 0.07, p<0.0001, equivalent to 2.09 fold decrease) and vs DM+2µM
Bpv(Hopic) (0.44 +/-0.08 vs 0.87+/-0.08, p<0.0001, equivalent to 1.98 fold
decrease). No significant decreases vs DM were observed with DM+1µM
Bpv(Hopic) or DM+2µM Bpv(Hopic), confirming the morphological
observations. Analyses of myogenin expression levels (Figure 5.3B) indicated a
significant decrease with DM+10µM Bpv(Hopic) vs DM (0.14 +/-0.02 vs 1,
equivalent to 7.14 fold decrease, p<0.0001), vs DM+1µM Bpv(Hopic), (0.14 +/-
0.02 vs 0.84+/-0.06, equivalent to 6 fold decrease, p<0.0001) and vs DM+2µM
Bpv(Hopic) (0.14 +/-0.02 vs 0.72+/-0.08, equivalent to 5.14 fold decrease,
p<0.0001). Decreases were also detected with DM+2µM Bpv(Hopic) vs DM
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(0.72 +/-0.08 vs 1, equivalent to 1.39 fold decrease, p<0.01), substantiating the
biochemical analyses above.
Figure 5.3. RT-PCR analyses of MyoD and Myogenin mRNA expression
levels following different concentrations of Bpv(Hopic). Myoblasts were
incubated for 24h with DM, DM+1µM Bpv(Hopic), DM+2µM Bpv(Hopic) and
DM+10µM Bpv(Hopic) before RNA was collected. All values are represented as fold
change to the calibrator (DM d1), which is set to 1 (mean Ct value (MyoD)=25.56 +/-
1.65; mean Ct value(Myogenin)=19.56 +/-0.39). Analysis of MyoD expression levels
indicated significant decreases with DM+10µM Bpv(Hopic) vs DM (p<0.0001,
represented by *), vs DM+1µM Bpv(Hopic) (p<0.0001, represented by #) and vs
DM+2µM Bpv(Hopic) (p<0.0001, represented by a) (A). Analyses of Myogenin
expression levels indicate significant decreases with DM+10µM Bpv(Hopic) vs DM
(p<0.0001, represented by *), vs DM+1µM Bpv(Hopic) (p<0.0001, represented by #), vs
DM+2µM Bpv(Hopic) (p<0.0001, represented by a). and also with DM+2µM
Bpv(Hopic) vs DM (p<0.01, represented by c) (B). Data are representative of 5
experiments performed in duplicate. (p-values obtained by One-way repeated measures
ANOVA)
5.4.2. INCREASED PERCENTAGE OF C2C12 MYOBLASTS IN S/G2-
PHASE OF THE CELL CYCLE AFTER TREATMENT WITH 10 µM
BPV(HOPIC)
Previous reports indicated that C2C12 cells treated with high concentrations of
BpV displayed a sustained percentage of cells in the s-phase of the cell cycle
compared with controls (Castaldi et al., 2007). As permanent withdrawal from the
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cell cycle is necessary for progression to myogenic differentiation, an increased
percentage of cells in the S/G2-phase of the cell cycle may underpin the inhibited
differentiation in the presence of sustained exposure to high dose Bpv(Hopic). To
verify this hypothesis, myoblasts were treated and isolated for FLOW cytometric
analyses following incubation for 20h in DM or DM+10µM Bpv(Hopic) (Figure
5.4). Data indicated significant increases in the percentage of cells in the S/G2-
phase with DM+10µM Bpv(Hopic) vs DM (42.76 +/-1.92% vs 17.08 +/-3.19%,
p<0.01), substantiating the theory that continued cell cycle progression may
underpin inhibition of differentiation in the presence of high dose Bpv(Hopic).
Figure 5.4. Flow cytometric analysis (DM vs DM+10µM BpV(Hopic)).
Examination of the percentage of C2C12 myoblasts in the S/G2-phase of the cell cycle
using FLOW cytometric analyses, following incubation of the cells for 20h with DM (A)
or DM+10µM Bpv (B). Analyses of the percentage of cells in S-phase of the cell cycle
(C) indicate significant increases with DM+10µM Bpv(Hopic) vs DM (p<0.01,
represented by *). Data are representative of 4 experiments performed in duplicate. (p-
values obtained by paired t-test)
5.4.3. THE PHOSPHO-TYROSINE PHOSPHATASE INHIBITOR
BPV(HOPIC) IS ABLE TO FURTHER ACTIVATE PI3K/AKT AND
MAPK/ERK SIGNALLING PATHWAYS AND TO INCREASE
MYOBLAST MIGRATION IN RESPONSE TO CM
It was demonstrated that PI3K/AKT and MAPK/ERK pathways are activated in
response to CM and was associated with migration; furthermore,it was
demonstrated that their silencing by LY294002 and UO126 resulted in reductions
of myoblast migration (Chapter 3.5.7). The action of Bpv(Hopic), reported to act
as a PTEN inhibitor (at lower concentrations) and thus suggested to activate PI3K
and MAPK pathways in different cell types, was further explored in our model. It
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was initially investigated whether Bpv(Hopic) could activate PI3K/AKT and
MAPK/ERK pathways in C2C12 myoblasts and whether myoblast migration
would subsequently be affected.
Three different concentrations of Bpv(Hopic) were again initially examined -
1µM, 2µM and 10µM. Western blots were performed using anti-phospho-tyrosine
antibody (py20) in an attempt to evaluate the specificity of these BpV(Hopic)
concentrations. As shown on Figure 5.5, 10µM Bpv (Hopic) is highly non-
specific, generically phosphorylating multiple tyrosine residues. Specificity of
Bpv(Hopic) increased with lowering the concentration, with 1µM appearing to be
the most specific over time and when compared to CM conditions.
Figure 5.5. Anti-phospho-tyrosine Western blot analyses (py20 antibody)
tested the specificity of different concentrations of Bpv(Hopic). As shown,
lower concentrations of Bpv(Hopic) are better in maintaining specificity of activity, with
1µM being the most specific of the 3 concentrations tested and 10µM showing no
specificity with regard to tyrosine phosphorylation. Data are representative of 3
experiments.
Western blots were subsequently performed to investigate the effect of 1µM,
2µM and 10µM BpV(Hopic) on activation of PI3K/AKT and MAPK/ERK
pathways (Figure 5.6) at 4 different time points (15m, 30m, 45m and 60m) after
treatment. Both p-AKT and pERK1/2 appeared to be increased with Bpv(Hopic)
vs CM, in a concentration and for higher dose BpV(Hopic), in temporal
dependent manner.
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Figure 5.6. Western blot analysis (CM with different concentrations of
Bpv(Hopic)). Western blots investigating the effect of 3 different concentrations of
Bpv(Hopic) (1µM, 2µM and 10µM) +  CM vs CM on the protein and phosphorylation
levels of members of the PI3K/AKT and MAPK/ERK pathways over 15m,30m,45m and
60m after cell treatment. Data are representative of 4 experiments.
Further quantification and analyses of the levels of p-AKT and pERK1/2 vs pan-
specific controls were performed on 1µM and 2µM concentrations of Bpv
(Hopic).  Given the lack of specificity of the 10µM concentration (detailed in
Figure 5.5 above), for the purposes of these studies, this concentration was
included as a positive control only and was not further analysed.
Quantitative analyses of pAKT (Ser 473) activation in response to CM,
CM+1µM Bpv(Hopic) and CM+2µM Bpv(Hopic) were performed (Figure 5.7).
pAKT phosphorylation was increased with CM+2µM Bpv(Hopic) vs CM at 15m
(264.5 +/-45% vs 100%, p<0.001), 30m (201.25 +/-27.68% vs 28.5 +/-3.97%,
p<0.0001), 45m (132.5 +/-18.46% vs 18 +/-1.22%, p<0.01) and 60m (146 +/-
20.26% vs 23.75 +/-5.19%, p<0.0001). Significant increases were also evident
also with CM+1µM Bpv(Hopic) vs CM at 15m (186.5 +/-14.63% vs 100%,
p<0.05), 30m (161.25 +/-16.78% vs 28.5 +/-3.97%, p<0.001), 45m (102.25 +/-
7.86% vs 18 +/-1.22%, p<0.01) and 60m (90.75 +/-14.27% vs 23.75 +/-5.19%,
p<0.01). Significant increases were also found with CM+2µM Bpv(Hopic) vs
CM+1µM Bpv(Hopic) at 15m (264.5 +/-45% vs 186.5 +/-14.63%, p<0.01), at
30m (201.25 +/-27.68% vs 161.25 +/-16.78%, p<0.05) and at 60m (146 +/-
20.26% vs 90.75 +/-14.27%, p<0.01). Reductions of pAKT phosphorylation with
time were indicated with CM at 30m vs 15m (28.5 +/-3.97% vs 100%, p<0.0001),
45m vs 15m (18 +/-1.22% vs 100%, p<0.0001) and 60m vs 15m (23.75 +/-5.19%
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vs 100%, p<0.0001). Similarly, reductions with time were also evident with
CM+1µM Bpv(Hopic) at 30m vs 15m (161.25 +/-16.78% vs 186.5 +/-14.63%,
p<0.05), 45m vs 15m (102.25 +/-7.86% vs 186.5 +/-14.63%, p<0.001) and 60m
vs 15m (90.75 +/-14.27% vs 186.5 +/-14.63%, p<0.001). Reductions with time
were also observed with CM+1 µM Bpv(Hopic) at 45m vs 30m (102.25 +/-7.86%
vs 161.25 +/-16.78%, p<0.01) and 60m vs 30m (90.75 +/-14.27% vs 161.25 +/-
16.78%, p<0.001). Reductions in the levels of pAKT with time with CM+2µM
Bpv(Hopic) were also evident, however, significance was not achieved.
Figure 5.7. Quantification of pAKT levels (CM, CM+1µM Bpv(Hopic) and
CM+2µM Bpv(Hopic)). Quantification of pAKT phosphorylation levels in response to
CM, CM+1µM Bpv(Hopic) and CM+2µM Bpv(Hopic) indicated significant increases
with CM+2µM BpV(Hopic) vs CM at 15m (p<0.001, represented as *), 30m (<0.0001,
represented as *), 45m (p<0.01, represented as *) and 60m (p<0.0001, represented as *).
Significant increases were indicated with CM+1µM BpV(Hopic) vs CM at 15m (p<0.05,
represented as #), 30m (<0.001, represented as #), 45m (p<0.01, represented as #) and
60m (p<0.01, represented as #). Significant increase was found with CM+2µM
Bpv(Hopic) vs CM+1µM Bpv(Hopic) at 15m (p<0.01, represented by a), 30m (p<0.05,
represented as a) and 60m (p<0.01, represented as a). Significant reductions of pAKT
phosphorylation levels with CM were observed at 30m vs 15m,45m vs 15m and 60m vs
15m (all p<0.0001, represented as t). Significant reductions were observed with
CM+1µM Bpv(Hopic) at 30m vs 15m (p<0.05, represented by x), at 45m vs 15m
(p<0.001, represented by x), at 60m vs 15m (p<0.001, represented by x) and also at 45m
vs 30m (p<0.01, represented by z) and 60m vs 30m (p<0.001, represented by z). Data are
representative of 4 experiments. (p-values obtained by One-way repeated measures
ANOVA)
146
Analyses of pERK1/2 phosphorylation in response to CM, CM+1µM
Bpv(Hopic) and CM+2µM Bpv(Hopic) were performed (Figure 5.8). Significant
increases were observed with CM+2µM Bpv(Hopic) vs CM at 15m (172.25 +/-
17.75% vs 100%, p<0.05), 30m (99.5 +/-8.42% vs 11.75 +/-3.88%, p<0.001),
45m (53 +/-2.58% vs 9 +/-4.92%, p<0.001) and 60m (72.25 +/-11.19% vs 9.75 +/-
2.21%, p<0.001). An increase was also observed with CM+1µM BpV(Hopic) vs
CM at 30m (67 +/-5.73% vs 11.75 +/-3.88%, p<0.01), 45m (52.25 +/-3.22% vs 9
+/-4.92%, p<0.001) and 60m (42.75 +/-4.25% vs 9.75 +/-2.21%, p<0.05).
Significant increases were indicated with CM+2µM Bpv(Hopic) vs CM+1µM
Bpv(Hopic) at 30m (99.5 +/-8.42% vs 67 +/-5.73%, p<0.05) and 60m (72.25 +/-
11.19% vs 42.75 +/-4.25%, p<0.05). Reductions in pERK1/2 phosphorylation
levels with time were observed with CM at 30m vs 15m (11.75 +/-3.88% vs
100%, p<0.0001), 45m vs 15m (9 +/-4.92% vs 100%, p<0.0001) and 60m (9.75
+/-2.21% vs 100%, p<0.0001). Reductions with time were also observed with
CM+1µM (Bpv(Hopic)) at 30m vs 15m (67 +/-5.73% vs 154.75 +/-27.31%,
p<0.05), 45m vs 15m (52.25 +/-3.22% vs 154.75 +/-27.31%, p<0.01) and 60m vs
15m (42.75 +/-4.25% vs 154.75 +/-27.31%, p<0.01). Significant reductions with
time were also indicated with CM+2µM (Bpv(Hopic)) at 30m vs 15m (99.5 +/-
8.42% vs 172.25 +/-17.75%, p<0.001), 45m vs 15m (53 +/-2.58% vs 172.25 +/-
17.75%, p<0.001) and 60m vs 15m (72.25 +/-11.19% vs 172.25 +/-17.75%,
p<0.001).
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Figure 5.8. Quantification of pERK1/2 levels (CM, CM+1µM Bpv(Hopic) and
CM+2µM Bpv(Hopic)). Quantification of pERK1/2 phosphorylation levels in
response to CM, CM+1µM Bpv(Hopic) and CM+2µM Bpv(Hopic) indicated significant
increases with CM+2µM BpV(Hopic) vs CM at 15m (p<0.05, represented by *), 30m
(p<0.001, represented by *), 45m (p<0.001, represented by *) and 60m (p<0.001,
represented by *). Significant increase was indicated with CM+1µM BpV(Hopic) vs CM
at 30m (p<0.01, represented by #), 45m (p<0.001, represented by #) and 60m (p<0.05,
represented by #). Significant increase was observed with CM+2µM BpV(Hopic) vs
CM+1µM BpV(Hopic) at 30m and 60m (for both p<0.05, represented by a). Reduction of
pERK1/2 levels at 30m vs 15m, 45m vs 15m and 60m vs 15m with CM was observed
(for all p<0.0001, represented by t). Reduction was also observed with CM+1µM
BpV(Hopic) at 30m vs 15m (p<0.05, represented by x), 45m vs 15m (p<0.01, represented
by x) and 60m vs 15m (p<0.01, represented by x). There was a significant reduction with
CM+2µM BpV(Hopic) at 30m vs 15m, 45m vs 15m and 60m vs 15m (for all p<0.001,
represented by z). Data are representative of 4 experiments. (p-values obtained by One-
way repeated measures ANOVA)
Having determined the dose responsiveness of Bpv(Hopic) on the C2C12 cells
for specificity, as well as activation of ERK and Akt, the action of Bpv(Hopic) on
wound closure was assessed in preliminary experiments (Figure 5.9). 10µM
concentration caused cell contraction and shrinking (illustrated in Figure 5.9
(panel D)), which continued for several hours and this caused a delay in the
progress of wound closure. 1µM and 2µM concentrations also caused cell
shrinking/contraction, although this lasted for much shorter time periods
compared to the 10µM concentration, with 1µM causing cells to contract for the
shortest period of time. Wound closure was visually improved with both 1µM and
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2µM concentrations of Bpv(Hopic) following 20h incubation, compared to CM
alone.  CM (Figure 5.9A), despite being more potent at inducing migration
compared to SF media (as detailed in chapter 3) was apparently less potent at
inducing cell migration over 20h compared to CM+1uM Bpv(Hopic) (Figure
5.9B) and CM+2uM Bpv(Hopic) (Figure 5.9C). CM+10uM Bpv(Hopic) caused
cell contraction and shrinking for several hours (Figure 5.9D) and hence
migration at 20h (Figure 5.9E) was delayed compared to 1µM and 2µM
concentrations. Following a time lag, wound closure with 10µM Bpv(Hopic) did
eventually occur, at 40h (Figure 5.9F). As cells migrated in a similar manner with
both concentrations (1µM and 2µM), the differences in migration distance/cell
counts was not investigated in detail between these concentrations of Bpv(Hopic).
Figure 5.9. Preliminary experiments examining the migration potential
between CM and 1µM, 2µM and 10µM concentrations of Bpv(Hopic). CM (A)
was less potent in inducing cell migration for 20h compared to CM+1uM Bpv(Hopic) (B)
and CM+2uM Bpv(Hopic) (C). CM+10uM Bpv(Hopic) caused cell contraction and
shrinking for several hours (D) and migration at 20h (E) was delayed compared to 1µM
and 2µM concentrations (B and C). Wound closure with 10µM Bpv(Hopic) was
eventually complete with a big delay at 40h (F). Data are representative of 3 experiments
performed in duplicate.
Considering the shrinking/contraction of myoblasts, induced by Bpv(Hopic), it
was of interest to examine  whether adhesion of the cells was affected by the
inhibitor. Cells were seeded in CM and the time for cell spreading on the substrate
149
was examined. As visualized in Figure 5.10, the majority of cells in CM were
adherent at 30min., with all cells attached and spreading at 60m. Time for
successful adhesion was increased with increasing concentrations of Bpv(Hopic),
with poor adhesion even at 60 min. for 2 µM treatment and 10µM application
resulting in no evident adhesion even following 60min incubation.
Figure 5.10. Cell adhesion assay examines the time required for cells to
adhere to the substratum (0.2% gelatin). The majority of cells in CM were
adhering at 30m, and well adhered at 60m. With increasing concentrations of
BpV(Hopic), the time required for adhesion was increased. Data are representative of 2
experiments performed in duplicate.
Given the derived data, 1µM Bpv(Hopic) demonstrated activation of both
PI3K/AKT (Figure 5.7) and MAPK/ERK (Figure 5.8) signalling pathways and
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little impact on cell adhesion or death compared to CM, while showing greater
specificity than either 2 or 10 µM (Figure 5.5) and no significant impact on
differentiation (Figure 5.1-5.3), this dose was therefore chosen for further
analyses.
Having examined the appropriate doses of Bpv (Hopic) to be utilized in these
studies, the migration of myoblasts with CM vs CM+1µM Bpv(Hopic) was
analyzed in the wound healing assay and indicated that cellular migration was
indeed increased following 20hrs incubation with CM+1µM Bpv(Hopic) vs CM
(Figure 5.11). Analyses of the total number of cells migrating into the wound site
indicated significant increases in the number of cells with CM+1µM Bpv(Hopic)
vs CM (91+/- 4 vs 66 +/-3, p<0.0001, equivalent to 38% increase; (Figure 5.11B).
The percentage of cells in the central section of the wound was also significantly
greater with CM+1µM Bpv(Hopic) vs CM (21.87 +/-1.28% vs 10.13 +/-1%, p<0.
0001; Figure 5.11C), thus confirming the preliminary data derived in Figure 5.9.
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Figure 5.11. Wound healing assay with cell count analysis (CM vs CM+1µM
Bpv(Hopic)). Wound healing assay comparing the wound closure between CM and
CM+1µM Bpv(Hopic) for 20h (A). Wound healing cell count quantifications between
CM and CM+1µM Bpv(Hopic) indicated significant increase with CM+1µM Bpv(Hopic)
vs CM (p<0.0001, represented by *) (B).  Quantification of the percentage of cells in the
middle of the wound indicated significant increase with CM+1µM Bpv(Hopic) vs CM
(p<0.0001, represented by *) (C). All data are representative of 15 experiments
performed in duplicate. (p-values obtained by paired t-test)
To confirm the quantification data, cell tracking analyses were performed
between cells treated with CM and CM+1µM Bpv(Hopic) (Figure 5.12A). The
analyses of cell tracking studies revealed significant increases in the migration
distances of CM+1µM Bpv(Hopic) vs CM (598 +/-47.4µm vs 422 +/-33.2µm,
p<0.0001, equivalent to 41% increase; Figure 5.12B). Furthermore, cell death
analyses indicated a very small, but significant decrease in the percentage of dead
cells with CM+1µM Bpv(Hopic) vs CM (0.75 +/-0.13% vs 1.39 +/-0.3%, p<0.05;
Figure 5.12C).
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Figure 5.12. Cell tracking and cell death analysis (CM vs CM+1µM
Bpv(Hopic)). Morphological photomicrographs of migration tracking comparing the
effects of CM and CM+1µM Bpv(Hopic) (A).  Quantification of cell migration distance
indicated significant increase with CM+1µM Bpv(Hopic) vs CM (p<0.0001, represented
by *) (B). Data are representative of 15 experiments performed in duplicate. Cell death
quantifications indicated a decrease in cell death with CM+1µM Bpv(Hopic) vs CM
(p<0.05) (C). Data are representative of 14 experiments performed in duplicate. (p-values
obtained by paired t-test)
5.4.4. THE ACTION OF BPV(HOPIC) ON CELL MIGRATION IS
REDUCED BY INHIBITING THE PI3K/AKT PATHWAY WITH
LY294002
Here it was demonstrated that Bpv(Hopic) in CM is able to facilitate myoblast
migration and to enhance the PI3K/AKT and MAPK/ERK pathways. On the other
hand, PI3K/AKT inhibitor LY294002 and MAPK/ERK inhibitor UO126, reduced
myoblast migration induced by CM. Wishing to substantiate the specificity of this
data using 1µM Bpv(Hopic), an assessment was made on how the myoblast
migration, enhanced by Bpv(Hopic), would be affected by co-incubations with
153
LY294002 or UO126; thus investigating more specifically (in the absence of
direct activators of these pathways) whether migration in this model is indeed
mediated by either PI3K or MAPK pathways.
Western blotting studies were performed to investigate the effect of CM,
CM+1µM BpV(Hopic) and CM+1µM BpV(Hopic)+10µM LY294002 on the
levels of of p-AKT and pERK1/2  activation over time (Figure 5.13). In the
absence of any impact on total Akt, ERK or beta actin levels, it is clear from the
blots that Bpv increases pAkt and pERK1/2 phosphorylation, as already
demonstrated.  Furthermore, the data suggest that in the presence of
BpV(Hopic)+10µM LY294002, pAkt activation is completely blocked, with no
impact on pERK1/2 activity, indicating the specificity of the co-incubations
(Figure 5.13).
Figure 5.13. Western blots (CM, CM+1µM Bpv(Hopic) and CM+1µM
Bpv(Hopic)+10µM LY294002). Western blots investigating the effects of CM (Lanes
1, 4, 7 and 10=CM), CM+1µM BpV(Hopic) (Lane 2, 5, 8 and 11=Bpv) and CM+1µM
BpV(Hopic)+10µM LY294002 (Lane 3, 6, 9 and 12 = BPV LY) with time on the
activation levels of p-AKT and pERK1/2. 1µM Bpv(Hopic) induced activation of Akt
and ERK, while its combination with 10µM LY294002 blocked the activation of pAKT,
but not of pERK1/2. Data are representative of at least 3 experiments.
Blots were subjected to further analyses using Quantity One software. Phospho-
Akt and Phospho-ERK1/2 levels were quantified across the 3 different treatments
conditions and the 4 time points. All values are represented as percentage of the
calibrator (CM 15m), which was set to 100%.
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Analyses of pAKT (Ser 473) were performed in response to CM, CM+1µM
Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM LY294002 (Figure 5.14).
Significant increases were observed with CM+1µM Bpv(Hopic) vs CM at 15m
(153.67 +/-12.23% vs 100%, p<0.01), at 30m (160.33 +/-23.24% vs 60.67 +/-
7.83%, p<0.001), at 45m (135.17 +/-17.02% vs 48.67 +/-10.84%, p<0.001) and at
60m (145.5 +/-16.91% vs 66.83 +/-6.58%, p<0.001). A decrease was found with
CM+1µM Bpv(Hopic)+10µM LY294002 vs CM+1µM Bpv(Hopic) at 15m
(24.67 +/-6.64% vs 153.67 +/-12.23%, p<0.0001), at 30m (46.33 +/-8.18% vs
160.33 +/-23.24%, p<0.001), at 45m (46.17 +/-5.24% vs 135.17 +/-17.02%,
p<0.001) and at 60m (59.83 +/-9.89% vs 145.5 +/-16.91%, p<0.0001). Decreases
were also indicated with CM+1µM Bpv(Hopic)+10µM LY294002 vs CM at 15m
(24.67 +/-6.64% vs 100%, p<0.001).
Figure 5.14. Quantification of pAKT levels (CM, CM+1µM Bpv(Hopic) and
CM+1µM Bpv(Hopic)+10µM LY294002). Quantification of pAKT levels in
response to CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM LY294002
indicated significant increases with CM+1µM Bpv(Hopic) vs CM at 15m (p<0.01,
represented by *), at 30m (p<0.001, represented by *), at 45m (p<0.001, represented by
*) and at 60m (p<0.001, represented by *). Decreases were indicated with CM+1µM
Bpv(Hopic)+10µM LY294002 vs CM+1µM Bpv(Hopic) at 15m (p<0.0001, represented
by #), at 30m (p<0.001, represented by #), at 45m (p<0.001, represented by #) and at 60m
(p<0.0001, represented by #). Decreases were also found with CM+1µM
Bpv(Hopic)+10µM LY294002 vs CM at 15m (p<0.001, represented by a). Data are
representative of 6 experiments. (p-values obtained by One-way repeated measures
ANOVA)
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Given the visual data above in Figure 5.13 in relation to ERK1/2
phosphorylation, analyses of pERK1/2 were performed to consolidate these
findings and to establish the impact of CM, CM+1µM Bpv(Hopic) and CM+1µM
Bpv(Hopic)+10µM LY294002 (Figure 5.15) on ERK1/2 phosphorylation. As
already described, significant increases in ERK1/2 phosphorylation were evident
with CM+1µM Bpv(Hopic) vs CM at 30m (88 +/-7.21% vs 8.67 +/-4.33%,
p<0.001), at 45m (65.33 +/-11.98% vs 7 +/-2.08%, p<0.05) and at 60m (41 +/-
4.58% vs 6.67 +/-1.76%, p<0.01). Similarly, increases with CM+1µM
Bpv(Hopic)+10µM LY294002 vs CM were found at 30m (91 +/-2.08% vs 8.67
+/-4.33%, p<0.001), at 45m (68.33 +/-8.67% vs 7 +/-2.08%, p<0.05) and at 60m
(44.33 +/-3.71% vs 6.67 +/-1.76%, p<0.01). Significant reductions in ERK1/2
activation with CM were observed at 30m vs 15m (8.67 +/-4.33% vs 100%,
p<0.001), 45m vs 15m (7 +/-2.08% vs 100%, p<0.001), 60m vs 15m (6.67 +/-
1.76% vs 100%, p<0.001). Decreases were also found with CM+1µM Bpv(Hopic)
at 60m vs 15m (41 +/-4.58% vs 123.67 +/-22.64%, p<0.05). Similar decreases
with time were evident with CM+1µM Bpv(Hopic)+10µM LY294002, although
not statistically significant. Critically, no differences in ERK1/2 phosphorylation
were evident between CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM
LY294002 at any of the times investigated, once again confirming the visual data
in Figure 5.13.
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Figure 5.15. Quantification of pERK1/2 levels (CM, CM+1µM Bpv(Hopic)
and CM+1µM Bpv(Hopic)+10µM LY294002). Quantification of pERK1/2
activation in response to CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM
LY294002 indicated significant increase with CM+1µM Bpv(Hopic) vs CM at 30m
(p<0.001, represented by *), at 45m (p<0.05, represented by *) and at 60m (p<0.01,
represented by *). Increase was found with CM+1µM Bpv(Hopic)+10µM LY294002 vs
CM at 30m (p<0.001, represented by #), at 45m (p<0.05, represented by #) and at 60m
(p<0.01, represented by #). Significant reduction was found with CM at 30m vs 15m
(p<0.001, represented by t), at 45m vs 15m (p<0.001, represented by t) and at 60m vs
15m (p<0.001, represented by t). Decrease was indicated with CM+1µM Bpv(Hopic) at
60m vs 15m (p<0.05, represented by x). Data are representative of 3 experiments
performed. (p-values obtained by One-way repeated measures ANOVA)
After confirming by Western blots that LY294002 induced specific inhibition of
the PI3K/Akt pathway, without significantly altering the MAPK/ERK pathway,
wound healing studies were performed to investigate the effect on wound closure
of CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM LY294002
(Figure 5.16A); it is evident from these morphological observations the the
inclusion of 10µM LY294002 in the presence of CM+1µM Bpv(Hopic), reduces
cellular migration to levels more visually comparable to those seen with CM
alone. Analyses of total cell counts in the damaged area (Figure 5.16B) indicated
significant increases with CM+1µM Bpv(Hopic) vs CM (90 +/-5 vs 65 +/-3,
p<0.001, equivalent to 38% increase) and a comparable decrease with CM+1µM
Bpv(Hopic)+10µM LY294002 vs CM+1µM Bpv(Hopic) (66 +/-3 vs 90 +/-5,
p<0.01, equivalent to 27% decrease). Analyses of the percentage of cells in the
middle of the wound (Figure 5.16C) indicated significant increases with
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CM+1µM Bpv(Hopic) vs CM (17.33 +/- 2.03% vs 5.17 +/-0.95%, p<0.0001) and
a decrease towards control conditions with CM+1µM Bpv(Hopic)+10µM
LY294002 vs CM+1µM Bpv(Hopic) (9.17 +/-1.28% vs 17.33 +/-2.03%,
p<0.0001). Although no difference was apparent between total cells migrating in
the presence of CM vs CM+1µM Bpv(Hopic)+10µM LY294002 (Figure 5.16B),
an increase in the percentage of cells in the middle of the wound was evident with
CM+1µM Bpv(Hopic)+10µM LY294002 vs CM (9.17 +/-1.28% vs 5.17 +/-
0.95%, p<0.01).
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Figure 5.16. Wound healing assay with cell count analyses (CM, CM+1µM
Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM LY294002). Wound healing assay
comparing the wound closure between CM, CM+1µM Bpv(Hopic) and CM+1µM
Bpv(Hopic)+10µM LY294002 (A).  Quantification of the total number of cells
infiltrating the wound site following 20h incubation indicated significant increases with
CM+1µM Bpv(Hopic) vs CM (p<0.001, represented by *). Significant decreases were
indicated with CM+1µM Bpv(Hopic)+10µM LY294002 v CM+1µM Bpv(Hopic)
(p<0.01, represented by #) (B).  Quantification of the percentage of cells in the middle of
the wound indicated significant increases with CM+1µM Bpv(Hopic) vs CM (p<0.0001,
represented by *). Significant decreases were observed with CM+1µM
Bpv(Hopic)+10µM LY294002 v CM+1µM Bpv(Hopic) (p<0.0001, represented by #).
Increases were also was indicated with CM+1µM Bpv(Hopic)+10µM LY294002 vs CM
(p<0.01, represented by a) (C). All data are representative of 6 experiments performed in
duplicate. (p-values obtained by One-way repeated measures ANOVA)
To consolidate the quantification investigations, cell tracking analyses were
performed (Figure 5.17A). Statistical analyses of the derived data indicated
significant increases in cell migration distance with CM+1µM Bpv(Hopic) vs CM
(678 +/-63.1µm vs 463 +/-49.4µm, p<0.0001, equivalent to 46% increase).
Significant decreases were observed with CM+1µM Bpv(Hopic)+10µM
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LY294002 vs CM+1µM Bpv(Hopic) (521 +/-54.3µm vs 678 +/-63.1µm, p<0.001,
equivalent to 23% decrease; Figure 5.17B), substantiating the data obtained from
Figure 5.16 and suggesting that migration itself was affected and not simply
directionality of migration. No significant increase/decrease in cell death was
observed between any of the treatments (Figure 5.17C).
Figure 5.17. Cell tracking and cell death analysis (CM, CM+1µM Bpv(Hopic)
and CM+1µM Bpv(Hopic)+10µM LY294002). Migration tracking comparing the
effects of CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM LY294002 (A).
Quantification of cell migration distance indicated significant increases with CM+1µM
Bpv(Hopic) vs CM (p<0.0001, represented by *). Significant decreases were observed
with CM+1µM Bpv(Hopic)+10µM LY294002 vs CM+1µM Bpv(Hopic) (p<0.001,
represented by #) (B).  Cell death quantifications and analyses found no significant
difference between CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+10µM
LY294002 (C). All data are representative of 6 experiments performed in duplicate. (p-
values obtained by One-way repeated measures ANOVA)
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5.4.5. THE ACTION OF BPV(HOPIC) ON CELL MIGRATION IS
REDUCED BY INHIBITING THE MAPK/ERK PATHWAY WITH UO126
Similar to the experiments performed in Section 5.4.4, in order to verify the
specificity of the MAPK/ERK signalling pathway inhibition by UO126 in the
presence of Bpv(Hopic), western blots were performed to investigate the effect of
CM, CM+1µM BpV(Hopic) and CM+1µM BpV(Hopic)+5µM UO126 on
PI3K/AKT and MAPK/ERK pathways (Figure 5.18). As is evident from
representative blots below, UO in the presence of Bpv(Hopic) was with little
impact on Akt phosphorylation, compared to Bpv(hopic) alone. By contrast and in
line with expectations, UO126 blocked the activation of ERK1/2 when added in
combination with and when compared to Bpv(Hopic) alone. Internal controls (pan
Akt, pan ERK and beta actin) were unaffected by any of the treatments.
Figure 5.18. Western blots (CM, CM+1µM Bpv(Hopic) and CM+1µM
Bpv(Hopic)+5µM UO126). Western blots investigating the effect of CM (Lanes 1, 4,
7 and 10=CM), CM+1µM BpV(Hopic) (Lanes 2, 5, 8 and 11=Bpv) and CM+1µM
BpV(Hopic)+5µM UO126 (Lanes 3, 6, 9 and 12=Bpv UO) on the activation levels of p-
AKT and pERK1/2. 1µM Bpv(Hopic) induced activation of Akt and ERK1/2, while its
combination with 5µM UO126 blocked the activation of pERK1/2, but not pAKT. Data
are representative of 4 experiments.
Blots were subjected to further analyses using Quantity One software. Phospho-
Akt and Phospho-ERK1/2 levels were quantified across the 3 different treatments
and the 4 time points. All values are represented as percentage of the calibrator
(CM 15m), which was set to 100%.
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Analyses of pAKT (Ser 473) was performed in response to CM, CM+1µM
Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM UO126 (Figure 5.19). Significant
increases were found in pAKT activation levels with CM+1µM Bpv(Hopic) vs
CM at 15m (143.75% +/-18.79 vs 100%, p<0.01), at 30m (138 +/-38.66% vs 45.5
+/-17.2%, p<0.05), at 45m (230.25 +/-37.14% vs 47.75 +/-19.3%, p<0.0001) and
at 60m (177.5 +/-41% vs 54.5 +/-19.27%, p<0.01). Significant increase in pAkt
were also observed with CM+1µM Bpv(Hopic)+5µm UO126 vs CM at 30m
(133.5 +/-38.7% vs 45.5 +/-17.2%, p<0.05), at 45m (210.5 +/-29.4% vs 47.75 +/-
19.3%) and at 60m (184.25 +/-37.95% vs 54.5 +/-19.27%, p<0.01). As anticipated
from the raw data in the blots, there were no differences in Akt activation in the
presence of Bpv(Hopic) in the absence or presence of UO126.
Figure 5.19. Quantification of pAKT levels (CM, CM+1µM Bpv(Hopic) and
CM+1µM Bpv(Hopic)+5µM UO126).. Quantification of pAKT levels in response to
CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM UO126 indicated
significant increases with CM+1µM Bpv(Hopic) vs CM at 15m (p<0.01, represented by
*), at 30m (p<0.05, represented by *), at 45m (p<0.0001, represented by *) and at 60m
(p<0.01, represented by *). Significant increase were also found with CM+1µM
Bpv(Hopic)+5µM UO126 vs CM at 30m (p<0.05, represented by #), at 45m (p<0.001,
represented by #) and at 60m (p<0.01, represented by #). No differences were found
between CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM UO126. Data are
representative of 4 experiments performed in duplicate. (p-values obtained by One-way
repeated measures ANOVA)
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Wishing to substantiate the specificity of these findings, analyses of pERK1/2
activation were performed in response to CM, CM+1µM Bpv(Hopic) and
CM+1µM Bpv(Hopic)+5µM UO126 (Figure 5.20). Confirming our earlier data,
significant increases were found with CM+1µM Bpv(Hopic) vs CM at 30m
(58.25 +/-2.59% vs 13.5 +/-4.33%, p<0.0001), at 45m (44.5 +/-6.81% vs 8 +/-
1.47%, p<0.001) and at 60m (39.75 +/-6.09% vs 4 +/-1.35%, p<0.01). Significant
decreases in ERK1/2 activation were observed with CM+1µM Bpv(Hopic)+5µM
UO126 vs CM+1µM Bpv(Hopic) at 15m (8.25 +/-3.04% vs 115 +/-12.02%,
p<0.0001), at 30m (10.5 +/-2.18% vs 58.25 +/-2.59%, p<0.0001), at 45m (9.25 +/-
1.93% vs 44.5 +/-6.81%, p<0.001) and at 60m (8.25 +/-3.92% vs 39.75 +/-6.09%,
p<0.01). Decreases were also observed with CM+1µM Bpv(Hopic)+5µM UO126
vs CM at 15m (8.25 +/-3.04% vs 100%, p<0.001). Furthermore, decreases with
time were evident with CM at 30m vs 15m (13.5 +/-4.33% vs 100%, p<0.001), at
45m vs 15m (8 +/-1.47% vs 100%, p<0.001) and at 60m vs 15m (4 +/-1.35% vs
100%, p<0.001), as also detailed previously in this chapter. Reductions in
pERK1/2 activation with time were also observed with CM+1µM Bpv(Hopic) at
30m vs 15m (58.25 +/-2.59% vs 115 +/-12.02%, p<0.01), at 45m vs 15m (44.5 +/-
6.81% vs 115 +/-12.02%, p<0.01) and at 60m vs 15m (39.75 +/-6.09% vs 115 +/-
12.02%, p<0.01). Suppression of ERK1/2 activation in the presence of CM+1µM
Bpv(Hopic)+5µM UO126 was complete at 15 min and was not further impacted
by time (Figure 5.20). Together these studies suggest that activation of ERK1/2
and PI3K is essential for myoblast migration in the presence of Bpv(Hopic) and
that suppression of one is sufficient to block the enhanced migration, despite
maintained signalling of the other signalling pathway.
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Figure 5.20. Quantification of pERK1/2 levels (CM, CM+1µM Bpv(Hopic)
and CM+1µM Bpv(Hopic)+5µM UO126). Quantification of pERK1/2 activation
levels in response to CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM
UO126 indicated significant increases with CM+1µM Bpv(Hopic) vs CM at 30m
(p<0.0001, represented by *), at 45m (p<0.001, represented by *) and at 60m (p<0.01,
represented by *). Significant decrease were indicated with CM+1µM Bpv(Hopic)+5µM
UO126 vs CM+1µM Bpv(Hopic) at 15m (p<0.0001, represented by #), at 30m
(p<0.0001, represented by #), at 45m (p<0.001, represented by #) and at 60m (p<0.01,
represented by #). Significant decreases were found with CM+1µM Bpv(Hopic)+5µM
UO126 vs CM at 15m (p<0.001, represented by a). Significant reductions with time were
observed with CM at 30m vs 15m (p<0.001, represented by t), at 45m vs 15m (p<0.001,
represented by t) and at 60m vs 15m (p<0.001, represented by t). Reductions with time
were also observed with CM+1µM Bpv(Hopic) at 30m vs 15m (p<0.01, represented by
x), at 45m vs 15m (p<0.01, represented by x) and at 60m vs 15m (p<0.01, represented by
x). Data are representative of 4 experiments performed in duplicate. (p-values obtained by
One-way repeated measures ANOVA)
Having determined that inhibition of Pi3K was able to reduce migration in the
face of activated ERK1/2, it was investigated whether inhibition of the
MAPK/ERK pathway by 5µM UO126 would affect the migration induced by
Bpv(Hopic). Wound healing studies were initially performed (Figure 5.21A),
which demonstrated decreases in cell migration, towards control levels (CM),
with CM+1µM Bpv(Hopic)+5µM UO126 vs CM+1µM Bpv(Hopic). To confirm
these observations, quantification of the total cell number infiltrating the wound
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site was performed (Figure 5.21B). Analyses demonstrated significant increases
with CM+1µM Bpv(Hopic) vs CM (97 +/-7 vs 68 +/-3, p<0.0001, equivalent to
43% increase) and a comparable decrease with CM+1µM Bpv(Hopic)+5µM
UO126 vs CM+1µM Bpv(Hopic) (68 +/-3 vs 97 +/-7, p<0.0001, equivalent to
30% decrease). Quantification of the percentage of cells in the centre of the
wounds (Figure 5.21C), demonstrated increases with CM+1µM Bpv(Hopic) vs
CM (23.83 +/-1.58% vs 11.33 +/-1.5%, p<0.0001), whereas decreases in cell
numbers in the centre of the wound site were observed with CM+1µM
Bpv(Hopic)+5µM UO126 vs CM+1µM Bpv(Hopic) (7.17 +/-1.99% vs 23.83 +/-
1.58%, p<0.0001) and vs CM (7.17 +/-1.99% vs 11.33 +/-1.5%), thus once again
substantiating the data depicted in the photomicrographs (Figure 5.21(A)).
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Figure 5.21. Wound healing assay with cell count analysis (CM, CM+1µM
Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM UO126). Wound healing assay
comparing the wound closure between CM , CM+1µM Bpv(Hopic) and CM+1µM
Bpv(Hopic)+5µM UO126 (A).  Quantification of the total number of cells infiltrating the
wound demonstrated significant increase with CM+1µM Bpv(Hopic) vs CM (p<0.0001,
represented by *). Significant decreases were observed with CM+1µM
Bpv(Hopic)+UO126 vs CM+1µM Bpv(Hopic) (p<0.0001, represented by #) (B).
Quantification of the percentage of cells in the middle of the wound revealed significant
increases with CM+1µM Bpv(Hopic) vs CM (p<0.0001, represented by *). A decrease
was also observed with CM+1µM Bpv(Hopic)+5µM UO126 vs CM+1µM Bpv(Hopic)
(p<0.0001, represented by #) and vs CM (p<0.05, represented by a) (C). Data are
representative of 6 experiments performed in duplicate. (p-values obtained by One-way
repeated measures ANOVA)
Cell tracking analyses were again performed to support the quantification data
(Figure 5.22A) and indicated clearly that migration was greater with CM+1µM
Bpv(Hopic) vs CM and that this increase in migration was suppressed by the co-
incubation of 5µM UO126. Analyses of these images demonstrated significant
increases in migration distance with CM+1µM Bpv(Hopic) vs CM (573 +/-
72.6µm vs 413 +/-44.4µm, p<0.01, equivalent to 39% increase) and a decreases
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with CM+1µM Bpv(Hopic)+5µM UO126 vs CM+1µM Bpv(Hopic) (346 +/-
42.1µm vs 573 +/-72.6µm, p<0.0001, equivalent to 40% decrease). No
differences in migration distance were evident between CM and CM+1µM
Bpv(Hopic)+5µM UO126 (Figure 5.22B). Cell death quantifications revealed no
significant differences in cell death between CM+1µM Bpv(Hopic) and CM,
however, surprisingly, there was a small but significant decrease in percentage
dead cells with CM+1µM Bpv(Hopic)+5µm UO126 vs CM (0.46 +/-0.29% vs
2.07 +/-0.28%, p<0.05), but no difference between CM+1µM Bpv(Hopic)+5µm
UO126 and CM+1µM Bpv(Hopic) (Figure 5.22C).
Figure 5.22. Cell tracking and cell death analyses (CM, CM+1µM
Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM UO126). Migration tracking
comparing the effects of CM, CM+1µM Bpv(Hopic) and CM+1µM Bpv(Hopic)+5µM
UO126 (A). Quantifications of the data tracking, showing significant increases in
migration with CM+1µM Bpv(Hopic) vs CM (p<0.01, represented by *) and a decrease
with CM+1µM Bpv(Hopic)+5µM UO126 vs CM+1µM Bpv(Hopic) (p<0.0001,
represented by #) (B). Data are representative of 6 experiments performed in duplicate.
Cell death quantifications indicated decreased cell death with CM+1µM
Bpv(Hopic)+5µM UO126 vs CM (p<0.05, represented by *) (C). Data are representative
of 4 experiments performed in duplicate. (p-values obtained by One-way repeated
measures ANOVA)
167
5.4.6. THE ACTION OF BPV(HOPIC) ON CELL MIGRATION IS
REDUCED BY INHIBITING THE FAK PATHWAY WITH PF-228,
DESPITE ONGOING PI3K/AKT AND MAPK/ERK ACTIVATION
Bpv(Hopic) was shown to activate PI3K and MAPK pathways, but at µM
concentrations it is possible that it also activates other protein targets, which
might be involved in the regulation of myoblast migration. Integrin signalling is
important for cell matrix interactions and the fact that Bpv(Hopic) impacts on
cellular adhesion warranted further investigation. Furthermore, FAK is known to
be regulated by PTEN and its tyrosine phosphorylated site may also be targeted
by the phospho-tyrosine phosphatase activity of Bpv(Hopic). It was therefore
investigated how FAK phosphorylation at tyrosine 397 was affected by
Bpv(Hopic) and whether inhibition of the FAK pathway using the FAK inhibitor
PF-228 would also affect myoblast migration induced by CM and by Bpv(Hopic).
Initially, preliminary western blots were performed to investigate the effect of
increasing concentrations of BpV(Hopic) on the levels of p-FAK activation
(Figure 5.23). No consistent differences in pFAK activation were visually
observed between CM and CM+1µM Bpv(Hopic). However, increased FAK
phosphorylation was evident with 2µM Bpv(Hopic) vs CM and FAK
phosphorylation was increased further in the presence of 10µM Bpv(Hopic). The
lack of specificity of high dose Bpv(Hopic), as previously suggested in this report
for tyrosine phoshorylated proteins, was again evident with an increased
phosphorylation of FAK at tyrsosine 397.
Figure 5.23. Western blots investigating the effect of 1µM, 2µM and 10µM
concentrations of Bpv(Hopic) on p-FAK(Tyr397) activation. An increase in
pFAK levels, as compared to CM, was obvious with 2µM and 10µM, but not with 1µM
concentration of Bpv(Hopic). Data are representative of at least 3 experiments.
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Although 1µM Bpv(Hopic) facilitated migration (as detailed above), it was
without impact on FAK phosphorylation compared with CM.  As it was wished to
assess whether silencing the FAK pathway using PF-228 would influence the
enhanced migration of myoblasts induced by Bpv(Hopic), 2µM dose was chosen
for further assessment, where FAK was activated above control levels. It was also
investigated whether the PI3K and MAPK pathways would remain activated
despite the FAK pathway being silenced and whether their activation would
impact on any migration changes affected by the FAK pathway inhibition.
Western blot analyses were performed to compare the effects of CM, CM+2µM
PF-228, CM+2µM Bpv(Hopic) and CM+2µM Bpv(Hopic)+2µM PF-228 on
protein activation levels of p-AKT, pERK1/2 and p-FAK (Figure 5.24). 2µM of
PF-228 reduced the levels of pFAK activation (although not completely when co-
incubated with 2µM Bpv(Hopic)), but did not appear to significantly affect the
levels of pAkt or pERK1/2 (Figure 5.24).
Figure 5.24. Western blots (CM, CM+2µM PF-228, CM+2µM Bpv(Hopic),
CM+2µM Bpv(Hopic)+2µM PF-228). Western blot comparing the effects of CM
(Lane 1, 5, 9, and 13=CM), CM+2µM PF-228 (Lane 2, 6, 8 and 14=FAK), CM+2µM
Bpv(Hopic) (Lane 3, 7, 9 and 15=BpV) and CM+2µM Bpv(Hopic)+2µM PF-228 (Lane
4, 8, 10 and 16=Bpv+FAK) on Akt, ERK1/2 and FAK activation. Obvious increases in
pAKT, pERK1/2 and pFAK activation were observed with 2µM Bpv(Hopic). A decrease
was observed in pFAK levels in the presence of 2µM of PF-228, while pAKT and
pERK1/2 levels did not seem to be significantly affected by the FAK inhibitor. Data are
representative of at least 3 experiments.
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Blots (Figure 5.24) were subsequently subjected to further analyses using
Quantity One software. Phospho-FAK, Phospho-Akt and Phospho-ERK1/2 levels
were quantified across the 4 different treatments and the 4 time points. All values
are represented as percentage of the calibrator (CM 15m), which was set to 100%
(Figure 5.25).
Analysis of pFAK (Tyr397) was performed in response to CM, CM+2µM PF-
228, CM+2µM Bpv(Hopic) and CM+2µM Bpv(Hopic)+2µM PF-228 (Figure
5.25). Significant increases were found with CM+2µM Bpv(Hopic) vs CM at 15m
(150.25 +/-10.81% vs 100%, p<0.01), at 30m (170.75 +/-18.33% vs 124.75 +/-
6.91%, p<0.05), at 45m (186 +/-17.5% vs 134.5 +/-21.2%, p<0.05) and at 60m
(176.25 +/-20.65% vs 124 +/-8.65%, p<0.05), suggesting that 2µM Bpv(Hopic) is
upregulating the levels of phosphorylated FAK. On the other hand, PF-228
inhibitor treatment, caused decreases in pFAK phosphorylation, as compared to
CM: decreases were observed with CM+2µM PF-228 vs CM at 15m (40.74 +/-
7.32% vs 100%, p<0.001), at 30m (58 +/-9.65% v 124.75 +/-6.91%, p<0.05), at
45m (72.25 +/-12.74% vs 134.5 +/21.2%, p<0.01) and at 60m (66.75 +/-12.55%
vs 124 +/-8.65%, p<0.01). Furthermore, PF-228 treatment, eliminated the increase
observed with 2µM Bpv(Hopic) treatment: decreases were observed with
CM+2µM Bpv(Hopic)+2µM PF-228 vs CM+2µM Bpv(Hopic) at 15m (78.25 +/-
4.64% vs 150.25 +/-10.81%, p<0.0001), at 30m (100.75 +/-12.34% vs 170.75 +/-
18.33%, p<0.01), at 45m (125.25 +/-12.87% vs 186 +/-17%, p<0.01) and at 60m
(103.25 +/-13% vs 176.25 +/-20.65%, p<0.01). Greater decreases were observed
with CM+2µM PF-228 vs CM+2µM Bpv(Hopic) at 15m (40.74 +/-7.32% vs
150.25 +/-10.81%, p<0.0001), at 30m (58 +/-9.65% vs 170.75 +/-18.33%,
p<0.0001), at 45m (72.25 +/-12.74% vs 186 +/-17.5%, p<0.0001) and at 60m
(66.75 +/-12.55% vs 176.25 +/-20.65%, p<0.0001). Significant decreases were
also found with CM+2µM PF-228 vs CM+2µM Bpv(Hopic)+2µM PF-228 at 15m
(40.74 +/-7.32% vs 78.25 +/-4.64%, p<0.05) and at 45m (72.25 +/-12.74% vs
125.25 +/-12.87%, p<0.05). Overall, these observations indicate an increase in the
phosphorylation of FAK at Tyr397 in response to 2µM Bpv(Hopic) treatment.
Treatment with 2µM PF-228 inhibitor either caused a decrease in the base levels
of pFAK (CM), or eliminated the increase observed with 2µM Bpv(Hopic)
treatment.
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Figure 5.25. Quantification of pFAK levels (CM, CM+2µM PF-228,
CM+2µM Bpv(Hopic), CM+2µM Bpv(Hopic)+2µM PF-228). Quantification of
pFAK levels in response to CM, CM+2µM PF-228, CM+2µM Bpv(Hopic) and
CM+2µM Bpv(Hopic)+2µM PF-228 indicated significant increases with CM+2µM
Bpv(Hopic) vs CM at 15m (p<0.01, represented by *), at 30m (p<0.05, represented by *),
at 45m (p<0.05, represented by *) and at 60m (p<0.05, represented by *). Decreases with
CM+2µM PF-228 vs CM was found at 15m (p<0.001, represented by #), at 30m (p<0.05,
represented by #), at 45m (p<0.01, represented by #) and at 60m (p<0.01, represented by
#). Decreases with CM+2µM PF-228 vs CM+2µM Bpv(Hopic) were found at 15m
(p<0.0001, represented by b), at 30m (p<0.0001, represented by b), at 45m (p<0.0001,
represented by b) and at 60m (p<0.0001, represented by b). Decreases were observed
with CM+PF-228 vs CM+2µM Bpv(Hopic)+2µM PF-228 at 15m (p<0.05, represented
by c) and at 45m (p<0.05, represented by c). Decreases with CM+2µM Bpv(Hopic)+PF-
228 vs CM+2µM Bpv(Hopic) was found at 15m (p<0.0001, represented as a), at 30m
(p<0.01, represented as a), at 45m (p<0.01, represented by a) and at 60m (p<0.01,
represented by a). Data are representative of 4 experiments. (p-values obtained by One-
way repeated measures ANOVA)
In order to verify whether pFAK inhibition resulted in changes in the levels of
pAKT, analyses of pAKT (Ser473) were performed in response to CM, CM+2µM
PF-228, CM+2µM Bpv(Hopic) and CM+2µM Bpv(Hopic)+2µM PF-228 (Figure
5.26). What is evident from these data, as indicated previously, is that Bpv(Hopic)
treatment significantly increased pAkt phosphorylation over the full time course,
relative to CM and that a co-incubation with PF-228 had not impact on this
increase.  PF-228 alone was also without significant effect on CM treatment alone
when pAkt activation was investigated (Figure 5.26).
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Figure 5.26. Quantification of pAKT levels (CM, CM+2µM PF-228,
CM+2µM Bpv(Hopic), CM+2µM Bpv(Hopic)+2µM PF-228). Quantification of
pAKT levels in response to CM, CM+2µM PF-228, CM+2µM Bpv(Hopic) and
CM+2µM Bpv(Hopic)+2µM PF-228 indicated significant increases with CM+2µM
Bpv(Hopic) vs CM at 15m (p<0.05, presented by *), at 30m (p<0.05, presented by *), at
45m (p<0.01, represented by *) and at 60m (p<0.05, presented by *). Significant
increases were found with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM at15m (p<0.05,
represented by #), at 30m (p<0.01, represented by #) and at 45m (p<0.05, represented by
#). Significant increases with CM+2µM Bpv(Hopic) vs CM+2µM PF-228 were found at
15m (p<0.01, represented by a), at 30m (p<0.05, represented by a), at 45m (p<0.01,
represented by a) and at 60m (p<0.05, represented by a). Significant increases were found
with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM+2µM PF-228 at 15m (p<0.01,
represented by b), at 30m (p<0.05, represented by b) and at 45m (p<0.05, represented by
b). Data are representative of 5 experiments. (p-values obtained by One-way repeated
measures ANOVA)
Analyses of pERK1/2 were performed in response to CM, CM+2µM PF-228,
CM+2µM Bpv(Hopic) and CM+2µM Bpv(Hopic)+2µM PF-228 (Figure 5.27).
As previously reported, Bpv (Hopic) induced a significantly increased activation
of pERK1/2, which was not altered in the presence of PF-228, regardless of time.
Similarly, PF228 was without impact on ERK1/2 phosphorylation when
compared to CM at any given time. There were, however, significant decreases in
ERK1/2 phosphorylation over time in the presence of CM and Bpv(Hopic). These
declines were not, however, further decreased by PF-228. Therefore, while PF-
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228 was able to decrease pFAK activation, it was without direct effect on Akt or
ERK1/2 phosphorylation under basal or Bpv(Hopic) conditions.
Figure 5.27. Quantification of pERK1/2 levels (CM, CM+2µM PF-228,
CM+2µM Bpv(Hopic), CM+2µM Bpv(Hopic)+2µM PF-228). Quantification of
pERK1/2 activation levels in response to CM, CM+2µM PF-228, CM+2µM Bpv(Hopic)
and CM+2µM Bpv(Hopic)+2µM PF-228 indicated significant increases with CM+2µM
Bpv(Hopic) vs CM at 15m (p<0.05, represented by *), at 30m (p<0.05, represented by *),
45m (p<0.05, represented by *) and at 60m (p<0.05, represented by *). Significant
increases were also found with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM at 15m
(p<0.05, represented by #), at 30m (p<0.05, represented by #) and at 45m (p<0.05,
represented by #). Significant increase was observed with CM+2µM Bpv(Hopic) vs
CM+2µM PF-228 at 15m (p<0.01, represented by a), at 30m (p<0.05, represented by a),
at 45m (p<0.05, represented by a) and at 60m (p<0.05, represented by a). Significant
increases were found with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM+2µM PF-228 at
15m (p<0.01, represented by b), at 30m (p<0.05, represented by b) and at 45m (p<0.05,
represented by b). Significant reductions with time were observed: with CM at 30m vs
15m (p<0.001, represented by t), at 45m vs 15m (p<0.001, represented by t) and at 60m
vs 15m (p<0.001, represented by t). Reductions were also observed with CM+2µM PF-
228 at 30m vs 15m (p<0.01, represented by x), at 45m vs 15m (p<0.01, represented by x)
and at 60m vs 15m (p<0.01, represented by x). Decreases were observed with CM+2µM
Bpv(Hopic) at 30m vs 15m (p<0.05, represented by z), at 45m vs 15m (p<0.01,
represented by z) and at 60m vs 15m (p<0.01, represented by z). Significant reductions
were also observed with time with CM+2µM Bpv(Hopic)+2µM PF-228 at 45m vs 15m
(p<0.05, represented as c) and 60m vs 15m (p<0.05, represented as c). Data are
representative of 3 experiments. (p-values obtained by One-way repeated measures
ANOVA)
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Wound healing assays were performed in C2C12 cells investigating the effect of
FAK inhibition using 2µM PF-228 in combination with CM (Figure 5.28A). Four
different treatments were compared: CM, CM+2µM PF-228, CM+2µM
Bpv(Hopic) and CM+2µM Bpv(Hopic)+2µM PF-228. As is evident from the
photomicrographs, PF-228 decreased migration vs CM, while Bpv(Hopic) alone
increased cellular migration vs. CM. In combination with PF-228, Bpv(Hopic)-
induced migration was reduced back to CM levels. Wishing to confirm these
findings, quantification of the total number of cells infiltrating the wound was
performed (Figure 5.28B) and indicated significant increases with CM+2µM
Bpv(Hopic) vs CM (111 +/-8 vs 83+/-1 cells, p<0.01, equivalent to 34%
increase). Decreases were observed with CM+2µM PF-228 vs CM (49 +/-5 vs 83
+/-1, p<0.001, equivalent to 41% decrease) and vs CM+2µM Bpv(Hopic) (49 +/-5
vs 111 +/-8, p<0.0001, equivalent to 56% decrease). A decrease was also detected
with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM+2µM Bpv(Hopic) (67 +/-7 vs
111+/-8, p<0.001, equivalent to 40% decrease). Quantification of the percentage
of cells in the middle of the wound (Figure 5.28C) indicated significant increases
with CM+2µM Bpv(Hopic) vs CM (19.75 +/-2.25% vs 7 +/-1.15%, p<0.001).
Decreases were observed with CM+2µM PF-228 vs CM (1 +/-0.58% vs 7 +/-
1.15%, p<0.05) and vs CM+2µM Bpv(Hopic) (1 +/-0.58% vs 19.75 +/-2.25%,
p<0.0001). A decrease was indicated with CM+2µM Bpv(Hopic)+2µM PF-228 vs
CM+2µM Bpv(Hopic) (3.5 +/-1.04% vs 19.75 +/-2.25%, p<0.0001).
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Figure 5.28. Wound healing assay with cell count analysis (CM, CM+2µM
PF-228, CM+2µM Bpv(Hopic), CM+2µM Bpv(Hopic)+2µM PF-228). Wound
healing assays comparing the effects of CM, CM+2µM PF-228, CM+2µM Bpv(Hopic)
and CM+2µM Bpv(Hopic)+2µM PF-228 (A).  Quantification of the number of cells
infiltrating the wound indicates significant increases with CM+2µM Bpv(Hopic) vs CM
(p<0.01, represented by *). A decrease was observed with CM+2µM PF-228 vs CM
(p<0.001, represented by #) and vs CM+2µM Bpv(Hopic) (p<0.0001, represented by a).
Decreases were indicated with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM+2µM
Bpv(Hopic) (p<0.001, represented by b) (B).  Quantification of percentage of cell in the
centre of the wound indicated increases with CM+2µM Bpv(Hopic) vs CM (p<0.001,
represented by *). A decrease was found with CM+2µM PF-228 vs CM (p<0.05,
represented by #) and vs CM+2µM Bpv(Hopic) (p<0.0001, represented by a). Decreases
were observed with CM+2µM Bpv(Hopic)+2µM PF-228 vs CM+2µM Bpv(Hopic)
(p<0.0001, represented by b) (C). All data are representative of 4 experiments performed
in duplicate. (p-values obtained by One-way repeated measures ANOVA)
Subsequently, cell tracking was performed to support the quantification data
(Figure 5.29A). As images indicate, supporting the quantification data, PF-228
decreased migration distance vs CM, Bpv(Hopic) increased migration vs CM and
PF-228 in the presence of Bpv(Hopic) decreased Bpv-induced migration to CM
levels. Analyses of cell migration distances (Figure 5.29B) confirmed the
morphological findings and indicated significant increases in migration distances
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with CM+2µM Bpv(Hopic) vs CM (481 +/-12.8µm vs 352 +/-11.6µm, p<0.0001,
equivalent to 37% increase). A decrease was found with CM+2µM PF-228 vs CM
(195 +/-8.18µm vs 352 +/-11.6µm, p<0.0001, equivalent to 45% decrease), vs
CM+2µM Bpv(Hopic) (195 +/-8.18µm vs 481 +/-12.8µm, p<0.0001, equivalent
to 247% increase) and vs CM+2µM Bpv(Hopic)+2µM PF-228 (195 +/-8.18µm vs
262 +/-5µm, p<0.01, equivalent to 26% decrease). A decrease was also observed
with CM+2µM Bpv(Hopic)+PF-228 vs CM (262 +/-5µm vs 352 +/11.6µm,
p<0.001, equivalent to 26% decrease) and vs CM+2µM Bpv(Hopic) (262 +/-5µm
vs 481 +/-12.8µm, p<0.0001, equivalent to 46% decrease).
Cell death analyses (Figure 5.29C) indicated an increase in cell death with
CM+2µM PF-228 vs CM (3.48 +/-1.03% vs 1.14 +/-0.43%, p<0.05), vs
CM+2µM Bpv(Hopic) (3.48 +/-1.03% vs 0.66 +/-0.19%, p<0.01) and vs
CM+2µM Bpv(Hopic)+PF-228 (3.48 +/-1.03% vs 1.58 +/-0.58%, p<0.05).
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Figure 5.29. Cell tracking and cell death analysis (CM, CM+2µM PF-228,
CM+2µM Bpv(Hopic), CM+2µM Bpv(Hopic)+2µM PF-228). Cell tracking
comparing the effects of CM, CM+2µM PF-228, CM+2µM Bpv(Hopic) and CM+2µM
Bpv(Hopic)+2µM PF-228 (A). Analyses of cell tracking indicated significant increases
with CM+2µM Bpv(Hopic) vs CM (p<0.0001, represented by *). A decrease was found
with CM+2µM PF-228 vs CM (p<0.0001, represented by b), vs CM+2µM Bpv(Hopic)
(p<0.0001, represented by c) and vs CM+2µM Bpv(Hopic)+2µM PF-228 (p<0.01,
represented by d). A significant decrease was observed with CM+2µM Bpv(Hopic)+2µM
PF-228 vs CM (p<0.001, represented by #) and vs CM+2µM Bpv(Hopic) (p<0.0001,
represented by a) (B). Cell death quantifications indicated increased death with CM+PF-
228  vs CM (p<0.05, represented as *), vs CM+2µM Bpv(Hopic) (p<0.01, represented as
a) and vs CM+2µM Bpv(Hopic)+PF-228 (p<0.05, represented as b) (C). All data are
representative of 4 experiments performed in duplicate. (p-values obtained by One-way
repeated measures ANOVA)
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SUMMARY OF MAJOR FINDINGS:
- 1µM Bpv(Hopic) is capable of increasing migration of myoblasts, stimulated by
myotube conditioned media, without significantly affecting their capacity to
differentiate and fuse into multinucleated myotubes.
- Increased migration of myoblasts following 1µM Bpv(Hopic) treatment is
associated with enhanced PI3K/AKT and MAPK/ERK signalling and inhibition
of each of these pathways with either LY294002 or UO126 leads to reduced
myoblast migration.
- Inhibition of FAK signalling by PF-228 leads to reduced myoblast migration,
regardless of the activity of PI3K/AKT and MAPK/ERK signalling.
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5.5. DISCUSSION
5.5.1. MYOBLAST DIFFERENTIATION IS REDUCED BY 10µM, BUT
NOT BY 1µM BPV(HOPIC)
Previous reports have demonstrated a significant reduction in the ability of
C2C12 cells to differentiate and fuse into myotubes following 10µM of BpV
treatment (Castaldi et al., 2007). It was here confirmed that 10µM Bpv(Hopic)
significantly reduced the differentiation capability of myoblasts grown in 2% HS
DM, which was characterised by delayed exit from the cell cycle, as shown by the
significantly higher percentage of cells in S/G2-phase. However, lower
concentrations of 1µM and 2µM Bpv(Hopic) did not seriously affect the fusion of
myoblasts into multinucleated myotubes. 2µM Bpv(Hopic) showed a slight, but
significant, reduction in the activity of CK and the expression levels of Myogenin,
although myotube formation was still evident. 1µM Bpv(Hopic) treatment did not
cause any statistically significant changes in CK activity, or in the expression of
MyoD or Myogenin, and myotube formation was visually unchanged, as
compared to control CM. These data demonstrate that the ability of BpV
compounds to affect myoblast differentiation is only exerted with higher
concentrations, or at least in the current in vitro model studied. Furthermore, as
demonstrated by Castaldi et al. and confirmed by our investigation (results not
shown), even the effects of high concentrations of Bpv(Hopic) on myoblast
differentiation were completely reversible, as upon withdrawal of the inhibitor
from the system, differentiation potential of myoblasts was restored and they were
able to fuse into myotubes (Castaldi et al., 2007). This effect of Bpv(Hopic) may
be important when considering its potential applications, as a tool for enhancing
cell migration, without seriously affecting the ability of myoblasts to differentiate
and fuse into myotubes. 1µM Bpv(Hopic) was therefore considered as an
attractive tool for further studies on its effect on myoblast migration.
5.5.2. BPV(HOPIC) INCREASED C2C12 MYOBLAST MIGRATION AND
ENHANCED ACTIVATION OF MAPK/ERK AND PI3K/AKT
PATHWAYS
BpV compounds are reported to act as a PTEN inhibitors (Schmid et al., 2004).
However, this specificity is not retained with increasing concentrations. Using
anti-phosphotyrosine (py20) antibodies, the phosphorylation of tyrosines under
increasing concentrations of BpV(Hopic) was examined by western blots. Non-
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specific phosphorylation of tyrosines with 10µM Bpv(Hopic) was observed and
reduced specificity decreased with decreasing concentrations of Bpv(Hopic). This
increased non-specific tyrosine phosphorylation coincided with cell shrinking and
loss of cell adhesion, along with decreased myoblast differentiation, as previously
reported. Thus, non-specific activation of many signalling pathways and
downstream target proteins was probably present when cells were stimulated with
10µM concentration. Furthermore, 10µM Bpv(Hopic) caused significant delays in
the initiation of migration, due to cell shrinking. Therefore, for further studies, it
was decided to explore in more detail the effects of lower concentrations of
Bpv(Hopic) on migration. Semi-quantitative analyses of Western blots
demonstrated activation of PI3K/AKT and MAPK/ERK pathways with 1µM
Bpv(Hopic), as compared to control CM. These pathways have previously been
suggested to be important for myoblast migration, although articles have not been
completely unanimous on this topic, with some suggesting either PI3K or MAPK
pathway inhibition not affecting migration (Leloup et al., 2007, Ranzato et al.,
2009, Suzuki et al., 2000), while others reporting their requirement for migration
of myogenic cells (Al-Shanti et al., 2011, Kawamura et al., 2004, Kim et al.,
2011). When migration of myoblasts was examined, it was reported that 1µM
Bpv(Hopic) treatment induced ~40% more migration in myoblasts, compared
with controls. These data were in agreement with the hypothesis that BpV was
capable of activating PI3K/AKT and MAPK/ERK pathways and was able to
further enhance the migration of myoblasts. At the same time, the same dose of
BpV did not significantly affect the differentiation potential of myoblasts. These
effects of BpV(Hopic) on myoblasts proposes interesting avenues for further
research, in order to investigate whether it can also promote myoblast migration in
vivo and how this would impact on the regeneration of muscle.
5.5.3. INHIBITION OF EITHER MAPK/ERK OR PI3K/AKT PATHWAYS
RESULTED IN INHIBITION OF MYOBLAST MIGRATION TO BASAL
CONTROL LEVELS
Despite PI3K/AKT and MAPK/ERK pathways being activated by BpV(Hopic), it
is possible that the enhanced migration is mediated by other signalling pathways
affected by the inhibitor. In order to reveal whether PI3K/AKT and MAPK/ERK
pathways are required for Bpv(Hopic)-induced migration, these pathways were
inhibited by LY294002 and UO126 in the presence of BpV and migration was
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assessed. Results showed that inhibition of PI3K/AKT pathway by 10µM
LY294002 did not affect the MAPK/ERK pathway, while migration of myoblasts
dropped to basal control levels. Similarly, inhibition of MAPK/ERK pathway
with 5µM UO126 did not affect the PI3K/AKT pathway, while migration was
inhibited to the levels of control CM. Cell death levels were not greatly affected
by any of the inhibitors, although, due to the high number of repetitions in section
5.4.3, a slight, but statistically significant decrease of less than 1% was detected
following Bpv(Hopic) treatment. A decrease in the percentage of dead cells would
be expected following PTEN inhibition and PI3K/Akt activation, a known
pathway involved in cell survival (Sun et al., 1999, Yamada and Araki, 2001).
However, basal cell death was very low and differences between treatments were
also extremely small and on the whole non-significant, therefore, it was concluded
that cell death does not inflouence the migratory capacity of cells.
The above findings are novel within the muscle field. However, a recent article,
published during the writing of this thesis, demonstrated very similar findings
using epithelial cells (Mihai et al., 2012). They also confirmed activation of
PI3K/AKT and MAPK/ERK pathways in response to phospho-tyrosine
phosphatase inhibitor Bpv(Phen), suggesting involvement of these pathways in
regulating cell migration in response to the inhibitor, and that silencing of each
pathway resulted in reduction of cell migration to basal control levels. It was
further suggested that alterations in biomechanical properties of cells is what
triggers the migration by Bpv. The similarity between our results and the findings
by Mihai et al. strengthen our findings and also suggest similar migration
mechanisms of action between different cell types.
5.5.4. FAK IS NOT AFFECTED BY BPV(HOPIC) AT
CONCENTRATIONS BELOW 2µM, BUT ITS INHIBITION REDUCES
MYOBLAST MIGRATION WITH OR WITHOUT  BPV(HOPIC)
Cell shrinking and reduced ability of myoblasts to adhere following treatment
with increasing concentration of Bpv(Hopic) was observed. Focal adhesion kinase
(FAK) is known to be of major importance for the regulation of cell adhesion
(Michael et al., 2009). It is a protein tyrosine kinase, known for its recruitment at
the focal adhesion sites of cells and also for mediating downstream signals
regulating processes such as survival, cell spreading and migration. Clustering of
integrins leads to the recruitment of FAK to the focal adhesion sites and to its
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activation by tyrosine phosphorylation, a key site being tyrosine 397 (Parsons et
al., 2000). Phosphorylation at tyr397 allows the binding of Src and the subsequent
activation of the FAK-Src complex, which is central to the regulation of
downstream signals, for processes including cell migration (Hamadi et al., 2005,
Siesser and Hanks, 2006). The involvement of FAK in cell migration has been
reported in a number of studies: FAK deficient cells migrate poorly, while
overexpression of FAK enhances cell migration (Cary et al., 1996, Desai et al.,
2009, Sieg et al., 1999). Inhibitor studies have also reported the importance of
FAK on cell migration (Slack-Davis et al., 2007). The FAK-Src complex
promotes migration by its association with several signalling pathways, including
JNK, paxillin and by changes in adhesion dynamics (Hanks et al., 2003,
Schlaepfer and Mitra, 2004, Schlaepfer et al., 2004). Furthermore, the level of
tyrosine phosphorylation of FAK is reportedly inversely correlated to the level of
PTEN protein in hepatoma cells (Zhang et al., 2004).  PTEN has been reported to
directly associate with FAK resulting in FAK dephosphorylation, thus regulating
cell migration and spreading (Gu et al., 1999). Taking this into consideration, a
potential involvement of FAK in the Bpv(Hopic)-induced migration of myoblasts
was suggested . It was suggested that the protein tyrosine phosphatase activity of
Bpv might influence FAK activation and thus cell migration. Initial studies,
however, revealed no observational differences with 1µM Bpv(Hopic) on pFAK
(tyr397). Recent studies, investigating the effect of Bpv(Phen) inhibitor on
epithelial cells, suggested that BpV might infact affect the FAK activity, however
only in migrating cells and not in confluent ones (Mihai et al., 2012). Thus, as
protein lysates were obtained from a confluent monolayer of myoblasts, the
potential activation of FAK in migrating cells might not have been accounted for
in these studies. It was observed that increasing concentrations of Bpv(Hopic),
such as 2µM, which have demonstrated to enhance the phosphorylation of
tyrosine residues, also increased the phosphorylation of FAK on tyr397 and
induced myoblast migration. To begin to assess the specificity of this response,
cells were also co-incubated with the FAK inhibitor PF-228. The purpose was to
investigate how myoblasts would migrate following activation of FAK and how
its inhibition would affect the levels of pAKT, pERK1/2 (e.g. specificity of the
inhibitor) and subsequently the capacity of the cells to migrate. Results here
suggested that inhibition of the FAK pathway by the inhibitor PF-228 (2µM)
resulted in reduced migration and enhanced cell death, concomitant with the role
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of FAK in mediating cell survival (Huang et al., 2007, Parsons et al., 2000).
Interestingly, a reduction in the PI3K/AKT pathway following FAK inhibition, as
reported by others, was not observed (Xia et al., 2004). As suggested by others, it
is possible that FAK inhibition mediates cell death via other pathways,
independent of PI3K, involving JNK, RIP or p53 (Almeida et al., 2000, Ilic et al.,
1998, Kurenova et al., 2004). Inhibition of FAK in the presence of Bpv(Hopic)
did not result in significant changes in the PI3K/AKT and MAPK/ERK pathways,
although a tendency for a small reduction in the levels of active ERK1/2
following PF-228 treatment in CM was observed. Interestingly, the rates of
migration followed the same trend as the levels of pFAK, regardless of the
activity of pERK1/2 and pAKT. Migration was enhanced with cells incubated in
Bpv(Hopic) vs all other conditions. At the same time, despite pAKT and
pERK1/2 levels being activated, the migration distance of cells incubated in
Bpv+PF-228 was reduced, compared to cells in CM. Similarly, despite greater
activation of pAKT and pERK1/2 levels, only slight increase in migration
distance was observed with cells incubated in Bpv+PF-228, as compared to cells
in CM+PF-228, which coincided with the slight increase in pFAK levels in cells
incubated with Bpv+PF-228. These observations could probably be explained, as
suggested by Mihai et al (Mihai et al., 2012), by the action of FAK on migrating,
but not confluent cells: similarly, FAK inhibition by PF-228 may affect the
migrating cells more than non-migrating, confluent cells. Migrating cells would
require constant focal adhesion turnover, in which FAK participates, and the
presence of FAK inhibitor may thus affect migrating cells more than confluent,
non-migrating ones. Furthermore, other pathways not investigated in our studies,
such as JNK, might be involved in the reduction of myoblast migration following
FAK inhibition in migrating cells (Desai et al., 2009, Liu et al., 2007). In
preliminary experiments it was observed that inhibition of JNK by SP600125,
indeed, led to decreased migration of myoblasts in wound healing assays (see
Appendix 1). Overall, the data suggest that inhibition of FAK results in significant
reductions in migration, regardless of the activity of MAPK and PI3K pathways.
The possibility that other pathways, beyond the scope of these studies, might also
contribute to the regulation of migration following 2µM Bpv(Hopic) or PF-228
treatments, cannot be excluded.
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5.5.5. CONCLUSION
In summary, the phospho-tyrosine phosphatase inhibitor Bpv(Hopic) at low
concentrations (1µM) did not significantly affect the differentiation potential of
myoblasts in DM, while being capable of inducing their migration in the presence
of myotube CM. The induced migration of myoblasts following Bpv(Hopic)
treatment was accompanied with activation of the PI3K/AKT and MAPK/ERK
pathways and inhibition of these pathways by 10µM LY294002 or 5µM UO126
resulted in decreased cell migration. At the same time, inhibition of the FAK
pathway using PF-228, following 2µM Bpv(Hopic) treatment, resulted in a
reduction of cell migration below basal levels, even in the presence of activated
PI3K/AKT and MAPK/ERK pathways. Overall, these data suggest that for
migration to be sustained, at least PI3K, ERK and FAK signalling pathways must
be constitutively active over the time frame studied. The reduced migration
following disruption by any one of these signalling pathway is not entirely
compensated for by the other pathways.
Given the results obtained from media conditioning experiments and inhibitor
treatments, a better idea was obtained on the regulation of myogenic precursors
migration by soluble factors released by myogenic cells themselves and also on
the requirement of signalling pathways, such as PI3K/AKT, MAPK/ERK and
FAK. Migration of myogenic cells, however, might also depend on the regulation
of different genes, some of them regulating migration by indirectly affecting other
cellular processes as well, such as myoblast fusion. In the last chapter of this
thesis, preliminary examination was performed on 4 genes, previously unexplored
in skeletal muscle, which were hypothesised to be involved in the processes of
myoblast migration or fusion. This examination was performed based on the
previous findings that both serial passaging (Chapter 4) and treatment with high
concentrations of BpV(Hopic) (Chapter 5) negatively affect the differentiation
and fusion of skeletal muscle myoblasts. Thus, a link was established between
these observations and the potential invovolvement of different genes in the
regulation of myoblast migration and fusion, which could serve as a base for
future experiments.
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CHAPTER 6
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6. SPIRE AND FORMIN GENES ARE EXPRESSED IN C2C12
MYOBLASTS
6.1. THESIS DIRECTIONS
In chapters 4 and 5, in addition to the influence of Bpv(Hopic) and serial
passaging on migration, it was also demonstrated that fusion of myoblasts into
multinucleated myotubes was blocked by treatment with high dose (10µM)
Bpv(Hopic) and was also reduced in serially passaged myoblasts. This provides
two distinct models for investigating the potential involvement of genes involved
in myoblast fusion, which could also be responsible for regulating their migration.
Numerous articles have reported a link between myoblast fusion and migration,
with many of the factors important for fusion, influencing migration as well
(Becciolini et al., 2006, Donati et al., 2005, Griffin et al., 2009, Lafreniere et al.,
2006, Louis et al., 2008, Makarenkova et al., 2009, Olguin et al., 2003).
Therefore, exploring the genetic regulators of myoblast fusion, might provide
important clues of regulators of myoblast migration and thusr improve our
knowledge of the molecular regulators of myogenesis.
6.2. BACKGROUND
The actin cytoskeleton is essential for many cellular functions, including cell
migration, shape determination, intracellular transport and also for myoblast
fusion (Guerin and Kramer, 2009, Kim et al., 2007). Due to a high kinetic barrier,
actin monomers present in the cytoplasm cannot spontaneously polymerise
therefore, for actin filaments to be formed, a catalyst, or actin nucleation factor is
required (Pollitt and Insall, 2009). Three classes of nucleation factors have been
discovered: the Arp2/3 complex, forming branched actin filaments, FH2 domain
containing nucleation factors of the Formin superfamily and the recently
discovered WH2 domain containing nucleation factors (including the Spire
subfamily), with the latter two being involved in nucleating unbranched actin
filaments (Pechlivanis et al., 2009, Quinlan et al., 2005). As reviewed in Guerin et
al., studies in Drosophila have revealed many genes involved in myoblast fusion
and the importance of the actin cytoskeleton for this process (Guerin and Kramer,
2009). Members of the Wiskott-Aldrich syndrome protein family (WASPs and
SCAR/WAVEs) and the Arp2/3 complexes they regulate, which initiate the
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polymerization of actin filaments (Pollitt and Insall, 2009), have been
demonstrated to be important for myoblast fusion in several studies (Gildor et al.,
2009, Mukherjee et al., 2011, Richardson et al., 2007, Schafer et al., 2007).
However, to our knowledge, no studies have investigated the potential roles of
Spires and Formins in skeletal muscle. Spire and Formin actin nucleators have
been implicated in regulating intracellular vesicle transport and have been
demonstrated to co-localize with the Rab11 GTPase (Kerkhoff, 2010, Kerkhoff et
al., 2001, Morel et al., 2009, Schuh, 2011). Furthermore, it is known that
endocytic recycling and intracellular trafficking are important for myoblast fusion
(Doherty et al., 2008, Rochlin et al., 2010). Rab11 is known to mediate endosome
recycling (Ullrich et al., 1996) and it has been shown to be required for myoblast
fusion (Bhuin and Roy, 2009). Intriguingly, Rab11 is also associated with cell
migration, which is known to be mediated by integrin recycling (Caswell and
Norman, 2006, Pellinen and Ivaska, 2006).
It has been shown that both mammalian Spire proteins, Spire-1 and Spire-2,
interact with mammalian Formin-1 and Formin-2 to form a regulatory complex,
with the interaction blocking Formin nucleation activity, while enhancing the
activity of Spire (Pechlivanis et al., 2009, Quinlan et al., 2007). However, their
expression profiles and the individual contribution of each gene in different cell
types is not widely explored. Formin-2 and Spire1 gene expression have been
detected in both the developing and adult nervous system (Schumacher et al.,
2004), while Formin-2 has also been shown to be important for mouse oogenesis
(Azoury et al., 2011, Dumont et al., 2007, Leader et al., 2002). Spire-1 and Spire-
2, although primarily expressed in central nervous system, have also been shown
to be expressed in many embryonic tissues (Schumacher et al., 2004). However,
little is known about their biological functions in different cell types. Furthermore,
no studies, to our knowledge, have investigated their expression or potential
functions in skeletal muscle.
6.3. AIMS, OBJECTIVES AND HYPOTHESIS
The aim of these studies was to reveal the involvement of Spire and Formin
genes in skeletal muscle myogenesis. The objectives were: 1) to investigate by
RT-PCR whether there was detectable expression of Spire-1, Spire-2, Formin-1
and Formin-2 genes and 2) whether expression of any of these genes would be
187
altered following inhibition of fusion by 10µM Bpv(Hopic) and serial passaging
of C2C12 myoblasts. It was hypothesised that detectable expression levels of
Spire and Formin genes, implicated in actin nucleation and intracellular
trafficking, would be present in C2C12 cells and that their expression would be
altered during myoblast fusion. If the hypothesis is accepted, this research could
provide a basis for future studies into the specific functions of these genes in
skeletal muscle and their potential involvement in myoblast fusion and migration.
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6.4. METHODS
6.4.1. CELL CULTURE
C2C12 myoblasts were cultured in a humidified 5% CO2 atmosphere at 37ºC.
Cells were grown in the presence of GM in T75 flasks until confluent and split
into multidish plates for experiments. In order to initiate differentiation, C2C12
cells were grown in 6 well plates until confluency was achieved, monolayers were
washed with PBS and differentiation media (DM) was added to the cell
monolayers. When differentiation experiments were performed for 5days, DM
was changed with a fresh media at d3.
6.4.2. RNA ISOLATIONS AND REAL-TIME  PCR
RNA extraction and TaqMan® Real-time PCR methods were performed as
described in sections 2.2.9 and 2.2.10, respectively. The following predesigned
primer sets were ordered from Applied Biosystems and were used with the
TaqMan® detection method: Polr2b (Mm00464214_m1), MyoD
(mm00440387_m1), Myogenin (mm00446194_m1), Spire1 (mm01258168_m1),
Spire2 (mm00552235_m1), Formin1 (mm00439021_m1) and Formin2
(mm00444598_m1).
6.4.3. CREATINE KINASE (CK) ASSAY
Samples for CK assay were prepared by adding 150µL per well (for 6 well plate)
of Tris Mes Triton (TMT buffer; composed of: 0.05M Tris/Mes and 1% Triton-
X100). Assay was performed, as described in section 2.2.7.2.
6.4.4. FLOW  CYTOMETRY
For investigating cell cycle, cells were collected 20hrs post treatment. Sample
preparation and Propidium iodide method for FACS are described in section
2.2.11.
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6.4.5. SERIAL PASSAGING
C2C12 cells of passage 20 (P20) were seeded in a T75 flasks at concentration of
500,000cell/ml and allowed to proliferate in GM for 48h before being passaged to
a new T75 flask. Upon passaging, total number of cells was counted, and on
average equated to 2,5 million cells per flask, confirming that 48h was enough
time for cells to perform at least 2 doublings (average doublings in 48 hrs was
2.4). Cycles of passaging were repeated 30 times until reaching 50 passages (thus,
C2C12 cells were designated as p50).
6.4.6. CELL TREATMENTS AND RECONSTITUTION OF INHIBITORS
All inhibitors were purchased from Merck-Calbiochem (Darmstadt, Germany).
Bpv(Hopic) inhibitor was diluted, according to manufacturer’s instructions, in
H20 and stored at -20ºC. It was kept in mM concentration stock and part of the
stock was diluted to working concentration in appropriate DMEM media before
cell treatments.
6.4.7. STATISTICAL ANALYSES
Statistical analyses and significance of data were determined using GraphPad
Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California
USA, www.graphpad.com. Statistical significance for interactions between two
paired groups was determined with a Paired t-test, while unpaired t-test was used
for unpaired groups (e.g. between p5 and p50 groups). Statistical significance for
interactions between more than two groups was determined with a one-way
ANOVA, or with a one-way repeated measures ANOVA, when matched
observations were investigated. When more than one factor was present, two-way
ANOVA was performed to investigate for significances of factors or interactions,
or two-way repeated measures (mixed model) ANOVA, when matched
observations were investigated. When significances of factors were indicated by
two-way ANOVA, this was followed up by examining the statistical significance
for interactions between more than two groups within the factor with a One-way
ANOVA with Bonferroni post-hoc analysis, or with a t-test for examination
between two groups. All results are presented as mean +/- standard error of the
mean (SEM). All values below p<0.05 were considered as significant.
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For determining the significances of the PCR results, 4x2x2 ANOVA was
performed to determine whether there were significances for any of the factors
(time, passage, inhibitor treatment). When significance was indicated for time,
one way ANOVA was performed to investigate the significances between the
different time points within one group. When significances were indicated for
passage/inhibitor treatment, 2x2 ANOVA was performed to determine the
significances of these factors individually for each time point. When significance
was indicated by 2x2 ANOVA for either passage or inhibitor treatment within a
time point, this was followed up by performing a paired t-test to determine the
significance between paired groups (e.g. p5 vs p5-bpv or p50 vs p50-bpv) or
unpaired t-test for significances between unpaired groups (e.e.g p5 vs p50, p5 vs
p50-bpv or p5-bpv vs p50).
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6.5. RESULTS
6.5.1. SERIALLY PASSAGED C2C12 MYOBLASTS (P50)
DEMONSTRATED IMPAIRED CAPACITY TO DIFFERENTIATE
COMPARED TO LOW PASSAGE CELLS (P5), WHICH WAS FURTHER
REDUCED BY TREATMENT WITH 10µM BPV(HOPIC)
Previous studies have addressed the decrease in fusion/differentiation capacity of
C2C12 myoblasts subjected to multiple population doublings. This work was
expanded by further exploring the differentiation capacity of C2C12 cells after 50
population doublings and examined the effect of 10µM BpV(Hopic) treatment on
differentiation of p50 vs p5 myoblasts. The findings coincide with a recent article,
using the same model of approx. 50 population doublings (passage 20) of C2C12
myoblasts (Sharples et al., 2011). In order to investigate the differences in
fusion/differentiation capacity, p5 and p50 myoblasts were incubated until
confluent and subsequently transferred to DM media with and without 10µM
Bpv(Hopic) for 3 days. Phase contrast microscopy (Figure 6.1) demonstrated
reduced capacity of p50 cells to fuse into myotubes compared with p5, which was
further decreased by Bpv(Hopic). Bpv (Hopic) also decreased the fusion capacity
of p5 cells.
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Figure 6.1. Effects of Bpv(Hopic) and serial passaging on myotube formation.
Phase-contrast microscopy investigating the effects of DM on p5 C2C12 myoblasts (A),
DM+10µM Bpv(Hopic) on p5 myoblasts (B), DM on p50 myoblasts (C) and DM+10µM
Bpv(Hopic) on p50 myoblasts (D). Reduction in myotubes formation was observed with
p50 myoblasts vs p5 myoblasts, with further reduction after 10µM Bpv(Hopic) treatment
in both p5 and p50. Data are representative of 4 experiments performed in duplicate. 10x
objective used.
In order to verify the phase-contrast microscopy observations, CK activity was
measured in the two different myoblast passages with and without 10µM
Bpv(Hopic) treatment (Figure 6.2). The data from CK assay supported the phase-
contrast microscopy images, showing significant decreases in CK activity with
p50 cells treated with DM vs p5 cells treated with DM (836.75 +/-90.48 vs 1123.2
+/-66.43 mU/mg, p<0.05, equivalent to 1.34 fold decrease). Decreases were also
found in p5 cells treated with DM+10µM Bpv(Hopic) vs DM (343.75 +/-29.92 vs
1123.2 +/-66.43 mU/mg, p<0.001, equivalent to 3.27 fold decrease) and in p50
cells treated with DM+10µM Bpv(Hopic) vs DM (154.5 +/-24.19 vs 836.75 +/-
90.48 mU/mg, p<0.01, equivalent to 5.42 fold decrease).
Greater decreases were observed with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM (154.5 +/-24.19 vs 1123.2 +/-66.43
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mU/mg, p<0.0001, equivalent to 7.27 fold decrease). The CK activity values
suggested that Bpv(Hopic) treatment was able to further reduce the differentiation
potential caused by serial passaging. Decreased CK activity was identified in p50
cells treated with 10µM Bpv(Hopic) vs p5 cells treated with 10µM Bpv(Hopic)
(154.5 +/-24.19 vs 343.75 +/-29.92 mU/mg, p<0.01, equivalent to 2.22 fold
decrease). Increases were observed with p50 myoblasts treated with DM vs p5
myoblasts treated with DM+10µM Bpv(Hopic) (836.75 +/-90.48 vs 343.75 +-
29.92 mU/mg, p<0.01, equivalent to 2.43 fold increase), suggesting the greater
inhibition effect that BpV(Hopic) treatment has on differentiation, as compared to
serial passaging alone. Overall, these observations indicate a reduced CK activity
after treatment with 10µM Bpv(Hopic), which is compounded by serial passaging
of myoblasts.
Figure 6.2. CK assay, measuring CK activity between p5 and p50 myoblasts
incubated for 3 days in DM with and without 10µM Bpv(Hopic). Significant
decreases in CK activity were present with p50 in control DM vs p5 cells in control DM
(p<0.05, represented by a). Reductions were observed with p5 cells treated with
DM+10µM Bpv(Hopic) vs DM-treated p5 cells (p<0.001, represented by *) and with p50
cells treated with DM+10µM Bpv(Hopic) vs DM-treated p50 cells (p<0.01, represented
by *). Reductions were also identified with p50 cells treated with 10µM Bpv(Hopic) vs
p5 cells treated with 10µM Bpv(Hopic) (p<0.01, represented by b) and with p50 cells
treated with DM+10µM Bpv(Hopic) vs p5 cells treated with DM (p<0.0001, represented
by d). An increase was found with p50 myoblasts treated with DM vs p5 myoblasts
treated with DM+10µM Bpv(Hopic) (p<0.01, represented by c). Data are representative
of 4 experiments performed in duplicate. (p-values obtained by paired t-test (within the
same passage) and unpaired t-test (between different passages))
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6.5.2. CELL CYCLE PROGRESSION:  IMPACT OF PASSAGING AND
BPV (HOPIC)
As fusion/differentiation was reduced in p50 vs p5 myoblasts, it was investigated
whether this occurred as a consequence of increased proliferation and cells in the
S-phase of the cell cycle were examined by FACS. Permanent withdrawal from
the cell cycle is necessary for progression to myogenic differentiation. Previous
studies have demonstrated increases percentages of cells in S-phase of the cell
cycle at early time points after the initiation of differentiation (Sharples et al.,
2011). As a consequence, the percentage of myoblasts in the S-phase of the cell
cycle at 20hr after addition of DM or DM+10µM Bpv(Hopic) in p5 or p50
myoblasts was examined and it was ascertained that BpV (Figure 6.3 B & D)
appears to actively move cells to the S phase of the cell cycle, regardless of
passage (Figure 6.3  A & C).
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Figure 6.3. Flow cytometric analysis (p5 and p50 myoblasts incubated in DM
with and without 10µM Bpv(Hopic)). Examination of the percentage of C2C12
myoblasts in the S/G2-phases of the cell cycle by FLOW cytometry, after incubation for
20h of p5 cells with DM (A), p5 cells with DM+10µM Bpv (B), p50 cells with DM (C)
and p50 cells with DM+10µM Bpv (D). Data are representative of 4 experiments.
Analyses (Figure 6.4) indicated significant increases of the percentage of cells in
the S/G2-phases of the cell cycle with p5 cells treated with DM+10µM
Bpv(Hopic) vs DM only (42.76 +/-1.92% vs 17.08 +/-3.19%, p<0.01) and with
p50 cells treated with DM+10µM Bpv(Hopic) vs DM only (44.2 +/-6.1% vs
17.59% +/-2.4, p<0.01) (Figure 6.4). However, no significant differences were
found between p5 and p50 in the absence or presence of Bpv (Hopic), 20hr after
differentiation was initiated.
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Figure 6.4. Analysis of the percentage of p5 and p50 cells in S/G2-phases of
the cell cycle after treatment with DM or DM+10µM Bpv for 20h. Significant
increases were observed with p5 cells treated with DM+10µM Bpv(Hopic) vs p5 cells
treated with DM (p<0.01, represented by *). Significant increases were also observed
with p50 cells treated with DM+10µM Bpv(Hopic) vs p50 cells treated with DM (p<0.01,
represented by *). Data are representative of 4 experiments. (p-values obtained by paired
t-test (within the same passage) and unpaired t-test (between different passages))
6.5.3. DIFFERENTIAL EXPRESSION OF MYOGENIC REGULATORY
FACTORS IN RESPONSE TO BPV(HOPIC) AND SERIAL PASSAGING
Having confirmed that multiple population doublings reduces the differentiation
potential of C2C12 cells and that this phenotype is worsened by the incubation
with Bpv(Hopic), further investigations aimed to explore how Spire1, Spire2,
Formin1 and Formin2 genes were influenced in response to serial passaging of
C2C12 myoblasts with and without Bpv(Hopic) treatment. Temporal
investigations were performed at 4 different time points (0 (d0), 24 (d1), 48 (d2)
and 72 (d3) hr) in both p5 and p50 myoblasts treated with either DM or
DM+10µM Bpv(Hopic). 4 different time points, unlike previous RT-PCR results
in this thesis, were used due to the fact that this chapter investigates the
expression of genes, which are previously not investigated in skeletal muscle and
it is not known how their expression is regulated during myogenesis.
Nevertheless, MyoD and Myogenin expression were also investigated at 4
different time points in this chapter, in order to examine how the combination of
serial passaging and inhibitor treatments influenced the expression of myogenic
regulatory factors in these models.
197
MyoD gene expression was examined in p5 and p50 myoblasts in response to
DM or DM+10µM Bpv(Hopic) (Figure 6.5). Reductions in MyoD expression
were observed with passage under basal conditions in p50 myoblasts treated with
DM vs p5 myoblasts treated with DM at d1 (0.56 +/-0.01 vs 1, p<0.0001,
equivalent to 1.79 fold decrease), at d2 (0.55 +/-0.04 vs 0.93 +/-0.06, p<0.01,
equivalent to 1.69 fold decrease) and at d3 (0.62 +/-0.04 vs 0.89 +/-0.06, p<0.01,
equivalent to 1.44 fold decrease). Reductions with time were observed with p5
myoblasts treated with DM at d1 vs d0 (1 vs 1.56 +/-0.17, p<0.01, equivalent to
1.56 fold decrease), at d2 vs d0 (0.93 +/-0.03 vs 1.56 +/-0.17, p<0.01, equivalent
to 1.68 fold decrease) and at d3 vs d0 (0.89 +/-0.06 vs 1.56 +/-0.17, p<0.01,
equivalent to 1.75 fold decrease) and also with p50 myoblasts treated with DM at
d1 vs d0 (0.56 +/-0.001 vs 1.13 +/-0.05, p<0.001, equivalent to 2.02 fold
decrease), at d2 vs d0 (0.55 +/-0.04 vs 1.13 +/-0.05, p<0.001, equivalent to 2.05
fold decrease) and at d3 vs d0 (0.62 +/-0.04 vs 1.13 +/-0.05, p<0.001, equivalent
to 1.82 fold decrease).
Inhibitor treatment was also found to have significant effect on MyoD
expression levels. Significant decreases in gene expression levels were observed
in p5 myoblasts treated with DM+10µM Bpv(Hopic) vs DM at d1 (0.52 +/-0.03
vs 1, p<0.001, equivalent to 1.92 fold decrease) and at d2 (0.65 +/-0.07 vs 0.93 +/-
0.06, p<0.001, equivalent to 1.43 fold decrease). Decreases in expression with
time were observed with p5 myoblasts treated with DM+10µM Bpv(Hopic) at d1
vs d0 (0.52 +/-0.03 vs 1.56 +/-0.17, p<0.001, equivalent to 3 fold decrease), d2 vs
d0 (0.65 +/-0.07 vs 1.56 +/-0.17, p<0.001, equivalent to 2.4 fold decrease) and at
d3 vs d0 (0.85 +/-0.05 vs 1.56 +/-0.17, p<0.01, equivalent to 1.84 fold decrease).
Although not statistically significant, a gradual increase with time was also
evident with p5 myoblasts treated with DM+10µM Bpv(Hopic), indicating that
myoblasts slowly recover the MyoD gene expression levels following a single
dose of 10µM Bpv(Hopic) at d0. Similarly, expression of MyoD was reduced
when p50 myoblasts were treated with DM+10µM Bpv(Hopic) vs DM at d1 (0.27
+/-0.02 vs 0.56 +/-0.01, p<0.001, equivalent to 2.07 fold decrease) and at d2 (0.39
+/-0.04 vs 0.55 +/-0.04, p<0.05, equivalent to 1.41 fold decrease). Decreases with
time were observed with p50 myoblasts treated with DM+10µM Bpv(Hopic) at
d1 vs d0 (0.27 +/-0.02 vs 1.13 +/-0.05, p<0.001, equivalent to 4.19 fold decrease),
at d2 vs d0 (0.39 +/-0.04 vs 1.13 +/-0.05, p<0.001, equivalent to 2.9 fold
decrease) and at d3 vs d0 (0.51 +/-0.03 vs 1.13 +/-0.05, p<0.001, equivalent to
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2.22 fold decrease). Increases with time were found with p50 myoblasts treated
with DM+10µM Bpv(Hopic) at d3 vs d1 (0.51 +/-0.03 vs 0.27 +/-0.02, p<0.01,
equivalent to 1.89 fold increase) and at d3 vs d2 (0.51 +/-0.03 vs 0.39 +/-0.04,
p<0.05, equivalent to 1.3 fold increase) and at d2 vs d1 (0.39 +/-0.04 vs 0.27 +/-
0.02, p<0.05, equivalent to 1.44 fold increase). These observations, similar to p5
myoblasts, suggest a gradual recovery with time of MyoD gene expression levels
in the presence of a single dose of 10µM Bpv(Hopic) at  d0.
Significant decreases were also observed with p50 myoblasts treated with
DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at
d1 (0.27 +/-0.02 vs 0.52 +/-0.03, p<0.001, equivalent to 1.93 fold decrease), at d2
(0.39 +/-0.04 vs 0.65 +/-0.07, p<0.05, equivalent to 1.67 fold decrease) and at d3
(0.51 +/-0.03 vs 0.85 +/-0.05, p<0.01, equivalent to 1.67 fold decrease),
suggesting that as with morphological and biochemical differentiation, serial
passaging reduces MyoD expression, which is further dampened by BpV(Hopic)
treatment. Not surprisingly, given the data above, an even greater reduction in
MyoD expression was found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM at d1 (0.27 +/-0.02 vs 1, p<0.0001,
equivalent to 3.7 fold decrease), at d2 (0.39 +/-0.04 vs 0.93 +/-0.06, p<0.001,
equivalent to 2.38 fold decrease) and at d3 (0.51 +/-0.03 vs 0.89 +/-0.06, p<0.01,
equivalent to 1.75 fold decrease), indicating that combination of serial passaging
and BpV(Hopic) treatment further decreases the MyoD expression of the cells, as
compared to either of these conditions alone.
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Figure 6.5. MyoD gene expression levels in p5 and p50 myoblasts incubated
for 3 days in DM with and without 10µM Bpv(Hopic). MyoD gene expression
levels examining the difference between p5 and p50 C2C12 myoblasts at d0, d1, d2 and
d3 following treatment with DM or DM+10µM Bpv(Hopic). All values are represented
as fold change to the calibrator (p5 DM d1), which was set to 1 (mean Ct value =24.54
+/-0.24). Effect of passage (p5-DM vs p50-DM): Decreases in MyoD expression were
found with p50 myoblasts vs p5 myoblasts at d1 (p<0.0001, represented by *), d2
(p<0.01, represented by *) and d3 (p<0.01, represented by *). Decreases in expression
with time were observed with p5 myoblasts treated with DM at d1 vs d0 (p<0.01,
represented by t), at d2 vs d0 (p<0.01, represented by t) and at d3 vs d0 (p<0.01,
represented by t). Decreases with time were also observed with p50 myoblasts treated
with DM at d1 vs d0 (p<0.001, represented by a), d2 vs d0 (p<0.001, represented by a)
and d3 vs d0 (p<0.001, represented by a) (p-values obtained by One-way repeated
measures ANOVA (changes in gene expression with time) and unpaired t-test (changes in
expression with p5 vs p50)) (A).  Effect of Bpv(Hopic) treatment on p5 myoblasts (p5-
DM vs p5-Bpv): Significant decreases in MyoD expression were observed in p5
myoblasts treated with DM+10µM Bpv(Hopic) vs DM at d1 (p<0.001, represented by *)
and at d2 (p<0.001, represented by *). Decreases in expression with time were observed
with p5 myoblasts treated with DM+10µM Bpv(Hopic) at d1 vs d0 (p<0.001, represented
by t), d2 vs d0 (p<0.001, represented by t) and d3 vs d0 (p<0.01, represented by t) (p-
values obtained by One-way repeated measures ANOVA (changes in gene expression
with time) and paired t-test (changes in expression with DM vs BpV)) (B). Effect of
Bpv(Hopic) treatment on p50 myoblasts (p50-DM vs p50-Bpv): Decreases in MyoD
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expression were found also in p50 myoblasts treated with DM+10µM Bpv(Hopic) vs DM
at d1 (p<0.001, represented by *) and at d2 (p<0.05, represented by *). Decreases in
expression with time were found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) at d1 vs do (p<0.001, represented by t), d2 vs d0 (p<0.001, represented by t)
and d3 vs d0 (p<0.001, represented by t). Increases in expression with time were found
with p50 myoblasts treated with DM+10µM Bpv(Hopic) at d3 vs d1 (p<0.01, represented
by a) and d3 vs d2 (p<0.05, represented by a). Increases were also found with p50
myoblasts treated with DM+10µM Bpv(Hopic) at d2 vs d1 (p<0.05, represented by b) (p-
values obtained by One-way repeated measures ANOVA (changes in gene expression
with time) and paired t-test (changes in expression with DM vs BpV)) (C).  Interactions
between groups: Reductions in MyoD expression were indicated with p50 myoblasts
treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM at d1 (p<0.0001,
represented by *), at d2 (p<0.001, represented by *) and at d3 (p<0.01, represented by *).
Decreases in expression were indicated with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at d1 (p<0.001,
represented by #), at d2 (p<0.05, represented by #) and at d3 (p<0.01, represented by #).
Decreases were also found with p50 myoblasts treated with DM vs p5 myoblasts treated
with DM+10µM Bpv(Hopic) at d3 (p<0.01, represented by a) (p-values obtained by
unpaired t-test (D). Data are representative of 4 experiments performed in duplicate.
Myogenin gene expression was examined in p5 and p50 myoblasts in response
to DM or DM+10µM Bpv(Hopic) (Figure 6.6). Similar to MyoD, passage
influenced the expression of Myogenin. Significant decreases were observed with
p50 myoblasts vs p5 myoblasts treated with DM at d1 (0.43 +/-0.02 vs 1,
p<0.0001, equivalent to 2.33 fold decrease), at d2 (0.44 +/-0.04 vs 0.86 +/-0.06,
p<0.01, equivalent to 1.95 fold decrease) and at d3 (0.41 +/-0.03 vs 0.78 +/-0.06,
p<0.01, equivalent to 1.9 fold decrease). Increases with time were found with p5
myoblasts treated with DM at d1 vs d0 (1 vs 0.38 +/-0.05, p<0.001, equivalent to
2.63 fold increase), at d2 vs d0 (0.86 +/-0.06 vs 0.38 +/-0.05, p<0.001, equivalent
to 2.26 fold increase) and at d3 vs d0 (0.78 +/-0.06 vs 0.38 +/-0.05, p<0.01,
equivalent to 2.05 fold increase). Similarly, although to a smaller extend,
increases were found with p50 myoblasts treated with DM at d1 vs d0 (0.43 +/-
0.02 vs 0.26 +/-0.03, p<0.05, equivalent to 1.65 fold increase), d2 vs d0 (0.44 +/-
0.04 vs 0.26 +/-0.03, p<0.01, equivalent to 1.69 fold increase) and d3 vs d0 (0.41
+/-0.03 vs 0.26 +/-0.03, p<0.05, equivalent to 1.58 fold increase). These
observations clearly demonstrate the upregulation of Myogenin after
differentiation is triggered. It also shows that serially passaged p50 myoblasts
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were able to upregulate Myogenin upon differentiation to a smaller, but perhaps
more sustained extent, as compared to p5 myoblasts.
Similar to MyoD, treatment with Bpv(Hopic) influenced the expression of
Myogenin in both p5 and p50 cells. Significant decreases were observed with p5
myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM
at d1 (0.18 +/-0.01 vs 1, p<0.001, equivalent to 5.56 fold decrease), at d2 (0.32 +/-
0.03 vs 0.86 +/-0.06, p<0.01, equivalent to 2.69 fold decrease) and at d3 (0.57 +/-
0.07 vs 0.78 +/-0.06, p<0.05, equivalent to 1.37 fold decrease). A decrease in
Myogenin expression with time was found with p5 myoblasts treated with
DM+10µM Bpv(Hopic) at d1 vs d0 (0.18 +/-0.01 vs 0.38 +/-0.05, p<0.05,
equivalent to 2.11 fold decrease). On the other hand, increases with time were
found with p5 myoblasts treated with DM+10µM Bpv(Hopic) at d3 vs d1 (0.57
+/-0.07 vs 0.18 +/-0.01, p<0.001, equivalent to 3.17 fold increase) and at d3 vs d2
(0.57 +/-0.07 vs 0.32 +/-0.03, p<0.05, equivalent to 1.78 fold increase),
suggesting, similar to myoD, recovery of Myogenin expression following
prolonged Bpv(Hopic) treatment. Similarly, decreases in expression were
observed with p50 myoblasts treated with DM+10µM Bpv(Hopic) vs DM at d1
(0.04 +/-0.01 vs 0.43 +/-0.02, p<0.001, equivalent to 10.75 fold decrease), at d2
(0.08 +/-0.01 vs 0.44 +/-0.04, p<0.01, equivalent to 5.5 fold decrease) and at d3
(0.15 +/-0.02 vs 0.41 +/-0.03, p<0.01, equivalent to 2.73 fold decrease). Increases
with time were found with p50 myoblasts treated with DM+10µM Bpv(Hopic) at
d3 vs d1 (0.15 +/-0.02 vs 0.04 +/-0.01, p<0.01, equivalent to 3.75 fold increase)
and at d3 vs d2 (0.15 +/-0.02 vs 0.08 +/-0.01, p<0.05, equivalent to 1.88 fold
increase). These observations again indicated a tendency for myoblasts to
gradually increase their Myogenin gene expression in to the face of Bpv(Hopic)
treatment, after an initial drop at d1. Further decreases were found with p50
myoblasts treated with DM+10µM Bpv(Hopic) at d1 vs d0 (0.04 +/-0.01 vs 0.26
+/-0.03, p<0.001, equivalent to 6.5 fold decrease), d2 vs d0 (0.08 +/-0.01 vs 0.26
+/-0.03, p<0.001, equivalent to 3.25 fold decrease) and d3 vs d0 (0.15 +/-0.02 vs
0.26 +/-0.03, p<0.01, equivalent to 1.73 fold decrease). These observations show
that Myogenin levels after treatment with 10µM Bpv(Hopic) decrease to levels
even lower than those evident at the d0 time point, before differentiation was
triggered.
Decreases were found with p50 myoblasts treated with DM+10µM Bpv(Hopic)
vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at d1 (0.04 +/-0.01 vs 0.18
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+/-0.01, p<0.0001, equivalent to 4.5 fold decrease), at d2 (0.08 +/-0.01 vs 0.32 +/-
0.03, p<0.0001, equivalent to 4 fold decrease) and d3 (0.15 +/-0.02 vs 0.57 +/-
0.07, p<0.01, equivalent to 3.8 fold decrease). A greater decrease was found with
p50 myoblasts treated with 10µM Bpv(Hopic) vs p5 myoblasts treated with DM
at d1 (0.04 +/-0.01 vs 1, p<0.0001, equivalent to 25 fold decrease), at d2 (0.08 +/-
0.01 vs 0.86 +/-0.06, p<0.0001, equivalent to 10.75 fold decrease) and at d3 (0.15
+/-0.02 vs 0.78 +/-0.06, p<0.0001, equivalent to 5.2 fold decrease). These
observations, similar to the MyoD expression studies, indicated that the
combination of serial passaging and Bpv(Hopic) treatment reduced the expression
of Myogenin to a greater extent than any of the treatments alone.  An increase in
expression was indicated with p50 myoblasts treated with DM vs p5 myoblasts
treated with DM+10µM Bpv(Hopic) at d1 (0.43 +/-0.02 vs 0.18 +/-0.01,
p<0.0001, equivalent to 2.39 fold increase), suggesting that Bpv(Hopic) treatment
induced stronger inhibition of Myogenin expression than serial passaging alone.
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Figure 6.6. Myogenin gene expression levels in p5 and p50 myoblasts
incubated for 3 days in DM with and without 10µM Bpv(Hopic). Myogenin
gene expression levels examining the difference between p5 and p50 C2C12 myoblasts at
d0, d1, d2 and d3 following treatment with DM or DM+10µM Bpv(Hopic). All values
are represented as fold change to the calibrator (p5 DM d1), which was set to 1 (mean Ct
value =19.21 +/-0.06). Effect of passage (p5-DM vs p50-DM): Significant decreases in
Myogenin expression were observed with p50 myoblasts vs p5 myoblasts at d1
(p<0.0001, represented by *), at d2 (p<0.01, represented by *) and at d3 (p<0.01,
represented by *). Increases of expression with time were found with p5 myoblasts
treated with DM at d1 vs d0 (p<0.001, represented by *), at d2 vs d0 (p<0.001,
represented by *) and at d3 vs d0 (p<0.01, represented by *). Increases were also found
with p50 myoblasts treated with DM at d1 vs d0 (p<0.05, represented by a), d2 vs d0
(p<0.01, represented by a) and d3 vs d0 (p<0.05, represented by a) (p-values obtained by
One-way repeated measures ANOVA (changes in gene expression with time) and
unpaired t-test (changes in expression with p5 vs p50)) (A).  Effect of Bpv(Hopic)
treatment on p5 myoblasts (p5-DM vs p5-Bpv):  Significant decreases in Myogenin
expression with time were observed with p5 myoblasts treated with 10µM Bpv(Hopic) vs
p5 myoblasts treated with DM at d1 (p<0.001, represented by *), at d2 (p<0.01,
represented by *) and at d3 (p<0.05, represented by *). Reductions in expression of
Myogenin with time were found with p5 myoblasts treated with DM+10µM Bpv(Hopic)
at d1 vs d0 (p<0.05, represented by t). Increases in expression were found with time with
p5 myoblasts treated with DM+10µM Bpv(Hopic) at d3 vs d1 (p<0.001, represented by
a) and at d3 vs d2 (p<0.05, represented by a) (p-values obtained by One-way repeated
measures ANOVA (changes in gene expression with time) and unpaired t-test (changes in
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expression with p5 vs p50)) (B).  Effect of Bpv(Hopic) treatment on p50 myoblasts (p50-
DM vs p50-Bpv): Decreases in expression with time were observed with p50 myoblasts
treated with DM+10µM Bpv(Hopic) vs DM at d1 (p<0.001, represented by *), at d2
(p<0.01, represented by *) and at d3 (p<0.01, represented by *).  Decreases were found
with p50 myoblasts treated with DM+10µM Bpv(Hopic) at d1 vs d0 (p<0.001,
represented by t), d2 vs d0 (p<0.001, represented by t) and d3 vs d0 (p<0.01, represented
by t). Increases in expression of Myogenin with time were found with p50 myoblasts
treated with DM+10µM Bpv(Hopic) at d3 vs d1 (p<0.01, represented by a) and at d3 vs
d2 (p<0.05, represented by a) (p-values obtained by One-way repeated measures
ANOVA (changes in gene expression with time) and paired t-test (changes in expression
with DM vs BpV)) (C).  Interactions between groups: Decreases in Myogenin expression
were found with p50 myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts
treated with DM at d1 (p<0.0001, represented by *), at d2 (p<0.0001, represented by *)
and at d3 (p<0.0001, represented by *). Decreases in expression were found with p50
myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM+10µM
Bpv(Hopic) at d1 (p<0.0001, represented by #), at d2 (p<0.0001, represented by #) and
d3 (p<0.01, represented by #). Increases were indicated with p50 myoblasts treated with
DM vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at d1 (p<0.0001, represented
by a) (p-values obtained by unpaired t-test (D). Data are representative of 4 experiments
performed in duplicate.
6.5.4. DIFFERENTIAL EXPRESSION OF SPIRE AND FORMIN GENES
IN RESPONSE TO BPV(HOPIC) AND SERIAL PASSAGING
Spire1 gene expression was examined in p5 and p50 myoblasts in response to DM
or DM+10µM Bpv(Hopic) (Figure 6.7). Similar to MyoD and Myogenin
expression, decreases were observed in Spire1 gene expression with passage.
Decreases were found with p50 myoblasts vs p5 myoblasts treated with DM at d1
(0.7 +/-0.06 vs 1, p<0.01, equivalent to 1.43 fold decrease) and, although not
statistically significant, the same tendency was observed at d2 (0.61 +/-0.04 vs
0.8+/-0.07, p=0.051, equivalent to 1.31 fold decrease). A slight, but significant
increase with time was observed with p5 myoblasts treated with DM at d1 vs d0
(1 vs 0.84 +/-0.06, p<0.05, equivalent to 1.19 fold increase), while a decrease was
observed at d3 vs d0 (0.66 +/-0.04 vs 0.84 +/-0.06, p<0.05, equivalent to 1.27 fold
decrease). A decrease with time was also found with p5 myoblasts treated with
DM at d3 vs d1 (0.66 +/-0.04 vs 1, p<0.001, equivalent to 1.52 fold decrease) and
at d2 vs d1 (0.8 +/-0.07 vs 1, p<0.05, equivalent to 1.25 fold decrease).  These
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data suggest a gradual decrease in Spire1 gene expression after differentiation has
been triggered. Similar observations were made with p50 myoblasts. Decreases
with time were found with p50 myoblasts treated with DM at d3 vs d0 (0.54 +/-
0.03 vs 0.73 +/-0.02, p<0.001, equivalent to 1.35 fold decrease) and at d2 vs d0
(0.61 +/-0.04 vs 0.73 +/-0.02, p<0.05, equivalent to 1.20 fold decrease), but not at
d1 vs d0, while a decrease was also observed with p50 myoblasts between d3 vs
d1 (0.54 +/-0.03 vs 0.7 +/-0.06, p<0.01, equivalent to 1.30 fold decrease).
Similar to MyoD and Myogenin expression, decreases were observed in Spire1
gene expression following Bpv(Hopic) treatment. Decreases were indicated with
p5 myoblasts treated with DM+10µM Bpv(Hopic) vs DM at d1 (0.4 +/-0.04 vs 1,
p<0.001, equivalent to 2.5 fold decrease) and at d2 (0.66 +/-0.07 vs 0.8 +/-0.07,
p<0.05, equivalent to 1.21 fold decrease). Decreases with time were indicated
with p5 myoblasts treated with DM+10µM Bpv(Hopic) at d1 vs d0 (0.4 +/-0.04 vs
0.84 +/-0.06, p<0.01, equivalent to 2.1 fold decrease) and at d2 vs d0 (0.66 +/-
0.07 vs 0.84 +/-0.06, p<0.05, equivalent to 1.27 fold decrease). Increases in
Spire1 expression with time were found with p5 myoblasts treated with
DM+10µM Bpv(Hopic) at d3 vs d1 (0.7 +/-0.08 vs 0.4 +/-0.04, p<0.001,
equivalent to 1.75 fold increase) and at d2 vs d1 (0.66 +/-0.07 vs 1, p<0.01,
equivalent to 1.52 fold decrease), indicating the same tendency, observed with
MyoD and Myogenin, of myoblasts to gradually increase their Spire1 gene
expression in the presence of Bpv(Hopic) treatment after an initial drop at d1.
Decreases were also observed with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p50 myoblasts treated with DM at d1 (0.37 +/-0.03 vs 0.7 +/-0.06,
p<0.001, equivalent to 1.89 fold decrease) and at d2 (0.47 +/-0.03 vs 0.61 +/-0.04,
p<0.01, equivalent to 1.30 fold decrease). Similar trend of time decrease, as with
p5 myoblasts, was observed with p50 myoblasts treated with DM+10µM
Bpv(Hopic): a decrease at d1 vs d0 (0.37 +/-0.03 0.73 +/-0.02, p<0.001,
equivalent to 1.97 fold decrease), at d2 vs d0 (0.47 +/-0.03 vs 0.73 +/-0.02,
p<0.001, equivalent to 1.55 fold decrease) and d3 vs d0 (0.49 +/-0.05 vs 0.73 +/-
0.02, p<0.001, equivalent to 1.49 fold decrease), followed by an increase with at
d2 vs d1 (0.47 +/-0.03 vs 1, p<0.01, equivalent to 2.12 fold increase) and at d3 vs
d1 (0.49 +/-0.05 vs 1, p<0.001, equivalent to 2.04 fold increase).  These data also
show that expression levels of Spire1, following treatment with the inhibitor, are
reduced below the expression levels evident at d0.
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Decreases were indicated with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM at d1 (0.37 +/-0.03 vs 1, p<0.0001,
equivalent to 2.7 fold decrease) and at d2 (0.47 +/-0.03 vs 0.8 +/-0.07, p<0.01,
equivalent to 1.7 fold decrease). Decreases were also evident with p50 myoblasts
treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM+10µM
Bpv(Hopic) at d2 (0.47 +/-0.03 vs 0.66 +/-0.07, p<0.05, equivalent to 1.4 fold
increase). These observations indicate, similarly to MyoD and Myogenin
expression, a negative regulation of both serial passaging and Bpv(Hopic)
treatment on the expression of Spire1 gene. However, the combination of serial
passaging and Bpv(Hopic) did not reduce Spire1 gene expression to the extent
which it did with MyoD and Myogenin.  An increase was found with p50
myoblasts treated with DM vs p5 myoblasts treated with DM+10µM Bpv(Hopic)
at d1 (0.7 +/-0.06 vs 0.4 +/-0.04, p<0.01, equivalent to 1.75 fold increase),
suggesting that the Bpv(Hopic) inhibitor is a more potent regulator of Spire1 at
d1, compared to serial passaging alone.
Overall, these observations indicate a similar expression pattern of Spire1 to
MyoD and Myogenin, following serial passaging and Bpv(Hopic) treatment.
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Figure 6.7. Spire1 gene expression levels in p5 and p50 myoblasts incubated
for 3 days in DM with and without 10µM Bpv(Hopic). Spire1 gene expression
levels examining the difference between p5 and p50 C2C12 myoblasts at d0, d1, d2 and
d3 following treatment with DM or DM+10µM Bpv(Hopic). All values are represented
as fold change to the calibrator (p5 DM d1), which was set to 1 (mean Ct value =25 +/-
0.49).  Effect of passage (p5-DM vs p50-DM): Decreases in Spire1 expression were
found with p50 myoblasts vs p5 myoblasts at d1 (p<0.01, represented by *) and, although
not significant, tendency of decrease was also observed at d2 (p=0.05). Decreases in
expression of Spire1 with time were found with p5 myoblasts treated with DM at d2 vs
d1 (p<0.05, represented by t) and at d3 vs d1 (p<0.001, represented by t). Increases in
Spire1 expression with time were found with p5 myoblasts treated with DM at d1 vs d0
(p<0.05, represented by a), while expression decreased at d3 vs d0 (p<0.05, represented
by b). Decreases were found with p50 myoblasts at d3 vs d0 (p<0.001, represented by c),
at d2 vs d0 (p<0.05, represented by c) and at d3 vs d1 (p<0.01, represented by d) (p-
values obtained by One-way repeated measures ANOVA (changes in gene expression
with time) and unpaired t-test (changes in expression with p5 vs p50)) (A).  Effect of
Bpv(Hopic) treatment on p5 myoblasts (p5-DM vs p5-Bpv): Decreases in Spire1
expression were observed with p5 myoblasts treated with DM+10µM Bpv(Hopic) vs
myoblasts treated with DM at d1 (p<0.001, represented by *) and at d2 (p<0.05,
represented by *). Decreases in expression with time were indicated with p5 myoblasts
treated with DM+10µM Bpv(Hopic) at d1 vs d0 (p<0.01, represented by t) and at d2 vs
d0 (p<0.05, represented by t). Increases in expression were found with p5 myoblasts
treated with DM+10µM Bpv(Hopic) at d3 vs d1 (p<0.001, represented by a) and at d2 vs
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d1 (p<0.01, represented by a) (p-values obtained by One-way repeated measures
ANOVA (changes in gene expression with time) and unpaired t-test (changes in
expression with p5 vs p50)) (B).  Effect of Bpv(Hopic) treatment on p50 myoblasts (p50-
DM vs p50-Bpv): Decreases in Spire1 expression were observed with p50 myoblasts
treated with DM+10µM Bpv(Hopic) vs p50 myoblasts treated with DM at d1 (p<0.001,
represented by *) and at d2 (p<0.01, represented by *). Decreases in expression with time
were found with p50 myoblasts treated with DM+10µM Bpv(Hopic) at d1 vs d0
(p<0.001, represented by t), d2 vs d0 (p<0.001, represented by t) and d3 vs d0 (p<0.001,
represented by t). Increases with time were found with p50 myoblasts treated with
DM+10µM Bpv(Hopic) at d2 vs d1 (p<0.01, represented by a) and at d3 vs d1 (p<0.001,
represented by a) (p-values obtained by One-way repeated measures ANOVA (changes in
gene expression with time) and paired t-test (changes in expression with DM vs BpV))
(C).  Interactions between groups: Decreases in Spire1 expression were indicated with
p50 myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM at
d1 (p<0.0001, represented by *) and at d2 (p<0.01, represented by *). Reductions in
expression were observed with p50 myoblasts treated with DM+10µM Bpv(Hopic) vs p5
myoblasts treated with DM+10µM Bpv(Hopic) at d2 (p<0.05, represented by #).
Increases were found with p50 myoblasts treated with DM vs p5 myoblasts treated with
DM+10µM Bpv(Hopic) at d1 (p<0.01, represented by a) (p-values obtained by unpaired
t-test (D). Data are representative of 4 experiments performed in duplicate.
Spire2 gene expression was examined in p5 and p50 myoblasts in response to
DM or DM+10µM Bpv(Hopic) (Figure 6.8). Contrary to what was observed with
MyoD, Myogenin and Spire1, no significant changes in gene expression of Spire2
were observed with passage. However, expression of Spire2 was altered with
time. Increases were evident with p5 myoblasts treated with DM at d1 vs d0 (1 vs
0.35 +/-0.07, p<0.01, equivalent to 2.86 fold increase), at d2 vs d0 (1.18 +/-0.06
vs 0.35 +/-0.07, p<0.001, equivalent to 3.37 fold increase) and at d3 vs d0 (1.43
+/-0.15 vs 0.35 +/-0.07, p<0.001, equivalent to 4.09 fold increase). Similar
increases were also found with p50 myoblasts at d1 vs d0 (0.98 +/-0.18 vs 0.48
+/-0.1, p<0.01, equivalent to 2.04 fold increase), at d2 vs d0 (1.25 +/-0.1 vs 0.48
+/-0.1, p<0.001, equivalent to 2.6 fold increase), at d3 vs d0 (1.36 +/-0.19 vs 0.48
+/-0.1, p<0.001, equivalent to 2.83 fold increase) and at d3 vs d1 (1.36 +/-0.19 vs
0.98 +/-0.18, p<0.05, equivalent to fold 1.39 increase), indicating a gradual
increase of Spire2 gene expression after differentiation had been triggered.
Bpv(Hopic) treatment induced changes in Spire2 gene expression, however,
contrary to what was previously observed with MyoD, Myogenin and Spire1, no
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significant changes were observed at day 1 following DM addition. A decrease
was observed with p5 myoblasts treated with DM+10µM Bpv(Hopic) vs p5
myoblasts treated with DM at d2 (0.69 +/-0.04 vs 1.18 +/-0.06, p<0.01, equivalent
to 1.71 fold decrease) and at d3 (0.66 +/-0.05 vs 1.43 +/-0.15, p<0.01, equivalent
to 2.17 fold decrease). Increases with time were indicated with p5 myoblasts
treated with DM+10µM Bpv(Hopic) at d1 vs d0 (0.98 +/- 0.15 vs 0.35 +/-0.07,
p<0.01, equivalent to 2.8 fold increase). Decreases, although not statistically
significant, were visible with p5 myoblasts treated with DM+10µM Bpv(Hopic)
at d2 vs d1 and d3 vs d1. This confirms the inhibitory effect of Bpv(Hopic) on the
expression of Spire2 at days 2 and 3 after differentiation has been triggered.
Similarly, decreases were observed with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p50 myoblasts treated with DM at d2 (0.72 +/-0.05 vs 1.25 +/-0.1,
p<0.05, equivalent to 1.74 fold decrease) and at d3 (0.47 +/-0.05 vs 1.36 +/-0.19,
p<0.05, equivalent to 2.89 fold decrease). An increase in expression with time
was found with p50 myoblasts treated with DM+10µM Bpv(Hopic) at d1 vs d0
(1.26 +/-0.13 vs 0.48 +/-0.1, p<0.001, equivalent to 2.63 fold increase). Decreases
were indicated with p50 myoblasts treated with DM+10µM Bpv(Hopic) at d2 vs
d1 (0.72 +/-0.05 vs 1.26 +/-0.13, p<0.01, equivalent to 1.75 fold decrease) and at
d3 vs d1 (0.47 +/-0.05 vs 1.26 +/-0.13, p<0.001, equivalent to 2.68 fold decrease).
Taken together with the previous data, these observations suggest identical
expression responses of Spire2 to Bpv(Hopic) treatment between p5 and p50
myoblasts.
Further decreases were observed with p5 myoblasts treated with DM+10µM
Bpv(Hopic) vs p50 myoblasts treated with DM at d2 (0.69 +/-0.04 vs 1.25+/-0.1,
p<0.01, equivalent to 1.81 fold decrease) and at d3 (0.66 +/-0.05 vs 1.36+/-0.19,
p<0.05, equivalent to 2.06 fold decrease) and also with p50 myoblasts treated with
DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM at d2 (0.72 +/-0.05 vs
1.18+/-0.06, p<0.01, 1.63 equivalent to fold decrease) and at d3 (0.47 +/-0.05 vs
1.43+/-0.15, p<0.001, equivalent to 3.04 fold decrease).
Overall, these observations indicate an increase of Spire2 gene expression after
differentiation has been triggered, which is reduced by treatment with 10µM
Bpv(Hopic) at days 2 and 3, but not at d1, no influence of serial passaging in the
absence or presence of Bpv (Hopic), on Spire 2 gene expression was observed,
suggesting that unlike other experimental observations in this chapter, Spire 2 is
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not involved in the declining differentiation associated with multiple populations
doublings.
Figure 6.8. Spire2 gene expression levels in p5 and p50 myoblasts incubated
for 3 days in DM with and without 10µM Bpv(Hopic). Spire2 gene expression
levels examining the difference between p5 and p50 C2C12 myoblasts at d0, d1, d2 and
d3 following treatment with DM or DM+10µM Bpv(Hopic). All values are represented
as fold change to the calibrator (p5 DM d1), which was set to 1 (mean Ct value =32.33
+/-0.21).  Effect of passage (p5-DM vs p50-DM): No significant effect in expression of
Spire2 was observed with passage. However, increases in Spire2 expression with time
were found with p5 myoblasts treated with DM at d1 vs d0 (p<0.01, represented by t), at
d2 vs d0 (p<0.001, represented by t) and at d3 vs d0 (p<0.001, represented by t).
Increases in expression with time were indicated with p50 myoblasts treated with DM at
d1 vs d0 (p<0.01, represented by a), at d2 vs d0 (p<0.001, represented by a), at d3 vs d0
(p<0.001, represented by a) and at d3 vs d1 (p<0.05, represented by b) (p-values obtained
by One-way repeated measures ANOVA (changes in gene expression with time) and
unpaired t-test (changes in expression with p5 vs p50)) (A).  Effect of Bpv(Hopic)
treatment on p5 myoblasts (p5-DM vs p5-Bpv): Decreases in Spire2 expression were
present with p5 myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated
with DM at d2 (p<0.01, represented by *) and at d3 (p<0.01, represented by *). Increases
in expression with time were indicated with p5 myoblasts treated with DM+10µM
Bpv(Hopic) at d1 vs d0 (p<0.01, represented by t) (p-values obtained by One-way
repeated measures ANOVA (changes in gene expression with time) and unpaired t-test
(changes in expression with p5 vs p50)) (B). Effect of Bpv(Hopic) treatment on p50
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myoblasts (p50-DM vs p50-Bpv): Decreases in Spire2 expression were indicated with
p50 myoblasts treated with DM+10µM Bpv(Hopic) vs p50 myoblasts treated with DM at
d2 (p<0.05, represented by *) and at d3 (p<0.05, represented by *). Increases in
expression with time were observed with p50 myoblasts treated with DM+10µM
Bpv(Hopic) at d1 vs d0 (p<0.001, represented by t). Decreases were found with p50
myoblasts treated with DM+10µM Bpv(Hopic) at d2 vs d1 (p<0.01, represented by a)
and at d3 vs d1 (p<0.001, represented by a) (p-values obtained by One-way repeated
measures ANOVA (changes in gene expression with time) and paired t-test (changes in
expression with DM vs BpV)) (C). Interactions between groups: Significant decreases
were found with p50 myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts
treated with DM at d2 (p<0.01, represented by *) and at d3 (p<0.001, represented by *).
Significant decreases were also indicated with p5 myoblasts treated with DM+10µM
Bpv(Hopic) vs p50 myoblasts treated with DM at d2 (p<0.01, represented by #) and at d3
(p<0.05, represented by #) (p-values obtained by unpaired t-test (D). Data are
representative of 4 experiments performed in duplicate.
Formin1 gene expression was examined in p5 and p50 myoblasts in response to
DM or DM+10µM Bpv(Hopic) (Figure 6.9). A slight, but significant, increase
with passage was discovered with p50 myoblasts vs p5 myoblasts treated with
DM at d2 (1.27 +/-0.02 vs 1.06 +/-0.07, p<0.05, equivalent to 1.2 fold increase)
and at d3 (1.17 +/-0.09 vs 0.92 +/-0.04, p<0.05, equivalent to 1.27 fold increase).
These observations are the contrary to what was previously observed with MyoD,
Myogenin and Spire genes. Reductions with time were found with p5 myoblasts
treated with DM at d1 vs d0 (1 vs 1.49 +/-0.09, p<0.01, equivalent to 1.49 fold
decrease), at d2 vs d0 (1.06 +/-0.07 vs 1.49 +/-0.09, p<0.01, equivalent to 1.41
fold decrease) and at d3 vs d0 (0.92 +/-0.04 vs 1.49 +/-0.09, p<0.001, equivalent
to 1.62 fold decrease), showing a decrease in expression levels after
differentiation has been triggered. No significant decrease was observed with time
when p50 cells were treated with DM and levels remained unchanged during the 4
different time points examined. Changes in Formin1 gene expression were
observed after treatment with 10µM Bpv(Hopic). An increase was found with p5
myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM
at d1 (1.33 +/-0.06 vs 1, p<0.05, equivalent to 1.33 fold increase), at d2 (1.94 +/-
0.05 vs 1.06 +/-0.07, p<0.01, equivalent to 1.83 fold increase) and at d3 (1.57 +/-
0.05 vs 0.92 +/-0.04, p<0.001, equivalent to 1.71 fold increase). Once again, these
observations are contrary to what was previously observed with MyoD, Myogenin
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and Spire genes. Increases with time were found with p5 myoblasts treated with
DM+10µM Bpv(Hopic) at d2 vs d0 (1.94 +/-0.05 vs 1.49 +/-0.09, p<0.01,
equivalent to 1.3 fold increase), at d2 vs d1 (1.94 +/-0.05 vs 1.33 +/-0.06,
p<0.001, equivalent to 1.46 fold increase) and at d2 vs d3 (1.94 +/-0.05 vs 1.57
+/-0.05, p<0.01, equivalent to 1.24 fold increase). Thus, Formin1 gene expression
seems to be slightly reduced (although not significant) after differentiation is
triggered, but Bpv(Hopic) treatment is able to increase the expression, with a peak
at 2 days. An increase was also found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p50 myoblasts treated with DM at d2 (1.46 +/-0.04 vs 1.27 +/-
0.02, p<0.05, equivalent to 1.15 fold increase) and, although not significant, an
increase was also observed at d3 (1.62 +/-0.08 vs 1.17 +/-0.09, p=0.06, equivalent
to 1.38 fold increase). This once again suggests an effect of Bpv(Hopic), opposite
to the one observed previously with MyoD, Myogenin, Spire1 and Spire 2 genes.
Gradual increases in Formin1 levels with time were observed when p50 myoblasts
were subject to 10µM Bpv(Hopic) treatment. An increase was found with p50
myoblasts treated with DM+10µM Bpv(Hopic) at d3 vs d0 (1.62 +/-0.08 vs 1.22
+/-0.08, p<0.01, equivalent to 1.33 fold increase), at d3 vs d1 (1.62 +/-0.08 vs 1
+/-0.04, p<0.001, equivalent to 1.62 fold increase), and at d2 vs d1 (1 +/-0.04 vs
1.46 +/-0.04, p<0.001, equivalent to 1.46 fold increase).
Further increases were found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM at d2 (1.46 +/-0.04 vs 1.06 +/-0.07,
p<0.01, equivalent to 1.38 fold increase) and at d3 (1.62 +/-0.08 vs 0.92+/-0.04,
p<0.001, equivalent to 1.76 fold increase). However, increased expression of
Formin1 with p50 vs p5 myoblasts treated with Bpv(Hopic) was not observed,
rather a decrease was found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at d2 (1.46 +/-
0.04 vs 1.94 +/-0.05, p<0.001, equivalent to 1.33 fold decrease).  A decrease in
Formin 1 expression was also found with p50 myoblasts treated with DM vs p5
myoblasts treated with DM+10µM Bpv(Hopic) at d2 (1.27 +/-0.02 vs 1.94 +/-
0.05, p<0.0001, equivalent to 1.53 fold decrease) and at d3 (1.17 +/-0.09 vs
1.57+/-0.05, p<0.01, equivalent to 1.34 fold decrease).
Overall, these findings indicate a tendency of increased Formin1 expression
when myoblasts have been treated with Bpv(Hopic) and displaye reduced
differentiation. Serial passaging also elevated the expression of Formin 1 in
myoblasts treated with DM, but not in the presence of inhibitor. These
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observations suggest that Formin1 expression is affected in an opposite manner to
MyoD, Myogenin, Spire1 and Spire2 genes, following Bpv(Hopic) treatment and
serial passaging.
Figure 6.9. Formin1 gene expression levels in p5 and p50 myoblasts
incubated for 3 days in DM with and without 10µM Bpv(Hopic). Formin1 gene
expression levels examining the difference between p5 and p50 C2C12 myoblasts at d0,
d1, d2 and d3 following treatment with DM or DM+10µM Bpv(Hopic). All values are
represented as fold change to the calibrator (p5 DM d1), which was set to 1 (mean Ct
value =26.8 +/-0.12).  Effect of passage (p5-DM vs p50-DM): Increases in Formin1
expression were observed between p50 cells treated with DM vs p5 cells treated with DM
at d2 (p<0.05, represented by *) and at d3 (p<0.05, represented by *). Decreases in
expression were found with p5 myoblasts treated with DM at d1 vs d0 (p<0.01,
represented by t), at d2 vs d0 (p<0.01, represented by t) and at d3 vs d0 (p<0.001,
represented by t) (p-values obtained by One-way repeated measures ANOVA (changes in
gene expression with time) and unpaired t-test (changes in expression with p5 vs p50))
(A).  Effect of Bpv(Hopic) treatment on p5 myoblasts (p5-DM vs p5-Bpv): Increases in
Formin1 expression were found with p5 myoblasts treated with DM+10µM Bpv(Hopic)
vs p5 myoblasts treated with DM at d1 (p<0.05, represented by *), at d2 (p<0.01,
represented by *) an at d3 (p<0.001, represented by *). Increase in expression with time
were found with p5 myoblasts treated with DM+10µM Bpv(Hopic) at d2 vs d0 (p<0.05,
represented by t). Increases were also found with p5 myoblasts treated with DM+10µM
Bpv(Hopic) at d2 vs d1 (p<0.01, represented by a) and at d2 vs d3 (p<0.05, represented
by a) (p-values obtained by One-way repeated measures ANOVA (changes in gene
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expression with time) and unpaired t-test (changes in expression with p5 vs p50)) (B).
Effect of Bpv(Hopic) treatment on p50 myoblasts (p50-DM vs p50-Bpv): Increase in
Formin1 expression were found with p50 myoblasts treated with DM+10µM Bpv(Hopic)
vs p50 myoblasts treated with DM at d2 (p<0.05, represented by *). Increases in
expression with time were found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) at d3 vs d0 (p<0.01, represented by t). Increase in expression with time were
also found with p50 myoblasts treated with DM+10µM Bpv(Hopic) at d2 vs d1 (p<0.001,
represented by a) and at d3 vs d1 (p<0.001, represented by a) (p-values obtained by One-
way repeated measures ANOVA (changes in gene expression with time) and paired t-test
(changes in expression with DM vs BpV)) (C).  Interactions between groups: Increases in
Formin1 expression were found with p50 myoblasts treated with DM+10µM Bpv(Hopic)
vs p5 myoblasts treated with DM at d2 (p<0.01, represented by *) and at d3 (p<0.001,
represented by *). Decreases in expression were found with p50 myoblasts treated with
DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at d2
(p<0.001, represented by #). Decreases were also found with p50 myoblasts treated with
DM vs p5 myoblasts treated with DM+10µM Bpv(Hopic) at d2 (p<0.0001, represented
by a) and at d3 (p<0.01, represented by a) (p-values obtained by unpaired t-test (D). Data
are representative of 4 experiments performed in duplicate.
Formin2 gene expression was examined in p5 and p50 myoblasts in response to
DM or DM+10µM Bpv(Hopic) (Figure 6.10). Its expression pattern was different
to what was previously observed with the other genes examined. Significant
increases were observed with p50 myoblasts treated with DM vs p5 myoblasts
treated with DM at d1 (4.36 +/-0.87 vs 1, p<0.05, equivalent to 4.36 fold
increase), at d2 (4.91 +/-0.89 vs 0.82 +/-0.13, p<0.05, equivalent to 6 fold
increase) and at d3 (5.62 +/-1.11 vs 0.89 +/-0.36, p<0.05, equivalent to 6.31 fold
increase). No significant changes in expression were observed with time.
Furthermore, no changes in expression were observed in response to BpV(Hopic)
in both p5 and p50 myoblasts. All changes in expression of Formin2 were due to
the effect of passage. Increases were indicated with p50 myoblasts treated with
DM+10µM Bpv(Hopic) vs p5 myoblasts treated with DM at d1 (4.18 +/-0.81 vs
1, p<0.01, equivalent to 4.18 fold increase), d2 (4.5 +/-0.78 vs 0.82 +/-0.13,
p<0.01, equivalent to 5.48 fold increase) and d3 (5.3 +/-1.58 vs 0.89 +/-0.36,
p<0.05, equivalent to 5.96 fold increase). Increases were also observed with p50
myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts treated with
DM+10µM Bpv(Hopic) at d1 (4.18 +/-0.81 vs 1.14 +/-0.19, p<0.05, equivalent to
3.67 fold increase), at d2 (4.5 +/-0.78 vs 0.8 +/-0.13, p<0.05, equivalent to 5.63
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fold increase) and, while significance was not achieved, the same tendency was
evident at d3 (5.3 +/-1.58 vs 0.58 +/-0.21, p=0.057, equivalent to 9.14 fold
increase).  Increases were further observed with p50 DM vs p5 myoblasts treated
with DM+10µM Bpv(Hopic) at d1 (4.36 +/-0.87 vs 1.14 +/-0.19, p<0.05,
equivalent to 3.82 fold increase) and d2 (4.91 +/-0.89 vs 0.8 +/-0.13, p<0.01,
equivalent to 6.14 fold increase) and at d3 (5.62 +/-1.11 vs 0.58 +/-0.21, p<0.01,
equivalent to 9.69 fold increase).
Overall, these data indicate increased expression of Formin2 gene in serially
passaged p50 cells, as compared to p5 cells, with Bpv(Hopic) treatment not
exerting significant effect, suggesting that while Formin 1 was affected by
BpV(Hopic), Formin 2 was affected by passage.
Figure 6.10. Formin2 gene expression levels in p5 and p50 myoblasts
incubated for 3 days in DM with and without 10µM Bpv(Hopic). Formin2 gene
expression levels examining the difference between p5 and p50 C2C12 myoblasts at d0,
d1, d2 and d3 following treatment with DM or DM+10µM Bpv(Hopic). All values are
represented as fold change to the calibrator (p5 DM d1), which was set to 1 (mean Ct
value =35.25 +/-0.24).  Effect of passage (p5-DM vs p50-DM): Increases in Formin2
expression were observed with p50 myoblasts treated with DM vs p5 myoblasts treated
with DM at d1 (p<0.05, represented by *), at d2 (p<0.05, represented by *) and at d3
(p<0.05, represented by *) (p-values obtained by One-way repeated measures ANOVA
(changes in gene expression with time) and unpaired t-test (changes in expression with p5
vs p50)) (A).  Effect of Bpv(Hopic) treatment on p5 myoblasts (p5-DM vs p5-Bpv):  No
216
significant differences were found between the groups with inhibitor or with time (p-
values obtained by One-way repeated measures ANOVA (changes in gene expression
with time) and unpaired t-test (changes in expression with p5 vs p50)) (B). Effect of
Bpv(Hopic) treatment on p50 myoblasts (p50-DM vs p50-Bpv): No significant
differences were found between the groups with inhibitor or with time (p-values obtained
by One-way repeated measures ANOVA (changes in gene expression with time) and
paired t-test (changes in expression with DM vs BpV)) (C).  Interactions between groups:
Increases in Formin2 expression were found with p50 myoblasts treated with DM+10µM
Bpv(Hopic) vs p5 myoblasts treated with DM at d1 (p<0.01, represented by *), at d2
(p<0.01, represented by *) and at d3 (p<0.05, represented by *). Increases in expression
were observed with p50 myoblasts treated with DM+10µM Bpv(Hopic) vs p5 myoblasts
treated with DM+10µM Bpv(Hopic) at d1 (p<0.05, represented by #), at d2 (p<0.05,
represented by #) and, although not significant,  the same tendency was observed also at
d3 (p=0.057).  Increases were found with p50 myoblasts treated with DM vs p5
myoblasts treated with DM+10µM Bpv(Hopic) at d1 (p<0.05, represented by a), at d2
(p<0.01, represented by a) and at d3 (p<0.01, represented by a) (p-values obtained by
unpaired t-test (D). Data are representative of 4 experiments performed in duplicate.
SUMMARY OF MAJOR FINDINGS
- Serially passaged (p50) myoblasts are less capable of differentiating, as
compared to p5 myoblasts, and demonstrate further reduction in
differentiation capacity following 10µM Bpv(Hopic) treatment, associated
with greater reduction in the gene expression of myogenic regulatory
factors, such as MyoD and Myogenin.
- Spire1 gene expression is reduced by serial passaging and by 10µM
Bpv(Hopic) treatment.
- Spire2 gene expression is reduced by 10µM Bpv(Hopic) treatment, notable
after d2 post treatment, but is unaffected by serial passaging.
- Formin1 gene expression demonstrates a tendency to increase following
serial passaging and is elevated by 10µM Bpv(Hopic) treatment, most
notable at d2 and d3 post treatment.
- Formin2 gene expression is unaffected by 10µM Bpv(Hopic) treatment,
but it is significantly increased following serial passaging of myoblasts.
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6.6. DISCUSSION
6.6.1. SERIALLY PASSAGED C2C12 MYOBLASTS (P50)
DEMONSTRATE IMPAIRED CAPACITY TO DIFFERENTIATE
COMPARED TO LOW PASSAGE CELLS (P5), WHICH IS FURTHER
REDUCED BY TREATMENT WITH 10µM BPV(HOPIC).
Previously, reduced differentiation potential was demonstrated by serial
passaging (Chapter 4) and following 10µM Bpv(Hopic) treatment (Chapter 5).
Here, it was demonstrated that inhibition of differentiation was even larger when
serially passaged myoblasts were treated with Bpv(Hopic), as compared to any of
these treatments alone, demonstrated by reduced levels of CK activity and lower
expression of MyoD and Myogenin genes. It must be noted that the reduction of
MyoD gene expression after DM addition is not what normally occurs. This is
probably due to the high confluency of cells at which differentiation was initiated,
which may have triggered high expression of MyoD at d0, committing cells to the
myogenic lineage before DM was added to the cells. Never the less, serial
passaging and Bpv(Hopic) treatment significantly reduced the expression levels of
MyoD, as compared to controls. Sharples et al. demonstrated that serially
passaged myoblasts (P20), at early time points upon transfer from GM to DM,
continue to progress through the cell cycle, with greater percentage of cells in S
and G2 phases (Sharples et al., 2011).  This, together with the reported decrease
in phosphorylation of AKT and decreased IGF-1 transcript levels in DM treated
myoblasts, could explain the reduced differentiation of serially passaged
myoblasts. It was here demonstrated that 20h following transfer to DM, serially
passaged cells no longer have higher percentage of cells in G2/S phases, as
compared to low passage of myoblasts. At the same time point, however, both p5
and p50 cells treated with 10µM Bpv(Hopic) had a significantly greater
percentage of cells in G2/S-phases. This could, at least partly, explain why
differentiation is further inhibited by addition of Bpv(Hopic) to serially passaged
cells, which even at 20hrs post addition of DM, caused myoblasts to continue to
progress through the cell cycle and thus further delayed their differentiation. Thus,
myoblast fusion into myotubes is reduced by serial passaging, but completely
blocked/delayed in the presence of 10µM Bpv(Hopic).
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6.6.2. DIFFERENTIAL EXPRESSION OF SPIRE AND FORMIN GENES
IN RESPONSE TO BPV(HOPIC) AND SERIAL PASSAGING
Using the expression of MyoD and Myogenin genes as a reference for how the
differentiation of myoblasts is affected in response to Bpv(Hopic) treatment, serial
passaging and the combination of both, it was next addressed how these stimuli
influenced the expression of Spire and Formin genes. As inhibition of myoblast
differentiation and fusion by both inhibitor treatment and serial passaging was
observed, it was hypothesised that if any of the Spire or Formin genes were
involved in the process of myoblast fusion, their expression could also be altered.
With a Ct value of 25 +/-0.49, Spire1 gene was expressed in C2C12 cells. Its
expression peaked at day1 following addition of DM, despite this increase being
smaller, as compared to Myogenin, and similar to MyoD and Myogenin,
decreased at day2 and day3. Expression of Spire1 gene seemed to be similar to
that of MyoD and Myogenin in its tendency to reduce its expression after
differentiation and fusion were inhibited by Bpv(Hopic) treatment and serial
passaging. These data suggest that Spire1 might be involved in the process of
myotube formation and promises to be an interesting target for further research
into its function in skeletal muscle. On the other hand, Spire2 gene expression was
lower in C2C12 cells, with a Ct value of 32.33 +/-0.21. Interestingly, its
expression increased 4-fold, as fusion progressed, suggesting its potential
involvement in the process, although not clear whether it is involved in its
regulation, or whether its expression is influenced by fusion/differentiation. The
link between Spire2 expression and fusion/differentiation of myoblasts was
supported by observations that its expression was significantly inhibited following
10µM Bpv(Hopic) treatment. However, no difference in Spire2 expression was
observed between p5 and p50 myoblasts. Thus, it seems that Spire2  expression is
not impacted by changes in basal differentiation, but is reduced globally by 10µM
Bpv(Hopic), suggesting it may display delayed suppression as a consequence of
global phosphotyrosine activation, independent of differentiation or fusion.
Formin1 gene was also expressed in C2C12 cells, with a Ct value of 26.8 +/-0.12.
Interestingly, it demonstrated an inverse expression trend in response to serial
passaging and 10µM Bpv(Hopic) treatment, as compared to what was previously
observed with MyoD, Myogenin and Spire genes. The expression of Formin1
seemed to be reduced with progression of differentiation with p5, but not with p50
myoblasts, and inhibition of differentiation and myoblast fusion was associated
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with increases in its expression. Both Bpv(Hopic) and serial passaging, negatively
affecting myoblast fusion, seemed to result in increases of Formin1 expression,
although this response was delayed and was obvious after day 2 of DM addition.
This suggested that Formin1 might be an interesting target for further research.
Finally, investigating the expression of Formin2 demonstrated that this gene was
very weakly expressed in p5 myoblasts, with Ct value of above 35, however,
interestingly, its expression in p50 myoblasts was significantly higher compared
to that in p5 myoblasts. Bpv(Hopic) treatment caused no changes in expression
pattern of Formin2. Its almost undetectable expression levels and no changes with
time or following Bpv(Hopic) question its involvement in myogenesis, although
its considerably higher expression in serially passaged cells might be of interest
for further studies into its potential functions in skeletal muscle ageing.
Despite reported alterations in expression of Spire and Formin genes with
Bpv(Hopic), serial passaging, or both, the function of these genes in skeletal
muscle remains unknown.  However, knowing that they are expressed in
myoblasts and that their expression differs in response to factors affecting
myoblast fusion, holds a promise that they might be involved in regulating this
process. Of particular interest would be Spire1 and Formin1 genes, whose
expression is inversely affected by inhibition of myoblast fusion with both serial
passaging and Bpv(Hopic). Despite Spire1 and Spire2 proteins being able to
interact with both Formin1 and Formin2 proteins, it is not known whether all of
these associations are indeed required for their functions in vivo, and in particular
in skeletal muscle. Thus, further studies on protein level are required to elucidate
the functions of Spires and Formins in skeletal muscle. Considering the
involvement of these genes in endocytic recycling and intracellular trafficking
(Kerkhoff et al., 2001, Kerkhoff, 2010, Morel et al., 2009, Schuh, 2011), which
are also associated with myoblast fusion and migration (Doherty et al., 2008,
Rochlin et al., 2010, Caswell and Norman, 2006, Pellinen and Ivaska, 2006), it
was suggested that these genes might provide to be interesting targets for future
research into their function in skeletal muscle.
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6.6.3. CONCLUSIONS
Overall, these studies demonstrate that Spire1, Spire2 and Formin1 genes are
expressed in C2C12 myoblasts and that their expression is altered by factors
influencing myoblast fusion. To our knowledge, these are the first data to
demonstrate the expression of these genes in skeletal muscle myoblasts, but their
particular function remains unknown. It was suggested that these genes are
involved in myoblast fusion and migration via their involvement in vesicle
transport. Of particular interest is the inverse expression of Spire1 and Formin1
genes in response to inhibition of myoblast differentiation and fusion by
Bpv(Hopic) and serial passaging. Further studies needed to confirm their
expression at a protein level. In addition, it would be interesting to investigate
how silencing and overexpression of these genes would affect myogenic precursor
cells and their differentiation potential. These studies might reveal in more detail
the significance of the actin cytoskeleton in regulating myogenesis and improve
our knowledge for muscle development and regeneration, which can ultimately
lead to the development of therapies aimed at treating loss of muscle mass
associated with injuries, degenerative disorders and ageing.
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CHAPTER 7
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7. DISCUSSION AND FUTURE DIRECTIONS
7.1. AIMS OF THESIS
Muscle loss can occur due to a variety of conditions, including genetic disorders,
traumatic injuries, cancer or ageing, which can ultimately lead to weakness, loss
of functional dependence or even death. Improving muscle regeneration for
conditions leading to muscle loss is an important area of research, which can
improve the lifestyle of millions of people worldwide and reduce the socio-
economic burden associated with these symptoms. The studies presented in this
thesis were performed in an attempt to elucidate in more details the cellular and
molecular regulators of skeletal muscle myogenesis and regeneration. Skeletal
muscle progenitor cells, satellite cells and their progeny of myoblasts, are key
contributors to the process of muscle regeneration with their ability to migrate to
the site of muscle damage, proliferate and and fuse with damaged muscle fibres,
thus promoting repair (reviewed in (Charge and Rudnicki, 2004, Hawke and
Garry, 2001, Turner and Badylak, 2011)). Therefore, in order to develop or
improve therapeutic approaches aimed at restoring muscle mass and to facilitate
the muscle regeneration process, in depth knowledge into the regulators of muscle
progenitor cell functions is required.
Migration of muscle progenitors is a necessary step in the process of muscle
regeneration, in order for these cells to reach the site of muscle damage (Hawke
and Garry, 2001, Watt et al., 1994). Further, migration is required for the
alignment of myoblasts prior to their subsequent fusion into myotubes (Louis et
al., 2008, Rochlin et al., 2010). Myoblast migration has also been reported to be
one of the limiting steps in proposed therapies of muscular dystrophies, which
rely on the introduction of donor myoblasts, in order to repair dystrophic muscles
(Fan et al., 1996, Gussoni et al., 1997, Moens et al., 1996, Skuk et al., 2004,
Smythe et al., 2001). Thus, improving our knowledge into the field of myoblast
migration might not only be important for a better understanding of myogenesis
and skeletal muscle regeneration, but might also have therapeutic applications. As
discussed, external factors, such as growth factors secreted by infiltrating
inflammatory cells or damaged skeletal muscle itself, are implicated in regulating
myoblast migration. Internal factors, in particular signalling pathways, are also
important for regulating and coordinating the migratory response of myogenic
cells in response to the milieu of external factors. Many studies have focused on
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investigating the effects of single factors on myoblast migration, but the
complexity of interactions between different factors also needs to be considered,
in both physiological and pathological conditions. Furthermore, muscle
myogenesis and regeneration each comprises a series of events, which need to be
strictly coordinated to enable the whole process. Extensive research is still
required in order to reveal in full, the complexity of these interactions and how
their modulation will culminate in developing therapies for conditions leading to
muscle loss. Here, an attempt was made to contribute to this knowledge, by
exploring the external and internal regulation of myoblast migration. The first aim
was to explore in vitro the contribution of factors secreted by myogenic cells
themselves by investigating the effect of myotube CM on the migration of
myoblasts. A model of serially passaged C2C12 myoblasts was then be used to
study how multiple divisions of these cells would affect their migration capacity
and whether this could also have impact on their potential ability to secrete factors
inducing migration of other myogenic cells. Further, CM inducing migration,
enriched with variety of factors, was used as a model to reveal the involvement of
biochemical signalling pathways, such as PI3K/AKT and MAPK/ERK, in
myoblast migration. The activation of these signalling pathways by phospho-
tyrosine phosphatase inhibitor Bpv(Hopic) was assessed in the context of
myoblast migration. The importance of these pathways, along with the FAK
signalling pathway, were explored by selective inhibition of each pathway under
conditions when the other pathways were still activated, in an attempt to
investigate possible redundancy in intracellular signalling, thus addressing the
importance of studying the complexity of factors influencing myoblast migration.
Finally, as fusion and migration processes often share similar regulators, the
possible involvement of 4 genes involved in actin nucleation was investigated and
their expression studied in response to conditions influencing myoblast fusion.
7.2. CONDITIONED MEDIA AND THE IMPORTANCE OF SECRETED
FACTORS FOR MYOBLAST MIGRATION
Migration of myogenic cells is regulated by a variety of extracellular factors.
Growth factors and cytokines, which can regulate various processes of muscle
progenitors, including migration, can both be secreted from inflammatory cells or
damaged muscle (Bischoff, 1986, Chen and Quinn, 1992, Merly et al., 1999,
Ranzato et al., 2009, Tidball, 2005). In vitro studies have investigated and
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confirmed that many soluble factors are able to induce migration of satellite cells
or myoblasts, including HGF, IL-4, TGFβ, TNFα, RANTES, PDGF-A, PDGF-B,
FGF, IGF-I (Amano et al., 2002, Bischoff, 1997, Corti et al., 2001, Lafreniere et
al., 2004, Lafreniere et al., 2006, Torrente et al., 2003). However, it must be
considered that the balance and concentration of soluble factors might be
particularly important for the regulation of muscle regeneration in vivo, including
the migration of myogenic cells. For example, studies from our group have
demonstrated that the combination of low doses of IGF-I and TNFα, is able to
induce apoptosis of myoblasts, which does not occur in the presence of either of
these two factors alone at equivalent concentrations (Saini et al., 2008). Growth
factors, such as HGF, TGFβ and PDGF, are known to induce migration of
myogenic cells, but this response is reduced with increasing growth factor
concentrations (Bischoff, 1997, De Donatis et al., 2008). It is therefore, important
to reveal the presence and source of soluble factors in both physiological and
pathological conditions, the combination of which, may influence muscel repair
and hypertrophy. Here, an attempt was made to reveal the contribution of secreted
soluble factors by myogenic cells themselves. It was demonstrated that SF media
conditioned by myotubes is capable of inducing migration of myoblasts in a
wound healing model and chemotaxis in transwell insert assays. Recent articles,
published in the course of this thesis work, demonstrated that myoblasts are
capable of upregulating the expression of many chemokines, with an expression
peak at the time of myoblast fusion and myotube formation (Griffin et al., 2009,
Griffin et al., 2010). They have further demonstrated that media conditioned by
myoblasts were capable of inducing migration of myocytes. This, together with
our data confirms the contribution of myogenic cells in different stages of
differentiation in the release of factors stimulating migration of myoblasts, and
most likely of other cell types and cellular processes as well. Further, the media
conditioned by myotubes, starved in SF media was more potent at inducing
migration, as compared to media conditioned by mechanically damaged/crushed
myotubes. Thus, although the question remains regarding the specific factors
released and their relative concentrations in both media, it is safe to suggest that
the soluble factor milieu is different when mechanical damage is present, as
opposed to a situation when myotubes are not mechanically damaged. It is
possible that starved myotubes, as the ones used in our model, are releasing
factors that are capable of stimulating myoblast migration, which can ultimately
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lead to recruitment of more myonuclei, which can contribute key proteins
enabling repair. In fact, numerous articles have demonstrated that diseased or
regenerating muscles are capable of increasing the expression of cyotkines,
growth factors and chemokines, along with their receptors (Civatte et al., 2005,
De Rossi et al., 2000, Griffin et al., 2010, Hirata et al., 2003, Peterson and Pizza,
2009, Porter et al., 2003, Sachidanandan et al., 2002, Summan et al., 2003,
Warren et al., 2004). Many of these factors will not only affect muscle
regeneration by direct effect on myogenic cells, but also indirectly by triggering
inflammatory responses and the recruitment of inflammatory cells. Except
migration, many of these factors are likely to be regulating other myogenic cell
processes as well, such as proliferation and survival (Nedachi et al., 2009,
Vasyutina et al., 2005, Yahiaoui et al., 2008). These findings were substantiated
by further demonstrating that myotubes, in the absence of exogenous
inflammatory responses, can release factors directly influencing the migration of
myoblasts. This model was further used to examine the signalling pathways
involved in this process.
7.3. THE IMPACT OF SERIAL PASSAGING ON MYOBLAST
MIGRATION AND SECRETOME - IMPLICATIONS FOR AGEING?
Only recently, has research been undertaken, investigating in more detail the
secretome of skeletal muscle cells (Chan et al., 2011, Cui et al., 2009, Griffin et
al., 2010, Henningsen et al., 2010, Henningsen et al., 2011). Thus, a better
understanding can be gained of the contribution of soluble factors released by
myogenic cells themselves during both embryonic and adult myogenesis.
Critically, different stages of myogenesis or different conditions might trigger the
release of different factors by muscle cells. For example, the expression of
chemokines can increase in contracting myotubes in vitro or at the time of
myocyte fusion, while being reduced at later time points (Griffin et al., 2009,
Griffin et al., 2010, Nedachi et al., 2009). In addition, pro-inflammatory cytokines
are able to trigger the expression of myogenic regualtory factors, which are not
constitutively expressed (De Rossi et al., 2000). Together these studies underpin
the importance of considering the release of factors under different experimental
situations and how this affects the various aspects of muscle regeneration. As it
was demonstrated, serum-starved, morphologically atrophying myotubes are
capable of releasing factors inducing myoblast migration and it was therefore
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asked whether the same model could be used to find potential differences in the
secretions between the low passage of myogenic cells used previously vs
myoblasts subjected to multiple divisions. The model of serially passaged
myoblasts provides a model of atrophy seen in elderly skeletal muscle, as
described by Sharples et al (Sharples et al., 2011). Serially passaged myoblasts
demonstrate decreased differentiation capacity, reduction in IGF-I expression and
reduced phosphorylation of Akt, and, as confirmed in this thesis, is also associated
with reduced CK activity and lower gene expression levels of myogenic
regulatory factors, such as MyoD and Myogenin. However, the migration of
serially passaged myogenic cells has not been examined. It was here assessed how
migration of these serially passaged myoblasts compares to that of control low
passage myoblasts and assessed whether there is a difference in the effect, of
soluble factors released by both passages, on migration of myoblasts. CM from p5
myotubes, as previously shown to induce migration, was used with wound healing
assays to compare between the migration capacity of p5 and p50 myoblasts. It
was demonstrated that p50 myoblasts were capable of migrating greater distances,
as compared to p5 myoblasts under these conditions, and increased migration was
associated with differences in the activation of signalling pathways, such as
PI3K/AKT and MAPK/ERK. Interestingly, significant decreases were found in
the migration of cells cultured in media conditioned by high passage vs low
passage of myotubes. These results propose different internal or external
regulation of migration in myoblasts that have undergone multiple divisions,
which might have implications in the field of sarcopenia. However, the increased
migration distance of p50 myoblasts vs p5 myoblasts is contrary to what was
expected, suggests that given appropriate cues, the older cells are fully capable of
extensive migration, potentially at the expense of fusion. It is known that
myogenic cells from aged skeletal muscle respond differently to the extracellular
environment, as compared to cell isolated from young muscle, with reports
suggesting for a reduced functionality of myogenic cells isolated from old muscle
(Conboy et al., 2005, Dumke and Lees, 2011, Jump et al., 2009, Lees et al., 2009,
Mezzogiorno et al., 1993). Our results are in contrast with previous reports that
have demonstrated a reduced migration capacity of myoblasts isolated from old vs
young animals (Dumke and Lees, 2011, Siriett et al., 2007). One would expect a
reduced, rather than increased migration with serially passaged myoblasts, which
have previously been shown to mimic the molecular regulation of elderly skeletal
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muscle (Sharples et al., 2011). A possible explanation is in the response of these
cells to paracrine signals released from the muscle environment. Of course, it
should also be considered that an in vitro model of skeletal muscle ageing might
not be the most appropriate one and differences with other models would be
present. It was demonstrated that CM of differentiated myotubes from young mice
or from saline extracts of muscle from young mice, are capable of greatly
inducing proliferation of aged satellite cells, while CM from old muscle was
reducing the proliferation of satellite cells isolated from both young and old
muscle (Mezzogiorno et al., 1993). It was reported that myotube CM from serially
passaged myotubes reduces the migration capacity of myoblasts, as compared to
myotube CM from low passage myoblasts. It is possible that the serially passaged
myoblasts are responsive to certain paracrine factors, but not other factors, such as
serum or mitogenic factors from immune cells (Dumke and Lees, 2011, Siriett et
al., 2007). Indeed, preliminary observation of migration behaviour between p5
and p50 myoblasts in the presence of GM (10% FBS DMEM) in wound healing
assay, was visually not different between both passages (results not shown),
which requires further investigation. Further studies are also required to reveal
potential differences in expression of cell surface receptors between p5 and p50
cells. Our data demonstrate that soluble factors released from myotubes are
capable of regulating myoblast migration, suggestive of the importance of
paracrine mechanisms in the process of muscle regeneration, and that the
paracrine mechanisms regulating the migration of myogenic cells are altered
following multiple divisions of myoblasts, suggestive of implications in the
process of ageing and sarcopenia. Key questions, warranting further investigation.
7.4. SIGNALLING PATHWAYS REGULATING MYOBLAST
MIGRATION - CONTRIBUTION OF PI3K/AKT, MAPK/ERK AND FAK
PATHWAYS
Following investigation of the impact of soluble factors released by myogenic
cells on myoblast migration, the role of intracellular regulators was examined.
PI3K/AKT and MAPK/ERK pathways are implicated in regulating migration of
various cell types, including skeletal muscle cells, although results from different
groups have been divergent. Some have reported that PI3K/AKT is required for
myogenic cell migration (Kawamura et al., 2004, Kim et al., 2011, Al-Shanti et
al., 2011, Ranzato et al., 2009), while others have reported it is not (Suzuki et al.,
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2000, Leloup et al., 2007). Similarly, some studies have reported that
MAPK/ERK pathway is required for myogenic cell migration (Leloup et al.,
2007, Al-Shanti et al., 2011), while others suggest that it is not required (Ranzato
et al., 2009, Suzuki et al., 2000). These discrepancies might be due to
investigating myoblast migration in different models, conditions or migration
inducers. Thus, the aim was to examine whether PI3K/AKT and MAPK/ERK
were required for myoblast migration induced by factors released from myotubes.
It was reported that both of these pathways were activated in response to CM.
Using LY294002 and UO126 for inhibiting PI3K/AKT and MAPK/ERK
pathways, respectively, it was demonstrated that both of these pathways were
required for myoblast migration induced by myotube CM. It was further
demonstrated that the increased migration of p50 myoblasts in response to p5 CM
was associated with elevated activity of MAPK/ERK and, to a lesser extend
PI3K/AKT.
Myotube CM induced migration was associated with activated PI3K/AKT and
MAPK/ERK pathways, while their inhibition led to a reduction in myoblast
migration. In addition, treatment of myoblasts with Bpv(Hopic), a phospho-
tyrsoine phosphatase and PTEN inhibitor, led to further activation of PI3K/AKT
and MAPK/ERK signalling, which was associated with further increases in
myoblast migration. The activation of these two pathways by Bpv(Hopic) can be
explained by previously reported effects of PTEN on PI3K and MAPK signalling
and their involvement in regulating migration (Cully et al., 2006, Dey et al., 2008,
Gu et al., 1998, Gu et al., 1999, Leslie et al., 2007, Raftopoulou et al., 2004,
Yamada and Araki, 2001, Zhao, 2007). The individual inhibition of each pathway
by LY294002 or UO126 led to an abolition of the effect of Bpv(Hopic) on
migration, while not affecting the activity of the other pathway. Very similar
results were reported in epithelial cells in an article published during the write up
period of this thesis (Mihai et al., 2012). Mihai et al. demonstrated an increase in
migration of epithelial cells, following incubation with the PTEN inhibitor
Bpv(Phen), which was in conjuction with activation of the Akt and ERK
signalling pathways. In the same article, it was reported that inhibition of these
pathways resulted in reduced migration to levels of the untreated control group.
PTEN inhibition resulted in biomechanical properties, such as cell stiffness,
mediated by both Akt and ERK pathways. The importance of biomechanical
properties, for cell migration is due to its association with lamellipodia ruffling,
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focal adhesions and cell contractility (Mihai et al., 2012, Pelham and Wang, 1997,
Riveline et al., 2001). As an adherent cell type, it is entirely possible that skeletal
muscle myoblasts would be regulated in a similar fashion and that the induced
migration by treatment with Bpv(Hopic) would exert similar alterations on
biomechanical properties of myoblasts. Further research would be needed to
verify this.
It was demonstrated that PI3K/AKT and MAPK/ERK pathways were required
for myoblast migration in response to CM, as well as for the Bpv(Hopic)-induced
increase in myoblast migration. The action of BpV compounds in other cell types
has also been reported to increase cell migration (Lai et al., 2007, Mihai et al.,
2012, Zhao, 2007) and PTEN regulation of cell migration is well known, although
not investigated in skeletal muscle (Dasari et al., 2010, Liliental et al., 2000,
Tamura et al., 1998). PTEN’s pleiotropic effect on different signalling pathways
and the phospho-tyrosine phosphatase activity of BpV compounds was suggestive
of possible activation of other signalling pathways, besides PI3K/AKT and
MAPK/ERK, which could contribute to the enhanced migration capacity. Another
signalling pathway, which has been reported to be downstream of PTEN, is
FAK/Src (Gu et al., 1999). FAK has a known effect on adhesion dynamics
(Hanks et al., 2003, Schlaepfer and Mitra, 2004, Schlaepfer et al., 2004) and is
also known as a regulator of cell migration (Cary et al., 1996, Desai et al., 2009,
Sieg et al., 1999, Slack-Davis et al., 2007). The Bpv(Hopic)-induced effect on
cell adhesion and the reported cell shrinking/rounding, possibly associated with
loss of contacts with the substratum, was a reason to investigate whether FAK
pathway is associated with the Bpv-induced myoblast migration. Low (1µM)
concentrations of Bpv(Hopic), capable of inducing myoblast migration, did not
lead to a global activation of pFAK on tyr397, while increasing the Bpv(Hopic)
concentration, in conjunction with the increase of phosphorylated tyrosine
residues and decreased specificity to PTEN, also resulted in increased pFAK
phosphorylation on tyr397. As suggested by Mihai et al. (Mihai et al., 2012), it is
possible that the effect of Bpv of FAK is exerted on migrating cells only.
However, if migration was compared between 2µM and 1µM Bpv(Hopic), it was
not visually different - both induced an approximate 40% increase, as compared to
control CM. This could be due either to limitations of the wound healing assay, or
possibly to the “saturation” of the signalling pathways or their downstream targets
in response to higher doses Bpv(Hopic). It is also possible that the lack of
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specificity of PTEN at greater concentrations affects other signalling pathways or
targets, acting negatively on cell migration. The delay caused by cell shrinking
must also be considered. In addition, it was observed that pFAK phosphorylation
levels were not vsisually elevated in myoblasts treated with GM or in p50 vs p5
myoblasts treated with CM, despite migration levels being higher (results not
shown). Thus, FAK could infact be activated in migrating cells, even if it is not
globally altered, but it is questionable to what extend it actually contributes to the
increases in myoblast migration.
FAK activation is, however required for myoblast migration, as shown by its
inhibition using the PF-228 inhibitor. Reductions of pFAK (tyr397) activation
levels by PF-228 resulted in decreased migration, induced by CM and
Bpv(Hopic). Strikingly, myoblast migration capacity seemed to be following the
pFAK activation levels and appeared independent on the PI3K/AKT and
MAPK/ERK levels. It was proposed that FAK inhibition might have direct effects
on migrating muscle cells.
Overall, these data suggest that requirement of PI3K/AKT, MAPK/ERK and
FAK pathways for myoblast migration. The possible redundancy between these
and other signalling pathways is yet to be examined in more detail, but our
observations suggest that even if certain redundancy exists between signalling
pathways regulating myoblast migration, each pathway is required for optimal
migration to take place and loss of one pathway cannot be compensated for by
activation of other pathways. Further investigation is required for elucidating in
more detail the coordination between different signalling pathways in regulating
myoblast migration.
7.5. CHANGES IN SIGNALLING PATHWAYS MIGHT EXERT EFFECTS
NOT ONLY ON MYOGENIC MIGRATION, BUT ALSO ON PROCESSES
SUCH AS CELL DEATH, PROLIFERATION OR DIFFERENTIATION
In addition to the examination of myoblast migration, the levels of cell death
were also quantified. Increased levels of cell death would contribute to a reduced
number of cells available for migration in the wound healing model and this could
lead to misleading results. It was found that cell death levels were not greatly
increased under most experimental conditions, with the exception of when
myoblasts were treated with SF media. The lack of growth factors and the low
levels of PI3K/AKT activation in myoblasts treated with SF media resulted in
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approximately 10% cell death and this could, in part, indeed contribute to the
reduced number of cells migrating into the wound. However, under other
experimental conditions, levels of death in cells treated with inhibitors hardly
exceeded 4%, with no big differences between conditions and it is therefore
unlikely that this contributed to significant differences in cell migration levels. In
fact, most death events were detected hours after migration was initiated and
frequently cell death was observed suddenly in motile cells, with these cells
showing no visible inhibition of migration speed beforehand. These observations,
along with the low percentage of dying cells, suggests that cell death would not
significantly effect the migration of myoblasts in response to the different
conditions examined. The slight increases in cell death levels observed were
associated with decreased levels of pAKT, a well known regulator of cell survival
(Brunet et al., 1999, Datta et al., 1997, Matsui et al., 2003). This could explain
also the slight reductions in cell death levels following PTEN inhibition, which
leads to activation of AKT signalling and promotes cell survival (Sun et al., 1999,
Yamada and Araki, 2001). Interestingly, not even small increases in cell death
were observed when PI3K/AKT signalling was inhibited with LY294002 in the
presence of Bpv(Hopic). Possibly, the induction of apoptosis by the inhibition of
the PI3K/AKT was compensated for by the effect of Bpv(Hopic) via its effect on
other signalling pathways, which were not examined. The potential crosstalk
between PI3K/AKT and JNK pathways, for example, is implicated in apoptosis
(Zhang et al., 2007) indeed the JNK pathway, which might also be affected has
been implicated in both pro- and anti-apoptotic roles (possibly in a cell type and
stimulus dependent manner, as discussed in (Liu and Lin, 2005)). This, however,
warrants further investigation and is out of the scope of this thesis.
As this thesis focused on investigating the migration of myogenic cells, other
events, such as proliferation and differentiation were not examined in detail.
PI3K/AKT and MAPK/ERK pathways were demonstrated to be required for
myoblast migration, but in addition it would be important to consider how these
signalling pathways affect other processes, such as proliferation and
differentiation. PI3K/AKT pathway is known to be necessary for myoblast
differentiation (Foulstone et al., 2004, Kaliman et al., 1996, Li et al., 2000). The
IGF-I/Akt pathway is central in muscle hypertrophy by its association with
downstream targets, such as mTOR and GSK-3beta, involved in protein synthesis,
and transcription factors of the FoxO family, involved in protein degradation
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(reviewed in (Saini et al., 2006, Schiaffino and Mammucari, 2011). On the other
hand, the MAPK pathway is a key regulator of myoblast proliferation (Coolican et
al., 1997, Foulstone et al., 2004, Johnson and Lapadat, 2002). The balance of
these signalling pathways is crucial for the coordination of skeletal muscle
myogenesis. It was demonstrated that inhibition of MAPK/ERK pathway,
regulating myoblast proliferation, by PD98059 resulted in increased
differentiation (Al-Shanti and Stewart, 2008, Coolican et al., 1997). Similarly,
FAK has also been shown to be involved in regulating the cell cycle of myoblast
and their differentiation and fusion into myotubes (Clemente et al., 2005, Quach
et al., 2009). The temporal regulation, coordination and switch between different
processes of myogenesis would involve a complex combination of extracellular
and intracellular cues and might be context dependent. Thus, although activation
of PI3K/AKT signalling is linked to increased hypertrophy and myotube
formation (Lai et al., 2004, Morissette et al., 2009) and the PI3K/AKT signalling
was demonstrated to be activated by 10µM Bpv(Hopic), the treatment of
myoblasts with 10µM Bpv(Hopic) in the presence of DM resulted in reduced
myoblast differentiation, as compared to untreated controls. This was shown to be
a result of the activation of NF-kB activity, upregulation of cyclin D1 expression
and decreased differentiation due to inability of cells to withdraw from the cell
cycle (Castaldi et al., 2007). Similarly, despite DM inducing more consistent
activation of PI3K/AKT and MAPK/ERK signalling, the migration of myoblasts
with DM in a wound healing assay was not higher than migration induced by CM.
This was associated with a decreased ability of CM to induce Myogenin
expression, as compared to DM. Therefore, it is important to reveal how the
activation or inhibition of signalling pathways alters the cellular responses, such
as migration, proliferation or differentiation, as this will have implications for
future therapeutic interventions. However, the activity of these signalling
pathways should also be considered in the context of the extracellular
environment and the potential crosstalk with or activation of other signalling
pathways, which can override their activity and trigger distinct cellular responses.
7.6. POTENTIAL THERAPEUTIC APPLICATIONS FOR
BISPEROXOVANADIUM COMPOUNDS IN MUSCLE REGENERATION
Muscular dystrophies are a group of muscle diseases, characterised by gene
mutation and muscle protein defects, leading to progressive skeletal muscle
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weakness, reduced locomotion and overall reduced quality of life or shortened life
span. The most common form, Duchenne muscular dystrophy, is a condition
caused by mutation in the dystrophin gene, which participates in maintaining the
integrity of a muscle cell, protecting the muscle fibres from injury when they
contract and relax (Blake et al., 2002, Petrof, 2002). Missing/mutated dystrophin
leads to vulnerability and damage of muscle fibres during contraction and
constant damage-repair cycles, ultimately lead to muscle loss, to wheelchair
dependency and in many patients, death due to respiratory failure between the
ages of 17 and 30 (reviews: (Cossu and Sampaolesi, 2007, Emery, 2002, Nowak
and Davies, 2004, Quattrocelli et al., 2010)). Cell therapy, such as myoblast
transplantation, has been investigated as a promising approach to deliver normal
variants of the gene to dystrophic muscles and to restore at least partially the
normal musculature and function. This strategy can also potentially be applied to
treating loss of muscle tissue after traumas (review: (Turner and Badylak, 2011)).
Although significant improvement of muscle regeneration and functionality was
achieved after cell therapy in mdx mice (Morgan et al., 1990, Partridge et al.,
1989), clinical trials in humans were far less successful (Mendell et al., 1995,
Tremblay et al., 1993). Three main problems were associated with the low
success: reduced survival of transplanted cells, limited spreading and migration of
transplanted cells and immune rejection (Fan et al., 1996, Gussoni et al., 1997,
Moens et al., 1996, Skuk et al., 2004, Smythe et al., 2001).
The significance of migration for the success of myoblast transfer therapy has
recently been questioned by articles published from the Tremblay group
(Lafreniere et al., 2009, Skuk et al., 2011). Lafreniere et al. demonstrated that
coinjection of bFGF and IGF-I was able to improve migration of myogenic cells
in nonhuman primates, but this did not improve the cell transplantation success, as
myoblasts did not fuse with undamaged fibres, but only with fibres injured in the
injection trajectories (Lafreniere et al., 2009). In addition, Skuk et al.
demonstrated using monkey models that transplanted myoblasts were capable of
migrating several millimetres, but only fused with regenerating, but not
undamaged myofibres (Skuk et al., 2011). Due to ethical reasons, dystrophic
primates do not exist and this study could not examine myoblast migration in a
model of dystrophic muscle, when more significant muscle damage would occur.
These studies argue that even if migration is improved, no improved
transplantation success could be achieved until donor myoblasts are able to fuse
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with undamaged myofibres. As discussed by Lafreneire et al., this could
potentially be achieved by either harming muscle fibres, or by stimulating fibre
hypertrophy, which would recruit more of the transplanted myoblasts (Lafreniere
et al., 2009). However, one would expect that in dystrophic muscles, where
extensive muscle damage occurs, recruitment of myoblasts would be enhanced.
Overall, the above mentioned findings do not prove that improving myoblast
migration cannot contribute to a better success of cell therapies, but rather
underlie the importance of the combination of factors, on which these therapeutic
strategies depend. Improving the migration of transplanted myoblasts could
indeed lead to an improved transplantation success, but it would need to be
combined with other approaches aimed at improving the fusion of these myoblasts
with muscle fibres. Improving the migration of myoblasts would also need to be
considered along with their ability to degrade and migrate through extracellular
matrix (El Fahime et al., 2000).
The effect of phospho-tyrosine phosphatase inhibitor Bpv(Hopic) on the
migration of myoblasts was examined and it was demonstrated that it is capable of
increasing their motility in a wound healing assay, in response to factors released
from starved myotubes. The application of BpV compounds and inhibition of
PTEN for inducing cell migration has previously been considered in the context
of lung pathogenesis and potential therapies for lung injuries, with PTEN
inhibition enhancing epithelial wound healing (Lai et al., 2007, Mihai et al.,
2012). In skeletal muscle, Castaldi et al. demonstrated that high concentrations
(10µM) of BpV triggered multi potency in myoblasts and inhibited their
differentiation. However, it enhanced the ability of these cells, transplanted intra-
arterially in alpha-sarcoglycan-deficient dystrophic mice, to circulate, cross vessel
walls and contribute to muscle regeneration, despite showing a delay in the
activation of myogenic phenotype (Castaldi et al., 2007). The effect of BpV on
migration, however, was not investigated. It was here demonstrated that lower
concentrations of Bpv(Hopic) are capable of increasing myoblast migration,
without significantly affecting the ability of myoblasts to differentiate and fuse
into myotubes. It is proposed that this compound and the inhibition of PTEN
might be considered as a potential tool to enhance the migration of grafted
myoblasts and improve transplantation success. It is suggested that other agents or
strategies to inhibit PTEN in transplanted myogenic cells might provide ways for
improving their spreading after muscle injection. It must be considered, however,
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that a persistent activation of PTEN would be unwanted in terms of the
tumorigenic phenotype it triggers (Stiles et al., 2002). A temporal inactivation of
PTEN in donor myoblasts, however, would be an interesting phenomenon to
examine in vivo. A temporary period of increased migration, proliferation and
survival of myogenic precursors following muscle injury would certainly be a
promising possibility for enhanced muscle repair. However, for practical reasons
this might be a task hard to accomplish with tools other than local or systemic
delivery of factors. And as muscle repair involves the coordinated activities of
several cell types, it is important to consider the effect of delivered compounds
not only on muscle cells, but on other cell types as well. A local delivery of a
compound acting as a PTEN inhibitor might exert negative effects on muscle
repair, as PTEN is known to inhibit myofibroblast differentiation and its
inhibition promotes fibrosis (White et al., 2006). Excessive fibrosis and scar
formation is associated with reduced motile and contractile functions of the
muscle and is a pathological feature observed in patients suffering with DMD
(Mann et al., 2011, Zhou and Lu, 2010). Therefore, the mechanisms of delivering
agents aimed at improving the migration of myogenic cells must also be
considered in the context of their effects on other cell processes, as well as their
general effect on the organ or organism, which is being “treated”. It is suggested
that Bpv(Hopic) treatment of myoblasts could provide a useful tool for enhancing
the migration of muscle injected donor myoblasts and propose further studies to
test this hypothesis in vivo.  However, any strategies aimed at enhancing donor
myoblast migration, in order to improve their transplantation success in future,
would need to be considered in combination with other strategies, such as
improving the fusion of myoblasts with muscle fibres.
7.7. SPIRE AND FORMIN GENES ARE EXPRESSED IN MYOBLASTS -
POSSIBLE IMPLICATIONS FOR MYOBLAST FUSION AND
MIGRATION
Improving our knowledge of both myoblast migration and fusion could lead to
the development of therapies for conditions, associated with loss of muscle mass,
such as DMD.  Despite being considered as separate events, myoblast migration
and fusion are often affected by the same regulators (Becciolini et al., 2006,
Bondesen et al., 2007, Donati et al., 2005, Griffin et al., 2009, Lafreniere et al.,
2006, Louis et al., 2008, Makarenkova et al., 2009, Olguin et al., 2003). Myotube
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formation depends on the ability of myoblasts to align and establish cell-cell
contacts, while increased differentiation and fusion may lead to decreased
migration (Griffin et al., 2010, Smythe and Grounds, 2001). Thus, any modulation
in the ability of myoblasts to differentiate and to fuse, might exert indirect effects
on the process of myoblast migration, and vice versa. As differentiation/fusion
potential of myoblasts following 10µM Bpv(Hopic) treatment and serial
passaging was significantly inhibited, it was hypothesised that these two
treatments could be useful in  identifying new targets for investigating the
mechanisms of myoblast fusion and migration. The expression of 4 genes (Spire1,
Spire2, Formin1 and Formin2), was examined using RT-PCR following the
inhibition of differentiation/fusion with Bpv(Hopic) treatment or serial passaging.
The protein products of Spire and Formin genes are reported to act as actin
nucleators, promoting the assembly of new actin filaments (Pechlivanis et al.,
2009, Quinlan et al., 2005). Regulators of actin polymerisation, such as WASPs
and SCAR/WAVEs, have been shown to regulate myoblast fusion (Gildor et al.,
2009, Guerin and Kramer, 2009, Kim et al., 2007, Mukherjee et al., 2011,
Richardson et al., 2007, Schafer et al., 2007), but the expression of Spire and
Formin genes or their protein products in skeletal muscle was not investigated.
Our results indicated that Spire1, Spire2 and Formin1 gene are expressed in
C2C12 myoblasts, with Formin2 gene expression almost undetectable. Of
particular interest is the expression of Spire1 and Formin1 genes, which seemed to
be associated with myoblast differentiation/fusion, with Spire1 gene levels
decreasing and Formin1 gene levels increasing upon inhibition of differentiation
following both 10µM Bpv(Hopic) and serial passaging. Spire2 gene expression
was affected only by BpV treatment, but not by serial passaging, while Formin 2
gene expression was affected by serial passaging, but not by BpV treatment,
suggesting that while signalling pathways may be shared, the gene responses may
uncouple. The expression of Formin and Spire genes raises the question of their
potential functions in skeletal muscle. Considering their involvement in endocytic
recycling and intracellular trafficking (Kerkhoff et al., 2001, Kerkhoff, 2010,
Morel et al., 2009, Schuh, 2011), which are associated with both myoblast fusion
and cell migration (Doherty et al., 2008, Rochlin et al., 2010, Caswell and
Norman, 2006, Pellinen and Ivaska, 2006), it was suggested that these genes
might indeed be associated with these processes, either directly or as a
consequence of altered fusion/migration. Further investigations, particularly at the
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protein level, should provide more details for their roles in skeletal muscle and
their potential implication in myoblast fusion or migration.
7.8. NOVELTY OF THE FINDINGS
The present study addressed the external and internal regulation of myoblast
migration. The regulation of myogenic cell migration by soluble factors has
previously been investigated by a number of studies (Amano et al., 2002,
Bischoff, 1997, Corti et al., 2001, Lafreniere et al., 2004, Lafreniere et al., 2006,
Torrente et al., 2003), but more attention is needed on how combinations of
factors are affecting the process. Additional research is required to address the
contribution of individual cell niches and the release of soluble factors that
influence the process of myogenesis and muscle regeneration, including migration
of myogenic cells. In the course of these studies, articles examined the expression
of chemokines in myoblasts and the contribution of factors released from fusing
myoblasts to migration of myogenic cells (Griffin et al., 2009, Griffin et al.,
2010). A number of other studies have demonstrated the expression of cyotkines,
growth factors, chemokines and their receptors at different stages of myogenic
development (Civatte et al., 2005, De Rossi et al., 2000, Griffin et al., 2010,
Hirata et al., 2003, Peterson and Pizza, 2009, Porter et al., 2003, Sachidanandan et
al., 2002, Summan et al., 2003, Warren et al., 2004). Here, these studies were
substantiated by further demonstrating that starved myotubes were capable of
releasing factors, which are capable of stimulating the migration of myoblasts,
although these factors were not biochemically identified. In addition, the question
was raised whether differences in the release of soluble factors would be observed
in myogenic cells during ageing, a topic which has not received enough attention.
A model of serially passaged myoblasts was used, which is known to mimic the
molecular regulators of aged skeletal muscle (Sharples et al., 2011) and
demonstrated differences in the potency of inducing myoblast migration between
media conditioned by passaged and non passaged myotubes. These observations
were substantiated by observing an increased capacity of serially passaged
myoblasts to migrate in the presence of media conditioned by unpassaged cells,
which provides initial cues for the existence of differences in the regulation of
myogenic cell migration following multiple divisions, which may be observed
during ageing. The release of soluble factors by myogenic cells was linked to the
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intracellular regulators, which mediate the response to these factors, which was
previously not addressed. PI3K/AKT and MAPK/ERK pathways were
demonstrated to be required for migration of myoblasts in response to myotube
CM. Reports of the involvement of these two pathways in regulating migration of
myogenic cells were not unanimous (Kawamura et al., 2004, Kim et al., 2011, Al-
Shanti et al., 2011, Suzuki et al., 2000, Leloup et al., 2007). A more detailed
investigation into the involvement of these two pathways in the regulation of
myoblast migration was performed. It was demonstrated that further upregulation
of PI3K/AKT and MAPK/ERK pathways by phospho-tyrosine phosphatase and
PTEN inhibitor Bpv(Hopic) was associated with a larger increase in the migration
of myoblasts and that PI3K/AKT and MAPK/ERK pathways were required for
this increase. The requirement of the FAK signalling pathway for basal myoblast
migration was also demonstrated, which previously was not assessed in this
context by other researchers. The involvement of high concentration of BpV was
previously investigated in skeletal muscle and shown to decrease the capacity of
C2C12 cells to differentiate, induce multipotency in these cells, increase their
ability to reach inflamed muscle tissue and contribute to muscle repair (Castaldi et
al., 2007). However, this is the first study in skeletal muscle reporting that low
dose BpV is capable of increasing migration of myoblasts, without seriously
affecting the differentiation capacity of these cells, proposing potential application
for increasing myoblast migration in myoblast transfer therapies. Finally, the
expression of Spire and Formin genes, previously not investigated in skeletal
muscle, was examined in response to inhibited differentiation/fusion by high
concentrations of Bpv(Hopic) and following serial passaging. It was demonstrated
that Spire1, Spire2 and Formin1 genes were expressed in C2C12 myoblasts, with
Formin2 expression being very weak, and that the expression of these genes was
altered by either Bpv(Hopic), serial passaging, or both. A potential involvement
of Spire1 and Formin1 genes in the process of myoblast fusion/migration was
proposed.  These data encourage further examination in the potential role of Spire
and Formin genes in skeletal muscle.
7.9. SUMMARY AND FUTURE DIRECTIONS
Only recently, research has revealed in more detail the secretagogues of
myogenic cells and partly addressed the differential secretion of soluble factors at
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different stages of myoblast development (Chan et al., 2011, Cui et al., 2009,
Griffin et al., 2010, Henningsen et al., 2010, Henningsen et al., 2011). Little
research, however, has focused on the effect of this pool of secreted factors on
different processes of myogenesis. Recently, the increased expression of a number
of chemokines in differentiating/fusing myoblasts was revealed and it was
demonstrated that media conditioned by myoblasts at the time of fusion was
capable of inducing migration of myogenic cells (Griffin et al., 2010). Previous
reports have also shown that crushed muscle extract, known to contain factors,
such as HGF and other soluble ligands, was capable of inducing migration of
myogenic cells (Bischoff, 1997, Chen and Quinn, 1992, Griffin et al., 2009,
Griffin et al., 2010, Tatsumi et al., 1998). Therefore, research has started
addressing the auto/paracrine mechanisms behind the regulation of myogenesis.
In this report, it was found that starved/atrophying myotubes are capable of
conditioning media with soluble factors inducing migration of myoblasts and that
this media is more potent at inducing myoblast migration to a media conditioned
by crushed myotubes. The factors present in the media, however, were not
revealed. Thus, previous findings were substantiated by showing that living
myotubes in a state of potential atrophy are capable of releasing factors inducing
migration of myogenic cells and likely influencing other myogenic processes. It is
proposed that further investigations should be performed into the expression
profile (PCR arrays) and secreted factors (Mass spectrometry) produced by
muscle cell cultures, not only at different stages of differentiation, but also under
different physiological states. Thus, thorough future studies should address the
differences in transcription profile and secreted proteins of quiescent myoblasts,
dying myoblasts, differentiating myoblasts, mature myotubes, starving/atrophying
myotubes and mechanically injured myotubes. These investigations should be
performed to examine how the pool of factors secreted at different stages of
muscle development influence different processes of myogenesis, such as
migration, proliferation, differentiation and survival. Thus, possible cross-talk or
interaction between different factors might be addressed. More detailed studies
could start identifying the importance of individual factors present in the
conditioned media. The potential identification of novel factors, previously not
investigated in the context of myogenesis or myogenic cell migration would
provide promising avenues for further research. Establishing the concentrations at
which these factors exert most potent action on myogenic progenitors migration,
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the potential interaction with other factors and the intracellular targets they affect,
would be a logical next step. The co-incubation of myogenic cells with other cell
types, such as inflammatory cells, and the subsequent release of factors by these
cells is also a necessary experimental model, which could provide more
information on the importance of the muscle environment in releasing soluble
factors that affect the regeneration process. Identifying and establishing the exact
action of soluble factors present in the muscle environment in different
physiological conditions could allow the creation of better therapies against
muscle wasting or reinforcing the muscle repair process. This could allow the
creation of a “”cocktail”of factors required for inducing high rates of myoblast
migration or muscle regeneration, which could speculatively be a mixture of
growth factors, cytokines, matrix metalloproteinases. An important consideration
would also be how these soluble factors would affect other cell processes and cell
types. Thus, a great amount of research effort would still be required to reveal
completely the importance of soluble factors on skeletal muscle myogenesis and
regeneration. Based on previous studies, the importance of the systemic
environment in the context of skeletal muscle ageing and regeneration is already
known (Conboy et al., 2005) and also the paracrine stimulation of aged satellite
cells by factors released from young muscle (Mezzogiorno et al., 1993). Changes
in the paracrine mechanisms following multiple divisions of myogenic cells,
which would occur during ageing, have not received attention. Future studies
should address the differences in the secretome between low and high passage
myogenic cells in different stages of differentiation. Identifying the change in
expression and secretions of serially passaged myogenic cells could give clues of
paracrine mechanisms influencing the adaptations of ageing of skeletal muscle. A
more thorough investigation would also need to be performed on how the pool of
factors secreted by different stages and states of myogenesis would influence not
only myogenic cell migration, but other processes of myogenesis, such as cell
survival, proliferation, differentiation. The response to these factors of other
tissues or cell types participating in muscle repair, such as inflammatory cells,
would also need to be addressed. Overall, these studies would contribute to our
better understanding of how myogenic cells participate in the regulation of
myogenesis and muscle regeneration, which factors are important for this process
and identify potentially important cross-talk between factors.
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A link was established between the migration induced by soluble factors released
from myogenic cells and intracellular pathways, such as PI3K/AKT and
MAPK/ERK, and their requirement for the process was demonstrated.
BpV(Hopic) treatment further activated these pathways and induced the migration
of myoblasts. The requirement of the FAK pathway was also demonstrated.
Overall, these studies demonstrated that each of the signalling pathways was
required for myoblast migration, regardless of the activation state of the others.
However, other pathways and downstream targets were not investigated. It is
entirely possible that the migration induced by Bpv(Hopic), despite being
dependent on the three signalling pathways investigated, is triggered by other
mechanisms, not investigated in this thesis. The phospho-tyrosine phosphatase
activity of BpV(Hopic) and the pleiotropic effects of PTEN could be responsible
for the activation of multiple intracellular targets. Future studies should address
this concept. Rac activation is known to be dependent on PI3K signalling (Royal
et al., 2000, Sander et al., 1998) and Rac itself is important for cell migration
through its involvement in actin polymerization and formation of membrane
protrusions, such as lamellipodia (Nobes and Hall, 1995, Raftopoulou and Hall,
2004). Thus, future investigation into the involvement of Rac in the induced
migration of myoblasts must also be performed. Preliminary studies demonstrated
that JNK inhibitor SP600125 is capable of inhibiting myoblast migration in
response to CM (see Appendix 1). However, a more detailed investigation into
how this pathway regulates myoblast migration has not been performed and could
also be addressed in future studies. In particular, the crosstalk between different
pathways would be an interesting research theme. Of particular interest would be
the investigation of the expression profiles of matrix metalloproteinases. MMP9
overexpression has been demonstrated to improve myoblast migration and
engrafment (Morgan et al., 2010). At the same time, PI3K/PTEN/AKT/mTOR
pathway is implicated in the upregulation of MMP9 in hepatocellular carcinoma,
thus involved in the invasion (Chen et al., 2009). The involvement of PTEN in
MMP-9 regulation has also been demonstrated in smooth muscle cells (Moon et
al., 2004) and warrants investigation in our models. Taken together, these data
provide promising prospects for the involvement of BpV compounds in
stimulating migration and invasion of donor myoblasts in myoblast transfer
therapy. Promising results were obtained with systemically injected myoblasts
pre-treated with 10µM BpV, which reached inflamed muscle and contributed to
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muscle repair (Castaldi et al., 2007). However, studies should be performed to
assess the potential of different concentrations of BpV(Hopic) to stimulate
myoblast migration in vivo, following local muscle injections. A temporary
inactivation of PTEN may prove to be a promising tool for enhancing the grafting
of donor myoblasts in proposed therapies of DMD, however, this might need to be
combined with other strategies, such as enhancing the fusion of these myoblasts
with muscle fibres. In a wider context, a more detailed investigation could be
performed on how signalling pathways are involved in the stimulation of different
cell processes by various mixtures and concentrations of soluble factors and
conditioned media, as discussed above. Identification and examining the action of
soluble factors, or mixture of factors, enhancing or reducing myoblast migration,
could be accompanied with a detailed investigation on the signalling pathways
they affect. Further exploration could be performed on which signalling pathways,
or combination of signalling pathways actions, exerts positive or negative effects
on myoblast migration, which could further lead to examining how knocking
down or overexpressing of these pathways affects the process. Thus, for example,
an interesting avenue for research might provide overexpressing of signalling
pathways acting positively on myogenic cell migration, associated with inhibiting
of signalling pathways acting negatively on myogenic cell migration. This would,
of course, require examination of other cell processes, as signalling pathways
often diverge to regulate several processes. It would also be essential to verify that
enhanced myogenic cell migration would lead to beneficial results for skeletal
muscle regeneration. Too much migration may lead to reduced fusion, which
eventually might lead to less regeneration. Different models, such as in vivo cell
imaging, could provide extremely useful for revealing how increased/reduced
migration of myogenic progenitors contributes to skeletal muscle regeneration and
to what extend migrating cells are recruited in regenerating myofibers. This
method could also be useful in observing how myoblasts stimulated in vivo by
BpV(Hopic), for example, are recruited to injured myofibers in both young and
old individuals. The tracking of myoblasts or satellite cells in aged muscles in
vivo and their stimulation by different factors would give invaluable information
on the contribution of cell migration to ageing and sarcopenia.
The expression of Spire and Formin genes, previously not investigated in
skeletal muscle, suggested a potential involvement of these genes in myogenesis.
Inhibited differentiation/fusion by 10µM Bpv(Hopic) treatment and serial
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passaging revealed that Spire1 and Formin1 gene expression was influenced by
both treatments, while Spire2 and Formin2 expression were influenced,
respectively, by only BpV treatment or serial passaging. These genes could play a
role in skeletal muscle myogenesis and potential association of Spire1 and
Formin1 genes in the process of myoblast fusion was proposed, which could
subsequently affect migration as well. However, this could not be verified through
the use of RT-PCR experiments only. Future studies should address the
involvement of Spires and Formins at the protein level and the roles they may
play in enabling migration. Spire and Formin proteins have been implicated in
intracellular trafficking (Kerkhoff et al., 2001, Kerkhoff, 2010, Morel et al., 2009,
Schuh, 2011) and immunostaining experiments should reveal their location in
both quiescent and differentiating/fusing myogenic cells. Silencing and
overexpression experiments should also reveal the potential functions of these
genes in skeletal muscle. In a wider context,, if these genes are indeed involved in
regulating skeletal muscle myogenesis and repair, their expression in different
physiological or pathological conditions could be examined, together with the
expression of their protein products. Thus, biopsies could be taken from
individuals with DMD, cancer cachexia, or following exercise induced
hypertrophy, and the expression of Spire and Formin genes and protein products
assessed. If changes exist, potential implication of these genes as targets of
different therapies could be considered.
Overall, these findings contribute to the field of skeletal muscle myogenesis by
revealing both intracellular and extracellular mechanisms for regulating myoblast
migration. Proposed future studies could provide more detailed data on the
regulation of this process, the cross-talk between different factors and the co-
ordination between myoblast migration and other processes, such as proliferation,
differentiation and fusion. This knowledge can serve to develop or improve
therapeutic approaches for conditions associated with loss of muscle mass
following disease, injury or ageing.
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APPENDICES
APPENDIX 1. WOUND HEALING ASSAY WITH JNK INHIBITOR
SP600125.
Wound healing assay with CM+vehicle (DMSO) (A) or with CM+10µM
SP600125 (JNK inhibitor) (B). Preliminary wound healing assay experiments
demonstrated inhibited wound healing of C2C12 myoblasts at 30h with
CM+10µM SP600125 (JNK inhibitor) vs CM. Data is representative of at least 2
experiments performed in triplicate.
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APPENDIX 2. ABSTRACT OF CONFERENCE PROCEEDINGS
Abstract presented on MYOAGE workshop “Muscle Mass regulation” (Acaya,
Italy. September, 2011)
Inhibition of C2C12 myoblast differentiation by serial passaging or
treatment with the phosphotyrosine phosphatase inhibitor BpV(Hopic),
differentially affects the expression of Spire1, Spire2 and Formin1, Formin2
genes
Introduction: Skeletal muscle growth and repair are complex processes,
depending on the proliferation, migration, differentiation and fusion of muscle
precursor cells. The differentiation and fusion of myoblasts into multinucleated
myotubes is a complex process requiring further investigation, particularly the
role of actin cytoskeleton regulation. It was hypothesized that the expression of 4
genes (Spire1, Spire2, Formin1 and Formin2), involved in actin nucleation, would
be altered during the differentiation of C2C12 cells. Spire and Formin proteins are
known to interact with each other to form a proposed cooperative mechanism for
actin nucleation.  The expression of Spire and Formin genes during skeletal
muscle differentiation has not been previously investigated. It was previously
demonstrated that serial passaging of C2C12 cells results in reduced myotube
formation (photomicroscopy), reduced creatine kinase activity (enzyme assay)
and reduced expression of myogenic regulatory factors MyoD and Myogenin
(RT-PCR).  Our objective was to study how the mRNA expression level (RT-
PCR) of  Spire1, Spire2, Formin1 and Formin2  genes was affected during C2C12
differentiation after replicative passaging or treatment with the phosphotyrosine
phosphatase inhibitor Bpv(Hopic), which is also able to inhibit the differentiation
process in these cells. Following growth to confluence, cells were transferred to
differentiation medium in the absence or presence of passaging or absence or
presence of a single dose of the Bpv(Hopic) (10 µM).
Results: Reduced MyoD and Myogenin gene expression levels were confirmed in
serially passaged (50 passages – p50) C2C12 cells vs non-passaged cells (p0) and
also in both p0 and p50 cells after treatment with 10µM BpV (Hopic).
A fold decrease (mean +/- SEM) in the expression  of Spire1 gene was observed
after treatment with BpV(Hopic) in p0 cells (2.52 +/- 0.34 at 24hr, P<0.001; 1.21
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+/- 0.064 at 48hr, P<0.05) and p50 cells (1.89 +/- 0.02 at 24hr, P<0.001; 1.31 +/-
0.04 at 48hr, P<0.005). A decrease was also observed in p50 DM cells vs p0 DM
cells (1.43 +/- 0.12 at 24hr, P<0.05; 1.3 +/-0.02 at 48hr, P=0.05; 1.21 +/-0.05 at
72hr, P<0.05).  Spire 2 expression was decreased by BpV(Hopic) in p0 cells (1.69
+/-0.13 at 48hr, P<0.01; 2.18 +/-0.09 at 72hr, P<0.005) and p50 cells (1.68 +/-0.2
at 48hr, P<0.05; 2.92 +/- 0.25 at 72hr, P<0.05). Spire2 expression was not
affected by passage. By contrast, Formin1 gene expression was increased after
treatment with Bpv(Hopic) in p0 cells (1.84 +/-0.17 at 48hr, P<0.005; 1.71 +/-
0.045 at 72 hrs, P<0.001) and to a smaller extent in p50 cells (1.15 +/-0.03 at
48hr, P<0.05).  Formin2 expression was very low in p0 cells, but significantly
increased in p50 cells (4.35 +/-0.88 at 24hr, P<0.05; 6 +/-1 at 48hr, P<0.05; 7 +/-
3.32 at 72hr, P<0.05).  Its expression was not affected by BpV(Hopic) treatment.
Conclusion: It was confirmed that both serial passaging and BpV (Hopic)
treatment reduce the expression of myogenic regulatory factors in C2C12
myoblasts and that when differentiation and fusion is inhibited by these
conditions, the expression levels of genes involved in actin nucleation are
differentially affected. It was proposed that balanced expression of Spire and
Formin genes is necessary for the formation of multinucleated myotubes, with
Spire 1 and 2 being suppressed with reduced fusion and Formin 1 and 2 increased
with reduced fusion, suggesting targets for future preventive wasting therapies.
Future gene knock-down studies and studies looking at the protein level of Spires
and Formins would be essential to verify their involvement and precise function
in skeletal muscle.
